<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE sequence-cwu SYSTEM "us-sequence-listing-v1_3-2020-10-08.dtd" [ ]><sequence-cwu id="SEQLST-1"><publication-reference><document-id><country>US</country><doc-number>20230000951</doc-number><kind>A1</kind><date>20230105</date></document-id></publication-reference><number>1</number><sequence-list-new-rules><s100><s160>594</s160></s100><s200><s210>1</s210><s211>33</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 1His Ala Asp Gly Ser Phe Ser Asp Glu Met Asn Thr Ile Leu Asp Asn1               5                   10                  15Leu Ala Ala Arg Asp Phe Ile Asn Trp Leu Ile Gln Thr Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>2</s210><s211>31</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 2His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly1               5                   10                  15Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Gly Arg Gly            20                  25                  30</s400><s200><s210>3</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-1 dual agonist peptide</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(2)..(2)</s222><s223>Xaa is Aib or G</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(5)..(5)</s222><s223>Xaa is T or S</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(7)..(7)</s222><s223>Xaa is T or S</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(8)..(8)</s222><s223>Xaa is S, E or D</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(10)..(10)</s222><s223>Xaa is L, M, V or a residue of K, k (D-lys), R,      Orn, Dap or Dab in which the side chain is conjugated to a      substituent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(11)..(11)</s222><s223>Xaa is A, N or S</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(15)..(15)</s222><s223>Xaa is D or E</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is G, E, A or a residue of K, k (D-lys), R,      Orn, Dap or Dab in which the side chain is conjugated to a      substituent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(17)..(17)</s222><s223>Xaa is Q, E, K, L or a residue of K, k (D-lys),      R, Orn, Dap or Dab in which the side chain is conjugated to a      substituent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(19)..(19)</s222><s223>Xaa is A, V or S</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(20)..(20)</s222><s223>Xaa is R, K or a residue of K, k (D-lys), R,      Orn, Dap or Dab in which the side chain is conjugated to a      substituent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(21)..(21)</s222><s223>Xaa is D, L or E</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(24)..(24)</s222><s223>Xaa is A, N or  S</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(27)..(27)</s222><s223>Xaa is I, Q, K, H or Y</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(28)..(28)</s222><s223>Xaa is Q, E, A, H, Y, L, K, R or S</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(29)..(29)</s222><s223>Xaa is H, Y, K or Q</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(33)..(33)</s222><s223>Xaa is D or  E</s223></s220></s200><s400> 3His Xaa Glu Gly Xaa Phe Xaa Xaa Glu Xaa Xaa Thr Ile Leu Xaa Xaa1               5                   10                  15Xaa Ala Xaa Xaa Xaa Phe Ile Xaa Trp Leu Xaa Xaa Xaa Lys Ile Thr            20                  25                  30Xaa</s400><s200><s210>4</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(2)..(2)</s222><s223>Xaa is Aib or G</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(5)..(5)</s222><s223>Xaa is T or S</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(7)..(7)</s222><s223>Xaa is T or S</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is G or a residue of K, k (D-lys), R, Orn,      Dap or Dab in which the side chain is conjugated to a substituent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(17)..(17)</s222><s223>Xaa is Q, E, K, L or a residue of K, k (D-lys),      R, Orn, Dap or Dab in which the side chain is conjugated to a      substituent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(21)..(21)</s222><s223>Xaa is D or L</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(28)..(28)</s222><s223>Xaa is Q, E, A, H, Y, L, K, R or S</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(29)..(29)</s222><s223>Xaa is H, Y or Q</s223></s220></s200><s400> 4His Xaa Glu Gly Xaa Phe Xaa Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Xaa Ala Ala Arg Xaa Phe Ile Ala Trp Leu Ile Xaa Xaa Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>5</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(5)..(5)</s222><s223>Xaa is T or S with at leasst one of Xaa at      position 5 or 7 being a T</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(7)..(7)</s222><s223>Xaa is T or S with at leasst one of Xaa at      position 5 or 7 being a T</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(10)..(10)</s222><s223>Xaa is L or a residue of K, k (D-lys), R, Orn,      Dap or Dab in which the side chain is conjugated to a substituent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is G, E, A or a residue of K, k (D-lys), R,      Orn, Dap or Dab in which the side chain is conjugated to a      substituent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(17)..(17)</s222><s223>Xaa is Q, E, K, L or a residue of K, k (D-lys),      R, Orn, Dap or Dab in which the side chain is conjugated to a      substituent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(20)..(20)</s222><s223>Xaa is R or a residue of K, k (D-lys), R, Orn,      Dap or Dab in which the side chain is conjugated to a substituent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(21)..(21)</s222><s223>Xaa is D or L</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(28)..(28)</s222><s223>Xaa is E, A or Q</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(29)..(29)</s222><s223>Xaa is H, Y or Q</s223></s220></s200><s400> 5His Xaa Glu Gly Xaa Phe Xaa Ser Glu Xaa Ala Thr Ile Leu Asp Xaa1               5                   10                  15Xaa Ala Ala Xaa Xaa Phe Ile Ala Trp Leu Ile Xaa Xaa Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>6</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(5)..(5)</s222><s223>Xaa is T or S with at least one of Xaa at      position 5 or 7 being a T</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(7)..(7)</s222><s223>Xaa is T or S with at least one of Xaa at      position 5 or 7 being a T</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is G or a residue of K, k (D-lys), R, Orn,      Dap or Dab in which the side chain is conjugated to a substituent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(17)..(17)</s222><s223>Xaa is E, K, L or a residue of K, k (D-lys), R,      Orn, Dap or Dab in which the side chain is conjugated to a      substituent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(21)..(21)</s222><s223>Xaa is D or L</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(28)..(28)</s222><s223>Xaa is E or A</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(29)..(29)</s222><s223>Xaa is H, Y or Q</s223></s220></s200><s400> 6His Xaa Glu Gly Xaa Phe Xaa Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Xaa Ala Ala Arg Xaa Phe Ile Ala Trp Leu Ile Xaa Xaa Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>7</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(5)..(5)</s222><s223>Xaa is T or S where at least one of Xaa at      position 5 or 7 is a T</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(7)..(7)</s222><s223>Xaa is T or S where at least one of Xaa at      position 5 or 7 is a T</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is a residue of K, k (D-lys), R, Orn, Dap      or Dab in which the side chain is conjugated to a substituent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(28)..(28)</s222><s223>Xaa is Q, E, A, H, Y, L, K, R or S, e.g. Q, E,      A, H, Y or L</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(29)..(29)</s222><s223>Xaa is H, Y or Q</s223></s220></s200><s400> 7His Xaa Glu Gly Xaa Phe Xaa Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Xaa Xaa Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>8</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220></s200><s400> 8Lys Glu Lys1</s400><s200><s210>9</s210><s211>6</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220></s200><s400> 9Glu Lys Glu Lys Glu Lys1               5</s400><s200><s210>10</s210><s211>6</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(1)..(1)</s222><s223>Xaa is D-lys</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(2)..(2)</s222><s223>Xaa is D-lys</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(3)..(3)</s222><s223>Xaa is D-lys</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(4)..(4)</s222><s223>Xaa is D-lys</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(5)..(5)</s222><s223>Xaa is D-lys</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(6)..(6)</s222><s223>Xaa is D-lys</s223></s220></s200><s400> 10Xaa Xaa Xaa Xaa Xaa Xaa1               5</s400><s200><s210>11</s210><s211>6</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(2)..(2)</s222><s223>Xaa is D-lys</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(4)..(4)</s222><s223>Xaa is D-lys</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(6)..(6)</s222><s223>Xaa is D-lys</s223></s220></s200><s400> 11Glu Xaa Glu Xaa Glu Xaa1               5</s400><s200><s210>12</s210><s211>6</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220></s200><s400> 12Ala Lys Ala Ala Glu Lys1               5</s400><s200><s210>13</s210><s211>6</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220></s200><s400> 13Ala Lys Glu Lys Glu Lys1               5</s400><s200><s210>14</s210><s211>6</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220></s200><s400> 14Ala Thr Ile Leu Glu Lys1               5</s400><s200><s210>15</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(3)..(3)</s222><s223>Xaa is a residue of K, k (D-lys), R, Orn, Dap      or Dab in which the side chain is conjugated to a substituent</s223></s220></s200><s400> 15Lys Glu Xaa1</s400><s200><s210>16</s210><s211>6</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(6)..(6)</s222><s223>Xaa is a residue of K, k (D-lys), R, Orn, Dap      or Dab in which the side chain is conjugated to a substituent</s223></s220></s200><s400> 16Glu Lys Glu Lys Glu Xaa1               5</s400><s200><s210>17</s210><s211>6</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(2)..(2)</s222><s223>Xaa is D-lys</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(4)..(4)</s222><s223>Xaa is D-lys</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(6)..(6)</s222><s223>Xaa is a residue of K, k (D-lys), R, Orn, Dap      or Dab in which the side chain is conjugated to a substituent</s223></s220></s200><s400> 17Glu Xaa Glu Xaa Glu Xaa1               5</s400><s200><s210>18</s210><s211>6</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(6)..(6)</s222><s223>Xaa is a residue of K, k (D-lys), R, Orn, Dap      or Dab in which the side chain is conjugated to a substituent</s223></s220></s200><s400> 18Ala Lys Ala Ala Glu Xaa1               5</s400><s200><s210>19</s210><s211>6</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(6)..(6)</s222><s223>Xaa is a residue of K, k (D-lys), R, Orn, Dap      or Dab in which the side chain is conjugated to a substituent</s223></s220></s200><s400> 19Ala Lys Glu Lys Glu Xaa1               5</s400><s200><s210>20</s210><s211>6</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(6)..(6)</s222><s223>xaa is a residue of K, k (D-lys), R, Orn, Dap      or Dab in which the side chain is conjugated to a substituent</s223></s220></s200><s400> 20Ala Thr Ile Leu Glu Xaa1               5</s400><s200><s210>21</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is a residue of K, k (D-lys), R, Orn, Dap      or Dab in which the side chain is conjugated to a substituent</s223></s220></s200><s400> 21His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Glu Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>22</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is a residue of K, k (D-lys), R, Orn, Dap      or Dab in which the side chain is conjugated to a substituent</s223></s220></s200><s400> 22His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Glu Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>23</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is a residue of K, k (D-lys), R, Orn, Dap      or Dab in which the side chain is conjugated to a substituent</s223></s220></s200><s400> 23His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Glu Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>24</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is a residue of K, k (D-lys), R, Orn, Dap      or Dab in which the side chain is conjugated to a substituent</s223></s220></s200><s400> 24His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Lys Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>25</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is a residue of K, k (D-lys), R, Orn, Dap      or Dab in which the side chain is conjugated to a substituent</s223></s220></s200><s400> 25His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Lys Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>26</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is a residue of K, k (D-lys), R, Orn, Dap      or Dab in which the side chain is conjugated to a substituent</s223></s220></s200><s400> 26His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Lys Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>27</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(17)..(17)</s222><s223>Xaa is a residue of K, k (D-lys), R, Orn, Dap      or Dab in which the side chain is conjugated to a substituent</s223></s220></s200><s400> 27His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Gly1               5                   10                  15Xaa Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>28</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(17)..(17)</s222><s223>Xaa is a residue of K, k (D-lys), R, Orn, Dap      or Dab in which the side chain is conjugated to a substituent</s223></s220></s200><s400> 28His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Gly1               5                   10                  15Xaa Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>29</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(17)..(17)</s222><s223>Xaa is a residue of K, k (D-lys), R, Orn, Dap      or Dab in which the side chain is conjugated to a substituent</s223></s220></s200><s400> 29His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Gly1               5                   10                  15Xaa Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>30</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is a residue of K, k (D-lys), R, Orn, Dap      or Dab in which the side chain is conjugated to a substituent</s223></s220></s200><s400> 30His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Leu Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>31</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is a residue of K, k (D-lys), R, Orn, Dap      or Dab in which the side chain is conjugated to a substituent</s223></s220></s200><s400> 31His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Leu Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>32</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is a residue of K, k (D-lys), R, Orn, Dap      or Dab in which the side chain is conjugated to a substituent</s223></s220></s200><s400> 32His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Leu Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>33</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is a residue of K, k (D-lys), R, Orn, Dap      or Dab in which the side chain is conjugated to a substituent</s223></s220></s200><s400> 33His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Leu Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Ala His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>34</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is a residue of K, k (D-lys), R, Orn, Dap      or Dab in which the side chain is conjugated to a substituent</s223></s220></s200><s400> 34His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Leu Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Ala His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>35</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is a residue of K, k (D-lys), R, Orn, Dap      or Dab in which the side chain is conjugated to a substituent</s223></s220></s200><s400> 35His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Leu Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Ala His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>36</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is a residue of K, k (D-lys), R, Orn, Dap      or Dab in which the side chain is conjugated to a substituent</s223></s220></s200><s400> 36His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Glu Ala Ala Arg Leu Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>37</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is a residue of K, k (D-lys), R, Orn, Dap      or Dab in which the side chain is conjugated to a substituent</s223></s220></s200><s400> 37His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Gln His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>38</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is a residue of K, k (D-lys), R, Orn, Dap      or Dab in which the side chain is conjugated to a substituent</s223></s220></s200><s400> 38His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Gln His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>39</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is a residue of K, k (D-lys), R, Orn, Dap      or Dab in which the side chain is conjugated to a substituent</s223></s220></s200><s400> 39His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Gln His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>40</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is a residue of K, k (D-lys), R, Orn, Dap      or Dab in which the side chain is conjugated to a substituent</s223></s220></s200><s400> 40His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>41</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is a residue of K, k (D-lys), R, Orn, Dap      or Dab in which the side chain is conjugated to a substituent</s223></s220></s200><s400> 41His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Ala His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>42</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is a residue of K, k (D-lys), R, Orn, Dap      or Dab in which the side chain is conjugated to a substituent</s223></s220></s200><s400> 42His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Ala His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>43</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is a residue of K, k (D-lys), R, Orn, Dap      or Dab in which the side chain is conjugated to a substituent</s223></s220></s200><s400> 43His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Ala His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>44</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is a residue of K, k (D-lys), R, Orn, Dap      or Dab in which the side chain is conjugated to a substituent</s223></s220></s200><s400> 44His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>45</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is a residue of K, k (D-lys), R, Orn, Dap      or Dab in which the side chain is conjugated to a substituent</s223></s220></s200><s400> 45His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>46</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is a residue of K, k (D-lys), R, Orn, Dap      or Dab in which the side chain is conjugated to a substituent</s223></s220></s200><s400> 46His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile His His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>47</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is a residue of K, k (D-lys), R, Orn, Dap      or Dab in which the side chain is conjugated to a substituent</s223></s220></s200><s400> 47His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Tyr His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>48</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is a residue of K, k (D-lys), R, Orn, Dap      or Dab in which the side chain is conjugated to a substituent</s223></s220></s200><s400> 48His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Leu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>49</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is a residue of K, k (D-lys), R, Orn, Dap      or Dab in which the side chain is conjugated to a substituent</s223></s220></s200><s400> 49His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Lys His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>50</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is a residue of K, k (D-lys), R, Orn, Dap      or Dab in which the side chain is conjugated to a substituent</s223></s220></s200><s400> 50His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Arg His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>51</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is a residue of K, k (D-lys), R, Orn, Dap      or Dab in which the side chain is conjugated to a substituent</s223></s220></s200><s400> 51His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Ser His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>52</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is a residue of K, k (D-lys), R, Orn, Dap      or Dab in which the side chain is conjugated to a substituent</s223></s220></s200><s400> 52His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Gln Gln His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>53</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is a residue of K, k (D-lys), R, Orn, Dap      or Dab in which the side chain is conjugated to a substituent</s223></s220></s200><s400> 53His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Tyr Gln His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>54</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is a residue of K, k (D-lys), R, Orn, Dap      or Dab in which the side chain is conjugated to a substituent</s223></s220></s200><s400> 54His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Lys Gln His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>55</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is a residue of K, k (D-lys), R, Orn, Dap      or Dab in which the side chain is conjugated to a substituent</s223></s220></s200><s400> 55His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Gln Gln Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>56</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is a residue of K, k (D-lys), R, Orn, Dap      or Dab in which the side chain is conjugated to a substituent</s223></s220></s200><s400> 56His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Gln Tyr Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>57</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is a residue of K, k (D-lys), R, Orn, Dap      or Dab in which the side chain is conjugated to a substituent</s223></s220></s200><s400> 57His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ser Thr Ile Leu Glu Xaa1               5                   10                  15Gln Ala Ser Arg Glu Phe Ile Ala Trp Leu Ile Ala Tyr Lys Ile Thr            20                  25                  30Glu</s400><s200><s210>58</s210><s211>39</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(34)..(38)</s222><s223>Xaa at positions 34-38 is D-Lys</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(39)..(39)</s222><s223>Xaa is a residue of K, k (D-lys), R, Orn, Dap      or Dab in which the side chain is conjugated to a substituent</s223></s220></s200><s400> 58His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Glu1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Ala His Lys Ile Thr            20                  25                  30Asp Xaa Xaa Xaa Xaa Xaa Xaa        35</s400><s200><s210>59</s210><s211>39</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(34)..(38)</s222><s223>Xaa at positions 34-38 is D-Lys</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(39)..(39)</s222><s223>Xaa is a residue of K, k (D-lys), R, Orn, Dap      or Dab in which the side chain is conjugated to a substituent</s223></s220></s200><s400> 59His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Glu1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Ala His Lys Ile Thr            20                  25                  30Asp Xaa Xaa Xaa Xaa Xaa Xaa        35</s400><s200><s210>60</s210><s211>39</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(34)..(38)</s222><s223>Xaa at positions 34-38 is D-Lys</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(39)..(39)</s222><s223>Xaa is a residue of K, k (D-lys), R, Orn, Dap      or Dab in which the side chain is conjugated to a substituent</s223></s220></s200><s400> 60His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Glu1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp Xaa Xaa Xaa Xaa Xaa Xaa        35</s400><s200><s210>61</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(10)..(10)</s222><s223>Xaa is a residue of K, k (D-lys), R, Orn, Dap      or Dab in which the side chain is conjugated to a substituent</s223></s220></s200><s400> 61His Xaa Glu Gly Ser Phe Thr Ser Glu Xaa Ala Thr Ile Leu Asp Glu1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>62</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(17)..(17)</s222><s223>Xaa is a residue of K, k (D-lys), R, Orn, Dap      or Dab in which the side chain is conjugated to a substituent</s223></s220></s200><s400> 62His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Glu Gly1               5                   10                  15Xaa Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>63</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(20)..(20)</s222><s223>Xaa is a residue of K, k (D-lys), R, Orn, Dap      or Dab in which the side chain is conjugated to a substituent</s223></s220></s200><s400> 63His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Glu1               5                   10                  15Gln Ala Ala Xaa Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>64</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(20)..(20)</s222><s223>Xaa is a residue of K, k (D-lys), R, Orn, Dap      or Dab in which the side chain is conjugated to a substituent</s223></s220></s200><s400> 64His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Glu1               5                   10                  15Gln Ala Ala Xaa Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>65</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(10)..(10)</s222><s223>Xaa is a residue of K, k (D-lys), R, Orn, Dap      or Dab in which the side chain is conjugated to a substituent</s223></s220></s200><s400> 65His Xaa Glu Gly Thr Phe Thr Ser Glu Xaa Ala Thr Ile Leu Asp Glu1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>66</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(17)..(17)</s222><s223>Xaa is a residue of K, k (D-lys), R, Orn, Dap      or Dab in which the side chain is conjugated to a substituent</s223></s220></s200><s400> 66His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Ala1               5                   10                  15Xaa Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>67</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(20)..(20)</s222><s223>Xaa is a residue of K, k (D-lys), R, Orn, Dap      or Dab in which the side chain is conjugated to a substituent</s223></s220></s200><s400> 67His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Ala1               5                   10                  15Lys Ala Ala Xaa Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>68</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa indicates an L-lysine residue in which the      side chain is conjugated to the substituent Z1- or Z1Z2</s223></s220></s200><s400> 68His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Glu Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>69</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa indicates an L-lysine residue in which the      side chain is conjugated to the substituent Z1- or Z1Z2</s223></s220></s200><s400> 69His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Glu Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>70</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa indicates an L-lysine residue in which the      side chain is conjugated to the substituent Z1- or Z1Z2</s223></s220></s200><s400> 70His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Glu Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>71</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa indicates an L-lysine residue in which the      side chain is conjugated to the substituent Z1- or Z1Z2</s223></s220></s200><s400> 71His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Lys Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>72</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa indicates an L-lysine residue in which the      side chain is conjugated to the substituent Z1- or Z1Z2</s223></s220></s200><s400> 72His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Lys Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>73</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa indicates an L-lysine residue in which the      side chain is conjugated to the substituent Z1- or Z1Z2</s223></s220></s200><s400> 73His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Lys Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>74</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(17)..(17)</s222><s223>Xaa indicates an L-lysine residue in which the      side chain is conjugated to the substituent Z1- or Z1Z2</s223></s220></s200><s400> 74His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Gly1               5                   10                  15Xaa Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>75</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(17)..(17)</s222><s223>Xaa indicates an L-lysine residue in which the      side chain is conjugated to the substituent Z1- or Z1Z2</s223></s220></s200><s400> 75His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Gly1               5                   10                  15Xaa Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>76</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(17)..(17)</s222><s223>Xaa indicates an L-lysine residue in which the      side chain is conjugated to the substituent Z1- or Z1Z2</s223></s220></s200><s400> 76His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Gly1               5                   10                  15Xaa Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>77</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>misc_feature</s221><s222>(16)..(16)</s222><s223>Xaa can be any naturally occurring amino acid</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(17)..(17)</s222><s223>Xaa indicates an L-lysine residue in which the      side chain is conjugated to the substituent Z1- or Z1Z2</s223></s220></s200><s400> 77His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Leu Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>78</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa indicates an L-lysine residue in which the      side chain is conjugated to the substituent Z1- or Z1Z2</s223></s220></s200><s400> 78His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Leu Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>79</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa indicates an L-lysine residue in which the      side chain is conjugated to the substituent Z1- or Z1Z2</s223></s220></s200><s400> 79His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Leu Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>80</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa indicates an L-lysine residue in which the      side chain is conjugated to the substituent Z1- or Z1Z2</s223></s220></s200><s400> 80His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Leu Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Ala His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>81</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa indicates an L-lysine residue in which the      side chain is conjugated to the substituent Z1- or Z1Z2</s223></s220></s200><s400> 81His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Leu Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Ala His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>82</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa indicates an L-lysine residue in which the      side chain is conjugated to the substituent Z1- or Z1Z2</s223></s220></s200><s400> 82His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Leu Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Ala His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>83</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa indicates an L-lysine residue in which the      side chain is conjugated to the substituent Z1- or Z1Z2</s223></s220></s200><s400> 83His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Glu Ala Ala Arg Leu Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>84</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa indicates an L-lysine residue in which the      side chain is conjugated to the substituent Z1- or Z1Z2</s223></s220></s200><s400> 84His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Gln His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>85</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa indicates an L-lysine residue in which the      side chain is conjugated to the substituent Z1- or Z1Z2</s223></s220></s200><s400> 85His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Gln His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>86</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa indicates an L-lysine residue in which the      side chain is conjugated to the substituent Z1- or Z1Z2</s223></s220></s200><s400> 86His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Gln His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>87</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa indicates an L-lysine residue in which the      side chain is conjugated to the substituent Z1- or Z1Z2</s223></s220></s200><s400> 87His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>88</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa indicates an L-lysine residue in which the      side chain is conjugated to the substituent Z1- or Z1Z2</s223></s220></s200><s400> 88His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Ala His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>89</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa indicates an L-lysine residue respectively      in which the side chain is conjugated to the substituent Z1- or      Z1Z2</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa indicates an L-lysine residue in which the      side chain is conjugated to the substituent Z1- or Z1Z2</s223></s220></s200><s400> 89His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Ala His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>90</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa indicates an L-lysine residue in which the      side chain is conjugated to the substituent Z1- or Z1Z2</s223></s220></s200><s400> 90His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Ala His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>91</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa indicates an L-lysine residue in which the      side chain is conjugated to the substituent Z1- or Z1Z2</s223></s220></s200><s400> 91His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>92</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa indicates an L-lysine residue in which the      side chain is conjugated to the substituent Z1- or Z1Z2</s223></s220></s200><s400> 92His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>93</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa indicates an L-lysine residue in which the      side chain is conjugated to the substituent Z1- or Z1Z2</s223></s220></s200><s400> 93His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile His His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>94</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa indicates an L-lysine residue in which the      side chain is conjugated to the substituent Z1- or Z1Z2</s223></s220></s200><s400> 94His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Tyr His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>95</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa indicates an L-lysine residue in which the      side chain is conjugated to the substituent Z1- or Z1Z2</s223></s220></s200><s400> 95His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Leu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>96</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa indicates an L-lysine residue in which the      side chain is conjugated to the substituent Z1- or Z1Z2</s223></s220></s200><s400> 96His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Lys His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>97</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa indicates an L-lysine residue in which the      side chain is conjugated to the substituent Z1- or Z1Z2</s223></s220></s200><s400> 97His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Arg His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>98</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa indicates an L-lysine residue in which the      side chain is conjugated to the substituent Z1- or Z1Z2</s223></s220></s200><s400> 98His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Ser His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>99</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa indicates an L-lysine residue in which the      side chain is conjugated to the substituent Z1- or Z1Z2</s223></s220></s200><s400> 99His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Gln Gln His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>100</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa indicates an L-lysine residue in which the      side chain is conjugated to the substituent Z1- or Z1Z2</s223></s220></s200><s400> 100His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Tyr Gln His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>101</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa indicates an L-lysine residue in which the      side chain is conjugated to the substituent Z1- or Z1Z2</s223></s220></s200><s400> 101His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Lys Gln His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>102</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa indicates an L-lysine residue in which the      side chain is conjugated to the substituent Z1- or Z1Z2</s223></s220></s200><s400> 102His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Gln Gln Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>103</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa indicates an L-lysine residue in which the      side chain is conjugated to the substituent Z1- or Z1Z2</s223></s220></s200><s400> 103His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Gln Tyr Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>104</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa indicates an L-lysine residue in which the      side chain is conjugated to the substituent Z1- or Z1Z2</s223></s220></s200><s400> 104His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ser Thr Ile Leu Glu Xaa1               5                   10                  15Gln Ala Ser Arg Glu Phe Ile Ala Trp Leu Ile Ala Tyr Lys Ile Thr            20                  25                  30Glu</s400><s200><s210>105</s210><s211>39</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(34)..(38)</s222><s223>Xaa at positions 34-38 is D-Lys</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(39)..(39)</s222><s223>Xaa indicates an D-lysine residue in which the      side chain is conjugated to the substituent Z1- or Z1Z2</s223></s220></s200><s400> 105His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Glu1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Ala His Lys Ile Thr            20                  25                  30Asp Xaa Xaa Xaa Xaa Xaa Xaa        35</s400><s200><s210>106</s210><s211>39</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(34)..(38)</s222><s223>Xaa at positions 34-38 is D-Lys</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(39)..(39)</s222><s223>Xaa indicates an D-lysine residue in which the      side chain is conjugated to the substituent Z1- or Z1Z2</s223></s220></s200><s400> 106His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Glu1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Ala His Lys Ile Thr            20                  25                  30Asp Xaa Xaa Xaa Xaa Xaa Xaa        35</s400><s200><s210>107</s210><s211>39</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(34)..(38)</s222><s223>Xaa at positions 34-38 is D-Lys</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(39)..(39)</s222><s223>Xaa indicates an D-lysine residue in which the      side chain is conjugated to the substituent Z1- or Z1Z2</s223></s220></s200><s400> 107His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Glu1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp Xaa Xaa Xaa Xaa Xaa Xaa        35</s400><s200><s210>108</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(10)..(10)</s222><s223>Xaa indicates an L-lysine residue in which the      side chain is conjugated to the substituent Z1- or Z1Z2</s223></s220></s200><s400> 108His Xaa Glu Gly Ser Phe Thr Ser Glu Xaa Ala Thr Ile Leu Asp Glu1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>109</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(17)..(17)</s222><s223>Xaa indicates an L-lysine residue in which the      side chain is conjugated to the substituent Z1- or Z1Z2</s223></s220></s200><s400> 109His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Glu Gly1               5                   10                  15Xaa Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>110</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(20)..(20)</s222><s223>Xaa indicates an L-lysine residue in which the      side chain is conjugated to the substituent Z1- or Z1Z2</s223></s220></s200><s400> 110His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Glu1               5                   10                  15Gln Ala Ala Xaa Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>111</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(20)..(20)</s222><s223>Xaa indicates an L-lysine residue in which the      side chain is conjugated to the substituent Z1- or Z1Z2</s223></s220></s200><s400> 111His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Glu1               5                   10                  15Gln Ala Ala Xaa Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>112</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(10)..(10)</s222><s223>Xaa indicates an L-lysine residue in which the      side chain is conjugated to the substituent Z1- or Z1Z2</s223></s220></s200><s400> 112His Xaa Glu Gly Thr Phe Thr Ser Glu Xaa Ala Thr Ile Leu Asp Glu1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>113</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(17)..(17)</s222><s223>Xaa indicates an L-lysine residue in which the      side chain is conjugated to the substituent Z1- or Z1Z2</s223></s220></s200><s400> 113His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Ala1               5                   10                  15Xaa Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>114</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(20)..(20)</s222><s223>Xaa indicates an L-lysine residue in which the      side chain is conjugated to the substituent Z1- or Z1Z2</s223></s220></s200><s400> 114His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Ala1               5                   10                  15Lys Ala Ala Xaa Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>115</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)</s223></s220></s200><s400> 115His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Glu Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>116</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)</s223></s220></s200><s400> 116His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Glu Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>117</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)</s223></s220></s200><s400> 117His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Glu Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>118</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)</s223></s220></s200><s400> 118His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Lys Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>119</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)</s223></s220></s200><s400> 119His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Lys Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>120</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)</s223></s220></s200><s400> 120His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Lys Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>121</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(17)..(17)</s222><s223>Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)</s223></s220></s200><s400> 121His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Gly1               5                   10                  15Xaa Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>122</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(17)..(17)</s222><s223>Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)</s223></s220></s200><s400> 122His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Gly1               5                   10                  15Xaa Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>123</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(17)..(17)</s222><s223>Xaa  is K([17-carboxy-heptadecanoyl]-isoGlu)</s223></s220></s200><s400> 123His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Gly1               5                   10                  15Xaa Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>124</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)</s223></s220></s200><s400> 124His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Leu Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>125</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)</s223></s220></s200><s400> 125His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Leu Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>126</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)</s223></s220></s200><s400> 126His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Leu Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>127</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)</s223></s220></s200><s400> 127His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Leu Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Ala His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>128</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)</s223></s220></s200><s400> 128His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Leu Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Ala His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>129</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)</s223></s220></s200><s400> 129His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Leu Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Ala His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>130</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)</s223></s220></s200><s400> 130His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Glu Ala Ala Arg Leu Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>131</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)</s223></s220></s200><s400> 131His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Gln His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>132</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)</s223></s220></s200><s400> 132His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Gln His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>133</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)</s223></s220></s200><s400> 133His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Gln His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>134</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)</s223></s220></s200><s400> 134His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>135</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)</s223></s220></s200><s400> 135His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Ala His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>136</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)</s223></s220></s200><s400> 136His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Ala His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>137</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)</s223></s220></s200><s400> 137His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Ala His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>138</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)</s223></s220></s200><s400> 138His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>139</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)</s223></s220></s200><s400> 139His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>140</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)</s223></s220></s200><s400> 140His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile His His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>141</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)</s223></s220></s200><s400> 141His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Tyr His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>142</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)</s223></s220></s200><s400> 142His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Leu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>143</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)</s223></s220></s200><s400> 143His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Lys His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>144</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)</s223></s220></s200><s400> 144His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Arg His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>145</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>misc</s221><s222>(16)..(16)</s222><s223>Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)</s223></s220></s200><s400> 145His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Ser His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>146</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is K([Hexadecanoyl]- betaAla)</s223></s220></s200><s400> 146His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Gln Gln His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>147</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is K([17-carboxy-heptadecanoyl]iso-Glu-      Peg3)</s223></s220></s200><s400> 147His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Tyr Gln His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>148</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is K([19-carboxy-nonadecanoyl]iso-Glu-Peg3-      Peg3)</s223></s220></s200><s400> 148His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Lys Gln His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>149</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is K([19-carboxy-nonadecanoyl]iso-Lys-Peg3-      Peg3-Peg3)</s223></s220></s200><s400> 149His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Gln Gln Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>150</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is K(Octadecanoyl)</s223></s220></s200><s400> 150His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Gln Tyr Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>151</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is K(Hexadecanoyl-isoGlu)</s223></s220></s200><s400> 151His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ser Thr Ile Leu Glu Xaa1               5                   10                  15Gln Ala Ser Arg Glu Phe Ile Ala Trp Leu Ile Ala Tyr Lys Ile Thr            20                  25                  30Glu</s400><s200><s210>152</s210><s211>40</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(34)..(39)</s222><s223>Xaa at positions 34-39 is D-Lys</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(40)..(40)</s222><s223>Xaa is ([17-carboxy-Heptadecanoyl]-isoGlu)</s223></s220></s200><s400> 152His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Glu1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Ala His Lys Ile Thr            20                  25                  30Asp Xaa Xaa Xaa Xaa Xaa Xaa Xaa        35                  40</s400><s200><s210>153</s210><s211>40</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(34)..(39)</s222><s223>Xaa at positions 34-39 is D-Lys</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(40)..(40)</s222><s223>Xaa is ([17-carboxy-Heptadecanoyl]-isoGlu)</s223></s220></s200><s400> 153His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Glu1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Ala His Lys Ile Thr            20                  25                  30Asp Xaa Xaa Xaa Xaa Xaa Xaa Xaa        35                  40</s400><s200><s210>154</s210><s211>40</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(34)..(39)</s222><s223>Xaa at positions 34-39 is D-Lys</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(40)..(40)</s222><s223>Xaa is ([17-carboxy-Heptadecanoyl]-isoGlu)</s223></s220></s200><s400> 154His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Glu1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp Xaa Xaa Xaa Xaa Xaa Xaa Xaa        35                  40</s400><s200><s210>155</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is K([19-Carboxy-nonadecanoyl]-isoGlu)</s223></s220></s200><s400> 155His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Gln His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>156</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(10)..(10)</s222><s223>Xaa is K([19-carboxy-nonadecanoyl]iso-Glu-Peg3-      Peg3)</s223></s220></s200><s400> 156His Xaa Glu Gly Ser Phe Thr Ser Glu Xaa Ala Thr Ile Leu Asp Glu1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>157</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is K([19-carboxy-nonadecanoyl]iso-Glu-Peg3-      Peg3)</s223></s220></s200><s400> 157His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Lys Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>158</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(17)..(17)</s222><s223>Xaa is K([19-carboxy-nonadecanoyl]iso-Glu-Peg3-      Peg3)</s223></s220></s200><s400> 158His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Glu Gly1               5                   10                  15Xaa Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>159</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(20)..(20)</s222><s223>Xaa is K([19-carboxy-nonadecanoyl]iso-Glu-Peg3-      Peg3)</s223></s220></s200><s400> 159His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Glu1               5                   10                  15Gln Ala Ala Xaa Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>160</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(20)..(20)</s222><s223>Xaa is K([19-carboxy-nonadecanoyl]iso-Glu-Peg3-      Peg3)</s223></s220></s200><s400> 160His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Glu1               5                   10                  15Gln Ala Ala Xaa Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>161</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is K([17-Carboxy-heptadecanoyl]-isoGlu-KEK-      Peg3)</s223></s220></s200><s400> 161His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Gln His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>162</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is K([19-Carboxy-nonadecanoyl]-isoGlu-KEK-      Peg3)</s223></s220></s200><s400> 162His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Gln His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>163</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is K([17-Carboxy-heptadecanoyl]-isoGlu-KEK-      Peg3)</s223></s220></s200><s400> 163His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>164</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is K([19-Carboxy-nonadecanoyl]-isoGlu-KEK-      Peg3)</s223></s220></s200><s400> 164His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>165</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is K([19-Carboxy-nonadecanoyl]-isoGlu-KEK)</s223></s220></s200><s400> 165His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Gln His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>166</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is K([19-Carboxy-nonadecanoyl]-isoGlu-KEK-      Peg3)</s223></s220></s200><s400> 166His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Gln His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>167</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(10)..(10)</s222><s223>Xaa is K([19-Carboxy-nonadecanoyl]-isoGlu-KEK-      Peg3)</s223></s220></s200><s400> 167His Xaa Glu Gly Ser Phe Thr Ser Glu Xaa Ala Thr Ile Leu Asp Glu1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>168</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(10)..(10)</s222><s223>Xaa is K([19-Carboxy-nonadecanoyl]-isoGlu-KEK-      Peg3)</s223></s220></s200><s400> 168His Xaa Glu Gly Thr Phe Thr Ser Glu Xaa Ala Thr Ile Leu Asp Glu1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>169</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(10)..(10)</s222><s223>Xaa is K([19-carboxy-nonadecanoyl]iso-Glu-KEK-      Peg3-Peg3)</s223></s220></s200><s400> 169His Xaa Glu Gly Ser Phe Thr Ser Glu Xaa Ala Thr Ile Leu Asp Glu1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>170</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is K([19-Carboxy-nonadecanoyl]-isoGlu-KEK-      Peg3)</s223></s220></s200><s400> 170His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>171</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is K([19-Carboxy-nonadecanoyl]-isoGlu-KEK-      Peg3)</s223></s220></s200><s400> 171His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>172</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is K([19-Carboxy-nonadecanoyl]-isoGlu-KEK-      Peg3)</s223></s220></s200><s400> 172His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Ala His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>173</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is K([19-Carboxy-nonadecanoyl]-isoGlu-KEK-      Peg3)</s223></s220></s200><s400> 173His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Lys Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>174</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is K([19-carboxy-nonadecanoyl]iso-Glu-KEK-      Peg3-Peg3)</s223></s220></s200><s400> 174His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>175</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(17)..(17)</s222><s223>Xaa is K([19-Carboxy-nonadecanoyl]-isoGlu-KEK-      Peg3)</s223></s220></s200><s400> 175His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Glu Gly1               5                   10                  15Xaa Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>176</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(17)..(17)</s222><s223>Xaa is K([19-Carboxy-nonadecanoyl]-isoGlu-KEK-      Peg3)</s223></s220></s200><s400> 176His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Ala1               5                   10                  15Xaa Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>177</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(17)..(17)</s222><s223>Xaa is K([19-carboxy-nonadecanoyl]iso-Glu-KEK-      Peg3-Peg3)</s223></s220></s200><s400> 177His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Ala1               5                   10                  15Xaa Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>178</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(20)..(20)</s222><s223>Xaa is K([19-Carboxy-nonadecanoyl]-isoGlu-KEK-      Peg3)</s223></s220></s200><s400> 178His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Glu1               5                   10                  15Gln Ala Ala Xaa Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>179</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(20)..(20)</s222><s223>Xaa is K([19-Carboxy-nonadecanoyl]-isoGlu-KEK-      Peg3)</s223></s220></s200><s400> 179His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Glu1               5                   10                  15Gln Ala Ala Xaa Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>180</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(20)..(20)</s222><s223>Xaa is K([19-carboxy-nonadecanoyl]iso-Glu-KEK-      Peg3-Peg3)</s223></s220></s200><s400> 180His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Glu1               5                   10                  15Gln Ala Ala Xaa Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>181</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(20)..(20)</s222><s223>Xaa is K([19-carboxy-nonadecanoyl]iso-Glu-KEK-      Peg3-Peg3)</s223></s220></s200><s400> 181His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Glu1               5                   10                  15Gln Ala Ala Xaa Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>182</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(20)..(20)</s222><s223>Xaa is K([19-Carboxy-nonadecanoyl]-isoGlu-KEK-      Peg3)</s223></s220></s200><s400> 182His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Ala1               5                   10                  15Lys Ala Ala Xaa Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>183</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Hydrogen</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)</s223></s220><s220><s221>MOD_RES</s221><s222>(33)..(33)</s222><s223>Hydroxyl</s223></s220></s200><s400> 183His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Glu Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>184</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Hydrogen</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)</s223></s220><s220><s221>MOD_RES</s221><s222>(33)..(33)</s222><s223>Hydroxyl</s223></s220></s200><s400> 184His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Glu Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>185</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Hydrogen</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)</s223></s220><s220><s221>MOD_RES</s221><s222>(33)..(33)</s222><s223>Hydroxyl</s223></s220></s200><s400> 185His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Glu Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>186</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Hydrogen</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)</s223></s220><s220><s221>MOD_RES</s221><s222>(33)..(33)</s222><s223>Hydroxyl</s223></s220></s200><s400> 186His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Lys Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>187</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Hydrogen</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)</s223></s220><s220><s221>MOD_RES</s221><s222>(33)..(33)</s222><s223>Hydroxyl</s223></s220></s200><s400> 187His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Lys Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>188</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Hydrogen</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)</s223></s220><s220><s221>MOD_RES</s221><s222>(33)..(33)</s222><s223>Hydroxyl</s223></s220></s200><s400> 188His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Lys Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>189</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Hydrogen</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(17)..(17)</s222><s223>Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)</s223></s220><s220><s221>MOD_RES</s221><s222>(33)..(33)</s222><s223>Hydroxyl</s223></s220></s200><s400> 189His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Gly1               5                   10                  15Xaa Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>190</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Hydrogen</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(17)..(17)</s222><s223>Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)</s223></s220><s220><s221>MOD_RES</s221><s222>(33)..(33)</s222><s223>Hydroxyl</s223></s220></s200><s400> 190His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Gly1               5                   10                  15Xaa Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>191</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Hydrogen</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(17)..(17)</s222><s223>Xaa  is K([17-carboxy-heptadecanoyl]-isoGlu)</s223></s220><s220><s221>MOD_RES</s221><s222>(33)..(33)</s222><s223>Hydroxyl</s223></s220></s200><s400> 191His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Gly1               5                   10                  15Xaa Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>192</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Hydrogen</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)</s223></s220><s220><s221>MOD_RES</s221><s222>(33)..(33)</s222><s223>Hydroxyl</s223></s220></s200><s400> 192His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Leu Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>193</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Hydrogen</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)</s223></s220><s220><s221>MOD_RES</s221><s222>(33)..(33)</s222><s223>Hydroxyl</s223></s220></s200><s400> 193His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Leu Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>194</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Hydrogen</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)</s223></s220><s220><s221>MOD_RES</s221><s222>(33)..(33)</s222><s223>Hydroxyl</s223></s220></s200><s400> 194His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Leu Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>195</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Hydrogen</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)</s223></s220><s220><s221>MOD_RES</s221><s222>(33)..(33)</s222><s223>Hydroxyl</s223></s220></s200><s400> 195His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Leu Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Ala His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>196</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Hydrogen</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)</s223></s220><s220><s221>MOD_RES</s221><s222>(33)..(33)</s222><s223>Hydroxyl</s223></s220></s200><s400> 196His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Leu Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Ala His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>197</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Hydrogen</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)</s223></s220><s220><s221>MOD_RES</s221><s222>(33)..(33)</s222><s223>Hydroxyl</s223></s220></s200><s400> 197His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Leu Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Ala His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>198</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Hydrogen</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)</s223></s220><s220><s221>MOD_RES</s221><s222>(33)..(33)</s222><s223>Hydroxyl</s223></s220></s200><s400> 198His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Glu Ala Ala Arg Leu Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>199</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Hydrogen</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)</s223></s220><s220><s221>MOD_RES</s221><s222>(33)..(33)</s222><s223>Hydroxyl</s223></s220></s200><s400> 199His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Gln His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>200</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Hydrogen</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)</s223></s220><s220><s221>MOD_RES</s221><s222>(33)..(33)</s222><s223>Hydroxyl</s223></s220></s200><s400> 200His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Gln His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>201</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Hydrogen</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)</s223></s220><s220><s221>MOD_RES</s221><s222>(33)..(33)</s222><s223>Hydroxyl</s223></s220></s200><s400> 201His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Gln His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>202</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Hydrogen</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)</s223></s220><s220><s221>MOD_RES</s221><s222>(33)..(33)</s222><s223>Hydroxyl</s223></s220></s200><s400> 202His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>203</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Hydrogen</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)</s223></s220><s220><s221>MOD_RES</s221><s222>(33)..(33)</s222><s223>Hydroxyl</s223></s220></s200><s400> 203His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Ala His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>204</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Hydrogen</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)</s223></s220><s220><s221>MOD_RES</s221><s222>(33)..(33)</s222><s223>Hydroxyl</s223></s220></s200><s400> 204His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Ala His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>205</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Hydrogen</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)</s223></s220><s220><s221>MOD_RES</s221><s222>(33)..(33)</s222><s223>Hydroxyl</s223></s220></s200><s400> 205His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Ala His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>206</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Hydrogen</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)</s223></s220><s220><s221>MOD_RES</s221><s222>(33)..(33)</s222><s223>Hydroxyl</s223></s220></s200><s400> 206His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>207</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Hydrogen</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)</s223></s220><s220><s221>MOD_RES</s221><s222>(33)..(33)</s222><s223>Hydroxyl</s223></s220></s200><s400> 207His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>208</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Hydrogen</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)</s223></s220><s220><s221>MOD_RES</s221><s222>(33)..(33)</s222><s223>Hydroxyl</s223></s220></s200><s400> 208His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile His His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>209</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Hydrogen</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)</s223></s220><s220><s221>MOD_RES</s221><s222>(33)..(33)</s222><s223>Hydroxyl</s223></s220></s200><s400> 209His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Tyr His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>210</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Hydrogen</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)</s223></s220><s220><s221>MOD_RES</s221><s222>(33)..(33)</s222><s223>Hydroxyl</s223></s220></s200><s400> 210His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Leu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>211</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Hydrogen</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)</s223></s220><s220><s221>MOD_RES</s221><s222>(33)..(33)</s222><s223>Hydroxyl</s223></s220></s200><s400> 211His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Lys His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>212</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Hydrogen</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)</s223></s220><s220><s221>MOD_RES</s221><s222>(33)..(33)</s222><s223>Hydroxyl</s223></s220></s200><s400> 212His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Arg His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>213</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Hydrogen</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)</s223></s220><s220><s221>MOD_RES</s221><s222>(33)..(33)</s222><s223>Hydroxyl</s223></s220></s200><s400> 213His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Ser His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>214</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Hydrogen</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is K([Hexadecanoyl]- betaAla), where      betaAla is betaAla is 3-Aminopropanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(33)..(33)</s222><s223>Hydroxyl</s223></s220></s200><s400> 214His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Gln Gln His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>215</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Hydrogen</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is K([17-carboxy-heptadecanoyl]iso-Glu-      Peg3), where Peg3 is 8-amino-3,6-dioxaoctanoyl group</s223></s220><s220><s221>MOD_RES</s221><s222>(33)..(33)</s222><s223>Hydroxyl</s223></s220></s200><s400> 215His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Tyr Gln His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>216</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Hydrogen</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is K([19-carboxy-nonadecanoyl]iso-Glu-Peg3-      Peg3), where Peg3 is 8-amino-3,6-dioxaoctanoyl group</s223></s220><s220><s221>MOD_RES</s221><s222>(33)..(33)</s222><s223>Hydroxyl</s223></s220></s200><s400> 216His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Lys Gln His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>217</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Hydrogen</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is K([19-carboxy-nonadecanoyl]iso-Lys-Peg3-      Peg3-Peg3), where Peg3 is 8-amino-3,6-dioxaoctanoyl group</s223></s220><s220><s221>MOD_RES</s221><s222>(33)..(33)</s222><s223>Hydroxyl</s223></s220></s200><s400> 217His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Gln Gln Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>218</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Hydrogen</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is K(Octadecanoyl)</s223></s220><s220><s221>MOD_RES</s221><s222>(33)..(33)</s222><s223>Hydroxyl</s223></s220></s200><s400> 218His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Gln Tyr Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>219</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Hydrogen</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is K(Hexadecanoyl-isoGlu)</s223></s220><s220><s221>MOD_RES</s221><s222>(33)..(33)</s222><s223>Hydroxyl</s223></s220></s200><s400> 219His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ser Thr Ile Leu Glu Xaa1               5                   10                  15Gln Ala Ser Arg Glu Phe Ile Ala Trp Leu Ile Ala Tyr Lys Ile Thr            20                  25                  30Glu</s400><s200><s210>220</s210><s211>40</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Hydrogen</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(34)..(39)</s222><s223>Xaa at positions 34-39 is D-Lys</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(40)..(40)</s222><s223>Xaa is ([17-carboxy-Heptadecanoyl]-isoGlu)</s223></s220><s220><s221>MOD_RES</s221><s222>(40)..(40)</s222><s223>Amine</s223></s220></s200><s400> 220His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Glu1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Ala His Lys Ile Thr            20                  25                  30Asp Xaa Xaa Xaa Xaa Xaa Xaa Xaa        35                  40</s400><s200><s210>221</s210><s211>40</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Hydrogen</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(34)..(39)</s222><s223>Xaa at positions 34-39 is D-Lys</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(40)..(40)</s222><s223>Xaa is ([17-carboxy-Heptadecanoyl]-isoGlu)</s223></s220><s220><s221>MOD_RES</s221><s222>(40)..(40)</s222><s223>Amine</s223></s220></s200><s400> 221His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Glu1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Ala His Lys Ile Thr            20                  25                  30Asp Xaa Xaa Xaa Xaa Xaa Xaa Xaa        35                  40</s400><s200><s210>222</s210><s211>40</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Hydrogen</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(34)..(39)</s222><s223>Xaa at positions 34-39 is D-Lys</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(40)..(40)</s222><s223>Xaa is ([17-carboxy-Heptadecanoyl]-isoGlu)</s223></s220><s220><s221>MOD_RES</s221><s222>(40)..(40)</s222><s223>Amine</s223></s220></s200><s400> 222His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Glu1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp Xaa Xaa Xaa Xaa Xaa Xaa Xaa        35                  40</s400><s200><s210>223</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Hydrogen</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is K([19-Carboxy-nonadecanoyl]-isoGlu)</s223></s220><s220><s221>MOD_RES</s221><s222>(33)..(33)</s222><s223>Hydroxyl</s223></s220></s200><s400> 223His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Gln His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>224</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Hydrogen</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(10)..(10)</s222><s223>Xaa is K([19-carboxy-nonadecanoyl]iso-Glu-Peg3-      Peg3), where Peg3 is 8-amino-3,6-dioxaoctanoyl group</s223></s220><s220><s221>MOD_RES</s221><s222>(33)..(33)</s222><s223>Hydroxyl</s223></s220></s200><s400> 224His Xaa Glu Gly Ser Phe Thr Ser Glu Xaa Ala Thr Ile Leu Asp Glu1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>225</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Hydrogen</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is K([19-carboxy-nonadecanoyl]iso-Glu-Peg3-      Peg3), where Peg3 is 8-amino-3,6-dioxaoctanoyl group</s223></s220><s220><s221>MOD_RES</s221><s222>(33)..(33)</s222><s223>Hydroxyl</s223></s220></s200><s400> 225His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Lys Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>226</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Hydrogen</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(17)..(17)</s222><s223>Xaa is K([19-carboxy-nonadecanoyl]iso-Glu-Peg3-      Peg3), where Peg3 is 8-amino-3,6-dioxaoctanoyl group</s223></s220><s220><s221>MOD_RES</s221><s222>(33)..(33)</s222><s223>Hydroxyl</s223></s220></s200><s400> 226His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Glu Gly1               5                   10                  15Xaa Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>227</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Hydrogen</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(20)..(20)</s222><s223>Xaa is K([19-carboxy-nonadecanoyl]iso-Glu-Peg3-      Peg3), where Peg3 is 8-amino-3,6-dioxaoctanoyl group</s223></s220><s220><s221>MOD_RES</s221><s222>(33)..(33)</s222><s223>Hydroxyl</s223></s220></s200><s400> 227His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Glu1               5                   10                  15Gln Ala Ala Xaa Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>228</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Hydrogen</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(20)..(20)</s222><s223>Xaa is K([19-carboxy-nonadecanoyl]iso-Glu-Peg3-      Peg3), where Peg3 is 8-amino-3,6-dioxaoctanoyl group</s223></s220><s220><s221>MOD_RES</s221><s222>(33)..(33)</s222><s223>Hydroxyl</s223></s220></s200><s400> 228His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Glu1               5                   10                  15Gln Ala Ala Xaa Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>229</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Hydrogen</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is K([17-Carboxy-heptadecanoyl]-isoGlu-KEK-      Peg3), where Peg3 is 8-amino-3,6-dioxaoctanoyl group</s223></s220><s220><s221>MOD_RES</s221><s222>(33)..(33)</s222><s223>Hydroxyl</s223></s220></s200><s400> 229His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Gln His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>230</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Hydrogen</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is K([19-Carboxy-nonadecanoyl]-isoGlu-KEK-      Peg3), where Peg3 is 8-amino-3,6-dioxaoctanoyl group</s223></s220><s220><s221>MOD_RES</s221><s222>(33)..(33)</s222><s223>Hydroxyl</s223></s220></s200><s400> 230His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Gln His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>231</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Hydrogen</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is K([17-Carboxy-heptadecanoyl]-isoGlu-KEK-      Peg3), where Peg3 is 8-amino-3,6-dioxaoctanoyl group</s223></s220><s220><s221>MOD_RES</s221><s222>(33)..(33)</s222><s223>Hydroxyl</s223></s220></s200><s400> 231His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>232</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Hydrogen</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is K([19-Carboxy-nonadecanoyl]-isoGlu-KEK-      Peg3), where Peg3 is 8-amino-3,6-dioxaoctanoyl group</s223></s220><s220><s221>MOD_RES</s221><s222>(33)..(33)</s222><s223>Hydroxyl</s223></s220></s200><s400> 232His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>233</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Hydrogen</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is K([19-Carboxy-nonadecanoyl]-isoGlu-KEK)</s223></s220><s220><s221>MOD_RES</s221><s222>(33)..(33)</s222><s223>Hydroxyl</s223></s220></s200><s400> 233His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Gln His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>234</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Hydrogen</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is K([19-Carboxy-nonadecanoyl]-isoGlu-KEK-      Peg3), where Peg3 is 8-amino-3,6-dioxaoctanoyl group</s223></s220><s220><s221>MOD_RES</s221><s222>(33)..(33)</s222><s223>Hydroxyl</s223></s220></s200><s400> 234His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Gln His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>235</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Hydrogen</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(10)..(10)</s222><s223>Xaa is K([19-Carboxy-nonadecanoyl]-isoGlu-KEK-      Peg3), where Peg3 is 8-amino-3,6-dioxaoctanoyl group</s223></s220><s220><s221>MOD_RES</s221><s222>(33)..(33)</s222><s223>Hydroxyl</s223></s220></s200><s400> 235His Xaa Glu Gly Ser Phe Thr Ser Glu Xaa Ala Thr Ile Leu Asp Glu1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>236</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Hydrogen</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(10)..(10)</s222><s223>Xaa is K([19-Carboxy-nonadecanoyl]-isoGlu-KEK-      Peg3), where Peg3 is 8-amino-3,6-dioxaoctanoyl group</s223></s220><s220><s221>MOD_RES</s221><s222>(33)..(33)</s222><s223>Hydroxyl</s223></s220></s200><s400> 236His Xaa Glu Gly Thr Phe Thr Ser Glu Xaa Ala Thr Ile Leu Asp Glu1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>237</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Hydrogen</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(10)..(10)</s222><s223>Xaa is K([19-carboxy-nonadecanoyl]iso-Glu-KEK-      Peg3-Peg3), where Peg3 is 8-amino-3,6-dioxaoctanoyl group</s223></s220><s220><s221>MOD_RES</s221><s222>(33)..(33)</s222><s223>Hydroxyl</s223></s220></s200><s400> 237His Xaa Glu Gly Ser Phe Thr Ser Glu Xaa Ala Thr Ile Leu Asp Glu1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>238</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Hydrogen</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is K([19-Carboxy-nonadecanoyl]-isoGlu-KEK-      Peg3), where Peg3 is 8-amino-3,6-dioxaoctanoyl group</s223></s220><s220><s221>MOD_RES</s221><s222>(33)..(33)</s222><s223>Hydroxyl</s223></s220></s200><s400> 238His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>239</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Hydrogen</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is K([19-Carboxy-nonadecanoyl]-isoGlu-KEK-      Peg3), where Peg3 is 8-amino-3,6-dioxaoctanoyl group</s223></s220><s220><s221>MOD_RES</s221><s222>(33)..(33)</s222><s223>Hydroxyl</s223></s220></s200><s400> 239His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>240</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Hydrogen</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is K([19-Carboxy-nonadecanoyl]-isoGlu-KEK-      Peg3), where Peg3 is 8-amino-3,6-dioxaoctanoyl group</s223></s220><s220><s221>MOD_RES</s221><s222>(33)..(33)</s222><s223>Hydroxyl</s223></s220></s200><s400> 240His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Ala His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>241</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Hydrogen</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is K([19-Carboxy-nonadecanoyl]-isoGlu-KEK-      Peg3), where Peg3 is 8-amino-3,6-dioxaoctanoyl group</s223></s220><s220><s221>MOD_RES</s221><s222>(33)..(33)</s222><s223>Hydroxyl</s223></s220></s200><s400> 241His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Lys Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>242</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Hydrogen</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is K([19-carboxy-nonadecanoyl]iso-Glu-KEK-      Peg3-Peg3), where Peg3 is 8-amino-3,6-dioxaoctanoyl group</s223></s220><s220><s221>MOD_RES</s221><s222>(33)..(33)</s222><s223>Hydroxyl</s223></s220></s200><s400> 242His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>243</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Hydrogen</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(17)..(17)</s222><s223>Xaa is K([19-Carboxy-nonadecanoyl]-isoGlu-KEK-      Peg3), where Peg3 is 8-amino-3,6-dioxaoctanoyl group</s223></s220><s220><s221>MOD_RES</s221><s222>(33)..(33)</s222><s223>Hydroxyl</s223></s220></s200><s400> 243His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Glu Gly1               5                   10                  15Xaa Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>244</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Hydrogen</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(17)..(17)</s222><s223>Xaa is K([19-Carboxy-nonadecanoyl]-isoGlu-KEK-      Peg3), where Peg3 is 8-amino-3,6-dioxaoctanoyl group</s223></s220><s220><s221>MOD_RES</s221><s222>(33)..(33)</s222><s223>Hydroxyl</s223></s220></s200><s400> 244His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Ala1               5                   10                  15Xaa Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>245</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Hydrogen</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(17)..(17)</s222><s223>Xaa is K([19-carboxy-nonadecanoyl]iso-Glu-KEK-      Peg3-Peg3), where Peg3 is 8-amino-3,6-dioxaoctanoyl group</s223></s220><s220><s221>MOD_RES</s221><s222>(33)..(33)</s222><s223>Hydroxyl</s223></s220></s200><s400> 245His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Ala1               5                   10                  15Xaa Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>246</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Hydrogen</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(20)..(20)</s222><s223>Xaa is K([19-Carboxy-nonadecanoyl]-isoGlu-KEK-      Peg3), where Peg3 is 8-amino-3,6-dioxaoctanoyl group</s223></s220><s220><s221>MOD_RES</s221><s222>(33)..(33)</s222><s223>Hydroxyl</s223></s220></s200><s400> 246His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Glu1               5                   10                  15Gln Ala Ala Xaa Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>247</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Hydrogen</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(20)..(20)</s222><s223>Xaa is K([19-Carboxy-nonadecanoyl]-isoGlu-KEK-      Peg3), where Peg3 is 8-amino-3,6-dioxaoctanoyl group</s223></s220><s220><s221>MOD_RES</s221><s222>(33)..(33)</s222><s223>Hydroxyl</s223></s220></s200><s400> 247His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Glu1               5                   10                  15Gln Ala Ala Xaa Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>248</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Hydrogen</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(20)..(20)</s222><s223>Xaa is K([19-carboxy-nonadecanoyl]iso-Glu-KEK-      Peg3-Peg3), where Peg3 is 8-amino-3,6-dioxaoctanoyl group</s223></s220><s220><s221>MOD_RES</s221><s222>(33)..(33)</s222><s223>Hydroxyl</s223></s220></s200><s400> 248His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Glu1               5                   10                  15Gln Ala Ala Xaa Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>249</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Hydrogen</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(20)..(20)</s222><s223>Xaa is K([19-carboxy-nonadecanoyl]iso-Glu-KEK-      Peg3-Peg3), where Peg3 is 8-amino-3,6-dioxaoctanoyl group</s223></s220><s220><s221>MOD_RES</s221><s222>(33)..(33)</s222><s223>Hydroxyl</s223></s220></s200><s400> 249His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Glu1               5                   10                  15Gln Ala Ala Xaa Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>250</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Hydrogen</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(20)..(20)</s222></s220><s220><s221>MOD_RES</s221><s222>(33)..(33)</s222><s223>Hydroxyl</s223></s220></s200><s400> 250His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Ala1               5                   10                  15Lys Ala Ala Xaa Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>251</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Hexadecanoyl</s223></s220></s200><s400> 251Lys Glu Lys1</s400><s200><s210>252</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Octadecanoyl</s223></s220></s200><s400> 252Lys Glu Lys1</s400><s200><s210>253</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Eicosanoyl</s223></s220></s200><s400> 253Lys Glu Lys1</s400><s200><s210>254</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Tetradecanoyl</s223></s220></s200><s400> 254Lys Glu Lys1</s400><s200><s210>255</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Dodecanoyl</s223></s220></s200><s400> 255Lys Glu Lys1</s400><s200><s210>256</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Dodecanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3, where Peg3 is 8-amino-3,6-dioxaoctanoyl      group</s223></s220></s200><s400> 256Lys Glu Lys1</s400><s200><s210>257</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Tetradecanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3, where Peg3 is 8-amino-3,6-dioxaoctanoyl      group</s223></s220></s200><s400> 257Lys Glu Lys1</s400><s200><s210>258</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Hexadecanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3, where Peg3 is 8-amino-3,6-dioxaoctanoyl      group</s223></s220></s200><s400> 258Lys Glu Lys1</s400><s200><s210>259</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Octadecanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3, where Peg3 is 8-amino-3,6-dioxaoctanoyl      group</s223></s220></s200><s400> 259Lys Glu Lys1</s400><s200><s210>260</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Eicosanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3, where Peg3 is 8-amino-3,6-dioxaoctanoyl      group</s223></s220></s200><s400> 260Lys Glu Lys1</s400><s200><s210>261</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Dodecanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3, where Peg3 is      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 261Lys Glu Lys1</s400><s200><s210>262</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Tetradecanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3, where Peg3 is 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 262Lys Glu Lys1</s400><s200><s210>263</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Hexadecanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3, where Peg3 is 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 263Lys Glu Lys1</s400><s200><s210>264</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Octadecanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3, where Peg3 is 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 264Lys Glu Lys1</s400><s200><s210>265</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Eicosanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3, where Peg3 is 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 265Lys Glu Lys1</s400><s200><s210>266</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Dodecanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3-Peg3, where Peg3 is 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 266Lys Glu Lys1</s400><s200><s210>267</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Tetradecanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3-Peg3, where Peg3 is 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 267Lys Glu Lys1</s400><s200><s210>268</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Hexadecanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3-Peg3, where Peg3 is 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 268Lys Glu Lys1</s400><s200><s210>269</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Octadecanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3-Peg3, where Peg3 is 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 269Lys Glu Lys1</s400><s200><s210>270</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Eicosanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3-Peg3, where Peg3 is 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 270Lys Glu Lys1</s400><s200><s210>271</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[Dodecanoyl]-isoGlu</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3, where Peg3 is 8-amino-3,6-dioxaoctanoyl      group</s223></s220></s200><s400> 271Lys Glu Lys1</s400><s200><s210>272</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[Tetradecanoyl]-isoGlu</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3, where Peg3 is 8-amino-3,6-dioxaoctanoyl      group</s223></s220></s200><s400> 272Lys Glu Lys1</s400><s200><s210>273</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Contruct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[Hexadecanoyl]-isoGlu</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3, where Peg3 is 8-amino-3,6-dioxaoctanoyl      group</s223></s220></s200><s400> 273Lys Glu Lys1</s400><s200><s210>274</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[Octadecanoyl]-isoGlu</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3, where Peg3 is 8-amino-3,6-dioxaoctanoyl      group</s223></s220></s200><s400> 274Lys Glu Lys1</s400><s200><s210>275</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Costruct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[Eicosanoyl]-isoGlu</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3, where Peg3 is 8-amino-3,6-dioxaoctanoyl      group</s223></s220></s200><s400> 275Lys Glu Lys1</s400><s200><s210>276</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[Dodecanoyl]-[4-aminobutanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3, where Peg3 is 8-amino-3,6-dioxaoctanoyl      group</s223></s220></s200><s400> 276Lys Glu Lys1</s400><s200><s210>277</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[Tetradecanoyl]-[4-aminobutanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3, where Peg3 is 8-amino-3,6-dioxaoctanoyl      group</s223></s220></s200><s400> 277Lys Glu Lys1</s400><s200><s210>278</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[Hexadecanoyl]-[4-aminobutanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3, where Peg3 is 8-amino-3,6-dioxaoctanoyl      group</s223></s220></s200><s400> 278Lys Glu Lys1</s400><s200><s210>279</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[Octadecanoyl]-[4-aminobutanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3, where Peg3 is 8-amino-3,6-dioxaoctanoyl      group</s223></s220></s200><s400> 279Lys Glu Lys1</s400><s200><s210>280</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[Eicosanoyl]-[4-aminobutanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3, where Peg3 is 8-amino-3,6-dioxaoctanoyl      group</s223></s220></s200><s400> 280Lys Glu Lys1</s400><s200><s210>281</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[Dodecanoyl]-isoLys</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3, where Peg3 is 8-amino-3,6-dioxaoctanoyl      group</s223></s220></s200><s400> 281Lys Glu Lys1</s400><s200><s210>282</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[Tetradecanoyl]-isoLys</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3, where Peg3 is 8-amino-3,6-dioxaoctanoyl      group</s223></s220></s200><s400> 282Lys Glu Lys1</s400><s200><s210>283</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[Hexadecanoyl]-isoLys</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3, where Peg3 is 8-amino-3,6-dioxaoctanoyl      group</s223></s220></s200><s400> 283Lys Glu Lys1</s400><s200><s210>284</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[Octadecanoyl]-isoLys</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3, where Peg3 is 8-amino-3,6-dioxaoctanoyl      group</s223></s220></s200><s400> 284Lys Glu Lys1</s400><s200><s210>285</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[Eicosanoyl]-isoLys</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3, where Peg3 is 8-amino-3,6-dioxaoctanoyl      group</s223></s220></s200><s400> 285Lys Glu Lys1</s400><s200><s210>286</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[Dodecanoyl]-Ala</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3, where Peg3 is 8-amino-3,6-dioxaoctanoyl      group</s223></s220></s200><s400> 286Lys Glu Lys1</s400><s200><s210>287</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[Tetradecanoyl]-Ala</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3, where Peg3 is 8-amino-3,6-dioxaoctanoyl      group</s223></s220></s200><s400> 287Lys Glu Lys1</s400><s200><s210>288</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[Hexadecanoyl]-Ala</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3, where Peg3 is 8-amino-3,6-dioxaoctanoyl      group</s223></s220></s200><s400> 288Lys Glu Lys1</s400><s200><s210>289</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[Octadecanoyl]-Ala</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3, where Peg3 is 8-amino-3,6-dioxaoctanoyl      group</s223></s220></s200><s400> 289Lys Glu Lys1</s400><s200><s210>290</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[Eicosanoyl]-Ala</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3, where Peg3 is 8-amino-3,6-dioxaoctanoyl      group</s223></s220></s200><s400> 290Lys Glu Lys1</s400><s200><s210>291</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[Dodecanoyl]-isoGlu</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3, where Peg3 is 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 291Lys Glu Lys1</s400><s200><s210>292</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[Tetradecanoyl]-isoGlu</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3, where Peg3 is 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 292Lys Glu Lys1</s400><s200><s210>293</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[Hexadecanoyl]-isoGlu</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3, where Peg3 is 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 293Lys Glu Lys1</s400><s200><s210>294</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[Octadecanoyl]-isoGlu</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3, where Peg3 is 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 294Lys Glu Lys1</s400><s200><s210>295</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[Eicosanoyl]-isoGlu</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3, where Peg3 is 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 295Lys Glu Lys1</s400><s200><s210>296</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[Dodecanoyl]-betaAla, where betaAla is      3-Aminopropanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3, where Peg3 is 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 296Lys Glu Lys1</s400><s200><s210>297</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[Tetradecanoyl]-betaAla, where betaAla is      3-Aminopropanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3, where Peg3 is 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 297Lys Glu Lys1</s400><s200><s210>298</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[Hexadecanoyl]-betaAla, where betaAla is      3-Aminopropanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3, where Peg3 is 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 298Lys Glu Lys1</s400><s200><s210>299</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[Octadecanoyl]-betaAla, where betaAla is      3-Aminopropanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3, where Peg3 is 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 299Lys Glu Lys1</s400><s200><s210>300</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[Eicosanoyl]-betaAla, where betaAla is      3-Aminopropanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3, where Peg3 is 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 300Lys Glu Lys1</s400><s200><s210>301</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[Dodecanoyl]-isoLys</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3, where Peg3 is 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 301Lys Glu Lys1</s400><s200><s210>302</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[Tetradecanoyl]-isoLys</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3, where Peg3 is 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 302Lys Glu Lys1</s400><s200><s210>303</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[Hexadecanoyl]-isoLys</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3, where Peg3 is 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 303Lys Glu Lys1</s400><s200><s210>304</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[Octadecanoyl]-isoLys</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3, where Peg3 is 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 304Lys Glu Lys1</s400><s200><s210>305</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[Eicosanoyl]-isoLys</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3, where Peg3 is 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 305Lys Glu Lys1</s400><s200><s210>306</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[Dodecanoyl]-[4-aminobutanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3, where Peg3 is 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 306Lys Glu Lys1</s400><s200><s210>307</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[Tetradecanoyl]-[4-aminobutanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3, where Peg3 is 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 307Lys Glu Lys1</s400><s200><s210>308</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[Hexadecanoyl]-[4-aminobutanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3, where Peg3 is 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 308Lys Glu Lys1</s400><s200><s210>309</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[Octadecanoyl]-[4-aminobutanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3, where Peg3 is 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 309Lys Glu Lys1</s400><s200><s210>310</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[Eicosanoyl]-[4-aminobutanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3, where Peg3 is 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 310Lys Glu Lys1</s400><s200><s210>311</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[Dodecanoyl]-isoGlu</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3-Peg3, where Peg3 is 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 311Lys Glu Lys1</s400><s200><s210>312</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[Tetradecanoyl]-isoGlu</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3-Peg3, where Peg3 is 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 312Lys Glu Lys1</s400><s200><s210>313</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[Hexadecanoyl]-isoGlu</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3-Peg3, where Peg3 is 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 313Lys Glu Lys1</s400><s200><s210>314</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[Octadecanoyl]-isoGlu</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3-Peg3, where Peg3 is 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 314Lys Glu Lys1</s400><s200><s210>315</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[Eicosanoyl]-isoGlu</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3-Peg3, where Peg3 is 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 315Lys Glu Lys1</s400><s200><s210>316</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[Dodecanoyl]-betaAla, where betaAla is      3-Aminopropanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3-Peg3, where Peg3 is 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 316Lys Glu Lys1</s400><s200><s210>317</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[Tetradecanoyl]-betaAla, where betaAla is      3-Aminopropanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3-Peg3, where Peg3 is 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 317Lys Glu Lys1</s400><s200><s210>318</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[Hexadecanoyl]-betaAla, where betaAla is      3-Aminopropanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3-Peg3, where Peg3 is 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 318Lys Glu Lys1</s400><s200><s210>319</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[Octadecanoyl]-betaAla, where betaAla is      3-Aminopropanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3-Peg3, where Peg3 is 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 319Lys Glu Lys1</s400><s200><s210>320</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[Eicosanoyl]-betaAla, where betaAla is      3-Aminopropanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3-Peg3, where Peg3 is 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 320Lys Glu Lys1</s400><s200><s210>321</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[Dodecanoyl]-isoLys</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3-Peg3, where Peg3 is 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 321Lys Glu Lys1</s400><s200><s210>322</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[Tetradecanoyl]-isoLys</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3-Peg3, where Peg3 is 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 322Lys Glu Lys1</s400><s200><s210>323</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[Hexadecanoyl]-isoLys</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3-Peg3, where Peg3 is 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 323Lys Glu Lys1</s400><s200><s210>324</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[Octadecanoyl]-isoLys</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3-Peg3, where Peg3 is 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 324Lys Glu Lys1</s400><s200><s210>325</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[Eicosanoyl]-isoLys</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3-Peg3, where Peg3 is 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 325Lys Glu Lys1</s400><s200><s210>326</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[Dodecanoyl]-[4-aminobutanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3-Peg3, where Peg3 is 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 326Lys Glu Lys1</s400><s200><s210>327</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[Tetradecanoyl]-[4-aminobutanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3-Peg3, where Peg3 is 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 327Lys Glu Lys1</s400><s200><s210>328</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[Hexadecanoyl]-[4-aminobutanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3-Peg3, where Peg3 is 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 328Lys Glu Lys1</s400><s200><s210>329</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[Octadecanoyl]-[4-aminobutanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3-Peg3, where Peg3 is 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 329Lys Glu Lys1</s400><s200><s210>330</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[Eicosanoyl]-[4-aminobutanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3-Peg3, wherein Peg-3 is an an 8-amino-      3,6-dioxaoctanoyl group</s223></s220></s200><s400> 330Lys Glu Lys1</s400><s200><s210>331</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Dodecanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>isoGlu-Peg3, wherein Peg-3 is an an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 331Lys Glu Lys1</s400><s200><s210>332</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Tetradecanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>isoGlu-Peg3, wherein Peg-3 is an an 8-amino-      3,6-dioxaoctanoyl group</s223></s220></s200><s400> 332Lys Glu Lys1</s400><s200><s210>333</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Hexadecanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>isoGlu-Peg3, wherein Peg-3 is an an 8-amino-      3,6-dioxaoctanoyl group</s223></s220></s200><s400> 333Lys Glu Lys1</s400><s200><s210>334</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Octadecanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>isoGlu-Peg3, wherein Peg-3 is an an 8-amino-      3,6-dioxaoctanoyl group</s223></s220></s200><s400> 334Lys Glu Lys1</s400><s200><s210>335</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Eicosanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>isoGlu-Peg3, wherein Peg-3 is an an 8-amino-      3,6-dioxaoctanoyl group</s223></s220></s200><s400> 335Lys Glu Lys1</s400><s200><s210>336</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Dodecanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>betaAla-Peg3, wherein betaAla is      3-Aminopropanoyl and Peg-3 is an an 8-amino-3,6-dioxaoctanoyl      group</s223></s220></s200><s400> 336Lys Glu Lys1</s400><s200><s210>337</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Tetradecanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>betaAla-Peg3, wherein betaAla is      3-Aminopropanoyl and Peg-3 is an an 8-amino-3,6-dioxaoctanoyl      group</s223></s220></s200><s400> 337Lys Glu Lys1</s400><s200><s210>338</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Hexadecanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>betaAla-Peg3, wherein betaAla is      3-Aminopropanoyl and Peg-3 is an an 8-amino-3,6-dioxaoctanoyl      group</s223></s220></s200><s400> 338Lys Glu Lys1</s400><s200><s210>339</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Octadecanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>betaAla-Peg3, wherein betaAla is      3-Aminopropanoyl and Peg-3 is an an 8-amino-3,6-dioxaoctanoyl      group</s223></s220></s200><s400> 339Lys Glu Lys1</s400><s200><s210>340</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Eicosanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>betaAla-Peg3, wherein betaAla is      3-Aminopropanoyl and Peg-3 is an an 8-amino-3,6-dioxaoctanoyl      group</s223></s220></s200><s400> 340Lys Glu Lys1</s400><s200><s210>341</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Dodecanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>[4-aminobutanoyl]-Peg3, wherein Peg-3 is an an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 341Lys Glu Lys1</s400><s200><s210>342</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Tetradecanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>[4-aminobutanoyl]-Peg3, wherein Peg-3 is an an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 342Lys Glu Lys1</s400><s200><s210>343</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Hexadecanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>[4-aminobutanoyl]-Peg3, wherein Peg-3 is an an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 343Lys Glu Lys1</s400><s200><s210>344</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Octadecanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>[4-aminobutanoyl]-Peg3, wherein Peg-3 is an an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 344Lys Glu Lys1</s400><s200><s210>345</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Eicosanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>[4-aminobutanoyl]-Peg3, wherein Peg-3 is an an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 345Lys Glu Lys1</s400><s200><s210>346</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Dodecanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>isoLys-Peg3, wherein Peg-3 is an an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 346Lys Glu Lys1</s400><s200><s210>347</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Tetradecanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>isoLys-Peg3, wherein Peg-3 is an an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 347Lys Glu Lys1</s400><s200><s210>348</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Hexadecanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>isoLys-Peg3, wherein Peg-3 is an an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 348Lys Glu Lys1</s400><s200><s210>349</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Octadecanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>isoLys-Peg3, wherein Peg3 is an 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 349Lys Glu Lys1</s400><s200><s210>350</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Eicosanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>isoLys-Peg3, wherein Peg3 is an 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 350Lys Glu Lys1</s400><s200><s210>351</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Dodecanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>isoGlu-Peg3-Peg3, wherein Peg3 is an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 351Lys Glu Lys1</s400><s200><s210>352</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Tetradecanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>isoGlu-Peg3-Peg3, wherein Peg3 is an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 352Lys Glu Lys1</s400><s200><s210>353</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Hexadecanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>isoGlu-Peg3-Peg3, wherein Peg3 is an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 353Lys Glu Lys1</s400><s200><s210>354</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Octadecanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>isoGlu-Peg3-Peg3, wherein Peg3 is an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 354Lys Glu Lys1</s400><s200><s210>355</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Eicosanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>isoGlu-Peg3-Peg3, wherein Peg3 is an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 355Lys Glu Lys1</s400><s200><s210>356</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Dodecanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>BetaAla-Peg3-Peg3, wherein betaAla is      3-Aminopropanoyl and Peg3 is an 8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 356Lys Glu Lys1</s400><s200><s210>357</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Tetradecanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>betaAla-Peg3-Peg3, wherein betaAla is      3-Aminopropanoyl and Peg3 is an 8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 357Lys Glu Lys1</s400><s200><s210>358</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Hexadecanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>betaAla-Peg3-Peg3, wherein betaAla is      3-Aminopropanoyl and Peg3 is an 8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 358Lys Glu Lys1</s400><s200><s210>359</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Octadecanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>betaAla-Peg3-Peg3, wherein betaAla is      3-Aminopropanoyl and Peg3 is an 8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 359Lys Glu Lys1</s400><s200><s210>360</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[Eicosanoyl]-betaAla, wherein betaAla is      3-Aminopropanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3, wherein Peg3 is an 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 360Lys Glu Lys1</s400><s200><s210>361</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Dodecanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>[4-aminobutanoyl]-Peg3-Peg3, wherein Peg3 is an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 361Lys Glu Lys1</s400><s200><s210>362</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Tetradecanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>[4-aminobutanoyl]-Peg3-Peg3, wherein Peg3 is an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 362Lys Glu Lys1</s400><s200><s210>363</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Hexadecanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>[4-aminobutanoyl]-Peg3-Peg3, wherein Peg3 is an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 363Lys Glu Lys1</s400><s200><s210>364</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Octadecanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>[4-aminobutanoyl]-Peg3-Peg3, wherein Peg3 is an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 364Lys Glu Lys1</s400><s200><s210>365</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Eicosanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>[4-aminobutanoyl]-Peg3-Peg3, wherein Peg3 is an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 365Lys Glu Lys1</s400><s200><s210>366</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Dodecanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>isoLys-Peg3-Peg3, wherein Peg3 is an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 366Lys Glu Lys1</s400><s200><s210>367</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Tetradecanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>isoLys-Peg3-Peg3, wherein Peg3 is an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 367Lys Glu Lys1</s400><s200><s210>368</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Hexadecanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>isoLys-Peg3-Peg3, wherein Peg3 is an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 368Lys Glu Lys1</s400><s200><s210>369</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Octadecanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>isoLys-Peg3-Peg3, wherein Peg3 is an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 369Lys Glu Lys1</s400><s200><s210>370</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Eicosanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>isoLys-Peg3-Peg3, wherein Peg3 is an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 370Lys Glu Lys1</s400><s200><s210>371</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Dodecanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>isoGlu-Peg3-Peg3-Peg3, wherein Peg3 is an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 371Lys Glu Lys1</s400><s200><s210>372</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Tetradecanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>isoGlu-Peg3-Peg3-Peg3, wherein Peg3 is an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 372Lys Glu Lys1</s400><s200><s210>373</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Hexadecanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>isoGlu-Peg3-Peg3-Peg3, wherein Peg3 is an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 373Lys Glu Lys1</s400><s200><s210>374</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Octadecanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>isoGlu-Peg3-Peg3-Peg3, wherein Peg3 is an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 374Lys Glu Lys1</s400><s200><s210>375</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Eicosanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>isoGlu-Peg3-Peg3-Peg3, wherein Peg3 is an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 375Lys Glu Lys1</s400><s200><s210>376</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Dodecanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>betaAla-Peg3-Peg3-Peg3, wherein betaAla is      3-Aminopropanoyl and Peg3 is an 8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 376Lys Glu Lys1</s400><s200><s210>377</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Tetradecanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>betaAla-Peg3-Peg3-Peg3, wherein betaAla is      3-Aminopropanoyl and Peg3 is an 8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 377Lys Glu Lys1</s400><s200><s210>378</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[Hexadecanoyl]-betaAla, wherein betaAla is      3-Aminopropanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3-Peg3, wherein Peg3 is an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 378Lys Glu Lys1</s400><s200><s210>379</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Octadecanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>betaAla-Peg3-Peg3-Peg3, wherein betaAla is      3-Aminopropanoyl and Peg3 is an 8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 379Lys Glu Lys1</s400><s200><s210>380</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Eicosanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>betaAla-Peg3-Peg3-Peg3, wherein betaAla is      3-Aminopropanoyl and Peg3 is an 8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 380Lys Glu Lys1</s400><s200><s210>381</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Dodecanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>[4-aminobutanoyl]-Peg3-Peg3-Peg3, wherein Peg3      is an 8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 381Lys Glu Lys1</s400><s200><s210>382</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Tetradecanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>[4-aminobutanoyl]-Peg3-Peg3-Peg3, wherein Peg3      is an 8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 382Lys Glu Lys1</s400><s200><s210>383</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Hexadecanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>[4-aminobutanoyl]-Peg3-Peg3-Peg3, wherein Peg3      is an 8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 383Lys Glu Lys1</s400><s200><s210>384</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Octadecanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>[4-aminobutanoyl]-Peg3-Peg3-Peg3, wherein Peg3      is an 8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 384Lys Glu Lys1</s400><s200><s210>385</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Eicosanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>[4-aminobutanoyl]-Peg3-Peg3-Peg3, wherein Peg3      is an 8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 385Lys Glu Lys1</s400><s200><s210>386</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Dodecanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>isoLys-Peg3-Peg3-Peg3, wherein Peg3 is an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 386Lys Glu Lys1</s400><s200><s210>387</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Tetradecanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>isoLys-Peg3-Peg3-Peg3, wherein Peg3 is an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 387Lys Glu Lys1</s400><s200><s210>388</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Hexadecanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>isoLys-Peg3-Peg3-Peg3, wherein Peg3 is an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 388Lys Glu Lys1</s400><s200><s210>389</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Octadecanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>isoLys-Peg3-Peg3-Peg3, wherein Peg3 is an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 389Lys Glu Lys1</s400><s200><s210>390</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Eicosanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>isoLys-Peg3-Peg3-Peg3, wherein Peg3 is an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 390Lys Glu Lys1</s400><s200><s210>391</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[17-carboxy-Heptadecanoyl]</s223></s220></s200><s400> 391Lys Glu Lys1</s400><s200><s210>392</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[19-carboxy-Nonadecanoyl]</s223></s220></s200><s400> 392Lys Glu Lys1</s400><s200><s210>393</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[21-carboxy-heneicosanoyl]</s223></s220></s200><s400> 393Lys Glu Lys1</s400><s200><s210>394</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[15-carboxy-Pentadecanoyl]</s223></s220></s200><s400> 394Lys Glu Lys1</s400><s200><s210>395</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[13-carboxy-tridecanoyl]</s223></s220></s200><s400> 395Lys Glu Lys1</s400><s200><s210>396</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[13-carboxy-tridecanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3, wherein Peg3 is an 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 396Lys Glu Lys1</s400><s200><s210>397</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[15-carboxy-Pentadecanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3, wherein Peg3 is an 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 397Lys Glu Lys1</s400><s200><s210>398</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[17-carboxy-Heptadecanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3, wherein Peg3 is an 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 398Lys Glu Lys1</s400><s200><s210>399</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[19-carboxy-Nonadecanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3, wherein Peg3 is an 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 399Lys Glu Lys1</s400><s200><s210>400</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[21-carboxy-heneicosanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3, wherein Peg3 is an 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 400Lys Glu Lys1</s400><s200><s210>401</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[13-carboxy-tridecanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3, wherein Peg3 is an 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 401Lys Glu Lys1</s400><s200><s210>402</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[15-carboxy-Pentadecanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3, wherein Peg3 is an 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 402Lys Glu Lys1</s400><s200><s210>403</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[17-carboxy-Heptadecanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3, wherein Peg3 is an 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 403Lys Glu Lys1</s400><s200><s210>404</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[19-carboxy-Nonadecanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3, wherein Peg3 is an 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 404Lys Glu Lys1</s400><s200><s210>405</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[21-carboxy-heneicosanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3, wherein Peg3 is an 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 405Lys Glu Lys1</s400><s200><s210>406</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[13-carboxy-tridecanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3-Peg3, wherein Peg3 is an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 406Lys Glu Lys1</s400><s200><s210>407</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[15-carboxy-Pentadecanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3-Peg3, wherein Peg3 is an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 407Lys Glu Lys1</s400><s200><s210>408</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[17-carboxy-Heptadecanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3-Peg3, wherein Peg3 is an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 408Lys Glu Lys1</s400><s200><s210>409</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[19-carboxy-Nonadecanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3-Peg3, wherein Peg3 is an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 409Lys Glu Lys1</s400><s200><s210>410</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[21-carboxy-heneicosanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3-Peg3, wherein Peg3 is an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 410Lys Glu Lys1</s400><s200><s210>411</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[13-carboxy-tridecanoyl]-isoGlu</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3, wherein Peg3 is an 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 411Lys Glu Lys1</s400><s200><s210>412</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[15-carboxy-Pentadecanoyl]-isoGlu</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3, wherein Peg3 is an 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 412Lys Glu Lys1</s400><s200><s210>413</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[17-carboxy-Heptadecanoyl]-isoGlu</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3, wherein Peg3 is an 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 413Lys Glu Lys1</s400><s200><s210>414</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[19-carboxy-Nonadecanoyl]-isoGlu</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3, wherein Peg3 is an 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 414Lys Glu Lys1</s400><s200><s210>415</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[21-carboxy-heneicosanoyl]-isoGlu</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3, wherein Peg3 is an 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 415Lys Glu Lys1</s400><s200><s210>416</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[13-carboxy-tridecanoyl]-[4-aminobutanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3, wherein Peg3 is an 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 416Lys Glu Lys1</s400><s200><s210>417</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[15-carboxy-Pentadecanoyl]-[4-aminobutanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3, wherein Peg3 is an 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 417Lys Glu Lys1</s400><s200><s210>418</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[17-carboxy-Heptadecanoyl]-[4-aminobutanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3, wherein Peg3 is an 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 418Lys Glu Lys1</s400><s200><s210>419</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[19-carboxy-Nonadecanoyl]-[4-aminobutanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3, wherein Peg3 is an 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 419Lys Glu Lys1</s400><s200><s210>420</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[21-carboxy-heneicosanoyl]-[4-aminobutanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3, wherein Peg3 is an 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 420Lys Glu Lys1</s400><s200><s210>421</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[13-carboxy-tridecanoyl]-isoLys</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3, wherein Peg3 is an 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 421Lys Glu Lys1</s400><s200><s210>422</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[15-carboxy-Pentadecanoyl]-isoLys</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3, wherein Peg3 is an 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 422Lys Glu Lys1</s400><s200><s210>423</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[17-carboxy-Heptadecanoyl]-isoLys</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3, wherein Peg3 is an 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 423Lys Glu Lys1</s400><s200><s210>424</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[19-carboxy-Nonadecanoyl]-isoLys</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3, wherein Peg3 is an 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 424Lys Glu Lys1</s400><s200><s210>425</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[21-carboxy-heneicosanoyl]-isoLys</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3, wherein Peg3 is an 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 425Lys Glu Lys1</s400><s200><s210>426</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[13-carboxy-tridecanoyl]-betaAla, wherein      betaAla is 3-Aminopropanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3, wherein Peg3 is an 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 426Lys Glu Lys1</s400><s200><s210>427</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[15-carboxy-Pentadecanoyl]-betaAla, wherein      betaAla is 3-Aminopropanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3, wherein Peg3 is an 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 427Lys Glu Lys1</s400><s200><s210>428</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[17-carboxy-Heptadecanoyl]-betaAla, wherein      betaAla is 3-Aminopropanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3, wherein Peg3 is an 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 428Lys Glu Lys1</s400><s200><s210>429</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[19-carboxy-Nonadecanoyl]-betaAla, wherein      betaAla is 3-Aminopropanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3, wherein Peg3 is an 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 429Lys Glu Lys1</s400><s200><s210>430</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[21-carboxy-heneicosanoyl]-betaAla, wherein      betaAla is 3-Aminopropanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3, wherein Peg3 is an 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 430Lys Glu Lys1</s400><s200><s210>431</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[13-carboxy-tridecanoyl]-isoGlu</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3, wherein Peg3 is an 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 431Lys Glu Lys1</s400><s200><s210>432</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[15-carboxy-Pentadecanoyl]-isoGlu</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3, wherein Peg3 is an 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 432Lys Glu Lys1</s400><s200><s210>433</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[17-carboxy-Heptadecanoyl]-isoGlu</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3, wherein Peg3 is an 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 433Lys Glu Lys1</s400><s200><s210>434</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[19-carboxy-Nonadecanoyl]-isoGlu</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3, wherein Peg3 is an 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 434Lys Glu Lys1</s400><s200><s210>435</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[21-carboxy-heneicosanoyl]-isoGlu</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3, wherein Peg3 is an 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 435Lys Glu Lys1</s400><s200><s210>436</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[13-carboxy-tridecanoyl]-betaAla, wherein      betaAla is 3-Aminopropanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3, wherein Peg3 is an 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 436Lys Glu Lys1</s400><s200><s210>437</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[15-carboxy-Pentadecanoyl]-betaAla, wherein      betaAla is 3-Aminopropanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3, wherein Peg3 is an 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 437Lys Glu Lys1</s400><s200><s210>438</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[17-carboxy-Heptadecanoyl]-betaAla, wherein      betaAla is 3-Aminopropanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3, wherein Peg3 is an 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 438Lys Glu Lys1</s400><s200><s210>439</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[19-carboxy-Nonadecanoyl]-betaAla, wherein      betaAla is 3-Aminopropanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3, wherein Peg3 is an 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 439Lys Glu Lys1</s400><s200><s210>440</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[21-carboxy-heneicosanoyl]-betaAla, wherein      betaAla is 3-Aminopropanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3, wherein Peg3 is an 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 440Lys Glu Lys1</s400><s200><s210>441</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[13-carboxy-tridecanoyl]-isoLys</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3, wherein Peg3 is an 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 441Lys Glu Lys1</s400><s200><s210>442</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[15-carboxy-Pentadecanoyl]-isoLys</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3, wherein Peg3 is an 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 442Lys Glu Lys1</s400><s200><s210>443</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[17-carboxy-Heptadecanoyl]-isoLys</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3, wherein Peg3 is an 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 443Lys Glu Lys1</s400><s200><s210>444</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[19-carboxy-Nonadecanoyl]-isoLys</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3, wherein Peg3 is an 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 444Lys Glu Lys1</s400><s200><s210>445</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[21-carboxy-heneicosanoyl]-isoLys</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3, wherein Peg3 is an 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 445Lys Glu Lys1</s400><s200><s210>446</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[13-carboxy-tridecanoyl]-[4-aminobutanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3, wherein Peg3 is an 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 446Lys Glu Lys1</s400><s200><s210>447</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[15-carboxy-Pentadecanoyl]-[4-aminobutanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3, wherein Peg3 is an 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 447Lys Glu Lys1</s400><s200><s210>448</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[17-carboxy-Heptadecanoyl]-[4-aminobutanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3, wherein Peg3 is an 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 448Lys Glu Lys1</s400><s200><s210>449</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[19-carboxy-Nonadecanoyl]-[4-aminobutanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3, wherein Peg3 is an 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 449Lys Glu Lys1</s400><s200><s210>450</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[21-carboxy-heneicosanoyl]-[4-aminobutanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3, wherein Peg3 is an 8-amino-3,6-      dioxaoctanoyl group</s223></s220></s200><s400> 450Lys Glu Lys1</s400><s200><s210>451</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[13-carboxy-tridecanoyl]-isoGlu</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3-Peg3, wherein Peg3 is an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 451Lys Glu Lys1</s400><s200><s210>452</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[15-carboxy-Pentadecanoyl]-isoGlu</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3-Peg3, wherein Peg3 is an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 452Lys Glu Lys1</s400><s200><s210>453</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[17-carboxy-Heptadecanoyl]-isoGlu</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3-Peg3, wherein Peg3 is an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 453Lys Glu Lys1</s400><s200><s210>454</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[19-carboxy-Nonadecanoyl]-isoGlu</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3-Peg3, wherein Peg3 is an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 454Lys Glu Lys1</s400><s200><s210>455</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[21-carboxy-heneicosanoyl]-isoGlu</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3-Peg3, wherein Peg3 is an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 455Lys Glu Lys1</s400><s200><s210>456</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[13-carboxy-tridecanoyl]-betaAla, wherein      betaAla is 3-Aminopropanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3-Peg3, wherein Peg3 is an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 456Lys Glu Lys1</s400><s200><s210>457</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[15-carboxy-Pentadecanoyl]-betaAla, wherein      betaAla is 3-Aminopropanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3-Peg3, wherein Peg3 is an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 457Lys Glu Lys1</s400><s200><s210>458</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[17-carboxy-Heptadecanoyl]-betaAla, wherein      betaAla is 3-Aminopropanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3-Peg3, wherein Peg3 is an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 458Lys Glu Lys1</s400><s200><s210>459</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[19-carboxy-Nonadecanoyl]-betaAla, wherein      betaAla is 3-Aminopropanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3-Peg3, wherein Peg3 is an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 459Lys Glu Lys1</s400><s200><s210>460</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[21-carboxy-heneicosanoyl]-betaAla, wherein      betaAla is 3-Aminopropanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3-Peg3, wherein Peg3 is an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 460Lys Glu Lys1</s400><s200><s210>461</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[13-carboxy-tridecanoyl]-isoLys</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3-Peg3, wherein Peg3 is an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 461Lys Glu Lys1</s400><s200><s210>462</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[15-carboxy-Pentadecanoyl]-isoLys</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3-Peg3, wherein Peg3 is an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 462Lys Glu Lys1</s400><s200><s210>463</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[17-carboxy-Heptadecanoyl]-isoLys</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3-Peg3, wherein Peg3 is an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 463Lys Glu Lys1</s400><s200><s210>464</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[19-carboxy-Nonadecanoyl]-isoLys</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3-Peg3, wherein Peg3 is an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 464Lys Glu Lys1</s400><s200><s210>465</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[21-carboxy-heneicosanoyl]-isoLys</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3-Peg3, wherein Peg3 is an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 465Lys Glu Lys1</s400><s200><s210>466</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[13-carboxy-tridecanoyl]-[4-aminobutanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3-Peg3, wherein Peg3 is an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 466Lys Glu Lys1</s400><s200><s210>467</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[15-carboxy-Pentadecanoyl]-[4-aminobutanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3-Peg3, wherein Peg3 is an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 467Lys Glu Lys1</s400><s200><s210>468</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[17-carboxy-Heptadecanoyl]-[4-aminobutanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3-Peg3, wherein Peg3 is an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 468Lys Glu Lys1</s400><s200><s210>469</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[19-carboxy-Nonadecanoyl]-[4-aminobutanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3-Peg3, wherein Peg3 is an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 469Lys Glu Lys1</s400><s200><s210>470</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[21-carboxy-heneicosanoyl]-[4-aminobutanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3-Peg3, wherein Peg3 is an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 470Lys Glu Lys1</s400><s200><s210>471</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[13-carboxy-tridecanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>isoGlu-Peg3, wherein Peg3 is an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 471Lys Glu Lys1</s400><s200><s210>472</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[15-carboxy-Pentadecanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>isoGlu-Peg3, wherein Peg3 is an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 472Lys Glu Lys1</s400><s200><s210>473</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[17-carboxy-Heptadecanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>isoGlu-Peg3, wherein Peg3 is an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 473Lys Glu Lys1</s400><s200><s210>474</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[19-carboxy-Nonadecanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>isoGlu-Peg3, wherein Peg3 is an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 474Lys Glu Lys1</s400><s200><s210>475</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[21-carboxy-heneicosanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>isoGlu-Peg3, wherein Peg3 is an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 475Lys Glu Lys1</s400><s200><s210>476</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[13-carboxy-tridecanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>betaAla-Peg3, wherein betaAla is      3-Aminopropanoyl and Peg3 is an 8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 476Lys Glu Lys1</s400><s200><s210>477</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[15-carboxy-Pentadecanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>betaAla-Peg3, wherein betaAla is      3-Aminopropanoyl and Peg3 is an 8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 477Lys Glu Lys1</s400><s200><s210>478</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[17-carboxy-Heptadecanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>betaAla-Peg3, wherein betaAla is      3-Aminopropanoyl and Peg3 is an 8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 478Lys Glu Lys1</s400><s200><s210>479</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[19-carboxy-Nonadecanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>betaAla-Peg3, wherein betaAla is      3-Aminopropanoyl and Peg3 is an 8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 479Lys Glu Lys1</s400><s200><s210>480</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[21-carboxy-heneicosanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>betaAla-Peg3, wherein betaAla is      3-Aminopropanoyl and Peg3 is an 8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 480Lys Glu Lys1</s400><s200><s210>481</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[13-carboxy-tridecanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>[4-aminobutanoyl]-Peg3, wherein Peg3 is an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 481Lys Glu Lys1</s400><s200><s210>482</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[15-carboxy-Pentadecanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>[4-aminobutanoyl]-Peg3, wherein Peg3 is an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 482Lys Glu Lys1</s400><s200><s210>483</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[17-carboxy-Heptadecanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>[4-aminobutanoyl]-Peg3, wherein Peg3 is an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 483Lys Glu Lys1</s400><s200><s210>484</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[19-carboxy-Nonadecanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>[4-aminobutanoyl]-Peg3, wherein Peg3 is an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 484Lys Glu Lys1</s400><s200><s210>485</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[21-carboxy-heneicosanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>[4-aminobutanoyl]-Peg3, wherein Peg3 is an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 485Lys Glu Lys1</s400><s200><s210>486</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[13-carboxy-tridecanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>isoLys-Peg3, wherein Peg3 is an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 486Lys Glu Lys1</s400><s200><s210>487</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[15-carboxy-Pentadecanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>isoLys-Peg3, wherein Peg3 is an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 487Lys Glu Lys1</s400><s200><s210>488</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[17-carboxy-Heptadecanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>isoLys-Peg3, wherein Peg3 is an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 488Lys Glu Lys1</s400><s200><s210>489</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[19-carboxy-Nonadecanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>isoLys-Peg3, wherein Peg3 is an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 489Lys Glu Lys1</s400><s200><s210>490</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[21-carboxy-heneicosanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>isoLys-Peg3,wherein Peg3 is an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 490Lys Glu Lys1</s400><s200><s210>491</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[13-carboxy-tridecanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>isoGlu-Peg3-Peg3, wherein Peg3 is an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 491Lys Glu Lys1</s400><s200><s210>492</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[15-carboxy-Pentadecanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>isoGlu-Peg3-Peg3, wherein Peg3 is an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 492Lys Glu Lys1</s400><s200><s210>493</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[17-carboxy-Heptadecanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>isoGlu-Peg3-Peg3, wherein Peg3 is an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 493Lys Glu Lys1</s400><s200><s210>494</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[19-carboxy-Nonadecanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>isoGlu-Peg3-Peg3, wherein Peg3 is an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 494Lys Glu Lys1</s400><s200><s210>495</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[21-carboxy-heneicosanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>isoGlu-Peg3-Peg3, wherein Peg3 is an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 495Lys Glu Lys1</s400><s200><s210>496</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[13-carboxy-tridecanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>betaAla-Peg3-Peg3, wherein betaAla is      3-Aminopropanoyl and Peg3 is an 8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 496Lys Glu Lys1</s400><s200><s210>497</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[15-carboxy-Pentadecanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>betaAla-Peg3-Peg3, wherein betaAla is      3-Aminopropanoyl and Peg3 is an 8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 497Lys Glu Lys1</s400><s200><s210>498</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[17-carboxy-Heptadecanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>betaAla-Peg3-Peg3, wherein betaAla is      3-Aminopropanoyl and Peg3 is an 8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 498Lys Glu Lys1</s400><s200><s210>499</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[19-carboxy-Nonadecanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>betaAla-Peg3-Peg3, wherein betaAla is      3-Aminopropanoyl and Peg3 is an 8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 499Lys Glu Lys1</s400><s200><s210>500</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[21-carboxy-heneicosanoyl]-betaAla, wherein      betaAla is 3-Aminopropanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3, wherein Peg3 is an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 500Lys Glu Lys1</s400><s200><s210>501</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[13-carboxy-tridecanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>[4-aminobutanoyl]-Peg3-Peg3, wherein Peg3 is an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 501Lys Glu Lys1</s400><s200><s210>502</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[15-carboxy-Pentadecanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>[4-aminobutanoyl]-Peg3-Peg3, wherein Peg3 is an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 502Lys Glu Lys1</s400><s200><s210>503</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[17-carboxy-Heptadecanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>[4-aminobutanoyl]-Peg3-Peg3, wherein Peg3 is an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 503Lys Glu Lys1</s400><s200><s210>504</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[19-carboxy-Nonadecanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>[4-aminobutanoyl]-Peg3-Peg3, wherein Peg3 is an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 504Lys Glu Lys1</s400><s200><s210>505</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[21-carboxy-heneicosanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>[4-aminobutanoyl]-Peg3-Peg3, wherein Peg3 is an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 505Lys Glu Lys1</s400><s200><s210>506</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[13-carboxy-tridecanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>isoLys-Peg3-Peg3, wherein Peg3 is an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 506Lys Glu Lys1</s400><s200><s210>507</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[15-carboxy-Pentadecanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>isoLys-Peg3-Peg3, wherein Peg3 is an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 507Lys Glu Lys1</s400><s200><s210>508</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[17-carboxy-Heptadecanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>isoLys-Peg3-Peg3, wherein Peg3 is an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 508Lys Glu Lys1</s400><s200><s210>509</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[19-carboxy-Nonadecanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>isoLys-Peg3-Peg3, wherein Peg3 is an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 509Lys Glu Lys1</s400><s200><s210>510</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[21-carboxy-heneicosanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>isoLys-Peg3-Peg3, wherein Peg3 is an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 510Lys Glu Lys1</s400><s200><s210>511</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[13-carboxy-tridecanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>isoGlu-Peg3-Peg3-Peg3, wherein Peg3 is an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 511Lys Glu Lys1</s400><s200><s210>512</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[15-carboxy-Pentadecanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>isoGlu-Peg3-Peg3-Peg3, wherein Peg3 is an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 512Lys Glu Lys1</s400><s200><s210>513</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[17-carboxy-Heptadecanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>isoGlu-Peg3-Peg3-Peg3, wherein Peg3 is an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 513Lys Glu Lys1</s400><s200><s210>514</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[19-carboxy-Nonadecanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>isoGlu-Peg3-Peg3-Peg3, wherein Peg3 is an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 514Lys Glu Lys1</s400><s200><s210>515</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[21-carboxy-heneicosanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>isoGlu-Peg3-Peg3-Peg3, wherein Peg3 is an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 515Lys Glu Lys1</s400><s200><s210>516</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[13-carboxy-tridecanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>betaAla-Peg3-Peg3-Peg3, wherein betaAla is      3-Aminopropanoyl and Peg3 is an 8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 516Lys Glu Lys1</s400><s200><s210>517</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[15-carboxy-Pentadecanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>betaAla-Peg3-Peg3-Peg3, wherein betaAla is      3-Aminopropanoyl and Peg3 is an 8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 517Lys Glu Lys1</s400><s200><s210>518</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[17-carboxy-Heptadecanoyl]-betaAla, wherein      betaAla is 3-Aminopropanoyl</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Peg3-Peg3-Peg3, wherein Peg3 is an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 518Lys Glu Lys1</s400><s200><s210>519</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[19-carboxy-Nonadecanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>betaAla-Peg3-Peg3-Peg3, wherein betaAla is      3-Aminopropanoyl and Peg3 is an 8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 519Lys Glu Lys1</s400><s200><s210>520</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[21-carboxy-heneicosanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>betaAla-Peg3-Peg3-Peg3, wherein betaAla is      3-Aminopropanoyl and Peg3 is an 8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 520Lys Glu Lys1</s400><s200><s210>521</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[13-carboxy-tridecanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>[4-aminobutanoyl]-Peg3-Peg3-Peg3, wherein Peg3      is an 8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 521Lys Glu Lys1</s400><s200><s210>522</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[15-carboxy-Pentadecanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>[4-aminobutanoyl]-Peg3-Peg3-Peg3, wherein Peg3      is an 8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 522Lys Glu Lys1</s400><s200><s210>523</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[17-carboxy-Heptadecanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>[4-aminobutanoyl]-Peg3-Peg3-Peg3, wherein Peg3      is an 8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 523Lys Glu Lys1</s400><s200><s210>524</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[19-carboxy-Nonadecanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>[4-aminobutanoyl]-Peg3-Peg3-Peg3, wherein Peg3      is an 8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 524Lys Glu Lys1</s400><s200><s210>525</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[21-carboxy-heneicosanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>[4-aminobutanoyl]-Peg3-Peg3-Peg3, wherein Peg3      is an 8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 525Lys Glu Lys1</s400><s200><s210>526</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[13-carboxy-tridecanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>isoLys-Peg3-Peg3-Peg3, wherein Peg3 is an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 526Lys Glu Lys1</s400><s200><s210>527</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[15-carboxy-Pentadecanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>isoLys-Peg3-Peg3-Peg3, wherein Peg3 is an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 527Lys Glu Lys1</s400><s200><s210>528</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[17-carboxy-Heptadecanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>isoLys-Peg3-Peg3-Peg3, wherein Peg3 is an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 528Lys Glu Lys1</s400><s200><s210>529</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[19-carboxy-Nonadecanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>isoLys-Peg3-Peg3-Peg3, wherein Peg3 is an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 529Lys Glu Lys1</s400><s200><s210>530</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[21-carboxy-heneicosanoyl]</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>isoLys-Peg3-Peg3-Peg3, wherein Peg3 is an      8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 530Lys Glu Lys1</s400><s200><s210>531</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[17-carboxy-Heptadecanoyl]-isoGlu</s223></s220></s200><s400> 531Lys Glu Lys1</s400><s200><s210>532</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[19-carboxy-Nonadecanoyl]-isoGlu</s223></s220></s200><s400> 532Lys Glu Lys1</s400><s200><s210>533</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[17-carboxy-Heptadecanoyl]-isoLys</s223></s220></s200><s400> 533Lys Glu Lys1</s400><s200><s210>534</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[19-carboxy-Nonadecanoyl]-isoLys</s223></s220></s200><s400> 534Lys Glu Lys1</s400><s200><s210>535</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct.</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[17-carboxy-Heptadecanoyl]-betaAla, wherein      betaAla is 3-Aminopropanoyl</s223></s220></s200><s400> 535Lys Glu Lys1</s400><s200><s210>536</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[19-carboxy-Nonadecanoyl]-betaAla, wherein      betaAla is 3-Aminopropanoyl</s223></s220></s200><s400> 536Lys Glu Lys1</s400><s200><s210>537</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[17-carboxy-Heptadecanoyl]-[4-aminobutanoyl]</s223></s220></s200><s400> 537Lys Glu Lys1</s400><s200><s210>538</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[19-carboxy-Nonadecanoyl]-[4-aminobutanoyl]</s223></s220></s200><s400> 538Lys Glu Lys1</s400><s200><s210>539</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Hydrogen</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)</s223></s220><s220><s221>MOD_RES</s221><s222>(16)..(16)</s222><s223>Hydroxyl</s223></s220></s200><s400> 539His Xaa Asp Gly Ser Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Gln His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>540</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic construct</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Hydrogen</s223></s220><s220><s221>MOD_RES</s221><s222>(2)..(2)</s222><s223>Aib</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(16)..(16)</s222><s223>Xaa is [K([17-carboxy-heptadecanoyl]-isoGlu)]</s223></s220><s220><s221>MOD_RES</s221><s222>(33)..(33)</s222><s223>Hydroxyl</s223></s220></s200><s400> 540His Xaa Glu Gly Ser Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Xaa1               5                   10                  15Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Gln His Lys Ile Thr            20                  25                  30Asp</s400><s200><s210>541</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>[19-carboxy-nonadecanoyl]-isoGlu</s223></s220></s200><s400> 541Lys Glu Lys1</s400><s200><s210>542</s210><s211>1</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(1)..(1)</s222><s223>Xaa is K([17-carboxy-heptadecanoyl]-isoGlu-      KEK-Peg3), where Peg3 is 8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 542Xaa1</s400><s200><s210>543</s210><s211>1</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(1)..(1)</s222><s223>Xaa is K([19-carboxy-nonadecanoyl]-isoGlu-KEK)</s223></s220></s200><s400> 543Xaa1</s400><s200><s210>544</s210><s211>1</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(1)..(1)</s222><s223>Xaa is K([19-carboxy-nonadecanoyl]-isoGlu-KEK-      Peg3), where Peg3 is 8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 544Xaa1</s400><s200><s210>545</s210><s211>1</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(1)..(1)</s222><s223>K([19-carboxy-nonadecanoyl]-isoGlu-KEK-Peg3-      Peg3), where Peg3 is 8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 545Xaa1</s400><s200><s210>546</s210><s211>15</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(2)..(2)</s222><s223>Xaa is Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(3)..(3)</s222><s223>Xaa is Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(4)..(4)</s222><s223>Xaa is Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(5)..(5)</s222><s223>Xaa is Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(6)..(6)</s222><s223>Xaa is Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(7)..(7)</s222><s223>Xaa is Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(8)..(8)</s222><s223>Xaa is Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(9)..(9)</s222><s223>Xaa is Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(10)..(10)</s222><s223>Xaa is Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(11)..(11)</s222><s223>Xaa is Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(12)..(12)</s222><s223>Xaa is Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(13)..(13)</s222><s223>Xaa is Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(14)..(14)</s222><s223>Xaa is Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(15)..(15)</s222><s223>Xaa is R, K or a residue of K, k (D-lys), R,      Orn, Dap or Dab in which the side chain is conjugated to a      substituent</s223></s220></s200><s400> 546Lys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa1               5                   10                  15</s400><s200><s210>547</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(2)..(2)</s222><s223>Xaa is Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(3)..(3)</s222><s223>Xaa is Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(4)..(4)</s222><s223>Xaa is Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(5)..(5)</s222><s223>Xaa is Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(6)..(6)</s222><s223>Xaa is Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(7)..(7)</s222><s223>Xaa is Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(8)..(8)</s222><s223>Xaa is Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(9)..(9)</s222><s223>Xaa is Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(10)..(10)</s222><s223>Xaa is R, K or a residue of K, k (D-lys), R,      Orn, Dap or Dab in which the side chain is conjugated to a      substituent</s223></s220></s200><s400> 547Lys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa1               5                   10</s400><s200><s210>548</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(2)..(2)</s222><s223>Xaa is Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(3)..(3)</s222><s223>Xaa is Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(4)..(4)</s222><s223>Xaa is Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(5)..(5)</s222><s223>Xaa is Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(6)..(6)</s222><s223>Xaa is Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(7)..(7)</s222><s223>Xaa is R, K or a residue of K, k (D-lys), R,      Orn, Dap or Dab in which the side chain is conjugated to a      substituent</s223></s220></s200><s400> 548Lys Xaa Xaa Xaa Xaa Xaa Xaa1               5</s400><s200><s210>549</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(3)..(3)</s222><s223>Xaa is R, K or a residue of K, k (D-lys), R,      Orn, Dap or Dab in which the side chain is conjugated to a      substituent</s223></s220></s200><s400> 549Lys Lys Xaa1</s400><s200><s210>550</s210><s211>4</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(4)..(4)</s222><s223>Xaa is R, K or a residue of K, k (D-lys), R,      Orn, Dap or Dab in which the side chain is conjugated to a      substituent</s223></s220></s200><s400> 550Lys Lys Lys Xaa1</s400><s200><s210>551</s210><s211>5</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(5)..(5)</s222><s223>Xaa is R, K or a residue of K, k (D-lys), R,      Orn, Dap or Dab in which the side chain is conjugated to a      substituent</s223></s220></s200><s400> 551Lys Lys Lys Lys Xaa1               5</s400><s200><s210>552</s210><s211>6</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(6)..(6)</s222><s223>Xaa is R, K or a residue of K, k (D-lys), R,      Orn, Dap or Dab in which the side chain is conjugated to a      substituent</s223></s220></s200><s400> 552Lys Lys Lys Lys Lys Xaa1               5</s400><s200><s210>553</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(7)..(7)</s222><s223>Xaa is R, K or a residue of K, k (D-lys), R,      Orn, Dap or Dab in which the side chain is conjugated to a      substituent</s223></s220></s200><s400> 553Lys Lys Lys Lys Lys Lys Xaa1               5</s400><s200><s210>554</s210><s211>15</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(1)..(1)</s222><s223>Xaa is D-Lys</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(2)..(2)</s222><s223>Xaa is D-Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(3)..(3)</s222><s223>Xaa is D-Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(4)..(4)</s222><s223>Xaa is D-Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(5)..(5)</s222><s223>Xaa is D-Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(6)..(6)</s222><s223>Xaa is D-Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(7)..(7)</s222><s223>Xaa is D-Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(8)..(8)</s222><s223>Xaa is D-Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(9)..(9)</s222><s223>Xaa is D-Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(10)..(10)</s222><s223>Xaa is D-Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(11)..(11)</s222><s223>Xaa is D-Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(12)..(12)</s222><s223>Xaa is D-Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(13)..(13)</s222><s223>Xaa is D-Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(14)..(14)</s222><s223>Xaa is D-Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(15)..(15)</s222><s223>Xaa is R, K or a residue of K, k (D-lys), R,      Orn, Dap or Dab in which the side chain is conjugated to a      substituent</s223></s220></s200><s400> 554Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa1               5                   10                  15</s400><s200><s210>555</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(1)..(1)</s222><s223>Xaa is D-Lys</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(2)..(2)</s222><s223>Xaa is D-Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(3)..(3)</s222><s223>Xaa is D-Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(4)..(4)</s222><s223>Xaa is D-Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(5)..(5)</s222><s223>Xaa is D-Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(6)..(6)</s222><s223>Xaa is D-Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(7)..(7)</s222><s223>Xaa is D-Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(8)..(8)</s222><s223>Xaa is D-Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(9)..(9)</s222><s223>Xaa is D-Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(10)..(10)</s222><s223>Xaa is R, K or a residue of K, k (D-lys), R,      Orn, Dap or Dab in which the side chain is conjugated to a      substituent</s223></s220></s200><s400> 555Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa1               5                   10</s400><s200><s210>556</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(1)..(1)</s222><s223>Xaa is D-lys</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(2)..(2)</s222><s223>Xaa is D-lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(3)..(3)</s222><s223>Xaa is D-lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(4)..(4)</s222><s223>Xaa is D-lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(5)..(5)</s222><s223>Xaa is D-lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(6)..(6)</s222><s223>Xaa is D-lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(7)..(7)</s222><s223>Xaa is R, K or a residue of K, k (D-lys), R,      Orn, Dap or Dab in which the side chain is conjugated to a      substituent</s223></s220></s200><s400> 556Xaa Xaa Xaa Xaa Xaa Xaa Xaa1               5</s400><s200><s210>557</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(1)..(2)</s222><s223>Xaa is D-Lys</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(3)..(3)</s222><s223>Xaa is R, K or a residue of K, k (D-lys), R,      Orn, Dap or Dab in which the side chain is conjugated to a      substituent</s223></s220></s200><s400> 557Xaa Xaa Xaa1</s400><s200><s210>558</s210><s211>4</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(1)..(3)</s222><s223>Xaa is D-Lys</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(4)..(4)</s222><s223>Xaa is R, K or a residue of K, k (D-lys), R,      Orn, Dap or Dab in which the side chain is conjugated to a      substituent</s223></s220></s200><s400> 558Xaa Xaa Xaa Xaa1</s400><s200><s210>559</s210><s211>5</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(1)..(4)</s222><s223>Xaa is D-Lys</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(5)..(5)</s222><s223>Xaa is R, K or a residue of K, k (D-lys), R,      Orn, Dap or Dab in which the side chain is conjugated to a      substituent</s223></s220></s200><s400> 559Xaa Xaa Xaa Xaa Xaa1               5</s400><s200><s210>560</s210><s211>6</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(1)..(5)</s222><s223>Xaa is D-Lys</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(6)..(6)</s222><s223>Xaa is R, K or a residue of K, k (D-lys), R,      Orn, Dap or Dab in which the side chain is conjugated to a      substituent</s223></s220></s200><s400> 560Xaa Xaa Xaa Xaa Xaa Xaa1               5</s400><s200><s210>561</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(1)..(6)</s222><s223>Xaa is D-Lys</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(7)..(7)</s222><s223>Xaa is R, K or a residue of K, k (D-lys), R,      Orn, Dap or Dab in which the side chain is conjugated to a      substituent</s223></s220></s200><s400> 561Xaa Xaa Xaa Xaa Xaa Xaa Xaa1               5</s400><s200><s210>562</s210><s211>15</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(2)..(2)</s222><s223>Xaa is Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(3)..(3)</s222><s223>Xaa is Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(4)..(4)</s222><s223>Xaa is Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(5)..(5)</s222><s223>Xaa is Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(6)..(6)</s222><s223>Xaa is Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(7)..(7)</s222><s223>Xaa is Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(8)..(8)</s222><s223>Xaa is Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(9)..(9)</s222><s223>Xaa is Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(10)..(10)</s222><s223>Xaa is Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(11)..(11)</s222><s223>Xaa is Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(12)..(12)</s222><s223>Xaa is Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(13)..(13)</s222><s223>Xaa is Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(14)..(14)</s222><s223>Xaa is Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(15)..(15)</s222><s223>Xaa is Lys or absent</s223></s220></s200><s400> 562Lys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa1               5                   10                  15</s400><s200><s210>563</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(2)..(2)</s222><s223>Xaa is Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(3)..(3)</s222><s223>Xaa is Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(4)..(4)</s222><s223>Xaa is Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(5)..(5)</s222><s223>Xaa is Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(6)..(6)</s222><s223>Xaa is Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(7)..(7)</s222><s223>Xaa is Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(8)..(8)</s222><s223>Xaa is Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(9)..(9)</s222><s223>Xaa is Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(10)..(10)</s222><s223>Xaa is Lys or absent</s223></s220></s200><s400> 563Lys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa1               5                   10</s400><s200><s210>564</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(2)..(2)</s222><s223>Xaa is Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(3)..(3)</s222><s223>Xaa is Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(4)..(4)</s222><s223>Xaa is Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(5)..(5)</s222><s223>Xaa is Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(6)..(6)</s222><s223>Xaa is Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(7)..(7)</s222><s223>Xaa is Lys or absent</s223></s220></s200><s400> 564Lys Xaa Xaa Xaa Xaa Xaa Xaa1               5</s400><s200><s210>565</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220></s200><s400> 565Lys Lys Lys1</s400><s200><s210>566</s210><s211>4</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220></s200><s400> 566Lys Lys Lys Lys1</s400><s200><s210>567</s210><s211>5</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220></s200><s400> 567Lys Lys Lys Lys Lys1               5</s400><s200><s210>568</s210><s211>6</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220></s200><s400> 568Lys Lys Lys Lys Lys Lys1               5</s400><s200><s210>569</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220></s200><s400> 569Lys Lys Lys Lys Lys Lys Lys1               5</s400><s200><s210>570</s210><s211>15</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(1)..(1)</s222><s223>Xaa is D-Lys</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(2)..(2)</s222><s223>Xaa is D-Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(3)..(3)</s222><s223>Xaa is D-Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(4)..(4)</s222><s223>Xaa is D-Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(5)..(5)</s222><s223>Xaa is D-Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(6)..(6)</s222><s223>Xaa is D-Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(7)..(7)</s222><s223>Xaa is D-Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(8)..(8)</s222><s223>Xaa is D-Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(9)..(9)</s222><s223>Xaa is D-Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(10)..(10)</s222><s223>Xaa is D-Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(11)..(11)</s222><s223>Xaa is D-Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(12)..(12)</s222><s223>Xaa is D-Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(13)..(13)</s222><s223>Xaa is D-Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(14)..(14)</s222><s223>Xaa is D-Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(15)..(15)</s222><s223>Xaa is D-Lys or absent</s223></s220></s200><s400> 570Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa1               5                   10                  15</s400><s200><s210>571</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(1)..(1)</s222><s223>Xaa is D-Lys</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(2)..(2)</s222><s223>Xaa is D-Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(3)..(3)</s222><s223>Xaa is D-Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(4)..(4)</s222><s223>Xaa is D-Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(5)..(5)</s222><s223>Xaa is D-Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(6)..(6)</s222><s223>Xaa is D-Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(7)..(7)</s222><s223>Xaa is D-Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(8)..(8)</s222><s223>Xaa is D-Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(9)..(9)</s222><s223>Xaa is D-Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(10)..(10)</s222><s223>Xaa is D-Lys or absent</s223></s220></s200><s400> 571Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa1               5                   10</s400><s200><s210>572</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(1)..(1)</s222><s223>Xaa is D-Lys</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(2)..(2)</s222><s223>Xaa is D-Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(3)..(3)</s222><s223>Xaa is D-Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(4)..(4)</s222><s223>Xaa is D-Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(5)..(5)</s222><s223>Xaa is D-Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(6)..(6)</s222><s223>Xaa is D-Lys or absent</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(7)..(7)</s222><s223>Xaa is D-Lys or absent</s223></s220></s200><s400> 572Xaa Xaa Xaa Xaa Xaa Xaa Xaa1               5</s400><s200><s210>573</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(1)..(3)</s222><s223>Xaa is D-Lys</s223></s220></s200><s400> 573Xaa Xaa Xaa1</s400><s200><s210>574</s210><s211>4</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(1)..(4)</s222><s223>Xaa is D-Lys</s223></s220></s200><s400> 574Xaa Xaa Xaa Xaa1</s400><s200><s210>575</s210><s211>5</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(1)..(5)</s222><s223>Xaa is D-Lys</s223></s220></s200><s400> 575Xaa Xaa Xaa Xaa Xaa1               5</s400><s200><s210>576</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(1)..(7)</s222><s223>Xaa is D-Lys</s223></s220></s200><s400> 576Xaa Xaa Xaa Xaa Xaa Xaa Xaa1               5</s400><s200><s210>577</s210><s211>1</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(1)..(1)</s222><s223>Xaa is isoGlu(KEK)(Peg3)0-3, where (Peg3)0-3 is      0-3 8-amino-3,6-dioxaoctanoyl groups</s223></s220></s200><s400> 577Xaa1</s400><s200><s210>578</s210><s211>1</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(1)..(1)</s222><s223>beta-Ala(KEK)(Peg3)0-3, where (Peg3)0-3 is 0-3      8-amino-3,6-dioxaoctanoyl groups</s223></s220></s200><s400> 578Xaa1</s400><s200><s210>579</s210><s211>1</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(1)..(1)</s222><s223>Xaa is isoLys(KEK)(Peg3)0-3, where (Peg3)0-3 is      0-3 8-amino-3,6-dioxaoctanoyl groups</s223></s220></s200><s400> 579Xaa1</s400><s200><s210>580</s210><s211>1</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(1)..(1)</s222><s223>Xaa is 4-aminobutanoyl(KEK)(Peg3)0-3, where      (Peg3)0-3 is 0-3 8-amino-3,6-dioxaoctanoyl groups</s223></s220></s200><s400> 580Xaa1</s400><s200><s210>581</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(3)..(3)</s222><s223>Xaa is K(isoGlu)</s223></s220></s200><s400> 581Lys Glu Xaa1</s400><s200><s210>582</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(3)..(3)</s222><s223>Xaa is K(beta-Ala)</s223></s220></s200><s400> 582Lys Glu Xaa1</s400><s200><s210>583</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(3)..(3)</s222><s223>Xaa is K(isoLys)</s223></s220></s200><s400> 583Lys Glu Xaa1</s400><s200><s210>584</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(3)..(3)</s222><s223>Xaa is K(4-aminobutanoyl)</s223></s220></s200><s400> 584Lys Glu Xaa1</s400><s200><s210>585</s210><s211>1</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(1)..(1)</s222><s223>Xaa is isoglu(KEK)</s223></s220></s200><s400> 585Xaa1</s400><s200><s210>586</s210><s211>1</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(1)..(1)</s222><s223>Xaa is beta-Ala(KEK)</s223></s220></s200><s400> 586Xaa1</s400><s200><s210>587</s210><s211>1</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(1)..(1)</s222><s223>Xaa is isoLys (KEK)</s223></s220></s200><s400> 587Xaa1</s400><s200><s210>588</s210><s211>1</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(1)..(1)</s222><s223>Xaa is 4-aminobutanoyl(KEK)</s223></s220></s200><s400> 588Xaa1</s400><s200><s210>589</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(3)..(3)</s222><s223>Xaa is K(isoGlu)(Peg3)0-3, where (Peg3)0-3 is      0-3 8-amino-3,6-dioxaoctanoyl groups</s223></s220></s200><s400> 589Lys Glu Xaa1</s400><s200><s210>590</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(3)..(3)</s222><s223>Xaa is K(beta-Ala)(Peg3)0-3, where (Peg3)0-3 is      0-3 8-amino-3,6-dioxaoctanoyl groups</s223></s220></s200><s400> 590Lys Glu Xaa1</s400><s200><s210>591</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(3)..(3)</s222><s223>Xaa is K(isoLys)(Peg3)0-3, where (Peg3)0-3 is      0-3 8-amino-3,6-dioxaoctanoyl groups</s223></s220></s200><s400> 591Lys Glu Xaa1</s400><s200><s210>592</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(3)..(3)</s222><s223>Xaa is K(4-aminobutanoyl)(Peg3)0-3, where      (Peg3)0-3 is 0-3 8-amino-3,6-dioxaoctanoyl groups</s223></s220></s200><s400> 592Lys Glu Xaa1</s400><s200><s210>593</s210><s211>1</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(1)..(1)</s222><s223>Xaa is K([Fatty acid]-isoGlu-KEK-Peg3), where      Peg3 is 8-amino-3,6-dioxaoctanoyl group</s223></s220></s200><s400> 593Xaa1</s400><s200><s210>594</s210><s211>1</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1/GLP-2 Dual agonist peptide</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(1)..(1)</s222><s223>Xaa is K([Fatty acid]isoGlu-KEK)</s223></s220></s200><s400> 594Xaa1</s400></sequence-list-new-rules></sequence-cwu><?xml version="1.0" encoding="UTF-8"?><!DOCTYPE us-patent-application SYSTEM "us-patent-application-v46-2022-02-17.dtd" [ ]><us-patent-application lang="EN" dtd-version="v4.6 2022-02-17" file="US20230000952A1-20230105.XML" status="PRODUCTION" id="us-patent-application" country="US" date-produced="20221220" date-publ="20230105"><us-bibliographic-data-application lang="EN" country="US"><publication-reference><document-id><country>US</country><doc-number>20230000952</doc-number><kind>A1</kind><date>20230105</date></document-id></publication-reference><application-reference appl-type="utility"><document-id><country>US</country><doc-number>17459556</doc-number><date>20210827</date></document-id></application-reference><us-application-series-code>17</us-application-series-code><classifications-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>K</subclass><main-group>38</main-group><subgroup>28</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>K</subclass><main-group>38</main-group><subgroup>26</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>K</subclass><main-group>38</main-group><subgroup>48</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>K</subclass><main-group>45</main-group><subgroup>06</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>07</class><subclass>K</subclass><main-group>14</main-group><subgroup>78</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>K</subclass><main-group>47</main-group><subgroup>65</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>K</subclass><main-group>47</main-group><subgroup>64</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>K</subclass><main-group>38</main-group><subgroup>22</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>07</class><subclass>K</subclass><main-group>19</main-group><subgroup>00</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>07</class><subclass>K</subclass><main-group>14</main-group><subgroup>575</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>07</class><subclass>K</subclass><main-group>14</main-group><subgroup>605</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>K</subclass><main-group>38</main-group><subgroup>16</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr></classifications-ipcr><classifications-cpc><main-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>38</main-group><subgroup>28</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></main-cpc><further-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>38</main-group><subgroup>26</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>38</main-group><subgroup>4846</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>45</main-group><subgroup>06</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>K</subclass><main-group>14</main-group><subgroup>78</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20170801</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>47</main-group><subgroup>65</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>K</subclass><main-group>2319</main-group><subgroup>31</subgroup><symbol-position>L</symbol-position><classification-value>A</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>38</main-group><subgroup>2278</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>K</subclass><main-group>19</main-group><subgroup>00</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>K</subclass><main-group>14</main-group><subgroup>575</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>K</subclass><main-group>14</main-group><subgroup>605</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>38</main-group><subgroup>16</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20170801</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>47</main-group><subgroup>6435</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></further-cpc></classifications-cpc><invention-title id="d2e43">THERAPEUTIC AGENTS COMPRISING ELASTIN-LIKE PEPTIDES</invention-title><us-related-documents><continuation><relation><parent-doc><document-id><country>US</country><doc-number>16720970</doc-number><date>20191219</date></document-id><parent-grant-document><document-id><country>US</country><doc-number>11103558</doc-number></document-id></parent-grant-document></parent-doc><child-doc><document-id><country>US</country><doc-number>17459556</doc-number></document-id></child-doc></relation></continuation><continuation><relation><parent-doc><document-id><country>US</country><doc-number>16000300</doc-number><date>20180605</date></document-id><parent-grant-document><document-id><country>US</country><doc-number>10596230</doc-number></document-id></parent-grant-document></parent-doc><child-doc><document-id><country>US</country><doc-number>16720970</doc-number></document-id></child-doc></relation></continuation><continuation><relation><parent-doc><document-id><country>US</country><doc-number>15816018</doc-number><date>20171117</date></document-id><parent-status>ABANDONED</parent-status></parent-doc><child-doc><document-id><country>US</country><doc-number>16000300</doc-number></document-id></child-doc></relation></continuation><continuation><relation><parent-doc><document-id><country>US</country><doc-number>14822512</doc-number><date>20150810</date></document-id><parent-grant-document><document-id><country>US</country><doc-number>9821036</doc-number></document-id></parent-grant-document></parent-doc><child-doc><document-id><country>US</country><doc-number>15816018</doc-number></document-id></child-doc></relation></continuation><continuation><relation><parent-doc><document-id><country>US</country><doc-number>13524812</doc-number><date>20120615</date></document-id><parent-grant-document><document-id><country>US</country><doc-number>9127047</doc-number></document-id></parent-grant-document></parent-doc><child-doc><document-id><country>US</country><doc-number>14822512</doc-number></document-id></child-doc></relation></continuation><continuation><relation><parent-doc><document-id><country>US</country><doc-number>13445979</doc-number><date>20120413</date></document-id><parent-grant-document><document-id><country>US</country><doc-number>9200083</doc-number></document-id></parent-grant-document></parent-doc><child-doc><document-id><country>US</country><doc-number>13524812</doc-number></document-id></child-doc></relation></continuation><continuation><relation><parent-doc><document-id><country>US</country><doc-number>12493912</doc-number><date>20090629</date></document-id><parent-grant-document><document-id><country>US</country><doc-number>8178495</doc-number></document-id></parent-grant-document></parent-doc><child-doc><document-id><country>US</country><doc-number>13445979</doc-number></document-id></child-doc></relation></continuation><us-provisional-application><document-id><country>US</country><doc-number>61076221</doc-number><date>20080627</date></document-id></us-provisional-application></us-related-documents><us-parties><us-applicants><us-applicant sequence="00" app-type="applicant" designation="us-only" applicant-authority-category="assignee"><addressbook><orgname>Duke University</orgname><address><city>Durham</city><state>NC</state><country>US</country></address></addressbook><residence><country>US</country></residence></us-applicant></us-applicants><inventors><inventor sequence="00" designation="us-only"><addressbook><last-name>CHILKOTI</last-name><first-name>Ashutosh</first-name><address><city>Durham</city><state>NC</state><country>US</country></address></addressbook></inventor></inventors></us-parties></us-bibliographic-data-application><abstract id="abstract"><p id="p-0001" num="0000">The present invention provides therapeutic agents and compositions comprising elastin-like peptides (ELPs) and therapeutic proteins. In some embodiments, the therapeutic protein is a GLP-1 receptor agonist, insulin, or Factor VII/VIIa, including functional analogs. The present invention further provides encoding polynucleotides, as well as methods of making and using the therapeutic agents. The therapeutic agents have improvements in relation to their use as therapeutics, including, inter alia, one or more of half-life, clearance and/or persistance in the body, solubility, and bioavailability.</p></abstract><drawings id="DRAWINGS"><figure id="Fig-EMI-D00001" num="00001"><img id="EMI-D00001" he="132.76mm" wi="121.33mm" file="US20230000952A1-20230105-D00001.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00002" num="00002"><img id="EMI-D00002" he="126.07mm" wi="123.27mm" file="US20230000952A1-20230105-D00002.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00003" num="00003"><img id="EMI-D00003" he="207.60mm" wi="153.84mm" file="US20230000952A1-20230105-D00003.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00004" num="00004"><img id="EMI-D00004" he="126.24mm" wi="135.89mm" file="US20230000952A1-20230105-D00004.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00005" num="00005"><img id="EMI-D00005" he="142.49mm" wi="122.85mm" file="US20230000952A1-20230105-D00005.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00006" num="00006"><img id="EMI-D00006" he="147.57mm" wi="122.94mm" file="US20230000952A1-20230105-D00006.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00007" num="00007"><img id="EMI-D00007" he="126.24mm" wi="118.62mm" file="US20230000952A1-20230105-D00007.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00008" num="00008"><img id="EMI-D00008" he="135.30mm" wi="137.92mm" file="US20230000952A1-20230105-D00008.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00009" num="00009"><img id="EMI-D00009" he="221.49mm" wi="128.44mm" file="US20230000952A1-20230105-D00009.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00010" num="00010"><img id="EMI-D00010" he="219.54mm" wi="124.80mm" file="US20230000952A1-20230105-D00010.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00011" num="00011"><img id="EMI-D00011" he="113.03mm" wi="149.10mm" file="US20230000952A1-20230105-D00011.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00012" num="00012"><img id="EMI-D00012" he="133.69mm" wi="136.31mm" file="US20230000952A1-20230105-D00012.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00013" num="00013"><img id="EMI-D00013" he="221.74mm" wi="128.44mm" file="US20230000952A1-20230105-D00013.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00014" num="00014"><img id="EMI-D00014" he="219.71mm" wi="124.80mm" file="US20230000952A1-20230105-D00014.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00015" num="00015"><img id="EMI-D00015" he="219.54mm" wi="124.80mm" file="US20230000952A1-20230105-D00015.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00016" num="00016"><img id="EMI-D00016" he="35.56mm" wi="153.75mm" file="US20230000952A1-20230105-D00016.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00017" num="00017"><img id="EMI-D00017" he="133.43mm" wi="141.56mm" file="US20230000952A1-20230105-D00017.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00018" num="00018"><img id="EMI-D00018" he="205.82mm" wi="122.60mm" file="US20230000952A1-20230105-D00018.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00019" num="00019"><img id="EMI-D00019" he="211.58mm" wi="124.80mm" file="US20230000952A1-20230105-D00019.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00020" num="00020"><img id="EMI-D00020" he="219.12mm" wi="124.88mm" file="US20230000952A1-20230105-D00020.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00021" num="00021"><img id="EMI-D00021" he="204.05mm" wi="124.80mm" file="US20230000952A1-20230105-D00021.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00022" num="00022"><img id="EMI-D00022" he="215.31mm" wi="124.80mm" file="US20230000952A1-20230105-D00022.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00023" num="00023"><img id="EMI-D00023" he="219.79mm" wi="153.75mm" file="US20230000952A1-20230105-D00023.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00024" num="00024"><img id="EMI-D00024" he="193.63mm" wi="151.81mm" file="US20230000952A1-20230105-D00024.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00025" num="00025"><img id="EMI-D00025" he="152.91mm" wi="113.79mm" file="US20230000952A1-20230105-D00025.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00026" num="00026"><img id="EMI-D00026" he="146.05mm" wi="132.00mm" file="US20230000952A1-20230105-D00026.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00027" num="00027"><img id="EMI-D00027" he="107.27mm" wi="135.13mm" file="US20230000952A1-20230105-D00027.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00028" num="00028"><img id="EMI-D00028" he="135.81mm" wi="162.05mm" file="US20230000952A1-20230105-D00028.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00029" num="00029"><img id="EMI-D00029" he="161.29mm" wi="165.61mm" file="US20230000952A1-20230105-D00029.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00030" num="00030"><img id="EMI-D00030" he="157.56mm" wi="154.35mm" file="US20230000952A1-20230105-D00030.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00031" num="00031"><img id="EMI-D00031" he="172.04mm" wi="161.21mm" file="US20230000952A1-20230105-D00031.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00032" num="00032"><img id="EMI-D00032" he="161.46mm" wi="170.77mm" file="US20230000952A1-20230105-D00032.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00033" num="00033"><img id="EMI-D00033" he="218.44mm" wi="143.68mm" orientation="landscape" file="US20230000952A1-20230105-D00033.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure></drawings><description id="description"><?cross-reference-to-related-applications description="Cross Reference To Related Applications" end="lead"?><heading id="h-0001" level="1">PRIORITY</heading><p id="p-0002" num="0001">This application is a continuation of U.S. application Ser. No. 16/720,970, filed Dec. 19, 2019 which is a continuation of U.S. application Ser. No. 16/000,300, filed Jun. 5, 2018, now U.S. Pat. No. 10,596,230, issued Mar. 24, 2020 which is a continuation of U.S. Ser. No. 15/816,018, filed Nov. 17, 2017, now abandoned, which is a continuation of U.S. application Ser. No. 14/822,512, filed Aug. 10, 2015, now U.S. Pat. No. 9,821,036, issued Nov. 21, 2017 which is a continuation of U.S. application Ser. No. 13/524,812, filed Jun. 15, 2012, now U.S. Pat. No. 9,127,047, issued Sep. 8, 2015 which is a continuation of U.S. application Ser. No. 13/445,979, filed Apr. 13, 2012, now U.S. Pat. No. 9,200,083, issued Dec. 1, 2015 which is a continuation of U.S. application Ser. No. 12/493,912, filed Jun. 29, 2009, now U.S. Pat. No. 8,178,495, issued May 15, 2012, which claims priority to U.S. Provisional Application No. 61/076,221, filed Jun. 27, 2008, the contents of each of which are hereby incorporated by reference in their entireties.</p><?cross-reference-to-related-applications description="Cross Reference To Related Applications" end="tail"?><?summary-of-invention description="Summary of Invention" end="lead"?><heading id="h-0002" level="1">FIELD OF THE INVENTION</heading><p id="p-0003" num="0002">This application discloses therapeutic agents comprising elastin-like-peptides, and is related to PCT/US2007/077767 (published as WO 2008/030968 on Mar. 13, 2008) having an International Filing Date of Sep. 6, 2007. This application is also related to PCT/US2006/048572 (published as WO 2007/073486 on Jun. 28, 2007) having an International Filing Date of Dec. 20, 2006. WO 2008/030968 and WO 2007/073486 are each hereby incorporated by reference in their entireties.</p><heading id="h-0003" level="1">DESCRIPTION OF THE TEXT FILE SUBMITTED ELECTRONICALLY</heading><p id="p-0004" num="0003">The contents of the text file submitted electronically herewith are incorporated herein by reference in their entirety: A computer readable format copy of the Sequence Listing (filename:PHAS-010_10US_SeqList_ST25.txt, date recorded: Aug. 27, 2021, file size 52.7 kb).</p><heading id="h-0004" level="1">BACKGROUND OF THE INVENTION</heading><p id="p-0005" num="0004">Therapeutic proteins or peptides in their native state or when recombinantly produced can be labile molecules exhibiting, inter alia, short periods of serum stability, serum half-life (i.e., circulatory half-life), or limited persistance in the body. Such molecules can also be extremely labile when formulated, such as when formulated in aqueous solutions.</p><p id="p-0006" num="0005">In some instances, polyethylene glycol (PEG) conjugated to a proteinaceous molecule results in a longer-acting, sustained activity of the molecule. PEG attachment, however, can often substantially reduce or even destroy the protein's therapeutic activity. Therapeutic proteins and/or peptides have also been stabilized by fusion to certain proteins that are capable of extending serum half-life. For example, in some instances, therapeutic proteins fused to albumin, transferrin, and antibody fragments exhibit extended serum half-life when compared to the therapeutic protein in the unfused state. See U.S. Pat. No. 7,238,667 (particularly with respect to albumin conjugates), U.S. Pat. No. 7,176,278 (particularly with respect to transferrin conjugates), and U.S. Pat. No. 5,766,883, which are each hereby incorporated by reference in their entireties.</p><p id="p-0007" num="0006">There remains a need in the art for more stable, longer acting, and/or effective proteinaceous molecules.</p><heading id="h-0005" level="1">SUMMARY OF THE INVENTION</heading><p id="p-0008" num="0007">The present invention provides therapeutic agents comprising an elastin-like peptide (ELP) component and a therapeutic proteinacious component. The ELP component contains structural peptide units, which may be repeating units, structurally related to, or derived from, sequences of the elastin protein. Such ELP components provide certain therapeutic advantages to the therapeutic agent, such as comparatively better stability, solubility, bioavailability, half-life, persistance, and/or biological action of the therapeutic proteinaceous component. Such properties may be determined, for example, with respect to the therapeutic component's unfused or unconjugated counterpart. In some embodiments, the ELP components may undergo a reversible inverse phase transition, which may impart additional practical and/or therapeutic advantages. The invention further provides polynucleotides encoding the therapeutic agents of the invention, as well as methods of treatment or prophylaxis for certain biological conditions.</p><p id="p-0009" num="0008">In a first aspect, the invention provides a therapeutic agent comprising an elastin-like peptide (ELP) component and a therapeutic proteinacious component, as well as pharmaceutical compositions containing the same for delivery to a subject or patient in need. The therapeutic component may be selected from active portions of the therapeutic proteins listed in Table 1, or functional analogs thereof. In certain embodiments, the therapeutic component is a GLP-1 receptor agonist, such as GLP-1, exendin-4, or a functional analog thereof. Such therapeutic components are generally effective for, among other things, increasing insulin secretion from the pancreas in a glucose-dependent manner. In other embodiments, the therapeutic component is an insulin or functional analog thereof, which is generally effective for promoting glucose uptake from the blood and storage within cells. In still other embodiments, the therapeutic component is a Factor VII/VIIa or functional analog thereof, which is generally effective for promoting coagulation by activation of Factor X or Factor IX.</p><p id="p-0010" num="0009">The ELP and therapeutic components may be covalently coupled by various means, including chemical coupling (e.g., conjugation) and recombinant fusion technology. In addition, the number of ELP or therapeutic components per molecule, and their respective positions within the molecule, may vary as needed. The therapeutic agent may further include one or more spacer or linker moieties, which in addition to providing the desired functional independence of the ELP and therapeutic components, may optionally provide for additional functionalities, such as a protease-sensitive feature to allow for proteolytic release or activation of the therapeutic component. The therapeutic agent may further include one or more targeting components such as, for example, a peptide or protein to target the therapeutic agent to a particular cell type, e.g., a cancer cell, or to a particular organ.</p><p id="p-0011" num="0010">In a second aspect, the invention provides polynucleotides, such polynucleotides comprising a nucleotide sequence encoding a therapeutic agent of the invention. For example, the nucleotide sequence encodes an ELP fusion with a functional portion of at least one therapeutic protein listed in Table 1 (or functional analog thereof). In certain embodiments, the therapeutic component is a GLP-1 receptor agonist (including GLP-1 and exendin-4), insulin, Factor VII/VIIa, or functional analog thereof. Such polynucleotides may further comprise additional control element(s) operably linked to the nucleotide sequence, such as promoter elements and/or other transcription or expression-related signals. The polynucleotide may be inserted into various vectors, which may be useful for production of the therapeutic agent in host cells, including, for example, bacterial and eukaryotic host cells.</p><p id="p-0012" num="0011">In a third aspect, the invention provides a method for treating or preventing a disease, disorder, or condition in a subject, such as in a mammalian patient, including a human patient. The method comprises administering an effective amount of the therapeutic agent of the invention (or pharmaceutical composition containing the same) to a subject or patient in need thereof. For example, the patient may be in need of an agent having a biological activity or preferred indication listed in Table 1. In certain embodiments employing a GLP-1 receptor agonist/ELP compound or employing an insulin/ELP compound, the invention provides a method for treating one or more disorders including type 1 or type 2 diabetes, hyperglycemia, and impaired glucose tolerance. In certain other embodiments employing Factor VII/VIIa/ELP compound, the invention provides a method for treating one or more disorders including hemophilia, post-surgical bleeding, anticoagulation-induced bleeding, thrombocytopenia, factor VII deficiency, factor XI deficiency, and intracranial hemorrhage.</p><p id="p-0013" num="0012">Various other aspects, features and embodiments of the invention will be more fully apparent from the following disclosure and appended claims.</p><?summary-of-invention description="Summary of Invention" end="tail"?><?brief-description-of-drawings description="Brief Description of Drawings" end="lead"?><description-of-drawings><heading id="h-0006" level="1">BRIEF DESCRIPTION OF THE FIGURES</heading><p id="p-0014" num="0013"><figref idref="DRAWINGS">FIG. <b>1</b></figref> depicts plasmid pET24d-ELP1-90, encoding an ELP component with a 10 unit VPGXG (SEQ ID NO: 3) repeat motif, where guest position X is V, G, and A in the ratio of 5:3:2. This motif is repeated eight times with a final C-terminal 10-unit repeat where X is V, G, A, and W in the ratio 4:3:2:1. This ELP component is represented generally as [(VPGXG)<sub>10</sub>]<sub>9</sub>.</p><p id="p-0015" num="0014"><figref idref="DRAWINGS">FIG. <b>2</b>A</figref> depicts plasmid pET24d-Ex-4 ELP1-90 encoding an ELP component with VPGXG (SEQ ID NO: 3) repeat motif (as in <figref idref="DRAWINGS">FIG. <b>1</b></figref>) cloned in frame with an N-terminal exendin-4 component. <figref idref="DRAWINGS">FIG. <b>2</b>B</figref> depicts the nucleotide and amino acid sequence of the exendin-4/ELP fusion (SEQ ID NOS: 23 and 24). Primer sequences are indicated (SEQ ID NOS:35-40).</p><p id="p-0016" num="0015"><figref idref="DRAWINGS">FIG. <b>3</b>A</figref> depicts the nucleotide and amino acid sequence of an exendin-4 construct having an N-terminal Tev (Tobacco Etch Virus cysteine protease) cleavage site (SEQ ID NOS: 25 and 26). Primer sequences are indicated (SEQ ID NOS:38, 41, 42). <figref idref="DRAWINGS">FIG. <b>3</b>B</figref> also depicts the nucleotide and amino acid sequence of an exendin-4 construct having an N-terminal Tev cleavage site, but with an additional sequence N-terminal to the Tev cleavage site to provide a better target for the protease (SEQ ID NOS: 27 and 28). Primer sequences are indicated (SEQ ID NOS:38, 43,44).</p><p id="p-0017" num="0016"><figref idref="DRAWINGS">FIG. <b>4</b>A</figref> depicts the nucleotide and amino acid sequence of an exendin-4/ELP fusion as in <figref idref="DRAWINGS">FIGS. <b>1</b>-<b>3</b></figref>, but with a DsbA leader sequence to direct secretion into the periplasmic space (SEQ ID NOS: 29 and 30). Primer sequences are indicated (SEQ ID NOS:38, 45, 46). <figref idref="DRAWINGS">FIG. <b>4</b>B</figref> depicts plasmid pET24d-DsbA-Ex-4 ELP1-90 encoding the fusion of <figref idref="DRAWINGS">FIG. <b>4</b>A</figref>.</p><p id="p-0018" num="0017"><figref idref="DRAWINGS">FIG. <b>5</b>A</figref> depicts pPB0868, which encodes GLP-1(A8G,7-37)ELP1-90.</p><p id="p-0019" num="0018"><figref idref="DRAWINGS">FIG. <b>5</b>B</figref> depicts the nucleotide and amino acid sequence of the encoded fusion protein (SEQ ID NOS: 53 and 54, respectively).</p><p id="p-0020" num="0019"><figref idref="DRAWINGS">FIG. <b>6</b>A</figref> depicts pPB1022, which encodes GLP-1(A8G,7-37)ELP1-120.</p><p id="p-0021" num="0020"><figref idref="DRAWINGS">FIG. <b>6</b>B</figref> depicts the nucleotide and amino acid sequence of the encoded fusion protein (SEQ ID NOS: 55 and 56, respectively).</p><p id="p-0022" num="0021"><figref idref="DRAWINGS">FIG. <b>7</b>A</figref> depicts pPB0788, which encodes Factor VII-ELP1-90. <figref idref="DRAWINGS">FIG. <b>7</b>B</figref> depicts the nucleotide and amino acid sequence of the encoded fusion protein (SEQ ID NOS: 57 and 58, respectively).</p><p id="p-0023" num="0022"><figref idref="DRAWINGS">FIG. <b>8</b>A</figref> depicts the nucleotide and amino acid sequence of an insulin (B, C, and A chains) having the ELP component cloned in frame (SEQ ID NOS: 31 and 32). Primer sequences are indicated (SEQ ID NOS: 47 and 48). <figref idref="DRAWINGS">FIG. <b>8</b>B</figref> depicts plasmid pET24d Insulin-ELP1-90 expressing the insulin/ELP fusion of <figref idref="DRAWINGS">FIG. <b>8</b>A</figref>.</p><p id="p-0024" num="0023"><figref idref="DRAWINGS">FIG. <b>9</b></figref> is a Western blot for FVII-ELP1-90 from transient transfection of Freestyle HEK293, detected with mouse anti-human FVII monoclonal antibody. Lanes are: (1) culture media; (2) FVII ELP1-90 after purification by phase transition; and FVII control.</p><p id="p-0025" num="0024"><figref idref="DRAWINGS">FIG. <b>10</b></figref> is an SDS-PAGE showing recombinant production of an Exendin-4/ELP4-60 fusion. Lanes are: (M) Protein markers; (1) Exendin-4 ELP4-60 from total lysate; (2) Exendin-4 ELP4-60 from insoluble lysate; (3) Exendin-4 ELP4-60 from soluble lysate; (4) Exendin-4 ELP4-60 from 1st transition (equal volume); (5) Exendin-4 ELP4-60 from 2nd transition (concentrated); (6) Exendin-4 ELP4-60 from 3rd transition (concentrated).</p><p id="p-0026" num="0025"><figref idref="DRAWINGS">FIG. <b>11</b></figref> shows the activation of Factor X by FactorVIIa-ELP1-90, and by Factor VIIa as a comparison. As shown, FactorVIIa-ELP retains full activity.</p><p id="p-0027" num="0026"><figref idref="DRAWINGS">FIG. <b>12</b></figref> shows that Factor VIIa-ELP1-90 has a long PK when administered by i.v. in rats. FactorVIIa has a T<sub>1/2 </sub>of about 690 min. as compared to about 45-60 min. for Factor VIIa.</p><p id="p-0028" num="0027"><figref idref="DRAWINGS">FIG. <b>13</b></figref> shows the high in vitro activity of GLP1-ELP and Exendin-4-ELP, when compared to the activity of Exendin peptide.</p><p id="p-0029" num="0028"><figref idref="DRAWINGS">FIG. <b>14</b></figref> shows that GLP1-ELP has a T<sub>1/2</sub>, of about 12.9 hours when administered by i.v. to rats, and a T<sub>1/2</sub>, of about 8.6 hours when administered subcutaneously (SQ).</p><p id="p-0030" num="0029"><figref idref="DRAWINGS">FIG. <b>15</b></figref> shows that GLP-1 ELP has a long half-life in rabbits of about 20 hours when administered i.v., and about 24 hours when administered sub-cutaneously.</p><p id="p-0031" num="0030"><figref idref="DRAWINGS">FIG. <b>16</b></figref> shows sustained glycemic control in diabetic mice with GLP-1-ELP.</p></description-of-drawings><?brief-description-of-drawings description="Brief Description of Drawings" end="tail"?><?detailed-description description="Detailed Description" end="lead"?><heading id="h-0007" level="1">DETAILED DESCRIPTION OF THE INVENTION</heading><p id="p-0032" num="0031">The present invention provides therapeutic agents comprising an elastin-like peptide (ELP) (&#x201c;the ELP component&#x201d;) and a therapeutic component. The therapeutic component may be selected from Table 1 (e.g., selected from a Therapeutic Protein, or functional portion or functional analog thereof, listed in Table 1). In certain embodiments, the therapeutic component is a GLP-1 receptor agonist, such as GLP-1 or exendin-4, or may be insulin, Factor VII/VIIa, or functional analog thereof. The ELP component contains structural units related to, or derived from, sequences of the elastin protein, which provides certain therapeutic advantages, such as comparatively better persistence, stability, solubility, bioavailability, half-life, and/or biological action of the therapeutic component. Such properties may be determined with respect to, for example, an unfused or unconjugated counterpart of the therapeutic component. The invention further provides polynucleotides encoding the therapeutic agents of the invention, as well as methods of treatment or prophylaxis for certain biological conditions, including the preferred indications listed in Table 1, and including diabetes (e.g., Type I and Type II), hyperglycemia, bleeding, hemophilia, and hemorrhage, among others.</p><p id="p-0033" num="0032">For ease of reference in the ensuing discussion, set out below are definitions of some terms appearing in the discussion.</p><p id="p-0034" num="0033">As used herein, the term &#x201c;therapeutic agent&#x201d; or &#x201c;therapeutic component&#x201d; refers to an agent or component capable of inducing a biological effect in vivo and/or in vitro. The biological effect may be useful for treating and/or preventing a condition, disorder, or disease in a subject or patient.</p><p id="p-0035" num="0034">As used herein, the term &#x201c;coupled&#x201d; means that the specified components are either directly covalently bonded to one another (e.g., via chemical conjugation or recombinant fusion technology), or indirectly covalently joined to one another (e.g., via chemical conjugation or recombinant fusion technology) through an intervening moiety or moieties, such as a bridge, spacer, or linker.</p><p id="p-0036" num="0035">As used herein, &#x201c;half-life&#x201d; (which generally refers to in vivo half-life or circulatory half-life) is the period of time that is required for a 50% diminution of bioactivity of the active agent to occur. Such term is to be contrasted with &#x201c;persistence,&#x201d; which is the overall temporal duration of the active agent in the body, and &#x201c;rate of clearance&#x201d; as being a dynamically changing variable that may or may not be correlative with the numerical values of half-life and persistence.</p><p id="p-0037" num="0036">The term &#x201c;functional analog&#x201d; refers to a protein that is an active analog (e.g., either chemical or protein analog), derivative, fragment, truncation isoform or the like of a native protein. For example, the functional analog may be a functional analog of a therapeutic protein listed in Table 1, or may be a functional analog of a GLP-1 receptor agonist (e.g., GLP-1, exendin), insulin, or Factor VII/VIIa. A polypeptide is active when it retains some or all of the biological activity of the corresponding native polypeptide, as determined in vivo or in one or more indicative in vitro assays. Exemplary activity assays for certain therapeutic proteins, which are determinative of activity, are listed Table 1. Further, such biological activities and assays for GLP-1 receptor agonists, insulin, and Factor VII/VIIa, which are determinative of whether a given molecule is a &#x201c;functional analog,&#x201d; are described in detail elsewhere herein.</p><p id="p-0038" num="0037">As used herein, the term &#x201c;native,&#x201d; as used in reference to an amino acid sequence, indicates that the amino acid sequence is found in a naturally-occurring protein.</p><p id="p-0039" num="0038">As used herein, the term &#x201c;spacer&#x201d; refers to any moiety, peptide or other chemical entity, that may be interposed between the ELP component and the therapeutic component. For example, the spacer may be a divalent group that is covalently bonded at one terminus to the ELP component, and covalently bonded at the other terminus to the therapeutic component. The therapeutic agents may therefore be open to the inclusion of additional chemical structure that does not preclude the efficacy of the agent for its intended purpose. The spacer may, for example, be a protease-sensitive spacer moiety that is provided to control the pharmacokinetics of the agent, or the spacer may be a protease-resistant moiety.</p><p id="p-0040" num="0039">The therapeutic component and the ELP component may be coupled with one another in any suitable covalent manner, including chemical coupling and recombinant technology, such that the therapeutic agent is efficacious for its intended purpose, and such that the presence of the ELP component enhances the therapeutic component in some functional, therapeutic or physiological aspect. For example, the ELP-coupled therapeutic component may be enhanced in, e.g., its bioavailability, bio-unavailability, therapeutically effective dose, biological action, formulation compatibility, resistance to proteolysis or other degradative modality, solubility, half-life or other measure of persistence in the body subsequent to administration, rate of clearance from the body subsequent to administration, etc. Such enhancement may be determined, for example, in relation to a corresponding unconjugated or unfused counterpart therapeutic (e.g., determined relative to native GLP-1, exendin, insulin, or Factor VII/VIIa, or a therapeutic protein listed in Table 1).</p><p id="p-0041" num="0040">In some embodiments, the therapeutic agent of the invention circulates or exists in the body in a soluble form, and escapes filtration by the kidney thereby persisting in the body in an active form. In some embodiments, the therapeutic agents of the invention have a molecular weight of less than the generally recognized cut-off for filtration through the kidney, such as less than about 60 kD, or in some embodiments less than about 55, 50, 45, 40, 30, or 20 kDa, and persist in the body by at least 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, 20-fold, or 100-fold longer than an uncoupled (e.g., unfused or unconjugated) therapeutic counterpart.</p><p id="p-0042" num="0041">The number of ELP and/or therapeutic components per molecule, and their respective positions within the molecule, may vary among embodiments of the invention. For example, in embodiments where the agent is a recombinant fusion, at least one ELP component may be placed at one or both of the N-terminus and the C-terminus. Where the ELP component is at both the N-terminus and C-terminus of the fusion, the ELP components will flank the therapeutic component. Alternatively, the therapeutic component may be positioned at either or both of the N-terminus and C-terminus. Where the therapeutic component is at both the N-terminus and C-terminus, the therapeutic component will flank the ELP component. In a further embodiment, different therapeutic components are positioned at the N-terminus and C-terminus of the molecule. As discussed in detail herein, in certain embodiments, such therapeutic component(s) may be released by proteolysis of a spacer moiety separating the ELP and therapeutic components. In certain embodiments, the therapeutic component may be inactive in the fused state, and becoming active upon proteolytic release from the ELP component(s). Alternatively, the therapeutic component remains active in the fused state, making proteolytic processing of the therapeutic agent unnecessary for biological activity.</p><p id="p-0043" num="0042">When prepared as recombinant fusions, the therapeutic agent can be prepared by known recombinant expression techniques. For example, to recombinantly produce the therapeutic agent, a nucleic acid sequence encoding the chimeric gene is operatively linked to a suitable promoter sequence such that the nucleic acid sequence encoding such fusion protein will be transcribed and/or translated into the desired fusion protein in the host cells. Preferred promoters are those useful for expression in <i>E. coli</i>, such as the T7 promoter. Any commonly used expression system may be used, including eukaryotic or prokaryotic systems. Specific examples include yeast (e.g., <i>Saccharomyces </i>spp., <i>Pichia </i>spp.), baculovirus, mammalian, and bacterial systems, such as <i>E. coli</i>, and <i>Caulobacter. </i></p><p id="p-0044" num="0043">The various aspects and embodiments of the invention are described in greater detail in the following sections.</p><heading id="h-0008" level="2">Elastin-Like Peptide (ELP) Component</heading><p id="p-0045" num="0044">The therapeutic agent of the invention may comprise one or more ELP components. The ELP components comprise or consist of structural peptide units or sequences that are related to, or derived from, the elastin protein. Such sequences are useful for improving the properties of therapeutic proteins, such as those listed in Table 1, as well as GLP-1 receptor agonists (e.g., GLP-1 or exendin-4), insulin, and Factor VII/VIIa in one or more of bioavailability, therapeutically effective dose, biological action, formulation compatibility, resistance to proteolysis, solubility, half-life or other measure of persistence in the body subsequent to administration, and/or rate of clearance from the body.</p><p id="p-0046" num="0045">The ELP component is constructed from structural units of from three to about twenty amino acids, or in some embodiments, from four to ten amino acids, such as five or six amino acids. The length of the individual structural units, in a particular ELP component, may vary or may be uniform. In certain embodiments, the ELP component is constructed of a polytetra-, polypenta-, polyhexa-, polyhepta-, polyocta, and polynonapeptide motif of repeating structural units. Exemplary structural units include units defined by SEQ ID NOS: 1-12 (below), which may be employed as repeating structural units, including tandem-repeating units, or may be employed in some combination, to create an ELP effective for improving the properties of the therapeutic component. Thus, the ELP component may comprise or consist essentially of structural unit(s) selected from SEQ ID NOS: 1-12, as defined below.</p><p id="p-0047" num="0046">The ELP component, comprising such structural units, may be of varying sizes. For example, the ELP component may comprise or consist essentially of from about 10 to about 500 structural units, or in certain embodiments about 15 to about 150 structural units, or in certain embodiments from about 20 to about 100 structural units, or from about 50 to about 90 structural units, including one or a combination of units defined by SEQ ID NOS: 1-12. Thus, the ELP component may have a length of from about 50 to about 2000 amino acid residues, or from about 100 to about 600 amino acid residues, or from about 200 to about 500 amino acid residues, or from about 200 to about 400 amino acid residues.</p><p id="p-0048" num="0047">In some embodiments, the ELP component, or in some cases the therapeutic agent, has a size of less than about 65 kDa, or less than about 60 kDa, or less than about 55 kDa, or less than about 50 kDa, or less than about 40 kDa, or less than about 30 or 25 kDa. Three major blood proteins, Human Serum Albumin (HSA), Transferrin (Tf) and IgG, or the Fc portion of IgGs in their glycosylated form, have been exploited to extend the half-lives of proteins and peptides for improved therapeutic use. These molecules are 585, 679 and 480 amino acids in length giving molecular weights of about 66, 77, and &#x2dc;75 kDa (including glycosylations), respectively. They are each globular and relatively compact. The half life of these molecules is determined by a number of factors, including charge distribution, rescue of molecules by the neonatal Fc receptor (FcRn) (HSA and Fc) or cycling of Tf through the Tf receptor (TfR), and their size which prevents filtering through the kidney glomerulus. HSA is slightly below the generally regarded cut-off for filtration through the kidney (&#x2dc;70 kDa) but its charge distribution helps prevent this. It would be anticipated that, in order to achieve half-life extension of the same order as that achieved with HSA, Tf and Fc, a protein of at least this molecular weight range would be required or desirable, i.e. having over 550 amino acids and being over 65 kDa. However, an ELP with a small number of amino acids relative to HSA, Tf and Fc (e.g., in the range of about 300 to 400) and around 30 to 40 kDa may have a half life that matches and/or exceeds that of HSA, Tf, and Fc.</p><p id="p-0049" num="0048">In some embodiments, the ELP component in the untransitioned state may have an extended, relatively unstructured and non-globular form, and thus such molecules may have a large expanded structure in comparison to HSA, Tf and Fc, so as to escape kidney filtration. In such embodiments, the therapeutic agents of the invention have a molecular weight of less than the generally recognized cut-off for filtration through the kidney, such as less than about 60 kD, or in some embodiments less than about 55, 50, 45, 40, 30, or 25 kDa, and persist in the body by at least 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, 20-fold, or 100-fold longer than an uncoupled (e.g., unfused or unconjugated) therapeutic counterpart.</p><p id="p-0050" num="0049">In certain embodiments, the ELP component undergoes a reversible inverse phase transition. That is, the ELP components are structurally disordered and highly soluble in water below a transition temperature (Tt), but exhibit a sharp (2-3&#xb0; C. range) disorder-to-order phase transition when the temperature is raised above the Tt, leading to desolvation and aggregation of the ELP components. For example, the ELP forms insoluble polymers, when reaching sufficient size, which can be readily removed and isolated from solution by centrifugation. Such phase transition is reversible, and isolated insoluble ELPs can be completely resolubilized in buffer solution when the temperature is returned below the Tt of the ELPs. Thus, the therapeutic agents of the invention can, in some embodiments, be separated from other contaminating proteins to high purity using inverse transition cycling procedures, e.g., utilizing the temperature-dependent solubility of the therapeutic agent, or salt addition to the medium. Successive inverse phase transition cycles can be used to obtain a high degree of purity. In addition to temperature and ionic strength, other environmental variables useful for modulating the inverse transition of the therapeutic agents include pH, the addition of inorganic and organic solutes and solvents, side-chain ionization or chemical modification, and pressure.</p><p id="p-0051" num="0050">In certain embodiments, the ELP component does not undergo a reversible inverse phase transition, or does not undergo such a transition at a biologically relevant Tt, and thus the improvements in the biological and/or physiological properties of the molecule (as described elsewhere herein), may be entirely or substantially independent of any phase transition properties. Nevertheless, such phase transition properties may impart additional practical advantages, for example, in relation to the recovery and purification of such molecules.</p><p id="p-0052" num="0051">In certain embodiments, the ELP component(s) may be formed of structural units, including but not limited to:<ul id="ul0001" list-style="none">    <li id="ul0001-0001" num="0000">    <ul id="ul0002" list-style="none">        <li id="ul0002-0001" num="0052">(a) the tetrapeptide Val-Pro-Gly-Gly, or VPGG (SEQ ID NO: 1);</li>        <li id="ul0002-0002" num="0053">(b) the tetrapeptide Ile-Pro-Gly-Gly, or IPGG (SEQ ID NO: 2);</li>        <li id="ul0002-0003" num="0054">(c) the pentapeptide Val-Pro-Gly-X-Gly (SEQ ID NO: 3), or VPGXG, where X is any natural or non-natural amino acid residue, and where X optionally varies among polymeric or oligomeric repeats;</li>        <li id="ul0002-0004" num="0055">(d) the pentapeptide Ala-Val-Gly-Val-Pro, or AVGVP (SEQ ID NO: 4);</li>        <li id="ul0002-0005" num="0056">(e) the pentapeptide Ile-Pro-Gly-X-Gly, or IPGXG (SEQ ID NO: 5), where X is any natural or non-natural amino acid residue, and where X optionally varies among polymeric or oligomeric repeats;</li>        <li id="ul0002-0006" num="0057">(e) the pentapeptide Ile-Pro-Gly-Val-Gly, or IPGVG (SEQ ID NO: 6);</li>        <li id="ul0002-0007" num="0058">(f) the pentapeptide Leu-Pro-Gly-X-Gly, or LPGXG (SEQ ID NO: 7), where X is any natural or non-natural amino acid residue, and where X optionally varies among polymeric or oligomeric repeats;</li>        <li id="ul0002-0008" num="0059">(g) the pentapeptide Leu-Pro-Gly-Val-Gly, or LPGVG (SEQ ID NO: 8);</li>        <li id="ul0002-0009" num="0060">(h) the hexapeptide Val-Ala-Pro-Gly-Val-Gly, or VAPGVG (SEQ ID NO: 9);</li>        <li id="ul0002-0010" num="0061">(I) the octapeptide Gly-Val-Gly-Val-Pro-Gly-Val-Gly, or GVGVPGVG (SEQ ID NO: 10);</li>        <li id="ul0002-0011" num="0062">(J) the nonapeptide Val-Pro-Gly-Phe-Gly-Val-Gly-Ala-Gly, or VPGFGVGAG (SEQ ID NO: 11); and</li>        <li id="ul0002-0012" num="0063">(K) the nonapeptides Val-Pro-Gly-Val-Gly-Val-Pro-Gly-Gly, or VPGVGVPGG (SEQ ID NO: 12).<br/>Such structural units defined by SEQ ID NOS:1-12 may form structural repeat units, or may be used in combination to form an ELP component in accordance with the invention. In some embodiments, the ELP component is formed entirely (or almost entirely) of one or a combination of (e.g., 2, 3 or 4) structural units selected from SEQ ID NOS: 1-12. In other embodiments, at least 75%, or at least 80%, or at least 90% of the ELP component is formed from one or a combination of structural units selected from SEQ ID NOS: 1-12, and which may be present as repeating units.</li>    </ul>    </li></ul></p><p id="p-0053" num="0064">In certain embodiments, the ELP component(s) contain repeat units, including tandem repeating units, of the pentapeptide Val-Pro-Gly-X-Gly (SEQ ID NO:3), where X is as defined above, and where the percentage of Val-Pro-Gly-X-Gly (SEQ ID NO:3) pentapeptide units taken with respect to the entire ELP component (which may comprise structural units other than VPGXG (SEQ ID NO:3)) is greater than about 75%, or greater than about 85%, or greater than about 95% of the ELP component. The ELP component may contain motifs having a 5 to 15-unit repeat (e.g. about 10-unit repeat) of the pentapeptide of SEQ ID NO: 3, with the guest residue X varying among at least 2 or at least 3 of the units. The guest residues may be independently selected, such as from the amino acids V, I, L, A, G, and W (and may be selected so as to retain a desired inverse phase transition property). The repeat motif itself may be repeated, for example, from about 5 to about 12 times, such as about 8 to 10 times, to create an exemplary ELP component. The ELP component as described in this paragraph may of course be constructed from any one of the structural units defined by SEQ ID NOS: 1-12, or a combination thereof.</p><p id="p-0054" num="0065">In some embodiments, the ELP component may include a &#x3b2;-turn structure. Exemplary peptide sequences suitable for creating a &#x3b2;-turn structure are described in International Patent Application PCT/US96/05186, which is hereby incorporated by reference in its entirety. For example, the fourth residue (X) in the elastin pentapeptide sequence, VPGXG (SEQ ID NO:3), can be altered without eliminating the formation of a &#x3b2;-turn. Alternatively, the ELP component may lack a &#x3b2;-turn, or otherwise have a different conformation and/or folding character.</p><p id="p-0055" num="0066">In certain embodiments, the ELP components include polymeric or oligomeric repeats of the pentapeptide VPGXG (SEQ ID NO: 3), where the guest residue X is any amino acid. X may be a naturally occurring or non-naturally occurring amino acid. In some embodiments, X is selected from alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, serine, threonine, tryptophan, tyrosine and valine. In some embodiments, X is a natural amino acid other than proline or cysteine.</p><p id="p-0056" num="0067">The guest residue X (e.g., with respect to SEQ ID NO: 3, or other ELP structural unit) may be a non-classical (non-genetically encoded) amino acid. Examples of non-classical amino acids include: D-isomers of the common amino acids, 2,4-diaminobutyric acid, &#x3b1;-amino isobutyric acid, A-aminobutyric acid, Abu, 2-amino butyric acid, &#x3b3;-Abu, &#x3b5;-Ahx, 6-amino hexanoic acid, Aib, 2-amino isobutyric acid, 3-amino propionic acid, omithine, norieucine, norvaline, hydroxyproline, sarcosine, citrulline, homocitrulline, cysteic acid, t-butylglycine, t-butylalanine, phenyiglycine, cyclohexylalanine, &#x3b2;-alanine, fluoro-amino acids, designer amino acids such as &#x3b2;-methyl amino acids, C&#x3b1;-methyl amino acids, N&#x3b1;-methyl amino acids, and amino acid analogs in general.</p><p id="p-0057" num="0068">Selection of X is independent in each ELP structural unit (e.g., for each structural unit defined herein having a guest residue X). For example, X may be independently selected for each structural unit as an amino acid having a positively charged side chain, an amino acid having a negatively charged side chain, or an amino acid having a neutral side chain, including in some embodiments, a hydrophobic side chain.</p><p id="p-0058" num="0069">In still other embodiments, the ELP component(s) may include polymeric or oligomeric repeats of the pentapeptides VPGXG (SEQ ID NO:3), IPGXG (SEQ ID NO:5) or LPGXG (SEQ ID NO:7), or a combination thereof, where X is as defined above.</p><p id="p-0059" num="0070">In each embodiment, the structural units, or in some cases polymeric or oligomeric repeats, of the ELP sequences may be separated by one or more amino acid residues that do not eliminate the overall effect of the molecule, that is, in imparting certain improvements to the therapeutic component as described. In certain embodiments, such one or more amino acids also do not eliminate or substantially affect the phase transition properties of the ELP component (relative to the deletion of such one or more amino acids).</p><p id="p-0060" num="0071">In each repeat, X is independently selected. The structure of the resulting ELP components may be described using the notation ELPk [X<sub>i</sub>Y<sub>j</sub>-n], where k designates a particular ELP repeat unit, the bracketed capital letters are single letter amino acid codes and their corresponding subscripts designate the relative ratio of each guest residue X in the structural units (where applicable), and n describes the total length of the ELP in number of the structural repeats. For example, ELP1 [V<sub>5</sub>A<sub>2</sub>G<sub>3</sub>-10] designates an ELP component containing 10 repeating units of the pentapeptide VPGXG (SEQ ID NO:3), where X is valine, alanine, and glycine at a relative ratio of 5:2:3; ELP1 [K<sub>1</sub>V<sub>2</sub>F<sub>1</sub>-4] designates an ELP component containing 4 repeating units of the pentapeptide VPGXG (SEQ ID NO:3), where X is lysine, valine, and phenylalanine at a relative ratio of 1:2:1; ELP1 [K<sub>1</sub>V<sub>7</sub>F<sub>1</sub>-9] designates a polypeptide containing 9 repeating units of the pentapeptide VPGXG (SEQ ID NO:3), where X is lysine, valine, and phenylalanine at a relative ratio of 1:7:1; ELP1 [V-5] designates a polypeptide containing 5 repeating units of the pentapeptide VPGXG (SEQ ID NO:3), where X is exclusively valine; ELP1 [V-20] designates a polypeptide containing 20 repeating units of the pentapeptide VPGXG (SEQ ID NO:3), where X is exclusively valine; ELP2 [5] designates a polypeptide containing 5 repeating units of the pentapeptide AVGVP (SEQ ID NO:4); ELP3 [V-5] designates a polypeptide containing 5 repeating units of the pentapeptide IPGXG (SEQ ID NO:5), where X is exclusively valine; ELP4 [V-5] designates a polypeptide containing 5 repeating units of the pentapeptide LPGXG (SEQ ID NO:7), where X is exclusively valine. Such ELP components as described in this paragraph may be used in connection with the present invention to increase the therapeutic properties of the therapeutic component.</p><p id="p-0061" num="0072">Further, the Tt is a function of the hydrophobicity of the guest residue. Thus, by varying the identity of the guest residue(s) and their mole fraction(s), ELPs can be synthesized that exhibit an inverse transition over a 0-100&#xb0; C. range. Thus, the Tt at a given ELP length may be decreased by incorporating a larger fraction of hydrophobic guest residues in the ELP sequence. Examples of suitable hydrophobic guest residues include valine, leucine, isoleucine, phenyalanine, tryptophan and methionine. Tyrosine, which is moderately hydrophobic, may also be used. Conversely, the Tt may be increased by incorporating residues, such as those selected from the group consisting of: glutamic acid, cysteine, lysine, aspartate, alanine, asparagine, serine, threonine, glycine, arginine, and glutamine; preferably selected from alanine, serine, threonine and glutamic acid.</p><p id="p-0062" num="0073">The ELP component in some embodiments is selected or designed to provide a Tt ranging from about 10 to about 80&#xb0; C., such as from about 35 to about 60&#xb0; C., or from about 38 to about 45&#xb0; C. In some embodiments, the Tt is greater than about 40&#xb0; C. or greater than about 42&#xb0; C., or greater than about 45&#xb0; C., or greater than about 50&#xb0; C. The transition temperature, in some embodiments, is above the body temperature of the subject or patient (e.g., &#x3e;37&#xb0; C.) thereby remaining soluble in vivo, or in other embodiments, the Tt is below the body temperature (e.g., &#x3c;37&#xb0; C.) to provide alternative advantages, such as in vivo formation of a drug depot for sustained release of the therapeutic agent.</p><p id="p-0063" num="0074">The Tt of the ELP component can be modified by varying ELP chain length, as the Tt generally increases with decreasing MW. For polypeptides having a molecular weight &#x3e;100,000, the hydrophobicity scale developed by Urry et al. (PCT/US96/05186, which is hereby incorporated by reference in its entirety) is preferred for predicting the approximate Tt of a specific ELP sequence. However, in some embodiments, ELP component length can be kept relatively small, while maintaining a target Tt, by incorporating a larger fraction of hydrophobic guest residues (e.g., amino acid residues having hydrophobic side chains) in the ELP sequence. For polypeptides having a molecular weight &#x3c;100,000, the Tt may be predicted or determined by the following quadratic function: Tt=M<sub>0</sub>+M<sub>1</sub>X+M<sub>2</sub>X<sup>2 </sup>where X is the MW of the fusion protein, and M<sub>0</sub>=116.21; M<sub>1</sub>=&#x2212;1.7499; M<sub>2</sub>=0.010349.</p><p id="p-0064" num="0075">While the Tt of the ELP component, and therefore of the ELP component coupled to a therapeutic component, is affected by the identity and hydrophobicity of the guest residue, X, additional properties of the molecule may also be affected. Such properties include, but are not limited to solubility, bioavailability, persistence, and half-life of the molecule.</p><p id="p-0065" num="0076">As described in PCT/US2007/077767 (published as WO 2008/030968), which is hereby incorporated by reference in its entirety, the ELP-coupled therapeutic component can retain the therapeutic component's biological activity. Additionally, ELPs themselves can exhibit long half-lives. Therefore, ELP components in accordance with the present invention substantially increase (e.g. by greater than 10%, 20%, 30%, 50%, 100%, 200%, 500% or more, in specific embodiments) the half-life of the therapeutic component when conjugated thereto. Such half-life (or in some embodiments persistance or rate of clearance) is determined in comparison to the half-life of the free (unconjugated or unfused) form of the therapeutic component. Furthermore, ELPs may target high blood content organs, when administered in vivo, and thus, can partition in the body, to provide a predetermined desired corporeal distribution among various organs or regions of the body, or a desired selectivity or targeting of a therapeutic agent. In sum, the therapeutic agents contemplated by the invention are administered or generated in vivo as active compositions having extended half-lives (e.g., circulatory half-life), among other potential benefits described herein.</p><p id="p-0066" num="0077">The invention thus provides various agents for therapeutic (in vivo) application, where the therapeutic component is biologically active. Such therapeutic components include those listed in Table 1 (e.g., full length or functional portions or functional analogs thereof), as well as GLP-1 receptor agonists such as GLP-1 or exendin-4, insulin, or Factor VII/VIIa, and functional analogs thereof. The structure and activity of such therapeutic components are described in detail below. In some forms of the therapeutic agent, the coupling of the therapeutic component to the ELP component is effected by direct covalent bonding or indirect (through appropriate spacer groups) bonding (as described elsewhere herein). Further, the therapeutic component(s) and the ELP component(s) can be structurally arranged in any suitable manner involving such direct or indirect covalent bonding, relative to one another.</p><heading id="h-0009" level="2">Glucagon-Like Peptide (GLP)-1 Receptor Agonists</heading><p id="p-0067" num="0078">In certain embodiments of the invention, the therapeutic agent comprises an ELP component fused or conjugated to a GLP-1 receptor agonist, such as GLP-1, exendin-4, or functional analogs thereof.</p><p id="p-0068" num="0079">Human GLP-1 is a 37 amino acid residue peptide originating from preproglucagon which is synthesized in the L-cells in the distal ileum, in the pancreas, and in the brain. Processing of preproglucagon to give GLP-1 (7-36)amide, GLP-1 (7-37) and GLP-2 occurs mainly in the L-cells. A simple system is used to describe fragments and analogs of this peptide. For example, Gly-GLP-1 (7-37) designates a fragment of GLP-1 formally derived from GLP-1 by deleting the amino acid residues Nos. 1 to 6 and substituting the naturally occurring amino acid residue in position 8 (Ala) by Gly. Similarly, Lys<sup>34 </sup>(N<sup>&#x3b5;</sup>-tetradecanoyl)-GLP-1(7-37) designates GLP-1 (7-37) wherein the &#x3b5;-amino group of the Lys residue in position 34 has been tetradecanoylated. Where reference in this text is made to C-terminally extended GLP-1 analogues, the amino acid residue in position 38 is Arg unless otherwise indicated, the optional amino acid residue in position 39 is also Arg unless otherwise indicated and the optional amino acid residue in position 40 is Asp unless otherwise indicated. Also, if a C-terminally extended analogue extends to position 41, 42, 43, 44 or 45, the amino acid sequence of this extension is as in the corresponding sequence in human preproglucagon unless otherwise indicated.</p><p id="p-0069" num="0080">The parent peptide of GLP-1, proglucagon (PG), has several cleavage sites that produce various peptide products dependent on the tissue of origin including glucagon (PG[32-62]) and GLP-1[7-36]NH<sub>2 </sub>(PG[72-107]) in the pancreas, and GLP-1[7-37] (PG[78-108]) and GLP-1[7-36]NH<sub>2 </sub>(PG [78-107]) in the L cells of the intestine where GLP-1[7-36]NH<sub>2 </sub>(78-107 PG) is the major product. The GLP-1 component in accordance with the invention may be any biologically active product or deivative of proglocagon, or functional analog thereof, including: GLP-1 (1-35), GLP-1(1-36), GLP-1 (1-36)amide, GLP-1 (1-37), GLP-1 (1-38), GLP-1 (1-39), GLP-1 (1-40), GLP-1 (1-41), GLP-1 (7-35), GLP-1 (7-36), GLP-1 (7-36)amide, GLP-1 (7-37), GLP-1 (7-38), GLP-1 (7-39), GLP-1 (7-40) and GLP-1 (7-41), or a analog of the foregoing. Generally, the GLP-1 component in some embodiments may be expressed as GLP-1 (A-B), where A is an integer from 1 to 7 and B is an integer from 38 to 45, optionally with one or more amino acid substitutions as defined below.</p><p id="p-0070" num="0081">As an overview, after processing in the intestinal L-cells, GLP-1 is released into the circulation, most notably in response to a meal. The plasma concentration of GLP-1 rises from a fasting level of approximately 15 pmol/L to a peak postprandial level of 40 pmol/L. For a given rise in plasma glucose concentration, the increase in plasma insulin is approximately threefold greater when glucose is administered orally compared with intravenously (Kreymann et al., 1987<i>, Lancet </i>2(8571): 1300-4). This alimentary enhancement of insulin release, known as the incretin effect, is primarily humoral and GLP-1 is now thought to be the most potent physiological incretin in humans. GLP-1 mediates insulin production via binding to the GLP-1 receptor, known to be expressed in pancreatic &#x3b2; cells. In addition to the insulinotropic effect, GLP-1 suppresses glucagon secretion, delays gastric emptying (Wettergen et al., 1993<i>, Dig Dis Sci </i>38: 665-73) and may enhance peripheral glucose disposal (D'Alessio et al., 1994<i>, J. Clin Invest </i>93: 2293-6).</p><p id="p-0071" num="0082">A combination of actions gives GLP-1 unique therapeutic advantages over other agents currently used to treat non-insulin-dependent diabetes mellitus (NIDDM). First, a single subcutaneous dose of GLP-1 can completely normalize post prandial glucose levels in patients with NIDDM (Gutniak et al., 1994<i>, Diabetes Care </i>17: 1039-44). This effect may be mediated both by increased insulin release and by a reduction in glucagon secretion. Second, intravenous infusion of GLP-1 can delay postprandial gastric emptying in patients with NIDDM (Williams et al., 1996<i>, J. Clin Endo Metab </i>81: 327-32). Third, unlike sulphonylureas, the insulinotropic action of GLP-1 is dependent on plasma glucose concentration (Holz et al., 1993<i>, Nature </i>361:362-5). Thus, the loss of GLP-1-mediated insulin release at low plasma glucose concentration protects against severe hypoglycemia.</p><p id="p-0072" num="0083">When given to healthy subjects, GLP-1 potently influences glycemic levels as well as insulin and glucagon concentrations (Orskov, 1992<i>, Diabetologia </i>35:701-11), effects which are glucose dependent (Weir et al., 1989<i>, Diabetes </i>38: 338-342). Moreover, it is also effective in patients with diabetes (Gutniak, M., 1992<i>, N. Engl J Med </i>226: 1316-22), normalizing blood glucose levels in type 2 diabetic subjects and improving glycemic control in type 1 patients (Nauck et al., 1993<i>, Diabetologia </i>36: 741-4, Creutzfeldt et al., 1996<i>, Diabetes Care </i>19:580-6).</p><p id="p-0073" num="0084">GLP-1 is, however, metabolically unstable, having a plasma half-life (t<sub>1/2</sub>) of only 1-2 minutes in vivo. Moreover, exogenously administered GLP-1 is also rapidly degraded (Deacon et al., 1995<i>, Diabetes </i>44: 1126-31). This metabolic instability has limited the therapeutic potential of native GLP-1.</p><p id="p-0074" num="0085">GLP-1[7-36]NH<sub>2 </sub>has the following amino acid sequence: HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR (SEQ ID NO: 13), which may be employed as the GLP-1 component in accordance with the invention. Alternatively, the GLP-1 component may contain glycine (G) at the second position, giving, for example, the sequence HGEGTFTSDVSSYLEGQAAKEFIAWLVKGR (SEQ ID NO: 17). The GLP-1 component may be a biologically active fragment of GLP-1, for example, as disclosed in US 2007/0041951, which is hereby incorporated by reference in its entirety. Other fragments and modified sequences of GLP-1 are known in the art (U.S. Pat. Nos. 5,614,492; 5,545,618; European Patent Application, Publication No. EP 0658568 A1; WO 93/25579, which are hereby incorporated by reference in their entireties). Such fragments and modified sequences may be used in connection with the present invention, as well as those described below.</p><p id="p-0075" num="0086">Certain structural and functional analogs of GLP-1 have been isolated from the venom of the Gila monster lizards (<i>Heloderma suspectum </i>and <i>Heloderma horridum</i>) and have shown clinical utility. Such molecules find use in accordance with the present invention. In particular, exendin-4 is a 39 amino acid residue peptide isolated from the venom of <i>Heloderma suspectum </i>and shares approximately 52% homology with human GLP-1. Exendin-4 is a potent GLP-1 receptor agonist that stimulates insulin release, thereby lowering blood glucose levels. Exendin-4 has the following amino acid sequence: HGEGTFTSDLSKQMEEEAVRLFEWLKNGGPSSGAPPPS (SEQ ID NO: 14). A synthetic version of exendin-4 known as exenatide (marketed as Byetta&#xae;) has been approved for the treatment of Type-2 Diabetes. Although exenatide is structurally analogous to native GLP-1, it has a longer half-life after injection.</p><p id="p-0076" num="0087">While exenatide has the ability to lower blood glucose levels on its own, it can also be combined with other medications such as metformin, a thiozolidinedione, a sulfonylureas, and/or insulin to improve glucose control. Exenatide is administered by injection subcutaneously twice per day using a pre-filled pen device. Typical human responses to exenatide include improvements in the initial rapid release of endogenous insulin, an increase in &#x3b2;-cell growth and replication, suppression of pancreatic glucagon release, delayed gastric emptying, and reduced appetite&#x2014;all of which function to lower blood glucose. Unlike sulfonylureas and meglitinides, exenatide increases insulin synthesis and secretion in the presence of glucose only, thus lessening the risk of hypoglycemia. Despite the therapeutic utility of exenatide, it has certain undesirable traits, including the requirement of twice daily injections, gastrointestional side effects, and similar to native GLP-1, a relatively short half-life (i.e. approximately 2 hr).</p><p id="p-0077" num="0088">Various functional analogs of GLP-1 and exendin-4 are known, and which find use in accordance with the invention. These include liraglutide (Novo Nordisk, WO98/008871), R1583/taspoglutide (Roche, WO00/034331), CJC-1131 (ConjuChem, WO00/069911), ZP-10/AVE0010 (Zealand Pharma, Sanofi-Aventis, WO01/004156), and LY548806 (Eli Lilly, WO03/018516).</p><p id="p-0078" num="0089">Liraglutide, also known as NN2211, is a GLP-1 receptor agonist analog that has been designed for once-daily injection (Harder et al., 2004<i>, Diabetes Care </i>27: 1915-21). Liraglutide has been tested in patients with type-2 diabetes in a number of studies and has been shown to be effective over a variety of durations. In one study, treatment with liraglutide improved glycemic control, improved &#x3b2;-cell function, and reduced endogenous glucose release in patients with type-2 diabetes after one week of treatment (Degn et al., 2004<i>, Diabetes </i>53: 1187-94). In a similar study, eight weeks of 0.6-mg liraglutide therapy significantly improved glycemic control without increasing weight in subjects with type 2 diabetes compared with those on placebo (Harder et al., 2004<i>, Diabetes Care </i>27: 1915-21).</p><p id="p-0079" num="0090">Thus, in certain embodiments, the GLP-1 receptor agonist in accordance with the invention is as described in WO98/008871, which is hereby incorporated by reference in its entirety. The GLP-1 receptor agonist may have at least one lipophilic substituent, in addition to one, two, or more amino acid substitutions with respect to native GLP-1. For example, the lipophilic substituent may be an acyl group selected from CH<sub>3</sub>(CH<sub>2</sub>)<sub>n</sub>CO&#x2014;, wherein n is an integer from 4 to 38, such as an integer from 4 to 24. The lipophilic substituent may be an acyl group of a straight-chain or branched alkyl or fatty acid (for example, as described in WO98/008871, which description is hereby incorporated by reference).</p><p id="p-0080" num="0091">In certain embodiments, the GLP-1 component is Arg<sup>26</sup>-GLP-1 (7-37), Arg<sup>34</sup>-GLP-1(7-37), Lys<sup>36</sup>-GLP-1 (7-37), Arg<sup>26,34</sup>Lys<sup>36</sup>-GLP-I (7-37), Arg<sup>26,34</sup>Lys<sup>36</sup>-GLP-1 (7-38), Arg<sup>28,34 </sup>Lys<sup>39</sup>-GLP-1 (7-39), Arg<sup>26,34</sup>Lys<sup>40</sup>-GLP-1(7-40), Arg<sup>26</sup>Lys<sup>36</sup>-GLP-1(7-37), Arg<sup>34</sup>Lys<sup>36</sup>-GLP-1(7-37), Arg<sup>26</sup>Lys<sup>39</sup>-GLP-1(7-39), Arg<sup>34</sup>Lys<sup>40</sup>-GLP-1(7-40), Arg<sup>26,34</sup>Lys<sup>36,39</sup>-GLP-I (7-39), Arg<sup>26,34</sup>Lys<sup>36,40</sup>-GLP-1(7-40), Gly<sup>8</sup>Arg<sup>26</sup>-GLP-1(7-37); Gly<sup>8</sup>Arg<sup>34</sup>-GLP-1(7-37); Gly<sup>8</sup>Lys<sup>38</sup>-GLP-1(7-37); Gly<sup>8</sup>Arg<sup>26,34</sup>Lys<sup>36</sup>-GLP-1(7-37), Gly<sup>8</sup>Arg<sup>26,34</sup>Lys<sup>39</sup>-GLP-1(7-39), Gly<sup>8</sup>Arg<sup>26,34</sup>Lys<sup>40</sup>-GLP-1(7-40), Gly<sup>8</sup>Arg<sup>26</sup>Lys<sup>36</sup>-GLP-1(7-37), Gly<sup>8</sup>Arg<sup>34</sup>Lys<sup>36</sup>-GLP-1(7-37), Gly<sup>8</sup>Arg<sup>26</sup>Lys<sup>39</sup>-GLP-1(7-39); Gly<sup>8</sup>Arg<sup>34</sup>Lys<sup>40</sup>-GLP-1(7-40), Gly<sup>8</sup>Arg<sup>26,34</sup>Lys<sup>36,39</sup>GLP-1(7-39) and Gly<sup>8</sup>Arg<sup>26,34</sup>Lys<sup>35,40</sup>-GLP-1(7-40), each optionally having a lipophilic substituent. For example, the GLP-1 receptor agonist may have the sequence/structure Arg<sup>34</sup>Lys<sup>26</sup>-(N-&#x3b5;-(&#x3b3;-Glu(N-&#x3b1;-hexadecanoyl)))-GLP-1(7-37).</p><p id="p-0081" num="0092">Taspoglutide, also known as R1583 or BIM 51077, is a GLP-1 receptor agonist that has been shown to improve glycemic control and lower body weight in subjects with type 2 diabetes mellitus treated with metformin (Abstract No. A-1604, Jun. 7, 2008, 68th American Diabetes Association Meeting, San Francisco, Calif.).</p><p id="p-0082" num="0093">Thus, in certain embodiments, the GLP-1 receptor agonist is as described in WO00/034331, which is hereby incorporated by reference in its entirety. In certain exemplary embodiments, the GLP-1 receptor agonist has the sequence [Aib<sup>8,35</sup>]hGLP-1(7-36)NH<sub>2 </sub>(e.g. taspoglutide), wherein Aib is alpha-aminoisobutyric acid.</p><p id="p-0083" num="0094">CJC-1131 is a GLP-1 analog that consists of a DPP-IV-resistant form of GLP-1 joined to a reactive chemical linker group that allows GLP-1 to form a covalent and irreversible bond with serum albumin following subcutaneous injection (Kim et al., 2003<i>, Diabetes </i>52: 751-9). In a 12-week, randomized, double-blind, placebo-controlled multicenter study, CJC-1131 and metformin treatment was effective in reducing fasting blood glucose levels in type 2 diabetes patients (Ratner et al., Abstract No. 10-OR, Jun. 10-14, 2005, 65th American Diabetes Association Meeting, San Francisco, Calif.).</p><p id="p-0084" num="0095">Thus, in certain embodiments, the GLP-1 receptor agonist is as described in WO00/069911, which is hereby incorporated by reference in its entirety. In some embodiments, the GLP-1 receptor agonist is modified with a reactive group which reacts with amino groups, hydroxyl groups or thiol groups on blood components to form a stable covalent bond. In certain embodiments, the GLP-1 receptor agonist is modified with a reactive group selected from the group consisting of succinimidyl and maleimido groups. In certain exemplary embodiments, the GLP-1 receptor agonist has the sequence/structure: D-Ala<sup>8</sup>Lys<sup>37</sup>-(2-(2-(2-maleimidopropionamido(ethoxy)ethoxy)acetamide))-GLP-1(7-37) (e.g. CJC-1131).</p><p id="p-0085" num="0096">AVE0010, also known as ZP-10, is a GLP-1 receptor agonist that may be employed in connection with the invention. In a recent double-blind study, patients treated with once daily dosing of AVE0010 demonstrated significant reductions in HbA1c levels (Ratner et al., Abstract No. 433-P, 68th American Diabetes Association Meeting, San Francisco, Calif.). At the conclusion of the study, the percentages of patients with HbA1c &#x3c;7% ranged from 47-69% for once daily dosing compared to 32% for placebo. In addition, AVE0010 treated patients showed dose-dependent reductions in weight and post-prandial plasma glucose.</p><p id="p-0086" num="0097">Thus, in certain embodiments, the GLP-1 receptor agonist is as described in WO01/004156, which is hereby incorporated by reference in its entirety. For example, the GLP-1 receptor agonist may have the sequence:</p><p id="p-0087" num="0000"><tables id="TABLE-US-00001" num="00001"><table frame="none" colsep="0" rowsep="0" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="right"/><tbody valign="top"><row><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;18)</entry></row><row><entry>HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPSKKKKKK-NH2.</entry></row><row><entry>(e.g.&#x2003;AVE0010)</entry></row></tbody></tgroup></table></tables></p><p id="p-0088" num="0098">LY548806 is a GLP-1 derivative designed to be resistant to proteolysis by dipeptidase-peptidyl IV (DPP-IV) (Jackson et al., Abstract No. 562, Jun. 10-14, 2005, 65th American Diabetes Association Meeting, San Francisco, Calif.). In an animal model of hyperglycemia, LY548806 has been shown to produce a significant lowering of blood glucose levels during the hyperglycemic phase (Saha et al., 2006, J. Pharm. Exp. Ther. 316: 1159-64). Moreover, LY548806 was shown to produce a significant increase in insulin levels consistent with its known mechanism of action, namely stimulation of insulin release in the presence of hyperglycemia.</p><p id="p-0089" num="0099">Thus, in certain embodiments, the GLP-1 receptor agonist is as described in WO03/018516, which is hereby incorporated by reference in its entirety. In some embodiments, the therapeutic agents of the present invention comprise GLP-1 analogs wherein the backbone for such analogs or fragments contains an amino acid other than alanine at position 8 (position 8 analogs). The backbone may also include L-histidine, D-histidine, or modified forms of histidine such as desamino-histidine, 2-amino-histidine, s-hydroxy-histidine, homohistidine, &#x3b1;-fluoromethyl-histidine, or &#x3b1;-methyl-histidine at position 7. In some embodiments, these position 8 analogs may contain one or more additional changes at positions 12, 16, 18, 19, 20, 22, 25, 27, 30, 33, and 37 compared to the corresponding amino acid of native GLP-1. In other embodiments, these position 8 analogs may contain one or more additional changes at positions 16, 18, 22, 25 and 33 compared to the corresponding amino acid of native GLP-1. In certain exemplary embodiments, the GLP-1 receptor agonist has the sequence: HVEGTFTSDVSSYLEEQAAKEFIAWLIKGRG-OH (SEQ ID NO: 19) (e.g. LY548806).</p><p id="p-0090" num="0100">Thus, the present invention provides therapeutic agents comprising an elastin-like peptide (ELP) and a GLP-1 receptor agonist. For example, in certain embodiments, the GLP-1 receptor agonist is GLP-1 (SEQ ID NO:13, 17, or 59) or a functional analog thereof. In other embodiments, the GLP-1 receptor agonist is exendin-4 (SEQ ID NO:14) or a functional analog thereof. Such functional analogs of GLP-1 or exendin-4 include functional fragments truncated at the C-terminus by from 1 to 10 amino acids, including by 1, 2, 3, or up to about 5 amino acids (with respect to SEQ ID NOS: 13, 14, 17, or 59). Such functional analogs may contain from 1 to 10 amino acid insertions, deletions, and/or substitutions (collectively) with respect to the native sequence (e.g., SEQ ID NOS 13, 14, and 59), and in each case retaining the activity of the peptide. For example, the functional analog of GLP-1 or exendin-4 may have from 1 to about 3, 4, or 5 insertions, deletions and/or substitutions (collectively) with respect to SEQ ID NOS: 13, 59 and 14, and in each case retaining the activity of the peptide. Such activity may be confirmed or assayed using any available assay, including those described herein. In these or other embodiments, the GLP-1 receptor agonist component has at least about 50%, 75%, 80%, 85%, 90%, or 95% identity with the native sequence (SEQ ID NOS: 13, 59, and 14). The determination of sequence identity between two sequences (e.g., between a native sequence and a functional analog) can be accomplished using any alignment tool, including Tatusova et al., <i>Blast </i>2 <i>sequences&#x2014;a new tool for comparing protein and nucleotide sequences, FEMS Miarobiol Left. </i>174:247-250 (1999). Such functional analogs may further comprise additional chemical modifications, such as those described in this section and/or others known in the art.</p><p id="p-0091" num="0101">In certain embodiments, the GLP1-ELP fusion has a sequence exemplified herein as SEQ ID NOS: 54 and 56. When processed, the mature form of such fusion protein will begin with the His<sup>7 </sup>of GLP.</p><p id="p-0092" num="0102">In another aspect, the present invention provides methods for the treatment or prevention of type 2 diabetes, impaired glucose tolerance, type 1 diabetes, hyperglycemia, obesity, binge eating, bulimia, hypertension, syndrome X, dyslipidemia, cognitive disorders, atheroschlerosis, non-fatty liver disease, myocardial infarction, coronary heart disease and other cardiovascular disorders. The method comprises administering the therapeutic agent comprising the elastin-like peptide (ELP) and the GLP-1 receptor agonist (as described above) to a patient in need of such treatment. In these or other embodiments, the present invention provides methods for decreasing food intake, decreasing &#x3b2;-cell apoptosis, increasing &#x3b2;-cell function and &#x3b2;-cell mass, and/or for restoring glucose sensitivity to &#x3b2;-cells. Generally, the patient may be a human or non-human animal patient (e.g., dog, cat, cow, or horse). Preferably, the patient is human.</p><p id="p-0093" num="0103">The treatment with a ELP/GLP-1 receptor agonist compound according to the present invention may also be combined with one or more pharmacologically active substances, e.g. selected from antidiabetic agents, antiobesity agents, appetite regulating agents, antihypertensive agents, agents for the treatment and/or prevention of complications resulting from or associated with diabetes and agents for the treatment and/or prevention of complications and disorders resulting from or associated with obesity. In the present context, the expression &#x201c;antidiabetic agent&#x201d; includes compounds for the treatment and/or prophylaxis of insulin resistance and diseases wherein insulin resistance is the pathophysiological mechanism.</p><p id="p-0094" num="0104">The ability of a GLP-1 or exendin-4 analog, or an GLP-1 receptor agonist/ELP compound, to bind the GLP-1 receptor may be determined by standard methods, for example, by receptor-binding activity screening procedures which involve providing appropriate cells that express the GLP-1 receptor on their surface, for example, insulinoma cell lines such as RINmSF cells or INS-1 cells. In addition to measuring specific binding of tracer to membrane using radioimmunoassay methods, cAMP activity or glucose dependent insulin production can also be measured. In one method, a polynucleotide encoding the GLP-1 receptor is employed to transfect cells to thereby express the GLP-1 receptor protein. Thus, these methods may be employed for testing or confirming whether a suspected GLP-1 receptor agonist is active. An exemplary assay is described in greater detail herein.</p><p id="p-0095" num="0105">In addition, known methods can be used to measure or predict the level of biologically activity of a GLP-1 receptor agonist or GLP-1 receptor agonist/ELP in vivo (See e.g. Siegel, et al., 1999<i>, Regul Pept </i>79(2-3): 93-102). In particular, GLP-1 receptor agonists or GLP-1 receptor agonist/ELP compounds can be assessed for their ability to induce the production of insulin in vivo using a variety of known assays for measuring GLP-1 activity. For example, an ELP/GLP-1 receptor agonist compound can be introduced into a cell, such as an immortalized &#x3b2;-cell, and the resulting cell can be contacted with glucose. If the cell produces insulin in response to the glucose, then the modified GLP-1 is generally considered biologically active in vivo (Fehmann et al., 1992<i>, Endoarinology </i>130: 159-166). An exemplary assay is described in greater detail herein.</p><p id="p-0096" num="0106">The ability of an GLP-1 receptor agonist/ELP compound to enhance &#x3b2;-cell proliferation, inhibit &#x3b2;-cell apoptosis, and regulate islet growth may also be measured using known assays. Pancreatic &#x3b2;-cell proliferation may be assessed by <sup>3</sup>H-tymidine or BrdU incorporation assays (See e.g. Buteau et al., 2003<i>, Diabetes </i>52: 124-32), wherein pancreatic &#x3b2;-cells such as INS(832/13) cells are contacted with an ELP/GLP-1 receptor agonist compound and analyzed for increases in <sup>3</sup>H-thymidine or BrdU incorporation. The antiapoptotic activity of an ELP/GLP-1 receptor agonist compound can be measured in cultured insulin-secreting cells and/or in animal models where diabetes occurs as a consequence of an excessive rate of beta-cell apoptosis (See e.g. Bulotta et al., 2004<i>, Cell Biochem Biophys </i>40(3 suppl): 65-78).</p><p id="p-0097" num="0107">In addition to GLP-1, other peptides of this family, such as those derived from processing of the pro-glucagon gene, such as GLP-2, GIP, and oxyntomodulin, could be conjugated or fused to the ELP component (as described herein) to enhance the therapeutic potential.</p><heading id="h-0010" level="2">Insulin</heading><p id="p-0098" num="0108">In other embodiments, the present invention provides a therapeutic agent comprising an ELP component coupled to insulin (e.g., via fusion or conjugation). Insulin injections, e.g. of human insulin, can be used to treat diabetes. The insulin-making cells of the body are called &#x3b2;-cells, and they are found in the pancreas gland. These cells clump together to form the &#x201c;islets of Langerhans&#x201d;, named for the German medical student who described them.</p><p id="p-0099" num="0109">The synthesis of insulin begins at the translation of the insulin gene, which resides on chromosome 11. During translation, two introns are spliced out of the mRNA product, which encodes a protein of 110 amino acids in length. This primary translation product is called preproinsulin and is inactive. It contains a signal peptide of 24 amino acids in length, which is required for the protein to cross the cell membrane.</p><p id="p-0100" num="0110">Once the preproinsulin reaches the endoplasmic reticulum, a protease cleaves off the signal peptide to create proinsulin. Proinsulin consists of three domains: an amino-terminal B chain, a carboxyl-terminal A chain, and a connecting peptide in the middle known as the C-peptide. Insulin is composed of two chains of amino acids named chain A (21 amino acids-GIVEQCCASVCSLYQLENYCN) (SEQ ID NO: 15) and chain B (30 amino acids FVNQHLCGSHLVEALYLVCGERGFFYTPKA) (SEQ ID NO: 16) that are linked together by two disulfide bridges. There is a 3rd disulfide bridge within the A chain that links the 6th and 11th residues of the A chain together. In most species, the length and amino acid compositions of chains A and B are similar, and the positions of the three disulfide bonds are highly conserved. For this reason, pig insulin can replace deficient human insulin levels in diabetes patients. Today, porcine insulin has largely been replaced by the mass production of human proinsulin by bacteria (recombinant insulin).</p><p id="p-0101" num="0111">Insulin molecules have a tendency to form dimers in solution, and in the presence of zinc ions, insulin dimers associate into hexamers. Whereas monomers of insulin readily diffuse through the blood and have a rapid effect, hexamers diffuse slowly and have a delayed onset of action. In the design of recombinant insulin, the structure of insulin can be modified in a way that reduces the tendency of the insulin molecule to form dimers and hexamers but that does not interrupt binding to the insulin receptor. In this way, a range of preparations are made, varying from short acting to long acting.</p><p id="p-0102" num="0112">Within the endoplasmic reticulum, proinsulin is exposed to several specific peptidases that remove the C-peptide and generate the mature and active form of insulin. In the Golgi apparatus, insulin and free C-peptide are packaged into secretory granules, which accumulate in the cytoplasm of the &#x3b2;-cells. Exocytosis of the granules is triggered by the entry of glucose into the beta cells. The secretion of insulin has a broad impact on metabolism.</p><p id="p-0103" num="0113">There are two phases of insulin release in response to a rise in glucose. The first is an immediate release of insulin. This is attributable to the release of preformed insulin, which is stored in secretory granules. After a short delay, there is a second, more prolonged release of newly synthesized insulin.</p><p id="p-0104" num="0114">Once released, insulin is active for a only a brief time before it is degraded by enzymes. Insulinase found in the liver and kidneys breaks down insulin circulating in the plasma, and as a result, insulin has a half-life of only about 6 minutes. This short duration of action results in rapid changes in the circulating levels of insulin.</p><p id="p-0105" num="0115">Insulin analogs have been developed with improved therapeutic properties (Owens et al., 2001<i>, Lancet </i>358: 739-46; Vajo et al., 2001<i>, Endocr Rev </i>22: 706-17), and such analogs may be employed in connection with the present invention. Various strategies, including elongation of the COOH-terminal end of the insulin B-chain and engineering of fatty acid-acylated insulins with substantial affinity for albumin are used to generate longer-acting insulin analogs. However, in vivo treatments with available longer-acting insulin compounds still result in a high frequency of hypo- and hyperglycemic excursions and modest reduction in HbA<sub>1c</sub>. Accordingly, development of a truly long-acting and stable human insulin analog still remains an important task.</p><p id="p-0106" num="0116">Functional analogs of insulin that may be employed in accordance with the invention include rapid acting analogs such as lispro, aspart and glulisine, which are absorbed rapidly (&#x3c;30 minutes) after subcutaneous injection, peak at one hour, and have a relatively short duration of action (3 to 4 hours). In addition, two long acting insulin analogs have been developed: glargine and detemir, and which may be employed in connection with the invention. The long acting insulin analogs have an onset of action of approximately two hours and reach a plateau of biological action at 4 to 6 hours, and may last up to 24 hours.</p><p id="p-0107" num="0117">Thus, in one embodiment, the insulin component may contain the A and/or B chain of lispro (also known as Humalog, Eli Lilly). Insulin lispro differs from human insulin by the substitution of proline with lysine at position 28 and the substitution of lysine with proline at position 29 of the insulin B chain. Although these modifications do not after receptor binding, they help to block the formation of insulin dimers and hexamers, allowing for larger amounts of active monomeric insulin to be available for postprandial injections.</p><p id="p-0108" num="0118">In another embodiment, the insulin may contain an A and/or B chain of aspart (also known as Novolog, Novo Nordisk). Insulin aspart is designed with the single replacement of the amino acid proline by aspartic acid at position 28 of the human insulin B chain. This modification helps block the formation for insulin hexamers, creating a faster acting insulin.</p><p id="p-0109" num="0119">In yet another embodiment, the insulin may contain an A and/or B chain of glulisine (also known as Apidra, Sanofi-Aventis). Insulin glulisine is a short acting analog created by substitution of asparagine at position 3 by lysine and lysine at position 29 by glutamine of human insulin B chain. Insulin glulisine has more rapid onset of action and shorter duration of action compared to regular human insulin.</p><p id="p-0110" num="0120">In another embodiment, the insulin may contain an A and/or B chain of glargine (also known as Lantus, Sanofi-Aventis). Insulin glargine differs from human insulin in that the amino acid asparagine at position 21 of the A chain is replaced by glycine and two arginines are added to the C-terminus of the B-chain. Compared with bedtime neutral protamine Hagedom (NPH) insulin (an intermediate acting insulin), insulin glargine is associated with less noctumal hypoglycemia in patients with type 2 diabetes.</p><p id="p-0111" num="0121">In yet another embodiment, the insulin may contain an A and/or B chain from detemir (also known as Levemir, Novo Nordisk). Insulin detemir is a soluble (at neutral pH) long-acting insulin analog, in which the amino acid threonine at B30 is removed and a 14-carbon, myristoyl fatty acid is acetylated to the epsilon-amino group of LysB29. After subcutaneous injection, detemir dissociates, thereby exposing the free fatty acid which enables reversible binding to albumin molecules. So at steady state, the concentration of free unbound insulin is greatly reduced resulting in stable plasma glucose levels.</p><p id="p-0112" num="0122">In some embodiments, the insulin may be a single-chain insulin analog (SIA) (e.g. as described in U.S. Pat. No. 6,630,438 and WO08/019368, which are hereby incorporated by reference in their entirety). Single-chain insulin analogs encompass a group of structurally-related proteins wherein the A and B chains are covalently linked by a polypeptide linker. The polypeptide linker connects the C-terminus of the B chain to the N-terminus of the A chain. The linker may be of any length so long as the linker provides the structural conformation necessary for the SIA to have a glucose uptake and insulin receptor binding effect. In some embodiments, the linker is about 5-18 amino acids in length. In other embodiments, the linker is about 9-15 amino acids in length. In certain embodiments, the linker is about 12 amino acids long. In certain exemplary embodiments, the linker has the sequence KDDNPNLPRLVR (SEQ ID NO.: 20) or GAGSSSRRAPQT (SEQ ID NO.: 21). However, it should be understood that many variations of this sequence are possible such as in the length (both addition and deletion) and substitutions of amino acids without substantially compromising the effectiveness of the produced SIA in glucose uptake and insulin receptor binding activities. For example, several different amino acid residues may be added or removed from either end without substantially decreasing the activity of the produced SIA.</p><p id="p-0113" num="0123">An exemplary single-chain insulin analog currently in clinical development is albulin (Duttaroy et al., 2005, Diabetes 54: 251-8). Albulin can be produced in yeast or in mammalian cells. It consists of the B and A chain of human insulin (100% identity to native human insulin) linked together by a dodecapeptide linker and fused to the NH<sub>2 </sub>terminals of the native human serum albumin. For expression and purification of albulin, Duttaroy et al. constructed a synthetic gene construct encoding a single-chain insulin containing the B- and A-chain of mature human insulin linked together by a dodecapeptide linker using four overlapping primers and PCR amplification. The resulting PCR product was ligated in-frame between the signal peptide of human serum albumin (HSA) and the NH<sub>2 </sub>terminus of mature HSA, contained within a pSAC35 vector for expression in yeast. In accordance with the present invention, the HSA component of abulin may be replaced with an ELP component as described herein.</p><p id="p-0114" num="0124">Thus, in one aspect, the present invention provides therapeutic agents comprising an elastin-like peptide (ELP) and an insulin or functional analog thereof. For example, in certain embodiments, the insulin is a mammalian insulin, such as human insulin or porcine insulin. In accordance with the invention, the ELP component may be coupled (e.g., via recombinant fusion or chemical conjugation) to the insulin A chain, or B chain, or both. The insulin may comprise each of chains A, B, and C (SEQ ID NOS: 51 and 52), or may contain a processed form, containing only chains A and B. In some embodiments, chains A and B are connected by a short linking peptide, to create a single chain insulin. The insulin may be a functional analog of human insulin, including functional fragments truncated at the N-terminus and/or C-terminus (of either or both of chains A and B) by from 1 to 10 amino acids, including by 1, 2, 3, or about 5 amino acids. Functional analogs may contain from 1 to 10 amino acid insertions, deletions, and/or substitutions (collectively) with respect to the native sequence (e.g., SEQ ID NOS 15 and 16), and in each case retaining the activity of the peptide. For example, functional analogs may have 1, 2, 3, 4, or 5 amino acid insertions, deletions, and/or substitutions (collectively) with respect to the native sequence (which may contain chains A and B, or chains A, B, and C). Such activity may be confirmed or assayed using any available assay, including those described herein. In these or other embodiments, the insulin component has at least about 75%, 80%, 85%, 90%, 95%, or 98% identity with each of the native sequences for chains A and B (SEQ ID NOS:15 and 16). The determination of sequence identity between two sequences (e.g., between a native sequence and a functional analog) can be accomplished using any alignment tool, including Tatusova et al., <i>Blast </i>2 <i>sequences&#x2014;a new tool for comparing protein and nucleotide seguences. FEMS Microbiol Left. </i>174:247-250 (1999). The insulin component may contain additional chemical modifications known in the art.</p><p id="p-0115" num="0125">In another aspect, the present invention provides methods for the treatment or prevention of diabetes, including type I and II diabetes. The method comprises administering an effective amount of the therapeutic agent comprising an elastin-like peptide (ELP) component and an insulin (or functional analog thereof) component to a patient in need thereof. Generally, the patient may be a human or non-human animal (e.g., dog, cat, cow, or horse) patient. Preferably, the patient is human.</p><p id="p-0116" num="0126">To characterize the in vitro binding properties of an insulin analog or an ELP-containing insulin analog, competition binding assays may be performed in various cell lines that express the insulin receptor (Jehle et al., 1996<i>, Diabetologia </i>39: 421-432). For example, competition binding assays using CHO cells overexpressing the human insulin receptor may be employed. Insulin can also bind to the IGF-1 receptor with a lower affinity than the insulin receptor. To determine the binding affinity of an ELP-containing insulin analog, a competition binding assay can be performed using <sup>125</sup>I-labeled IGF-1 in L6 cells.</p><p id="p-0117" num="0127">The activities of insulin include stimulation of peripheral glucose disposal and inhibition of hepatic glucose production. The ability of an ELP-containing insulin analog to mediate these biological activities can be assayed in vitro using known methodologies. For example, the effect of an ELP-containing analog on glucose uptake in 3T3-L1 adipocytes can be measured and compared with that of insulin. Pretreatment of the cells with a biologically active analog will generally produce a dose-dependent increase in 2-deoxyglucose uptake. The ability of an ELP-containing insulin analog to regulate glucose production may be measured in any number of cells types, for example, H4IIe hepatoma cells. In this assay, pretreatment with a biologically active analog will generally result in a dose-dependent inhibition of the amount of glucose released.</p><heading id="h-0011" level="2">Factor VII (VIIa)</heading><p id="p-0118" num="0128">In certain embodiments, the invention provides therapeutic agents comprising an ELP component coupled (e.g., via fusion or conjugation) to a Factor VII/VIIa. Coagulation is the biological process of blood clot formation involving many different serine proteases as well as their essential cofactors and inhibitors. It is initiated by exposure of Factor VII (FVII) and Factor VIIa (FVIIa) to its membrane bound cofactor, tissue factor (TF), resulting in production of Factor Xa (FXa) and more FVIIa. The process is propagated upon production of Factor IXa (FIXa) and additional FXa that, upon binding with their respective cofactors FVIIIa and FVa, form platelet bound complexes, ultimately resulting in the formation of thrombin and a fibrin clot. Thrombin also serves to further amplify coagulation by activation of cofactors such as FV and FVII and zymogens such as Factor XI. Moreover, thrombin activates platelets leading to platelet aggregation, which is necessary for the formation of a hemostatic plug.</p><p id="p-0119" num="0129">Factor VII circulates in the blood in a zymogen form, and is converted to its active form, Factor VIIa, by either factor IXa, factor Xa, factor XIIa, or thrombin by minor proteolysis. Factor VIIa is a two-chain, 50 kilodalton (kDa) plasma serine protease. The active form of the enzyme comprises a heavy chain (254 amino acid residues) containing a catalytic domain and a light chain (152 residues) containing 2 epidermal growth factor (EGF)-like domains. The mature factor VII/VIIa that circulates in plasma is composed of 406 amino acid residues (SEQ ID NO: 33). The light and heavy chains are held together by a disulfide bond.</p><p id="p-0120" num="0130">As noted above, Factor VIIa is generated by proteolysis of a single peptide bond from its single chain zymogen, Factor VII, which is present at approximately 0.5 &#x3bc;g/ml in plasma. The conversion of zymogen Factor VII into the activated two-chain molecule occurs by cleavage of an internal peptide bond. In human Factor VII, the cleavage site is at Arg152-Ile153 (Hagen et al., 1986<i>, PNAS USA </i>83: 2412-6).</p><p id="p-0121" num="0131">&#x201c;Factor VII/VIIa&#x201d; as used in this application means a product consisting of either the unactivated form (factor VII) or the activated form (factor VIIa) or mixtures thereof. &#x201c;Factor VII/VIIa&#x201d; within the above definition includes proteins that have an amino acid sequence of native human factor VII/VIIa. It also includes proteins with a slightly modified amino acid sequence, for instance, a modified N-terminal end including N-terminal amino acid deletions or additions so long as those proteins substantially retain the activity of factor VIIa. &#x201c;Factor VII&#x201d; within the above definition also includes natural allelic variations that may exist and occur from one individual to another. Also, degree and location of glycosylation or other post-translation modifications may vary depending on the chosen host cells and the nature of the host cellular environment.</p><p id="p-0122" num="0132">In the presence of calcium ions, Factor VIIa binds with high affinity to TF. TF is a 263 amino acid residue glycoprotein composed of a 219 residue extracellular domain, a single transmembrane domain, and a short cytoplasmic domain (Morrissey et al., 1987<i>, Cell </i>50: 129-35). The TF extracellular domain is composed of two fibronectin type Ill domains of about 105 amino acids each. The binding of FVIIa is mediated entirely by the TF extracellular domain (Muller et al., 1994<i>, Biochem. </i>33:10864-70). Residues in the area of amino acids 16-26 and 129-147 contribute to the binding of FVIIa as well as the coagulant function of the molecule. Residues Lys20, Trp45, Asp58, Tyr94, and Phe140 make a large contribution (1 kcal/mol) to the free energy (&#x394;G) of binding to FVIIa.</p><p id="p-0123" num="0133">TF is expressed constitutively on cells separated from plasma by the vascular endothelium. Its expression on endothelial cells and monocytes is induced by exposure to inflammatory cytokines or bacterial lipopolysacchardes (Drake et al., 1989<i>, J. Cell Biol. </i>109: 389). Upon tissue injury, the exposed extracellular domain of TF forms a high affinity, calcium dependent complex with FVII. Once bound to TF, FVII can be activated by peptide bond cleavage to yield serine protease FVIIa. The enzyme that catalyzes this step in vivo has not been elucidated, but in vitro FXa, thrombin, TF:FVIIa and FIXa can catalyze this cleavage. FVIIa has only weak activity upon its physiological substrates FX and FIX whereas the TF:FVIIa complex rapidly activates FX and FIX.</p><p id="p-0124" num="0134">The TF:FVIIa complex constitutes the primary initiator of the extrinsic pathway of blood coagulation. The complex initiates the extrinsic pathway by activation of FX to Factor Xa (FXa), FIX to Factor IXa (FIXa), and additional FVII to FVIIa. The action of TF:FVIIa leads ultimately to the conversion of prothrombin to thrombin, which carries out many biological functions. Among the most important activities of thrombin is the conversion of fibrinogen to fibrin, which polymerizes to form a clot. The TF:FVIIa complex also participates as a secondary factor in extending the physiological effects of the contact activation system.</p><p id="p-0125" num="0135">The initiation and subsequent regulation of coagulation is complex, since maintenance of hemostasis is crucial for survival. There is an exquisite balance between hemostasis (normal clot formation and dissolution) and thrombosis (pathogenic clot formation). Serious clinical conditions involving aberrations in coagulation include deep vein thrombosis, myocardial infarction, pulmonary embolism, stroke and disseminated intravascular coagulation (in sepsis). There are also many bleeding coagulopathies where there is insufficient clot formation. These include hemophilia A (FVIII deficiency) or hemophilia B (FIX deficiency), where procoagulant therapy is required. The challenge in this therapeutic area is to operate in the narrow window between too much and too little coagulation.</p><p id="p-0126" num="0136">The use of exogenous FVIIa as a therapeutic agent has been shown to induce hemostasis in patients with hemophilia A and B (Hedner, 2001<i>, Seminars Hematol. </i>38 (suppl. 12): 43-7; Hedner, 2004<i>, Seminars Hematol. </i>41 (suppl. 1): 35-9). It also has been used to treat bleeding in patients with liver disease, anticoagulation-induced bleeding, surgery, thrombocytopenia, thrombasthenia, Bemard-Soulier syndrome, von Willebrand disease, and other bleeding disorders (See e.g. Roberts et al., 2004<i>, Blood </i>104: 3858-64).</p><p id="p-0127" num="0137">Commercial preparations of human recombinant FVIIa are sold as NovoSeven.&#x2122; NovoSeven&#x2122; is indicated for the treatment of bleeding episodes in hemophilia A or B patients and is the only recombinant FVIIa effective for bleeding episodes currently available. A circulating recombinant FVIIa half-life of 2.3 hours was reported in &#x201c;Summary Basis for Approval for NovoSevenm&#x201d; FDA reference number 96-0597. Moreover, the half-life of recombinant FVIIa is shorter in pediatric patients (&#x2dc;1.3 hours), suggesting that higher doses of recombinant FVIIa may be required in this population (Roberts et al., 2004<i>, Blood </i>104: 3858-64). Accordingly, relatively high doses and frequent administration are necessary to reach and sustain the desired therapeutic or prophylactic effect. As a consequence, adequate dose regulation is difficult to obtain and the need of frequent intravenous administrations imposes restrictions on the patient's way of living.</p><p id="p-0128" num="0138">A molecule with a longer circulation half-life would decrease the number of necessary administrations. Given the frequent injections associated with currently available FVIIa therapy and the potential for obtaining more optimal therapeutic FVIIa levels with concomitant enhanced therapeutic effect, there is a clear need for improved FVII or FVIIa-like molecules with a longer half-life in vivo.</p><p id="p-0129" num="0139">Recombinant human coagulation factor VIIa (rFVIIa, NovoSeven; Novo Nordisk A/S, Copenhagen, Denmark) has proven to be efficacious for the treatment of bleeding episodes in hemophilia patients with inhibitors. A small fraction of patients may be refractory to rFVIIa treatment and could potentially benefit from genetically modified FVIIa molecules with increased potencies. To this end, FVIIa analogs with increased intrinsic activity have been investigated that exhibit superior hemostatic profiles in vitro (see e.g. WO02/077218 or WO05/074975, which are hereby incorporated by reference in their entirety, and Tranholm et al., 2003<i>, Blood </i>102(10): 3615-20, which is also incorporated by reference). These analogs may also be used as more efficacious hemostatic agents in other indications where efficacy of rFVIIa has been observed, including in thrombocytopenia and trauma.</p><p id="p-0130" num="0140">Thus, in some embodiments, the Factor VIIa analog that may be used in accordance with the invention is as described in WO02/077218 or WO05/074975. For example, the FVIIa analog may have a glutamine substituted for methionine at position 298 (i.e. M298Q-FVIIa). In certain exemplary embodiments, the FVIIa analog contains two additional mutations, valine at position 158 replaced by aspartic acid and glutamic acid at position 296 replaced by valine (i.e. V158D/E296V/M298Q-FVIIa). Additionally or alternatively, the Factor VIIa analog may have an alanine residue substitution for lysine at position 337 (i.e. V158D/E296V/M298Q/K337A-FVIIa). In still other embodiments, the Factor VIIa analog has a substitution or insertion selected from Q250C; P406C; and 407C, wherein a cysteine has also been introduced in the C-terminal sequence (see, e.g. U.S. Pat. No. 7,235,638, which is hereby incorporated by reference in its entirety). The Factor VIIa analog may further comprise a substitution or insertion at one or more of positions 247, 260, 393, 396, and/or 405.</p><p id="p-0131" num="0141">In these or other embodiments, the Factor VIIa analog comprises a substitution relative to the sequence of native Factor VIIa selected from: (a) a substitution of Lys157 with an amino acid selected from the group consisting of Gly, Val, Ser, Thr, Asp, and Glu; (b) a substitution of Lys337 with an amino acid selected from the group consisting of Ala, Gly, Val, Ser, Thr, GIn, Asp, and Glu; (c) a substitution of Asp334 with any amino acid other than Ala or Asn; and (d) a substitution of Ser336 with any amino acid other than Ala or Cys (see e.g. U.S. Pat. No. 7,176,288, which is hereby incorporated by reference in its entirety). Additionally or alternatively, the Factor VIIa analog comprises a substitution of the Leu at position 305 of Factor VII with an amino acid residue selected from the group consisting of Val, lie, Met, Phe, Trp, Pro, Gly, Ser, Thr, Cys, Tyr, Asn, Glu, Lys, Arg, His, Asp and GIn (see e.g. U.S. Pat. No. 6,905,683, which is hereby incorporated by reference in its entirety).</p><p id="p-0132" num="0142">Thus, in one aspect, the present invention provides therapeutic agents comprising an elastin-like peptide (ELP) and a Factor VII/VIIa, or functional analog thereof. For example, in certain embodiments, the Factor VII/VIIa is human Factor VII/VIIa (e.g., SEQ ID NO: 33). The Factor VII/VIIa may be a functional analog of human Factor VII/VIIa, including functional fragments truncated at the N-terminus and/or C-terminus by from 1 to 10 amino acids, including by 1, 2, 3, or about 5 amino acids. Functional analogs may contain from 1 to 10 amino acid insertions, deletions, and/or substitutions (collectively) with respect to the native sequence (e.g., SEQ ID NO: 33), and in each case retaining the activity of the peptide. For example, such analogs may have from 1 to about 5 amino acid insertions, deletions, and/or substitutions (collectively) with respect to the native full length sequence, or with respect to one or both of the heavy and light chains. Such activity may be confirmed or assayed using any available assay, including those described herein. In these or other embodiments, the Factor VII/VIIa component has at least about 75%, 80%, 85%, 90%, 95%, or 98% identity with the native sequence (SEQ ID NO:33). The determination of sequence identity between two sequences (e.g., between a native sequence and a functional analog) can be accomplished using any alignment tool, including Tatusova et al., <i>Blast </i>2 <i>sequences &#x2014;a new tool for comparing protein and nucleotide sequences, FEMS Microbiol Left. </i>174:247-250 (1999).</p><p id="p-0133" num="0143">In exemplary embodiments, the FactorVII-ELP fusion has the amino acid sequence of SEQ ID NO:58. SEQ ID NO:58 further comprises a TEV protease cleavage site between the FactorVII and ELP sequences, which may be beneficial for removing the ELP sequence post expression where desired. However, in accordance with the invention, the tev sequence may be entirely removed, or replaced with another linking sequence as disclosed herein.</p><p id="p-0134" num="0144">In another aspect, the present invention provides methods for the treatment or prevention of bleeding-related disorders. The method comprises administering an effective amount of the therapeutic agent comprising an elastin-like peptide (ELP) and a Factor VII/VIIa or functional analog thereof to a patient in need. In certain embodiments, the bleeding-related disorder is one or more of hemophilia (A or B), post-surgical bleeding, anticoagulation-induced bleeding, thrombocytopenia, Factor VII deficiency, Factor X deficiency, bleeding in patients with liver disease, thrombasthenia, Bemard-Soulier syndrome, von Willebrand disease, and intracranial hemorrhage. Generally, the patient is a human or non-human animal (e.g., dog, cat, cow, or horse) patient. Preferably, the patient is human.</p><p id="p-0135" num="0145">To characterize the in vitro binding properties of a suspected Factor VII/VIIa analog, or an ELP-containing Factor VIIa analog, TF binding assays can be performed as described previously (See, e.g., Chaing et al., 1994<i>, Blood </i>83(12): 3524-35). Briefly, recombinant human TF can be coated onto Immulon II plates in carbonate antigen buffer overnight at 4&#xb0; C. BSA is also coated onto the plates for use as a control. ELP-containing Factor VIIa analogs may be added at various concentrations in TBS-T buffer. After several washes, monospecific polyclonal rabbit anti-human FVIIa sera is added and incubated for approximately an hour at room temperature. Next, goat anti-rabbit IgG conjugated to alkaline phosphatase is added, followed by the alkaline phosphatase substrate PNPP, which is used for detection. After subtraction of background, the absorbance at &#x2dc;405 nm is taken to be directly proportional to the degree of Factor VIIa binding to the immobilized TF. These values can then be compared to control plasma containing Factor VIIa.</p><p id="p-0136" num="0146">The clotting ability of a Factor VII/VIIa analog or an ELP-containing Factor VIIa analog can be measured in human FVII deficient plasma. In this assay, the ELP-containing Factor VIIa analog diluted to varying concentrations directly into FVII deficient plasma. In a coagulometer, one part plasma&#xb1; a FVIIa analog can be mixed with 2 parts Innovin&#x2122; (Dade, Miami, Fla.) prothrombin time reagent (recombinant human tissue factor with phospholipids and CaCl<sub>2</sub>). Clot formation is detected optically and time to clotting measured. Clotting time (seconds) is compared to the mean clotting time of FVII-deficient plasma alone and plotted as the fractional clotting time versus FVIIa analog concentration.</p><heading id="h-0012" level="2">Therapeutic Proteins</heading><p id="p-0137" num="0147">The present invention further provides therapeutic agents comprising an ELP component and at least one therapeutic protein selected from Table 1. The ELP component and therapeutic protein may be coupled by recombinant fusion or chemical conjugation as described herein. Such therapeutic proteins are listed in Table 1 by protein name and GeneSeq Accession No. The amino acid sequence of each Therapeutic Protein, which is known in the art, is hereby incorporated by reference for each Therapeutic Protein listed in Table 1. Such therapeutic proteins are further described in US patent or PCT publications that are also listed in Table 1, and such US patent and PCT publications are hereby incorporated by reference, especially with respect to the structure of such therapeutic proteins and described functional analogs.</p><p id="p-0138" num="0148">Table 1 further describes the biological activity of each listed Therapeutic Protein, as well as an exemplary assay for determining the activity of functional analogs or agents of the invention (e.g., fusion with an ELP component). Generally, functional analogs of therapeutic proteins listed in Table 1 may include functional fragments truncated at the N-terminus and/or C-terminus by from 1 to 10 amino acids, including by 1, 2, 3, 4 or about 5 amino acids. Functional analogs may contain from 1 to 10 amino acid insertions, deletions, and/or substitutions (collectively) with respect to the base sequence (e.g., as listed in Table 1), and in each case retaining the full or partial biological activity (as listed in Table 1) of the therapeutic protein. For example, functional analogs may have 1, 2, 3, 4, or 5 amino acid insertions, deletions, and/or substitutions (collectively) with respect to the base sequence. Such activity may be confirmed or assayed using any available assay, including those described in the Table. In these or other embodiments, the therapeutic protein has at least about 75%, 80%, 85%, 90%, 95%, or 98% identity with the corresponding base sequence. The molecules may further comprise additional chemical modifications known for each in the art.</p><p id="p-0139" num="0149">In some embodiments, the therapeutic protein (e.g., as selected from Table 1) has a size of less than about 25 kDa, or less than about 10 kDa, or less than about 5 kDa, and the corresponding therapeutic agent of the invention (e.g., comprising the ELP component) has a molecular weight of less than about 60 kDa, 55 kDa, 50 kDa, or 40 kDa.</p><p id="p-0140" num="0150">Table 1 further lists preferred indications for each therapeutic protein, for which the corresponding therapeutic agent finds use, such as in a method for treatment or prevention related to such indication.</p><p id="p-0141" num="0000"><tables id="TABLE-US-00002" num="00002"><table frame="none" colsep="0" rowsep="0" orient="land"><tgroup align="left" colsep="0" rowsep="0" cols="6"><colspec colname="1" colwidth="70pt" align="left"/><colspec colname="2" colwidth="84pt" align="left"/><colspec colname="3" colwidth="105pt" align="left"/><colspec colname="4" colwidth="140pt" align="left"/><colspec colname="5" colwidth="154pt" align="left"/><colspec colname="6" colwidth="77pt" align="left"/><thead><row><entry namest="1" nameend="6" rowsep="1">TABLE 1</entry></row><row><entry namest="1" nameend="6" align="center" rowsep="1"/></row><row><entry/><entry>Exemplary Identifier</entry><entry>PCT/Patent Reference</entry><entry/><entry>Exemplary Activity Assay</entry><entry/></row><row><entry/><entry>(the sequences listed in</entry><entry>(the patents and publications</entry><entry/><entry>(the publications listed in this</entry></row><row><entry>Therapeutic</entry><entry>this column are each hereby</entry><entry>listed in this column are each</entry><entry/><entry>column are each hereby incorporated</entry></row><row><entry>Protein X</entry><entry>incorporated by reference)</entry><entry>hereby incorporated by reference)</entry><entry>Biological Activity</entry><entry>by reference)</entry><entry>Preferred Indication Y</entry></row><row><entry namest="1" nameend="6" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry>BMP-1</entry><entry>GeneSeq Acession</entry><entry>WO8800205</entry><entry>BMP1 belongs to the transforming</entry><entry>BMP-1 activity can be determined</entry><entry>Induction of Cartilage,</entry></row><row><entry/><entry>P80618</entry><entry/><entry>growth factor-beta (TGFB) superfamily.</entry><entry>using the following assays known in</entry><entry>Tissue and Bone</entry></row><row><entry/><entry/><entry/><entry>Bone morphogenic proteins induce</entry><entry>the art: Nat Genet. 2001</entry><entry>Growth, and Diabetes</entry></row><row><entry/><entry/><entry/><entry>cartilage and bone formation, play</entry><entry>January; 27(1): 84-8; Eur J Biochem 1996</entry></row><row><entry/><entry/><entry/><entry>important role in nephrogesis, and play</entry><entry>Apr. 1; 237(1): 295-302; J Biol Chem,</entry></row><row><entry/><entry/><entry/><entry>an important role in the development of</entry><entry>Vol. 274, Issue 16, 10897-10902,</entry></row><row><entry/><entry/><entry/><entry>many organs, including lung, heart,</entry><entry>Apr. 16, 1999; and Hogan, B. L. M.</entry></row><row><entry/><entry/><entry/><entry>teeth, gut, skin, and particularly the</entry><entry>(1996) Genes Dev. 10, 1580-1594.</entry></row><row><entry/><entry/><entry/><entry>kidney.</entry></row><row><entry>BMP-2</entry><entry>GeneSeq Accession</entry><entry>WO8800205</entry><entry>BMP-2 belongs to the transforming</entry><entry>BMP-2 activity can be determined</entry><entry>Induction of Cartilage,</entry></row><row><entry/><entry>P80619</entry><entry/><entry>growth factor-beta (TGFB) superfamily.</entry><entry>using the following assays known in</entry><entry>Tissue and Bone</entry></row><row><entry/><entry/><entry/><entry>Bone morphogenic protein induces bone</entry><entry>the art: Nat Genet. 2001 January;</entry><entry>Growth, and Diabetes</entry></row><row><entry/><entry/><entry/><entry>formation.</entry><entry>27(1): 84-8; Eur J Biochem 1996 Apr.</entry></row><row><entry/><entry/><entry/><entry/><entry>1; 237(1): 295-302; J Biol Chem, Vol.</entry></row><row><entry/><entry/><entry/><entry/><entry>274, Issue 16, 10897-10902, Apr. 16,</entry></row><row><entry/><entry/><entry/><entry/><entry>1999; and Hogan, B. L. M. (1996)</entry></row><row><entry/><entry/><entry/><entry/><entry>Genes Dev. 10, 1580-1594.</entry></row><row><entry>BMP-2B</entry><entry>GeneSeq Accession</entry><entry>U.S. Pat. No. 5,631,142</entry><entry>BMP-2b belongs to the transforming</entry><entry>BMP-2b activity can be determined</entry><entry>Induction of Cartilage,</entry></row><row><entry/><entry>W24850</entry><entry/><entry>growth factor-beta (TGFB) superfamily.</entry><entry>using the following assays known in</entry><entry>Tissue and Bone</entry></row><row><entry/><entry/><entry/><entry>Bone morphogenic protein induces bone</entry><entry>the art: Nat Genet. 2001 January;</entry><entry>Growth, and Diabetes</entry></row><row><entry/><entry/><entry/><entry>formation.</entry><entry>27(1): 84-8; Eur J Biochem 1996 Apr.</entry></row><row><entry/><entry/><entry/><entry/><entry>1; 237(1): 295-302; I Biol Cbcre, Vol.</entry></row><row><entry/><entry/><entry/><entry/><entry>274, Issue 16, 10897-10902, Apr. 16,</entry></row><row><entry/><entry/><entry/><entry/><entry>1999; and Hogan, B. L. M. (1996)</entry></row><row><entry/><entry/><entry/><entry/><entry>Genes Dev. 10, 1580-1594.</entry></row><row><entry>BMP-4</entry><entry>GeneSeq Accession</entry><entry>WO0020591</entry><entry>BMP-4 belongs to the transforming</entry><entry>BMP-4 activity can be determined</entry><entry>Induction of Cartilage,</entry></row><row><entry/><entry>B02796</entry><entry/><entry>growth factor-beta (TGFB) superfamily.</entry><entry>using the following assays known in</entry><entry>Tissue and Bone</entry></row><row><entry/><entry/><entry/><entry>Bone morphogenic protein induces bone</entry><entry>the art: Nat Genet. 2001 January;</entry><entry>Growth, and Diabetes</entry></row><row><entry/><entry/><entry/><entry>formation.</entry><entry>27(1): 84-8; Eur J Biochem 1996 Apr.</entry></row><row><entry/><entry/><entry/><entry/><entry>1; 237(1): 295-302; J Biol Chem, Vol.</entry></row><row><entry/><entry/><entry/><entry/><entry>274, Issue 16, 10897-10902, Apr. 16,</entry></row><row><entry/><entry/><entry/><entry/><entry>1999; and Hogan, B. L. M. (1996)</entry></row><row><entry/><entry/><entry/><entry/><entry>Genes Dev. 10, 1580-1594.</entry></row><row><entry>BMP-5</entry><entry>GeneSeq Accession</entry><entry>WO0020591</entry><entry>BMP-5 belongs to the transforming</entry><entry>BMP-5 activity can be determined</entry><entry>Induction of Cartilage,</entry></row><row><entry/><entry>B02797</entry><entry/><entry>growth factor-beta (TGFB) superfamily.</entry><entry>using the following assays known in</entry><entry>Tissue and Bone</entry></row><row><entry/><entry/><entry/><entry>Bone morphogenic protein induces bone</entry><entry>the art: Nat Genet. 2001 January;</entry><entry>Growth, and Diabetes</entry></row><row><entry/><entry/><entry/><entry>formation.</entry><entry>27(1): 84-8; Eur J Biochem 1996 Apr.</entry></row><row><entry/><entry/><entry/><entry/><entry>1; 237(1): 295-302; J Biol Chem, Vol.</entry></row><row><entry/><entry/><entry/><entry/><entry>274, Issue 16, 10897-10902, Apr. 16,</entry></row><row><entry/><entry/><entry/><entry/><entry>1999; and Hogan, B. L. M. (1996)</entry></row><row><entry/><entry/><entry/><entry/><entry>Genes Dev. 10, 1580-1594.</entry></row><row><entry>BMP-6</entry><entry>GeneSeq Accession</entry><entry>U.S. Pat. No. 5,187,076</entry><entry>BMP-6 belongs to the transforming</entry><entry>BMP-6 activity can be determined</entry><entry>Induction of Cartilage,</entry></row><row><entry/><entry>R32904</entry><entry/><entry>growth factor-beta (TGFB) superfamily.</entry><entry>using the following assays known in</entry><entry>Tissue and Bone</entry></row><row><entry/><entry/><entry/><entry>Bone morphogenic protein induces bone</entry><entry>the art: Nat Genet. 2001 January;</entry><entry>Growth, and Diabetes</entry></row><row><entry/><entry/><entry/><entry>formation.</entry><entry>27(1): 84-8; Eur J Biochem 1996 Apr.</entry></row><row><entry/><entry/><entry/><entry/><entry>1; 237(1): 295-302; J Biol Chem, Vol.</entry></row><row><entry/><entry/><entry/><entry/><entry>274, Issue 16, 10897-10902, Apr. 16,</entry></row><row><entry/><entry/><entry/><entry/><entry>1999; and Hogan, B. L. M. (1996)</entry></row><row><entry/><entry/><entry/><entry/><entry>Genes Dev. 10, 1580-1594.</entry></row><row><entry>Osteogenic</entry><entry>GeneSeq Accession</entry><entry>WO973462</entry><entry>OP-1 belongs to the transforming</entry><entry>OP-1 activity can be determined</entry><entry>Induction of Cartilage,</entry></row><row><entry>Protein-1; OP-1;</entry><entry>W34783</entry><entry/><entry>growth factor-beta (TGFB) superfamily.</entry><entry>using the following assays known in</entry><entry>Tissue and Bone</entry></row><row><entry>BMP-7</entry><entry/><entry/><entry>Bone morphogenic protein induces bone</entry><entry>the art: Nat Genet. 2001 January;</entry><entry>Growth, and Diabetes</entry></row><row><entry/><entry/><entry/><entry>formation.</entry><entry>27(1): 84-8; Eur J Biochem 1996 Apr.</entry></row><row><entry/><entry/><entry/><entry/><entry>1; 237(1): 295-302; J Biol Chem, Vol.</entry></row><row><entry/><entry/><entry/><entry/><entry>274, Issue 16, 10897-10902, Apr. 16,</entry></row><row><entry/><entry/><entry/><entry/><entry>1999; and Hogan, B. L. M. (1996)</entry></row><row><entry/><entry/><entry/><entry/><entry>Genes Dev. 10, 1580-1594.</entry></row><row><entry>Osteogenic</entry><entry>GeneSeq Accession</entry><entry>WO9406399</entry><entry>OP-2 belongs to the transforming</entry><entry>OP-2 activity can be determined</entry><entry>Induction of Cartilage,</entry></row><row><entry>Protein-2</entry><entry>R57973</entry><entry/><entry>growth factor-beta (TGFB) superfamily.</entry><entry>using the following assays known in</entry><entry>Tissue and Bone</entry></row><row><entry/><entry/><entry/><entry>Bone morphogenic Protein induces bone</entry><entry>the art: Nat Genet. 2001 January;</entry><entry>Growth, and Diabetes</entry></row><row><entry/><entry/><entry/><entry>formation.</entry><entry>27(1): 84-8; Eur J Biochem 1996 Apr.</entry></row><row><entry/><entry/><entry/><entry/><entry>1; 237(1): 295-302; J Biol Chem, Vol.</entry></row><row><entry/><entry/><entry/><entry/><entry>274, Issue 16, 10897-10902, Apr. 16,</entry></row><row><entry/><entry/><entry/><entry/><entry>1999; and Hogan, B. L. M. (1996)</entry></row><row><entry/><entry/><entry/><entry/><entry>Genes Dev. 10, 1580-1594.</entry></row><row><entry>GDP-1</entry><entry>GeneSeq Accession</entry><entry>WO9406449</entry><entry>Members of the TGF-beta family of</entry><entry>The effect of GDF-1 on signaling can</entry><entry>Developmental</entry></row><row><entry/><entry>R60961</entry><entry/><entry>proteins initiate cell signaling by</entry><entry>be assayed by treating Primary</entry><entry>disorders, Induction of</entry></row><row><entry/><entry/><entry/><entry>binding to heteromeric receptor</entry><entry>BAECs transferred with a construct</entry><entry>Cartilage, Tissue and</entry></row><row><entry/><entry/><entry/><entry>complexes of type I (TbetaRI) and</entry><entry>called p3TP-Lux, containing a TGF-</entry><entry>Bone Growth, and</entry></row><row><entry/><entry/><entry/><entry>type II (TbetaRII) serine/threonine</entry><entry>beta responsive promoter fused to a</entry><entry>Diabetes</entry></row><row><entry/><entry/><entry/><entry>kinase receptors (reviewed by</entry><entry>reporter gene, and measuring</entry></row><row><entry/><entry/><entry/><entry>Massague, J. et al. (1994) Trends Cell</entry><entry>luciferase gene expression (Wrana et</entry></row><row><entry/><entry/><entry/><entry>Biol. 4: 172 178; Miyazono, K. et al.</entry><entry>al., 1994, Nature 370: 341-347).</entry></row><row><entry/><entry/><entry/><entry>(1994) Adv. Immunol. 55: 181-220).</entry></row><row><entry/><entry/><entry/><entry>Activation of this heteromeric receptor</entry></row><row><entry/><entry/><entry/><entry>complex occurs when TGF-beta binds to</entry></row><row><entry/><entry/><entry/><entry>TbetaRII, which then recruits and</entry></row><row><entry/><entry/><entry/><entry>phosphorylates TbetaRI. Activated</entry></row><row><entry/><entry/><entry/><entry>TbetaRI then propagates the signal to</entry></row><row><entry/><entry/><entry/><entry>downstream targets (Chen, F. and</entry></row><row><entry/><entry/><entry/><entry>Weinberg, R. A. (1995) PNA892: 1565-1569;</entry></row><row><entry/><entry/><entry/><entry>Wrana, J. L. et al. (1994) Nature</entry></row><row><entry/><entry/><entry/><entry>370: 341 347).</entry></row><row><entry>BMP-9</entry><entry>GeneSeq Accession</entry><entry>WO9533830</entry><entry>BMP-9 belongs to the transforming</entry><entry>BMP-9 activity can be determined</entry><entry>Induction of Cartilage,</entry></row><row><entry/><entry>R86903</entry><entry/><entry>growth factor-beta (TGFB) superfamily.</entry><entry>using the following assays known in</entry><entry>Tissue and Bone</entry></row><row><entry/><entry/><entry/><entry>Bone morphogenic protein induces bone</entry><entry>the art: Nat Genet. 2001 January;</entry><entry>Growth, and Diabetes</entry></row><row><entry/><entry/><entry/><entry>formation.</entry><entry>27(1): 84-8; Eur J Biochem 1996 Apr.</entry></row><row><entry/><entry/><entry/><entry/><entry>1; 237(1): 295-302; J Biol Chem, Vol.</entry></row><row><entry/><entry/><entry/><entry/><entry>274, Issue 16, 10897-10902, Apr. 16,</entry></row><row><entry/><entry/><entry/><entry/><entry>1999; and Hogan, B. L. M. (1996)</entry></row><row><entry/><entry/><entry/><entry/><entry>Genes Dev. 10, 1580-1594.</entry></row><row><entry>BMP-10</entry><entry>GeneSeq Accession</entry><entry>WO9426893</entry><entry>BMP-10 belongs to the transforming</entry><entry>BMP-10 activity can be determined</entry><entry>Induction of Cartilage,</entry></row><row><entry/><entry>R66202</entry><entry/><entry>growth factor-beta (TGFB) superfamily.</entry><entry>using the following assays known in</entry><entry>Tissue and Bone</entry></row><row><entry/><entry/><entry/><entry>Bone morphogenic protein induces bone</entry><entry>the art: Nat Genet. 2001 January;</entry><entry>Growth, and Diabetes</entry></row><row><entry/><entry/><entry/><entry>formation.</entry><entry>27(1): 84-8; Eur J Biochem 1996 Apr.</entry></row><row><entry/><entry/><entry/><entry/><entry>1; 237(1): 295-302; J Biol Chem, Vol.</entry></row><row><entry/><entry/><entry/><entry/><entry>274, Issue 16, 10897-10902, Apr. 16,</entry></row><row><entry/><entry/><entry/><entry/><entry>1999; and Hogan, B. L. M. (1996)</entry></row><row><entry/><entry/><entry/><entry/><entry>Genes Dev. 10, 1580-1594.</entry></row><row><entry>BMP-12</entry><entry>GeneSeq Accession</entry><entry>WO9516035</entry><entry>BMP-12 belongs to the transforming</entry><entry>BMP-12 activity can be determined</entry><entry>Induction of Cartilage,</entry></row><row><entry/><entry>R78734</entry><entry/><entry>growth factor-beta (TGFB) superfamily.</entry><entry>using the following assays known in</entry><entry>Tissue and Bone</entry></row><row><entry/><entry/><entry/><entry>Bone morphogenic protein induces bone</entry><entry>the art: Nat Genet. 2001 January;</entry><entry>Growth, and Diabetes</entry></row><row><entry/><entry/><entry/><entry>formation.</entry><entry>27(1): 84-8; Eur J Biochem 1996 Apr.</entry></row><row><entry/><entry/><entry/><entry/><entry>1; 237(1): 295-302; J Biol Chem, Vol.</entry></row><row><entry/><entry/><entry/><entry/><entry>274, Issue 16, 10897-10902, Apr. 16,</entry></row><row><entry/><entry/><entry/><entry/><entry>1999; and Hogan, B. L. M. (1996)</entry></row><row><entry/><entry/><entry/><entry/><entry>Genes Dev. 10, 1580-1594.</entry></row><row><entry>BMP-15</entry><entry>GeneSeq Accession</entry><entry>W09636710</entry><entry>BMP-15 belongs to the transforming</entry><entry>BMP-15 activity can be determined</entry><entry>Induction of Cartilage,</entry></row><row><entry/><entry>W11261</entry><entry/><entry>growth factor-beta (TGFB) superfamily.</entry><entry>using the following assays known in</entry><entry>Tissue and Bone</entry></row><row><entry/><entry/><entry/><entry>Bone morphogenic protein induces bone</entry><entry>the art: Nat Genet. 2001 January;</entry><entry>Growth, and Diabetes</entry></row><row><entry/><entry/><entry/><entry>formation.</entry><entry>27(1): 84-8; Eur J Biochem 1996 Apr.</entry></row><row><entry/><entry/><entry/><entry/><entry>1; 237(1): 295-302; J Biol Chem, Vol.</entry></row><row><entry/><entry/><entry/><entry/><entry>274, Issue 16, 10897-10902, Apr. 16,</entry></row><row><entry/><entry/><entry/><entry/><entry>1999; and Hogan, B. L. M. (1996)</entry></row><row><entry/><entry/><entry/><entry/><entry>Genes Dev. 10, 1580-1594.</entry></row><row><entry>BMP-17</entry><entry>GeneSeq Accession</entry><entry>WO9929718</entry><entry>BMP-17 belongs to the transforming</entry><entry>BMP-17 activity can be determined</entry><entry>Induction of Cartilage,</entry></row><row><entry/><entry>Y17870</entry><entry/><entry>growth factor-beta (TGFB) superfamily.</entry><entry>using the following assays known in</entry><entry>Tissue and Bone</entry></row><row><entry/><entry/><entry/><entry>Bone morphogenic protein induces bone</entry><entry>the art: Nat Genet. 2001 January;</entry><entry>Growth, and Diabetes</entry></row><row><entry/><entry/><entry/><entry>formation.</entry><entry>27(1): 84-8; Eur J Biochem 1996 Apr.</entry></row><row><entry/><entry/><entry/><entry/><entry>1; 237(1): 295-302; J Biol Chem, Vol.</entry></row><row><entry/><entry/><entry/><entry/><entry>274, Issue 16, 10897-10902, Apr. 16,</entry></row><row><entry/><entry/><entry/><entry/><entry>1999; and Hogan, B. L. M. (1996)</entry></row><row><entry/><entry/><entry/><entry/><entry>Genes Dev. 10, 1580-1594.</entry></row><row><entry>BMP-18</entry><entry>GeneSeq Accession</entry><entry>WO9929718</entry><entry>BMP-18 belongs to the transforming</entry><entry>BMP-18 activity can be determined</entry><entry>Induction of Cartilage,</entry></row><row><entry/><entry>Y17871</entry><entry/><entry>growth factor-beta (TGFB) superfamily.</entry><entry>using the following assays known in</entry><entry>Tissue and Bone</entry></row><row><entry/><entry/><entry/><entry>Bone morphogenic protein induces bone</entry><entry>the art: Nat Genet. 2001 January;</entry><entry>Growth, and Diabetes</entry></row><row><entry/><entry/><entry/><entry>formation.</entry><entry>27(1): 84-8; Eur J Biochem 1996 Apr.</entry></row><row><entry/><entry/><entry/><entry/><entry>1; 237(1): 295-302; J Biol Chem, Vol.</entry></row><row><entry/><entry/><entry/><entry/><entry>274, Issue 16, 10897-10902, Apr. 16,</entry></row><row><entry/><entry/><entry/><entry/><entry>1999; and Hogan, B. L. M. (1996)</entry></row><row><entry/><entry/><entry/><entry/><entry>Genes Dev. 10, 1580-1594.</entry></row><row><entry>Inhibin alpha</entry><entry>GeneSeq Accession</entry><entry>WO0020591</entry><entry>The inhibin beta A subunit joins the</entry><entry>Tumor suppressor activity of inhibin</entry><entry>Tumor suppression.</entry></row><row><entry/><entry>B02806</entry><entry/><entry>alpha subunit to form a pituitary FSH</entry><entry>can be determined using assays</entry></row><row><entry/><entry/><entry/><entry>secretion inhibitor. Inhibin has been</entry><entry>known in the art: Matzuk et al.,</entry></row><row><entry/><entry/><entry/><entry>shown to regulate gonadal stromal cell</entry><entry>Nature 1992 Nov. 26: 360 (6402);</entry></row><row><entry/><entry/><entry/><entry>proliferation negatively and to have</entry><entry>313-9.</entry></row><row><entry/><entry/><entry/><entry>tumour-suppressor activity. In addition,</entry></row><row><entry/><entry/><entry/><entry>serum levels of inhibin have been shown</entry></row><row><entry/><entry/><entry/><entry>to reflect the size of granulosa-cell</entry></row><row><entry/><entry/><entry/><entry>tumors and can therefore be used as a</entry></row><row><entry/><entry/><entry/><entry>marker for primary as well as recurrent</entry></row><row><entry/><entry/><entry/><entry>disease.</entry></row><row><entry>Inhibin beta</entry><entry>GeneSeq Accession</entry><entry>WO0020591</entry><entry>The inhibin beta A subunit joins the</entry><entry>Tumor suppressor activity of inhibin</entry><entry>Tumor suppression.</entry></row><row><entry/><entry>H02808</entry><entry/><entry>alpha subunit to form a pituitary FSH</entry><entry>can be determined using assays</entry></row><row><entry/><entry/><entry/><entry>secretion inhibitor. Inhibin has been</entry><entry>known in the art: Matzuk et al.,</entry></row><row><entry/><entry/><entry/><entry>shown to regulate gonadal stromal cell</entry><entry>Nature 1992 Nov. 26: 360 (6402);</entry></row><row><entry/><entry/><entry/><entry>proliferation negatively and to have</entry><entry>313-9.</entry></row><row><entry/><entry/><entry/><entry>tumour-suppressor activity. In addition,</entry></row><row><entry/><entry/><entry/><entry>serum levels of inhibin have been shown</entry></row><row><entry/><entry/><entry/><entry>to reflect the size of granulosa-cell</entry></row><row><entry/><entry/><entry/><entry>tumors and can therefore be used as a</entry></row><row><entry/><entry/><entry/><entry>marker for primary as well as recurrent</entry></row><row><entry/><entry/><entry/><entry>disease.</entry></row><row><entry>Cerebus Protein</entry><entry>GeneSeq Accession</entry><entry>WO9849296</entry><entry>Cerebus is believed to be involved in the</entry><entry>BMP activity, in the presence of the</entry><entry>BMP Antagonist useful</entry></row><row><entry/><entry>W86032</entry><entry/><entry>inhibition of BMP activity</entry><entry>antagonist Cerebus, can be</entry><entry>for Osteosarcoma,</entry></row><row><entry/><entry/><entry/><entry/><entry>determined using the following</entry><entry>abnormal bone growth.</entry></row><row><entry/><entry/><entry/><entry/><entry>assays known in the art: Nat Genet.</entry></row><row><entry/><entry/><entry/><entry/><entry>2001 January; 27(1): 84-8; Eur J Biochem</entry></row><row><entry/><entry/><entry/><entry/><entry>1996 Apr. 1; 237(1): 295-302; J Biol</entry></row><row><entry/><entry/><entry/><entry/><entry>Chem, Vol. 274, Issue 16, 10897-10902,</entry></row><row><entry/><entry/><entry/><entry/><entry>Apr. 16, 1999; and Hogan, B. L. M.</entry></row><row><entry/><entry/><entry/><entry/><entry>(1996) Genes Dev. 10, 1580-1594.</entry></row><row><entry>Soluble BMP</entry><entry>GeneSeq Accession</entry><entry>WO9614579</entry><entry>Soluble BMP receptor kinase protein-3</entry><entry>BMP activity, in the presence of the</entry><entry>BMP Antagonist useful</entry></row><row><entry>Receptor Kinase</entry><entry>R95227</entry><entry/><entry>is involved in the binding of BMPs.</entry><entry>soluble antagonist BMP receptor</entry><entry>for Osteosarcoma,</entry></row><row><entry>Protein-3</entry><entry/><entry/><entry>Soluble BMP receptor kinase protein-3</entry><entry>kinase protein-3, can be determined</entry><entry>abnormal bone growth.</entry></row><row><entry/><entry/><entry/><entry>is useful as an antagonist for the</entry><entry>using the following assays known in</entry></row><row><entry/><entry/><entry/><entry>inhibition of BMP activity.</entry><entry>the art: Nat Genet. 2001 January;</entry></row><row><entry/><entry/><entry/><entry/><entry>27(1): 84-8; Eur J Biochem 1996 Apr.</entry></row><row><entry/><entry/><entry/><entry/><entry>1; 237(1): 295-302; J Biol Chem, Vol.</entry></row><row><entry/><entry/><entry/><entry/><entry>274, Issue 16, 10897-10902, Apr. 16,</entry></row><row><entry/><entry/><entry/><entry/><entry>1999; and Hogan, B. L. M. (1996)</entry></row><row><entry/><entry/><entry/><entry/><entry>Genes Dev. 10, 1580-1594.</entry></row><row><entry>BMP Processing</entry><entry>GeneSeq Accession</entry><entry>WO9741250</entry><entry>BMPs belong to the transforming</entry><entry>BMP activity, in the presence of the</entry><entry>Bone formation or</entry></row><row><entry>Enzyme Furin</entry><entry>W36099</entry><entry/><entry>growth factor-beta (TGFB) superfamily.</entry><entry>Furin, can be determined using the</entry><entry>Regeneration</entry></row><row><entry/><entry/><entry/><entry>Bone morphogenic protein induces bone</entry><entry>following assays known in the art:</entry><entry>Abnormalities</entry></row><row><entry/><entry/><entry/><entry>formation.</entry><entry>Nat Genet. 2001 January; 27(1): 84-8; Eur</entry></row><row><entry/><entry/><entry/><entry/><entry>J Biochem 1996 Apr. 1; 237(1): 295-302;</entry></row><row><entry/><entry/><entry/><entry/><entry>J Biol Chem, Vol. 274, Issue 16,</entry></row><row><entry/><entry/><entry/><entry/><entry>10897-10902, Apr. 16, 1999; and</entry></row><row><entry/><entry/><entry/><entry/><entry>Hogan, B. L. M. (1996) Genes Dev.</entry></row><row><entry/><entry/><entry/><entry/><entry>10, 1580-1594.</entry></row><row><entry>TGF-beta 1</entry><entry>GeneSeq Accession</entry><entry>WO9216228</entry><entry>Members of the TGF-beta family of</entry><entry>The effect of TGF betas on signaling</entry><entry>Useful for treating</entry></row><row><entry/><entry>R29657</entry><entry/><entry>proteins initiate cell signaling by</entry><entry>can be assayed by treating Primary</entry><entry>cancer and to promote</entry></row><row><entry/><entry/><entry/><entry>binding to heteromeric receptor</entry><entry>BAECs transfected with a construct</entry><entry>wound healing.</entry></row><row><entry/><entry/><entry/><entry>complexes of type I (TbetaRI) and type</entry><entry>called p3TP-Lux, containing a TGF-</entry></row><row><entry/><entry/><entry/><entry>II (TbetaRII) serine/threonine kinase</entry><entry>beta responsive promoter fused to a</entry></row><row><entry/><entry/><entry/><entry>receptors (reviewed by Massague, J. et</entry><entry>reporter gene, and measuring</entry></row><row><entry/><entry/><entry/><entry>al. (1994) Trends Cell Biol. 4: 172 178;</entry><entry>luciferase gene expression (Wrana et</entry></row><row><entry/><entry/><entry/><entry>Miyazono, K. et al. (1994) Adv.</entry><entry>al., 1994, Nature 370: 341-347).</entry></row><row><entry/><entry/><entry/><entry>Immunol. 55: 181-220). Activation of</entry></row><row><entry/><entry/><entry/><entry>this heteromeric receptor complex</entry></row><row><entry/><entry/><entry/><entry>occurs when TGF-beta. binds to</entry></row><row><entry/><entry/><entry/><entry>TbetaRII, which then recruits and</entry></row><row><entry/><entry/><entry/><entry>phosphorylates TbetaRI. Activated</entry></row><row><entry/><entry/><entry/><entry>TbetaRI then propagates the signal to</entry></row><row><entry/><entry/><entry/><entry>downstream targets (Chen, F. and</entry></row><row><entry/><entry/><entry/><entry>Weinberg. R. A. (1995) PNA892: 1565-1569;</entry></row><row><entry/><entry/><entry/><entry>Wrana, J. L. et al. (1994) Nature</entry></row><row><entry/><entry/><entry/><entry>370: 341.</entry></row><row><entry>TGF-beta 2</entry><entry>GeneSeq Accession</entry><entry>EP542679</entry><entry>Members of the TGF-beta family of</entry><entry>The effect of TGF betas on signaling</entry><entry>Useful for treating</entry></row><row><entry/><entry>R39659</entry><entry/><entry>proteins initiate cell signaling by</entry><entry>can be assayed by treating Primary</entry><entry>cancer and to promote</entry></row><row><entry/><entry/><entry/><entry>binding to heteromeric receptor</entry><entry>BAECs transfected with a construct</entry><entry>wound healing.</entry></row><row><entry/><entry/><entry/><entry>complexes of type I (TbetaRI) and type</entry><entry>called p3TP-Lux, containing a TGF-</entry></row><row><entry/><entry/><entry/><entry>II (TbetaRII) serine/threonine kinase</entry><entry>beta responsive promoter fused to a</entry></row><row><entry/><entry/><entry/><entry>receptors (reviewed by Massague, J. et</entry><entry>reporter gene, and measuring</entry></row><row><entry/><entry/><entry/><entry>al. (1994) Trends Cell Biol. 4: 172 178;</entry><entry>luciferase gene expression (Wrana et</entry></row><row><entry/><entry/><entry/><entry>Miyazono, K. et al. (1994) Adv.</entry><entry>al., 1994, Nature 370: 341-347).</entry></row><row><entry/><entry/><entry/><entry>Immunol. 55: 181-220). Activation of</entry></row><row><entry/><entry/><entry/><entry>this heteromeric receptor complex</entry></row><row><entry/><entry/><entry/><entry>occurs when TGF-beta. binds to</entry></row><row><entry/><entry/><entry/><entry>TbetaRII, which then recruits and</entry></row><row><entry/><entry/><entry/><entry>phosphorylates TbetaRI. Activated</entry></row><row><entry/><entry/><entry/><entry>TbetaRI then propagates the signal to</entry></row><row><entry/><entry/><entry/><entry>downstream targets (Chen, F. and</entry></row><row><entry/><entry/><entry/><entry>Weinberg. R. A. (1995) PNA892: 1565-1569;</entry></row><row><entry/><entry/><entry/><entry>Wrana, J. L. et al. (1994) Nature</entry></row><row><entry/><entry/><entry/><entry>370: 341.</entry></row><row><entry>ZTGF-beta 9</entry><entry>GeneSeq Accession</entry><entry>WO0015798</entry><entry>Members of the TGF-beta family of</entry><entry>The effect of TGF betas on signaling</entry><entry>Useful for treating</entry></row><row><entry/><entry>Y70654</entry><entry/><entry>proteins initiate cell signaling by</entry><entry>can be assayed by treating Primary</entry><entry>cancer and to promote</entry></row><row><entry/><entry/><entry/><entry>binding to heteromeric receptor</entry><entry>BAECs transfected with a construct</entry><entry>wound healing.</entry></row><row><entry/><entry/><entry/><entry>complexes of type I (TbetaRI) and type</entry><entry>called p3TP-Lux, containing a TGF-</entry></row><row><entry/><entry/><entry/><entry>II (TbetaRII) serine/threonine kinase</entry><entry>beta responsive promoter fused to a</entry></row><row><entry/><entry/><entry/><entry>receptors (reviewed by Massague, J. et</entry><entry>reporter gene, and measuring</entry></row><row><entry/><entry/><entry/><entry>al. (1994) Trends Cell Biol. 4: 172 178;</entry><entry>luciferase gene expression (Wrana et</entry></row><row><entry/><entry/><entry/><entry>Miyazono, K. et al. (1994) Adv.</entry><entry>al., 1994, Nature 370: 341-347).</entry></row><row><entry/><entry/><entry/><entry>Immunol. 55: 181-220). Activation of</entry></row><row><entry/><entry/><entry/><entry>this heteromeric receptor complex</entry></row><row><entry/><entry/><entry/><entry>occurs when TGF-beta. binds to</entry></row><row><entry/><entry/><entry/><entry>TbetaRII, which then recruits and</entry></row><row><entry/><entry/><entry/><entry>phosphorylates TbetaRI. Activated</entry></row><row><entry/><entry/><entry/><entry>TbetaRI then propagates the signal to</entry></row><row><entry/><entry/><entry/><entry>downstream targets (Chen, F. and</entry></row><row><entry/><entry/><entry/><entry>Weinberg. R. A. (1995) PNA892: 1565-1569;</entry></row><row><entry/><entry/><entry/><entry>Wrana, J. L. et al. (1994) Nature</entry></row><row><entry/><entry/><entry/><entry>370: 341.</entry></row><row><entry>Anti-TGF beta</entry><entry/><entry>GB2305921</entry><entry>Members of the TGF-beta family of</entry><entry>The effect of TGF betas on signaling</entry><entry>Useful for control of</entry></row><row><entry>family antibodies</entry><entry/><entry/><entry>proteins initiate cell signaling by</entry><entry>in the presence of an anti-TGF beta</entry><entry>fibrosis, immune, and</entry></row><row><entry/><entry/><entry/><entry>binding to heteromeric receptor</entry><entry>antibody, can be assayed by treating</entry><entry>inflammatory disease.</entry></row><row><entry/><entry/><entry/><entry>complexes of type I (TbetaRI) and type</entry><entry>Primary BAECs transfected with a</entry></row><row><entry/><entry/><entry/><entry>II (TbetaRII) serine/threonine kinase</entry><entry>construct called p3TP-Lux,</entry></row><row><entry/><entry/><entry/><entry>receptors (reviewed by Massague, J. et</entry><entry>containing a TGF-beta responsive</entry></row><row><entry/><entry/><entry/><entry>al. (1994) Trends Cell Biol. 4: 172 178;</entry><entry>promoter fused to a reporter gene, and</entry></row><row><entry/><entry/><entry/><entry>Miyazono, K. et al. (1994) Adv.</entry><entry>measuring luciferase gene expression</entry></row><row><entry/><entry/><entry/><entry>Immunol. 55: 181-220). Activation of</entry><entry>(Wrana et al., 1994, Nature 370: 341-347).</entry></row><row><entry/><entry/><entry/><entry>this heteromeric receptor complex</entry></row><row><entry/><entry/><entry/><entry>occurs when TGF-beta. binds to</entry></row><row><entry/><entry/><entry/><entry>TbetaRII, which then recruits and</entry></row><row><entry/><entry/><entry/><entry>phosphorylates TbetaRI. Activated</entry></row><row><entry/><entry/><entry/><entry>TbetaRI then propagates the signal to</entry></row><row><entry/><entry/><entry/><entry>downstream targets (Chen, F. and</entry></row><row><entry/><entry/><entry/><entry>Weinberg. R. A. (1995) PNA892: 1565-1569;</entry></row><row><entry/><entry/><entry/><entry>Wrana, J. L. et al. (1994) Nature</entry></row><row><entry/><entry/><entry/><entry>370: 341.</entry></row><row><entry>Latent TGF beta</entry><entry>GeneSeq Accession</entry><entry>WO0012551</entry><entry>Members of the TGF-beta family of</entry><entry>The effect of TGF betas on signaling</entry><entry>Useful for inhibiting</entry></row><row><entry>binding protein II</entry><entry>Y70552</entry><entry/><entry>proteins initiate cell signaling by</entry><entry>in the presence of a TGF beta binding</entry><entry>tissue or tumor growth.</entry></row><row><entry/><entry/><entry/><entry>binding to heteromeric receptor</entry><entry>protein, can be assayed by treating</entry></row><row><entry/><entry/><entry/><entry>complexes of type I (TbetaRI) and type</entry><entry>Primary BAECs transfected with a</entry></row><row><entry/><entry/><entry/><entry>II (TbetaRII) serine/threonine kinase</entry><entry>construct called p3TP-Lux,</entry></row><row><entry/><entry/><entry/><entry>receptors (reviewed by Massague, J. et</entry><entry>containing a TGF-beta responsive</entry></row><row><entry/><entry/><entry/><entry>al. (1994) Trends Cell Biol. 4: 172 178;</entry><entry>promoter fused to a reporter gene, and</entry></row><row><entry/><entry/><entry/><entry>Miyazono, K. et al. (1994) Adv.</entry><entry>measuring luciferase gene expression</entry></row><row><entry/><entry/><entry/><entry>Immunol. 55: 181-220). Activation of</entry><entry>(Wrana et al., 1994, Nature 370: 341-347).</entry></row><row><entry/><entry/><entry/><entry>this heteromeric receptor complex</entry></row><row><entry/><entry/><entry/><entry>occurs when TGF-beta. binds to</entry></row><row><entry/><entry/><entry/><entry>TbetaRII, which then recruits and</entry></row><row><entry/><entry/><entry/><entry>phosphorylates TbetaRI. Activated</entry></row><row><entry/><entry/><entry/><entry>TbetaRI then propagates the signal to</entry></row><row><entry/><entry/><entry/><entry>downstream targets (Chen, F. and</entry></row><row><entry/><entry/><entry/><entry>Weinberg. R. A. (1995) PNA892: 1565-1569;</entry></row><row><entry/><entry/><entry/><entry>Wrana, J. L. et al. (1994) Nature</entry></row><row><entry/><entry/><entry/><entry>370: 341.</entry></row><row><entry>MP52</entry><entry>GeneSeq Accession</entry><entry>WO9741250</entry><entry>Members of the TGF-beta family of</entry><entry>The effect of TGF betas on signaling</entry><entry>Bone formation or</entry></row><row><entry/><entry>W36100</entry><entry/><entry>proteins initiate cell signaling by</entry><entry>can be assayed by treating Primary</entry><entry>Regeneration</entry></row><row><entry/><entry/><entry/><entry>binding to heteromeric receptor</entry><entry>BAECs transfected with a construct</entry><entry>Abnormalities</entry></row><row><entry/><entry/><entry/><entry>complexes of type I (TbetaRI) and type</entry><entry>called p3TP-Lux, containing a TGF-</entry></row><row><entry/><entry/><entry/><entry>II (TbetaRII) serine/threonine kinase</entry><entry>beta responsive promoter fused to a</entry></row><row><entry/><entry/><entry/><entry>receptors (reviewed by Massague, J. et</entry><entry>reporter gene, and measuring</entry></row><row><entry/><entry/><entry/><entry>al. (1994) Trends Cell Biol. 4: 172 178;</entry><entry>luciferase gene expression (Wrana et</entry></row><row><entry/><entry/><entry/><entry>Miyazono, K. et al. (1994) Adv.</entry><entry>al., 1994, Nature 370: 341-347).</entry></row><row><entry/><entry/><entry/><entry>Immunol. 55: 181-220). Activation of</entry></row><row><entry/><entry/><entry/><entry>this heteromeric receptor complex</entry></row><row><entry/><entry/><entry/><entry>occurs when TGF-beta. binds to</entry></row><row><entry/><entry/><entry/><entry>TbetaRII, which then recruits and</entry></row><row><entry/><entry/><entry/><entry>phosphorylates TbetaRI. Activated</entry></row><row><entry/><entry/><entry/><entry>TbetaRI then propagates the signal to</entry></row><row><entry/><entry/><entry/><entry>downstream targets (Chen, F. and</entry></row><row><entry/><entry/><entry/><entry>Weinberg. R. A. (1995) PNA892: 1565-1569;</entry></row><row><entry/><entry/><entry/><entry>Wrana, J. L. et al. (1994) Nature</entry></row><row><entry/><entry/><entry/><entry>370: 341.</entry></row><row><entry>b57 Protein</entry><entry>GeneSeq Accession</entry><entry>WO9837195</entry><entry>BMPs are involved in the induction of</entry><entry>BMP activity, in the presence of b57</entry><entry>BMP Antagonist useful</entry></row><row><entry/><entry>W69293</entry><entry/><entry>bone formation. Specific antagonists are</entry><entry>protein, can be determined using the</entry><entry>for Osteosarcoma,</entry></row><row><entry/><entry/><entry/><entry>useful is preventing this activity from</entry><entry>following assays known in the art:</entry><entry>abnormal bone growth.</entry></row><row><entry/><entry/><entry/><entry>occurring.</entry><entry>Nat Genet. 2001 January; 27(1): 84-8; Eur</entry></row><row><entry/><entry/><entry/><entry/><entry>J Biochem 1996 Apr. 1; 237(1): 295-302;</entry></row><row><entry/><entry/><entry/><entry/><entry>J Biol Chem, Vol. 274, Issue 16,</entry></row><row><entry/><entry/><entry/><entry/><entry>1089-10902, Apr. 16, 1999; and</entry></row><row><entry/><entry/><entry/><entry/><entry>Hogan, B. L. M. (1996) Genes Deve.</entry></row><row><entry/><entry/><entry/><entry/><entry>10, 1580-1594.</entry></row><row><entry>Resistin</entry><entry>GeneSeq Accession</entry><entry>WO0064920</entry><entry>This gcne belongs to the family defined</entry><entry>Ability of resistin to influence type</entry><entry>Type II diabetes and</entry></row><row><entry/><entry>W69293</entry><entry/><entry>by mouse FIZZI and FIZZ3/Resistin</entry><entry>II diabetes can be determined using</entry><entry>Syndrome X.</entry></row><row><entry/><entry/><entry/><entry>genes. The characteristic feature of this</entry><entry>assays known in the art: Pontoglio et</entry></row><row><entry/><entry/><entry/><entry>family is the C-terminal stretch of 10 cys</entry><entry>al., J Clin Invest 1998 May 15;</entry></row><row><entry/><entry/><entry/><entry>residues with identical spacing. The</entry><entry>101(10): 2215-22.</entry></row><row><entry/><entry/><entry/><entry>mouse homolog of this protein is secreted</entry></row><row><entry/><entry/><entry/><entry>by adipocytes, may be the hormone</entry></row><row><entry/><entry/><entry/><entry>potantially linking obesity to type II</entry></row><row><entry/><entry/><entry/><entry>diabetes.</entry></row><row><entry>Galectin-4</entry><entry>GeneSeq Accession</entry><entry>WO9703190</entry><entry>Galectins are a family of carbohydrate-</entry><entry>Ability of Galectin-4 polypeptides to</entry><entry>Lactose intolerance.</entry></row><row><entry/><entry>W11841</entry><entry/><entry>binding proteins characterized by an</entry><entry>bind lactose can be determined using</entry></row><row><entry/><entry/><entry/><entry>affinity for beta-galactoside containing</entry><entry>assays known in the art: Wada, et al.,</entry></row><row><entry/><entry/><entry/><entry>glycoconjugates.</entry><entry>J Biol Chem 1997 Feb. 28;</entry></row><row><entry/><entry/><entry/><entry/><entry>272(9): 6078-86.</entry></row><row><entry>APM-I; ACRP-30;</entry><entry>GeneSeq Accession</entry><entry>W00026363</entry><entry>ACPR30 gene is exclusively expressed in</entry><entry>Ability of ACRP30 polypeptides to</entry><entry>Obesity, Metabolic</entry></row><row><entry>Famoxin</entry><entry>Y71035</entry><entry/><entry>adipose tissue. ACRP30 is thought to</entry><entry>influence obesity and fat oxidation</entry><entry>disorders, Lipid</entry></row><row><entry/><entry/><entry/><entry>increase fatty acid oxidation by muscle</entry><entry>can be determined using assays</entry><entry>Metabolism; Hormone</entry></row><row><entry/><entry/><entry/><entry>tissue.</entry><entry>known in the art: Fruebis et al., Proc</entry><entry>Secretion.</entry></row><row><entry/><entry/><entry/><entry/><entry>Nat'l Acad Sci USA 2001 Feb. 13;</entry></row><row><entry/><entry/><entry/><entry/><entry>98(4): 2005-10.</entry></row><row><entry>ACRP-30</entry><entry>GeneSeq Accession</entry><entry>WO0063376</entry><entry>ACPR30 gene is exclusively expressed in</entry><entry>Ability of ACRP30 homologue</entry><entry>Obesity, Metabolic</entry></row><row><entry>Homologue;</entry><entry>B30234</entry><entry/><entry>adipose tissue. ACRP30 is thought to</entry><entry>polypeptides to influence obesity</entry><entry>disorders, Lipid</entry></row><row><entry>Complement</entry><entry/><entry/><entry>increase fatty acid oxidation by muscle</entry><entry>and fat oxidation can be determined</entry><entry>Metabolism; Hormone</entry></row><row><entry>Component Clq C</entry><entry/><entry/><entry>tissue.</entry><entry>using assays known in the art:</entry><entry>Secretion.</entry></row><row><entry/><entry/><entry/><entry/><entry>Fruebis et al., Proc Nat'l Acad Sci</entry></row><row><entry/><entry/><entry/><entry/><entry>USA 2001 Feb. 13; 98(4): 2005-10.</entry></row><row><entry>Calpain-10a</entry><entry>GeneSeq Accession</entry><entry>WO0023603</entry><entry>Calpain is believed to play a role in</entry><entry>Ability of Calpain-10 to influence</entry><entry>Diabetes mellitus;</entry></row><row><entry/><entry>Y79567</entry><entry/><entry>insulin secretion and insulin activity, and</entry><entry>type II diabetes can be determined</entry><entry>Regulation of Insulin</entry></row><row><entry/><entry/><entry/><entry>therefore may be useful in the treatment</entry><entry>using assays known in the art:</entry><entry>secretory response;</entry></row><row><entry/><entry/><entry/><entry>of type II diabetes.</entry><entry>Pontoglio et al., J Clin Invest 1998</entry><entry>Insulin mediated</entry></row><row><entry/><entry/><entry/><entry/><entry>May 15; 101(10): 2215-22.</entry><entry>glucose transport</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>disorders.</entry></row><row><entry>Calpain-10b</entry><entry>GeneSeq Accession</entry><entry>WO0023603</entry><entry>Calpain is believed to play a role in</entry><entry>Ability of Calpain-10 to influence</entry><entry>Diabetes mellitus;</entry></row><row><entry/><entry>Y79568</entry><entry/><entry>insulin secretion and insulin activity, and</entry><entry>type II diabetes can be determined</entry><entry>Regulation of Insulin</entry></row><row><entry/><entry/><entry/><entry>therefore may be useful in the treatment</entry><entry>using assays known in the art:</entry><entry>secretory response;</entry></row><row><entry/><entry/><entry/><entry>of type II diabetes.</entry><entry>Pontoglio et al., J Clin Invest 1998</entry><entry>Insulin mediated</entry></row><row><entry/><entry/><entry/><entry/><entry>May 15; 101(10): 2215-22.</entry><entry>glucose transport</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>disorders.</entry></row><row><entry>Calpain-10c</entry><entry>GeneSeq Accession</entry><entry>WO0023603</entry><entry>Calpain is believed to play a role in</entry><entry>Ability of Calpain-10 to influence</entry><entry>Diabetes mellitus;</entry></row><row><entry/><entry>Y79569</entry><entry/><entry>insulin secretion and insulin activity, and</entry><entry>type II diabetes can be determined</entry><entry>Regulation of Insulin</entry></row><row><entry/><entry/><entry/><entry>therefore may be useful in the treatment</entry><entry>using assays known in the art:</entry><entry>secretory response;</entry></row><row><entry/><entry/><entry/><entry>of type II diabetes.</entry><entry>Pontoglio et al., J Clin Invest 1998</entry><entry>Insulin mediated</entry></row><row><entry/><entry/><entry/><entry/><entry>May 15; 101(10): 2215-22.</entry><entry>glucose transport</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>disorders</entry></row><row><entry>PDGF-D</entry><entry>GeneSeq Accession</entry><entry>WO0027879</entry><entry>Vascular Endothelial Growth Factor.</entry><entry>Proliferation assay using NR6R-3T3</entry><entry>Wound Healing;</entry></row><row><entry/><entry>Y71130</entry><entry/><entry/><entry>cells (Rizzino 1988 Cancer Res. 48:</entry><entry>Atherosclermis.</entry></row><row><entry/><entry/><entry/><entry/><entry>4266).</entry></row><row><entry>FasL</entry><entry>GeneSeq Accession</entry><entry>WO9936079</entry><entry>Activities associated with apoptosis and</entry><entry>Activity can be determined using</entry><entry>Apoptosis-related</entry></row><row><entry/><entry>Y28594</entry><entry/><entry>immune system functions.</entry><entry>Apoptosis assays known in the art:</entry><entry>disorders; Autoimmune</entry></row><row><entry/><entry/><entry/><entry/><entry>Walczak et al. (1996) EMBOJ 16:</entry><entry>disorders; Graft v-Host</entry></row><row><entry/><entry/><entry/><entry/><entry>5386-5397.</entry><entry>disorders.</entry></row><row><entry>Chondro modulin-</entry><entry>GeneSeq Accession</entry><entry>W00029579</entry><entry>Chondromodulin proteins are cartilage</entry><entry>Ability of Chondromodulin-like</entry><entry>Antianglogenic agent;</entry></row><row><entry>like protein</entry><entry>Y71262</entry><entry/><entry>proteins thought to confer resistance to</entry><entry>protein to inhibit vascularization can</entry><entry>Osteoblast proliferation</entry></row><row><entry/><entry/><entry/><entry>anglogeneis, and thus are useful as anti-</entry><entry>be determined using assays known</entry><entry>stimulator; prevents</entry></row><row><entry/><entry/><entry/><entry>angiogenic agents that may have utility in</entry><entry>in the art: Hirakie et al., J Biol Chem</entry><entry>vascularization of</entry></row><row><entry/><entry/><entry/><entry>combating cancer.</entry><entry>1997 Dec. 19; 272(51): 32419-26.</entry><entry>cartilage tissue; Useful</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>to treat cancer.</entry></row><row><entry>Patched</entry><entry>GeneSeq Accession</entry><entry>U.S. Pat. No. 5837538</entry><entry>Patched is a tumour-suppressor receptor</entry><entry>Ability of soluble Patched to bind to</entry><entry>Receptor for Hedgehog</entry></row><row><entry/><entry>W72969</entry><entry/><entry>for Sonic hedgehog (shh), which is a</entry><entry>and inhibit the activities of shh can</entry><entry>cellular proliferation</entry></row><row><entry/><entry/><entry/><entry>protein that controls developmental</entry><entry>be determined using assays known</entry><entry>signaling molecule.</entry></row><row><entry/><entry/><entry/><entry>patterning and growth.</entry><entry>in the art: Stone et al., Nature 1996</entry><entry>This receptor is useful</entry></row><row><entry/><entry/><entry/><entry/><entry>Nov. 14; 384(6605): 129-34.</entry><entry>as a means of</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>preventing cellular</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>proliferation via the shh</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>signaling pathway, thus</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>useful for cancers.</entry></row><row><entry>Patched-2</entry><entry>GeneSeq Accession</entry><entry>WO9953058</entry><entry>Patched is a tumour-suppressor receptor</entry><entry>Ability of soluble Patched to bind to</entry><entry>Receptor for Hedgehog</entry></row><row><entry/><entry>Y43261</entry><entry/><entry>for Sonic hedgehog (shh), which is a</entry><entry>and inhibit the activities of shh can</entry><entry>cellular proliferation</entry></row><row><entry/><entry/><entry/><entry>protein that controls developmental</entry><entry>be determined using assays known</entry><entry>signaling molecule.</entry></row><row><entry/><entry/><entry/><entry>patterning and growth.</entry><entry>in the art: Stone et al., Nature 1996</entry><entry>This receptor is useful</entry></row><row><entry/><entry/><entry/><entry/><entry>Nov. 14; 384(6605): 129-34.</entry><entry>as a means of</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>preventing cellular</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>proliferation via the shh</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>signaling pathway, thus</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>useful for cancers.</entry></row><row><entry>Maspin; Protease</entry><entry>GeneSeq Accession</entry><entry>WO9405804</entry><entry>Maspin is a member of the serpin family</entry><entry>The inhibitory effects of Maspin and</entry><entry>Tumor suppressor which</entry></row><row><entry>Inhibitor 5</entry><entry>R50938</entry><entry/><entry>of serine protease inhibitors that is</entry><entry>other protease inhibitors can be</entry><entry>is down-regulated in</entry></row><row><entry/><entry/><entry/><entry>thought to suppress tumor metastasis.</entry><entry>assayed using methods known in the</entry><entry>breast cancers. The</entry></row><row><entry/><entry/><entry/><entry/><entry>art such as a labeled protease</entry><entry>maspin protein has</entry></row><row><entry/><entry/><entry/><entry/><entry>substrate, for example, Universal</entry><entry>tumour suppressing and</entry></row><row><entry/><entry/><entry/><entry/><entry>Protease Substrate (casein, resorufin-</entry><entry>invasion suppressing</entry></row><row><entry/><entry/><entry/><entry/><entry>labeled): Roche Molecular</entry><entry>activity.</entry></row><row><entry/><entry/><entry/><entry/><entry>Biochemicals, Cat. No. 1080733.</entry></row><row><entry>Endostatin</entry><entry>GeneSeq Accession</entry><entry>WO0064946</entry><entry>Endostatin is believed to inhibit effects of</entry><entry>The inhibitory effects of endostatin</entry><entry>Anti-angiogenic activity.</entry></row><row><entry/><entry>B28399</entry><entry/><entry>capillary endothelial cell proliferation.</entry><entry>can be assayed using assays</entry><entry>Useful in the prevention</entry></row><row><entry/><entry/><entry/><entry/><entry>disclosed by Cao et al. (1996) J.</entry><entry>and/or treatment of</entry></row><row><entry/><entry/><entry/><entry/><entry>Biol. Chem. 271 29461-29467.</entry><entry>cancers.</entry></row><row><entry>aFGF; FGF-1</entry><entry>GeneSeq Accession</entry><entry>EP298723</entry><entry>Fibroblast Growth Factor</entry><entry>Proliferation assay using NR6R-3T3</entry><entry>Promotion of growth and</entry></row><row><entry/><entry>P94037</entry><entry/><entry/><entry>cells (Rizzino 1988 Cancer Res. 48:</entry><entry>proliferation of cells,</entry></row><row><entry/><entry/><entry/><entry/><entry>4266); Examples 23 and 39</entry><entry>such as epithelial cells</entry></row><row><entry/><entry/><entry/><entry/><entry>disclosed herein,</entry><entry>and keratinocytes.</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>Antagonists may be</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>useful as anti-cancer</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>agents.</entry></row><row><entry>bFGF; FGF-2</entry><entry>GeneSeq Accession</entry><entry>FR2642086</entry><entry>Fibroblast Growth Factor</entry><entry>Proliferation assay using NR6R-3T3</entry><entry>Promotion of growth and</entry></row><row><entry/><entry>R06685</entry><entry/><entry/><entry>cells (Rizzino 1988 Cancer Res. 48:</entry><entry>proliferation of cells,</entry></row><row><entry/><entry/><entry/><entry/><entry>4266); Examples 23 and 39</entry><entry>such as epithelial cells</entry></row><row><entry/><entry/><entry/><entry/><entry>disclosed herein.</entry><entry>and keratinocytes.</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>Antagonists may be</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>useful as anti-cancer</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>agents.</entry></row><row><entry>FGF-3; INT-2</entry><entry>GeneSeq Accession</entry><entry>WO9503831</entry><entry>Fibroblast Growth Factor</entry><entry>Proliferation assay using NR6R-3T3</entry><entry>Promotion of growth and</entry></row><row><entry/><entry>R07824</entry><entry/><entry/><entry>cells (Rizzino 1988 Cancer Res. 48:</entry><entry>proliferation of cells,</entry></row><row><entry/><entry/><entry/><entry/><entry>4266); Examples 23 and 39</entry><entry>such as epithelial cells</entry></row><row><entry/><entry/><entry/><entry/><entry>disclosed herein.</entry><entry>and keratinocytes.</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>Antagonists may he</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>useful as anti-cancer</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>agents.</entry></row><row><entry>FGF-4; HST-1;</entry><entry>GeneSeq Accession</entry><entry>WO9503831</entry><entry>Fibroblast Growth Factor</entry><entry>Proliferation assay using NR6R-3T3</entry><entry>Promotion of growth and</entry></row><row><entry>HBGF-4</entry><entry>R07825</entry><entry/><entry/><entry>cells (Rizzino 1988 Cancer Res. 48:</entry><entry>proliferation of cells,</entry></row><row><entry/><entry/><entry/><entry/><entry>4266); Examples 23 and 39</entry><entry>such as epithelial cells</entry></row><row><entry/><entry/><entry/><entry/><entry>disclosed herein.</entry><entry>and keratinocytes.</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>Antagonists may be</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>useful as anti-cancer</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>agents.</entry></row><row><entry>FGF-5</entry><entry>GeneSeq Accession</entry><entry>WO9730155</entry><entry>Fibroblast Growth Factor</entry><entry>Proliferation assay using NR6R-3T3</entry><entry>Promotion of growth and</entry></row><row><entry/><entry>W22600</entry><entry/><entry/><entry>cells (Rizzino 1988 Cancer Res. 48:</entry><entry>proliferation of cells,</entry></row><row><entry/><entry/><entry/><entry/><entry>4266); Examples 23 and 39</entry><entry>such as epithelial cells</entry></row><row><entry/><entry/><entry/><entry/><entry>disclosed herein.</entry><entry>and keratinocytes.</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>Antagonists may be</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>useful as anti-cancer</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>agents.</entry></row><row><entry>FGF-6; Heparin</entry><entry>GeneSeq Accession</entry><entry>EP613946</entry><entry>Fibroblast Growth Factor</entry><entry>Proliferation assay using NR6R-3T3</entry><entry>Promotion of growth and</entry></row><row><entry>binding secreted</entry><entry>R58555</entry><entry/><entry/><entry>cells (Rizzino 1988 Cancer Res. 48:</entry><entry>proliferation of cells,</entry></row><row><entry>transforming</entry><entry/><entry/><entry/><entry>4266); Examples 23 and 39</entry><entry>such as epithelial cells</entry></row><row><entry>factor-2</entry><entry/><entry/><entry/><entry>disclosed herein.</entry><entry>and keratinocytes.</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>Antagonists may be</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>useful as anti-cancer</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>agents.</entry></row><row><entry>FGF-8</entry><entry>GeneSeq Accession</entry><entry>WO9524928</entry><entry>Fibroblast Growth Factor</entry><entry>Proliferation assay using NR6R-3T3</entry><entry>Promotion of growth and</entry></row><row><entry/><entry>R80783</entry><entry/><entry/><entry>cells (Rizzino 1988 Cancer Res. 48:</entry><entry>proliferation of cells,</entry></row><row><entry/><entry/><entry/><entry/><entry>4266); Examples 23 and 39</entry><entry>such as epithelial cells</entry></row><row><entry/><entry/><entry/><entry/><entry>disclosed herein.</entry><entry>and keratinocytes.</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>Antagonists may be</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>useful as anti-cancer</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>agents.</entry></row><row><entry>FGF-9; Gila</entry><entry>GeneSeq Accession</entry><entry>WO9503831</entry><entry>Fibroblast Growth Factor</entry><entry>Proliferation assay using NR6R-3T3</entry><entry>Promotion of growth and</entry></row><row><entry>activating factor</entry><entry>R70822</entry><entry/><entry/><entry>cells (Rizzino 1988 Cancer Res. 48:</entry><entry>proliferation of cells,</entry></row><row><entry/><entry/><entry/><entry/><entry>4266); Examples 23 and 39</entry><entry>such as epithelial cells</entry></row><row><entry/><entry/><entry/><entry/><entry>disclosed herein.</entry><entry>and keratinocytes.</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>Antagonists may be</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>useful as anti-cancer</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>agents.</entry></row><row><entry>FGF-12; Fibroblast</entry><entry>GeneSeq Accession</entry><entry>WO9635708</entry><entry>Fibroblast Growth Factor</entry><entry>Proliferation assay using NR6R-3T3</entry><entry>Promotion of growth and</entry></row><row><entry>growth factor</entry><entry>W06309</entry><entry/><entry/><entry>cells (Rizzino 1988 Cancer Res. 48:</entry><entry>proliferation of cells,</entry></row><row><entry>homologous</entry><entry/><entry/><entry/><entry>4266); Examples 23 and 39</entry><entry>such as epithelial cells</entry></row><row><entry>factor-1</entry><entry/><entry/><entry/><entry>disclosed herein.</entry><entry>and keratinocytes.</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>Antagonists may be</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>useful as anti-cancer</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>agents.</entry></row><row><entry>FGF-15</entry><entry>GeneSeq Accession</entry><entry>WO9927100</entry><entry>Fibroblast Growth Factor</entry><entry>Proliferation assay using NR6R-3T3</entry><entry>Promotion of growth and</entry></row><row><entry/><entry>Y08582</entry><entry/><entry/><entry>cells (Rizzino 1988 Cancer Res. 48:</entry><entry>proliferation of cells,</entry></row><row><entry/><entry/><entry/><entry/><entry>4266); Examples 23 and 39</entry><entry>such as epithelial cells</entry></row><row><entry/><entry/><entry/><entry/><entry>disclosed herein.</entry><entry>and keratinocytes.</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>Antagonists may be</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>useful as anti-cancer</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>agents.</entry></row><row><entry>FGF-16</entry><entry>GeneSeq Accession</entry><entry>WO9918128</entry><entry>Fibroblast Growth Factor</entry><entry>Proliferation assay using NR6R-3T3</entry><entry>Promotion of growth and</entry></row><row><entry/><entry>Y05474</entry><entry/><entry/><entry>cells (Rizzino 1988 Cancer Res. 48:</entry><entry>proliferation of cells,</entry></row><row><entry/><entry/><entry/><entry/><entry>4266); Examples 23 and 39</entry><entry>such as epithelial cells</entry></row><row><entry/><entry/><entry/><entry/><entry>disclosed herein.</entry><entry>and keratinocytes.</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>Antagonists may be</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>useful as anti-cancer</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>agents.</entry></row><row><entry>FGF-18</entry><entry>GeneSeq Accession</entry><entry>WO9927100</entry><entry>Fibroblast Growth Factor</entry><entry>Proliferation assay using NR6R-3T3</entry><entry>Promotion of growth and</entry></row><row><entry/><entry>Y08590</entry><entry/><entry/><entry>cells (Rizzino 1988 Cancer Res. 48:</entry><entry>proliferation of cells,</entry></row><row><entry/><entry/><entry/><entry/><entry>4266); Examples 23 and 39</entry><entry>such as epithelial cells</entry></row><row><entry/><entry/><entry/><entry/><entry>disclosed herein.</entry><entry>and keratinocytes.</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>Antagonists may be</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>useful as anti-cancer</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>agents.</entry></row><row><entry>fit-3 ligand</entry><entry>GeneSeq Accession</entry><entry>EP627487</entry><entry>Stem Cell Progenitor</entry><entry>Chemokine activities can be</entry><entry>Promotion of immune</entry></row><row><entry/><entry>R67541</entry><entry/><entry/><entry>determined using assays known in</entry><entry>cell growth and/or</entry></row><row><entry/><entry/><entry/><entry/><entry>the art: Methods in Molecular</entry><entry>differentiation.</entry></row><row><entry/><entry/><entry/><entry/><entry>Biology, 2000, vol. 138: Chemokine</entry></row><row><entry/><entry/><entry/><entry/><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry></row><row><entry/><entry/><entry/><entry/><entry>T. N. C. Wells, and C. A. Power.</entry></row><row><entry/><entry/><entry/><entry/><entry>&#x2009;&#xa9;Humana Press Inc.,</entry></row><row><entry/><entry/><entry/><entry/><entry>Totowa, NJ</entry></row><row><entry>VEGF-110</entry><entry>GeneSeq Accession</entry><entry>WO0013702</entry><entry>Promotes the growth and/or proliferation</entry><entry>VEGF activity can be determined</entry><entry>Promotion of growth and</entry></row><row><entry/><entry>Y69417</entry><entry/><entry>of endothelial cells.</entry><entry>using assays known in the art, such</entry><entry>proliferation of cells,</entry></row><row><entry/><entry/><entry/><entry/><entry>as those disclosed in International</entry><entry>such as vascular</entry></row><row><entry/><entry/><entry/><entry/><entry>Publication No. WO0045835, for</entry><entry>endothelial cells.</entry></row><row><entry/><entry/><entry/><entry/><entry>example.</entry><entry>Antagonists may be</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>useful as anti-angiogenic</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>agents, and may be</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>applicable for cancer.</entry></row><row><entry>VEGB-121</entry><entry>GeneSeq Accession</entry><entry>WO0071713</entry><entry>Promotes the growth and/or proliferation</entry><entry>VEGF activity can be determined</entry><entry>Promotion of growth and</entry></row><row><entry/><entry>B50432</entry><entry/><entry>of endothelial cells.</entry><entry>using assays known in the art, such</entry><entry>proliferation of cells,</entry></row><row><entry/><entry/><entry/><entry/><entry>as those disclosed in International</entry><entry>such as vascular</entry></row><row><entry/><entry/><entry/><entry/><entry>Publication No. WO0045835, for</entry><entry>endothelial cells.</entry></row><row><entry/><entry/><entry/><entry/><entry>example.</entry><entry>Antagonists may be</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>useful as anti-angiogenic</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>agents, and may be</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>applicable for cancer.</entry></row><row><entry>VEGF-138</entry><entry>GeneSeq Accession</entry><entry>WO9940197</entry><entry>Promotes the growth and/or proliferation</entry><entry>VEGF activity can be determined</entry><entry>Promotion of growth and</entry></row><row><entry/><entry>Y43483</entry><entry/><entry>of endothelial cells.</entry><entry>using assays known in the art, such</entry><entry>proliferation of cells,</entry></row><row><entry/><entry/><entry/><entry/><entry>as those disclosed in International</entry><entry>such as vascular</entry></row><row><entry/><entry/><entry/><entry/><entry>Publication No. WO0045835, for</entry><entry>endothelial cells.</entry></row><row><entry/><entry/><entry/><entry/><entry>example.</entry><entry>Antagonists may be</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>useful as anti-angiogenic</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>agents, and may be</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>applicable for cancer.</entry></row><row><entry>VEGF-145</entry><entry>GeneSeq Accession</entry><entry>WO0013702</entry><entry>Promotes the growth and/or proliferation</entry><entry>VEGF activity can be determined</entry><entry>Promotion of growth and</entry></row><row><entry/><entry>Y69413</entry><entry/><entry>of endothelial cells.</entry><entry>using assays known in the art, such</entry><entry>proliferation of cells,</entry></row><row><entry/><entry/><entry/><entry/><entry>as those disclosed in International</entry><entry>such as vascular</entry></row><row><entry/><entry/><entry/><entry/><entry>Publication No. WO0045835, for</entry><entry>endothelial cells.</entry></row><row><entry/><entry/><entry/><entry/><entry>example.</entry><entry>Antagonists may be</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>useful as anti-angiogenic</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>agents, and may be</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>applicable for cancer.</entry></row><row><entry>VEGF-162</entry><entry>GeneSeq Accession</entry><entry>W09940197</entry><entry>Promotes the growth and/or proliferation</entry><entry>VEGF activity can be determined</entry><entry>Promotion of growth and</entry></row><row><entry/><entry>Y43484</entry><entry/><entry>of endothelial cells.</entry><entry>using assays known in the art, such</entry><entry>proliferation of cells,</entry></row><row><entry/><entry/><entry/><entry/><entry>as those disclosed in International</entry><entry>such as vascular</entry></row><row><entry/><entry/><entry/><entry/><entry>Publication No. WO0045835, for</entry><entry>endothelial cells.</entry></row><row><entry/><entry/><entry/><entry/><entry>example.</entry><entry>Antagonists may be</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>useful as anti-angiogenic</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>agents, and may be</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>applicable for cancer.</entry></row><row><entry>VEGF-165</entry><entry>GeneSeq Accession</entry><entry>WO0013702</entry><entry>Promotes the growth and/or proliferation</entry><entry>VEGF activity can be determined</entry><entry>Promotion of growth and</entry></row><row><entry/><entry>Y69414</entry><entry/><entry>of endothelial cells.</entry><entry>using assays known in the art, such</entry><entry>proliferation of cells,</entry></row><row><entry/><entry/><entry/><entry/><entry>as those disclosed in International</entry><entry>such as vascular</entry></row><row><entry/><entry/><entry/><entry/><entry>Publication No. WO0045835, for</entry><entry>endothelial cells.</entry></row><row><entry/><entry/><entry/><entry/><entry>example.</entry><entry>Antagonists may be</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>useful as anti-angiogenic</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>agents, and may be</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>applicable for cancer.</entry></row><row><entry>VEGF-182</entry><entry>GeneSeq Accession</entry><entry>W09940197</entry><entry>Promotes the growth and/or proliferation</entry><entry>VEGF activity can be determined</entry><entry>Promotion of growth and</entry></row><row><entry/><entry>Y43483</entry><entry/><entry>of endothelial cells.</entry><entry>using assays known in the art, such</entry><entry>proliferation of cells,</entry></row><row><entry/><entry/><entry/><entry/><entry>as those disclosed in International</entry><entry>such as vascular</entry></row><row><entry/><entry/><entry/><entry/><entry>Publication No. WO0045835, for</entry><entry>endothelial cells.</entry></row><row><entry/><entry/><entry/><entry/><entry>example.</entry><entry>Antagonists may be</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>useful as anti-angiogenic</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>agents, and may be</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>applicable for cancer.</entry></row><row><entry>VEGF-189</entry><entry>GeneSeq Accession</entry><entry>WO0013702</entry><entry>Promotes the growth and/or proliferation</entry><entry>VEGF activity can be determined</entry><entry>Promotion of growth and</entry></row><row><entry/><entry>Y69415</entry><entry/><entry>of endothelial cells.</entry><entry>using assays known in the art, such</entry><entry>proliferation of cells,</entry></row><row><entry/><entry/><entry/><entry/><entry>as those disclosed in International</entry><entry>such as vascular</entry></row><row><entry/><entry/><entry/><entry/><entry>Publication No. WO0045835, for</entry><entry>endothelial cells.</entry></row><row><entry/><entry/><entry/><entry/><entry>example.</entry><entry>Antagonists may be</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>useful as anti-angiogenic</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>agents, and may be</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>applicable for cancer.</entry></row><row><entry>VEGF-206</entry><entry>GeneSeq Accession</entry><entry>W00013702</entry><entry>Promotes the growth and/or proliferation</entry><entry>VEGF activity can be determined</entry><entry>Promotion of growth and</entry></row><row><entry/><entry>Y69416</entry><entry/><entry>of endothelial cells.</entry><entry>using assays known in the art, such</entry><entry>proliferation of cells,</entry></row><row><entry/><entry/><entry/><entry/><entry>as those disclosed in International</entry><entry>such as vascular</entry></row><row><entry/><entry/><entry/><entry/><entry>Publication No. WO0045835, for</entry><entry>endothelial cells.</entry></row><row><entry/><entry/><entry/><entry/><entry>example.</entry><entry>Antagonists may be</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>useful as anti-angiogenic</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>agents, and may be</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>applicable for cancer.</entry></row><row><entry>VEGF-D</entry><entry>GeneSeq Accession</entry><entry>WO9807832</entry><entry>Promotes the growth and/or proliferation</entry><entry>VEGF activity can be determined</entry><entry>Promotion of growth and</entry></row><row><entry/><entry>W53240</entry><entry/><entry>of endothelial cells.</entry><entry>using assays known in the art, such</entry><entry>proliferation of cells,</entry></row><row><entry/><entry/><entry/><entry/><entry>as those disclosed in International</entry><entry>such as vascular</entry></row><row><entry/><entry/><entry/><entry/><entry>Publication No. WO0045835, for</entry><entry>endothelial cells.</entry></row><row><entry/><entry/><entry/><entry/><entry>example.</entry><entry>Antagonists may be</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>useful as anti-angiogenic</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>agents, and may be</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>applicable for cancer.</entry></row><row><entry>VEGF-E; VEGF-X</entry><entry>GeneSeq Accession</entry><entry>W09947677</entry><entry>Promotes the growth and/or proliferation</entry><entry>VEGF activity can be determined</entry><entry>Promotion of growth and</entry></row><row><entry/><entry>Y33679</entry><entry/><entry>of endothelial cells.</entry><entry>using assays known in the art, such</entry><entry>proliferation of cells,</entry></row><row><entry/><entry/><entry/><entry/><entry>as those disclosed in International</entry><entry>such as vascular</entry></row><row><entry/><entry/><entry/><entry/><entry>Publication No. WO0045835, for</entry><entry>endothelial cells.</entry></row><row><entry/><entry/><entry/><entry/><entry>example.</entry><entry>Antagonists may be</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>useful as anti-angiogenic</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>agents, and may be</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>applicable for cancer.</entry></row><row><entry>VEGF Receptor;</entry><entry>GeneSeq Accession</entry><entry>WO9831794</entry><entry>Receptor for VEGF polypeptides</entry><entry>VEGF activity, in the presence of</entry><entry>VEGF Receptor. Fusion</entry></row><row><entry>KDR; flk-1</entry><entry>W69679</entry><entry/><entry/><entry>flk-1 polypeptides, can be</entry><entry>protein with the</entry></row><row><entry/><entry/><entry/><entry/><entry>determined using assays known in</entry><entry>extracellular domain is</entry></row><row><entry/><entry/><entry/><entry/><entry>the art, such as those disclosed in</entry><entry>useful as an anti-</entry></row><row><entry/><entry/><entry/><entry/><entry>International Publication No.</entry><entry>angiogenic agent.</entry></row><row><entry/><entry/><entry/><entry/><entry>WO0045835, for example.</entry><entry>Antagonists may be</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>useful in the promotion</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>of angiogenesis.</entry></row><row><entry>Soluble VEGF</entry><entry>GeneSeq Accession</entry><entry>U.S. Pat. No. 5,712,380</entry><entry>Receptor for VEGF polypeptides</entry><entry>VEGF activity, in the presence of</entry><entry>VEGF Receptor. Fusion</entry></row><row><entry>Receptor</entry><entry>W47037</entry><entry/><entry/><entry>VEGF Receptor polypeptides, can</entry><entry>protein with the</entry></row><row><entry/><entry/><entry/><entry/><entry>be determined using assays known</entry><entry>extracellular domain is</entry></row><row><entry/><entry/><entry/><entry/><entry>in the art, such as those disclosed in</entry><entry>useful as an anti-</entry></row><row><entry/><entry/><entry/><entry/><entry>International Publication No.</entry><entry>angiogenic agent.</entry></row><row><entry/><entry/><entry/><entry/><entry>WO0045835, for example.</entry><entry>Antagonists may be</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>useful in the promotion</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>of angiogenesis.</entry></row><row><entry>flt-1</entry><entry>GeneSeq Accession</entry><entry>WO0021560</entry><entry>Receptor for VEGF polypeptides</entry><entry>VEGF activity, in the presence of</entry><entry>VEGF Receptor. Fusion</entry></row><row><entry/><entry>Y70751</entry><entry/><entry/><entry>flt-1 polypeptides, can be</entry><entry>protein with the</entry></row><row><entry/><entry/><entry/><entry/><entry>determined using assays known in</entry><entry>extracellular domain is</entry></row><row><entry/><entry/><entry/><entry/><entry>the art, such as those disclosed in</entry><entry>useful as an anti-</entry></row><row><entry/><entry/><entry/><entry/><entry>International Publication No.</entry><entry>angiogenic agent.</entry></row><row><entry/><entry/><entry/><entry/><entry>WO0045835, for example.</entry><entry>Antagonists may be</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>useful in the promotion</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>of angiogenesis.</entry></row><row><entry>VEGF R-3; flt-4</entry><entry>GeneSeq Accession</entry><entry>WO0058511</entry><entry>Receptor for VEGF polypeptides</entry><entry>VEGF activity, in the presence of</entry><entry>VEGF Receptor. Fusion</entry></row><row><entry/><entry>B29047</entry><entry/><entry/><entry>flt-4 polypeptides, can be</entry><entry>protein with the</entry></row><row><entry/><entry/><entry/><entry/><entry>determined using assays known in</entry><entry>extracellular domain is</entry></row><row><entry/><entry/><entry/><entry/><entry>the art, such as those disclosed in</entry><entry>useful as an anti-</entry></row><row><entry/><entry/><entry/><entry/><entry>International Publication No.</entry><entry>angiogenic agent.</entry></row><row><entry/><entry/><entry/><entry/><entry>WO0045835, for example.</entry><entry>Antagonists may be</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>useful in the promotion</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>of angiogenesis.</entry></row><row><entry>Neuropilin-1</entry><entry>GeneSeq Accession</entry><entry>WO9929858</entry><entry>Vascular Endothelial Growth Factor</entry><entry>VEGF activity can be determined</entry><entry>Promotion of growth and</entry></row><row><entry/><entry>Y06319</entry><entry/><entry/><entry>using assays known in the art, such</entry><entry>proliferation of cells,</entry></row><row><entry/><entry/><entry/><entry/><entry>as those disclosed in International</entry><entry>such as vascular</entry></row><row><entry/><entry/><entry/><entry/><entry>Publication No. WO0045835, for</entry><entry>endothelial cells.</entry></row><row><entry/><entry/><entry/><entry/><entry>example.</entry><entry>Antagonists may be</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>useful as anti-angiogenic</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>agents, and may be</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>applicable for cancer.</entry></row><row><entry>Neuropilin-2</entry><entry>GeneSeq Accession</entry><entry>WO9929858</entry><entry>Vascular Endothelial Growth Factor</entry><entry>VEGF activity can be determined</entry><entry>Promotion of growth and</entry></row><row><entry/><entry>Y03618</entry><entry/><entry/><entry>using assays known in the art, such</entry><entry>proliferation of cells,</entry></row><row><entry/><entry/><entry/><entry/><entry>as those disclosed in International</entry><entry>such as vascular</entry></row><row><entry/><entry/><entry/><entry/><entry>Publication No. WO0045835, for</entry><entry>endothelial cells.</entry></row><row><entry/><entry/><entry/><entry/><entry>example.</entry><entry>Antagonists may be</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>useful as anti-angiogenic</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>agents, and may be</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>applicable for cancer.</entry></row><row><entry>Human fast twitch</entry><entry>GeneSeq Accession</entry><entry>W09730085</entry><entry>Troponins are contractile proteins that are</entry><entry>Ability of soluble Troponins to</entry><entry>Anti-angiogenesis</entry></row><row><entry>skeletal muscle</entry><entry>W22597</entry><entry/><entry>thought to inhibit angiogenesis. High</entry><entry>inhibit anglogenesis can be</entry></row><row><entry>troponin C</entry><entry/><entry/><entry>levels may contribute to the difficulty</entry><entry>determined using assays known in</entry></row><row><entry/><entry/><entry/><entry>encountered in revascularizing the</entry><entry>the art:. Proc Natl Acad Sci USA</entry></row><row><entry/><entry/><entry/><entry>ischemic myocardium after</entry><entry>1999 Mar. 16; 96(6): 2645-50.</entry></row><row><entry/><entry/><entry/><entry>cardiovascular injury.</entry></row><row><entry>Human fast twitch</entry><entry>GeneSeq Accession</entry><entry>W09730085</entry><entry>Troponins are contractile proteins that are</entry><entry>Ability of soluble Troponins to</entry><entry>Anti-angiogenesis</entry></row><row><entry>skeletal muscle</entry><entry>W18054</entry><entry/><entry>thought to inhibit angiogenesis. High</entry><entry>inhibit anglogenesis can be</entry></row><row><entry>troponin I</entry><entry/><entry/><entry>levels may contribute to the difficulty</entry><entry>determined using assays known in</entry></row><row><entry/><entry/><entry/><entry>encountered in revascularizing the</entry><entry>the art:. Proc Natl Acad Sci USA</entry></row><row><entry/><entry/><entry/><entry>ischemic myocardium after</entry><entry>1999 Mar. 16; 96(6): 2645-50.</entry></row><row><entry/><entry/><entry/><entry>cardiovascular injury.</entry></row><row><entry>Human fast twitch</entry><entry>GeneSeq Accession</entry><entry>W09730085</entry><entry>Troponins are contractile proteins that are</entry><entry>Ability of soluble Troponins to</entry><entry>Anti-angiogenesis</entry></row><row><entry>skeletal muscle</entry><entry>W22599</entry><entry/><entry>thought to inhibit angiogenesis. High</entry><entry>inhibit anglogenesis can be</entry></row><row><entry>troponin T</entry><entry/><entry/><entry>levels may contribute to the difficulty</entry><entry>determined using assays known in</entry></row><row><entry/><entry/><entry/><entry>encountered in revascularizing the</entry><entry>the art:. Proc Natl Acad Sci USA</entry></row><row><entry/><entry/><entry/><entry>ischemic myocardium after</entry><entry>1999 Mar. 16; 96(6): 2645-50.</entry></row><row><entry/><entry/><entry/><entry>cardiovascular injury.</entry></row><row><entry>fragment.</entry><entry>GeneSeq Accession</entry><entry>W09719955</entry><entry>Troponins are contractile proteins that are</entry><entry>Ability of soluble Troponins to</entry><entry>Anti-angiogenesis</entry></row><row><entry>myofibrillar</entry><entry>W18053</entry><entry/><entry>thought to inhibit angiogenesis. High</entry><entry>inhibit anglogenesis can be</entry></row><row><entry>protein troponin I</entry><entry/><entry/><entry>levels may contribute to the difficulty</entry><entry>determined using assays known in</entry></row><row><entry/><entry/><entry/><entry>encountered in revascularizing the</entry><entry>the art:. Proc Natl Acad Sci USA</entry></row><row><entry/><entry/><entry/><entry>ischemic myocardium after</entry><entry>1999 Mar. 16; 96(6): 2645-50.</entry></row><row><entry/><entry/><entry/><entry>cardiovascular injury.</entry></row><row><entry>myofibrillar</entry><entry>GeneSeq Accession</entry><entry>W09719955</entry><entry>Troponins are contractile proteins that are</entry><entry>Ability of soluble Troponins to</entry><entry>Anti-angiogenesis</entry></row><row><entry>protein troponin I</entry><entry>W18054</entry><entry/><entry>thought to inhibit angiogencsis. High</entry><entry>inhibit anglogenesis can be</entry></row><row><entry/><entry/><entry/><entry>levels may contribute to the difficulty</entry><entry>determined using assays known in</entry></row><row><entry/><entry/><entry/><entry>encountered in revascularizing the</entry><entry>the art:. Proc Natl Acad Sci USA</entry></row><row><entry/><entry/><entry/><entry>ischemic myocardium after</entry><entry>1999 Mar. 16; 96(6): 2645-50.</entry></row><row><entry/><entry/><entry/><entry>cardiovascular injury.</entry></row><row><entry>Troponin peptides</entry><entry>GeneSeq Accessions</entry><entry>WO9933874</entry><entry>Troponins are contractile proteins that are</entry><entry>Ability of soluble Troponins to</entry><entry>Anti-angiogenesis</entry></row><row><entry/><entry>Y29581, Y29582,</entry><entry/><entry>thought to inhibit angiogencsis. High</entry><entry>inhibit anglogenesis can be</entry></row><row><entry/><entry>Y29583, Y29584,</entry><entry/><entry>levels may contribute to the difficulty</entry><entry>determined using assays known in</entry></row><row><entry/><entry>Y29585, and</entry><entry/><entry>encountered in revascularizing the</entry><entry>the art:. Proc Natl Acad Sci USA</entry></row><row><entry/><entry>Y29586</entry><entry/><entry>ischemic myocardium after</entry><entry>1999 Mar. 16; 96(6): 2645-50.</entry></row><row><entry/><entry/><entry/><entry>cardiovascular injury.</entry></row><row><entry>Human fast twitch</entry><entry>GeneSeq Accession</entry><entry>WO0054770</entry><entry>Troponins are contractile proteins that are</entry><entry>Ability of soluble Troponins to</entry><entry>Anti-angiogenesis</entry></row><row><entry>skeletal muscle</entry><entry>B00134</entry><entry/><entry>thought to inhibit angiogencsis. High</entry><entry>inhibit anglogenesis can be</entry></row><row><entry>Troponin subunit C</entry><entry/><entry/><entry>levels may contribute to the difficulty</entry><entry>determined using assays known in</entry></row><row><entry/><entry/><entry/><entry>encountered in revascularizing the</entry><entry>the art:. Proc Natl Acad Sci USA</entry></row><row><entry/><entry/><entry/><entry>ischemic myocardium after</entry><entry>1999 Mar. 16; 96(6): 2645-50.</entry></row><row><entry/><entry/><entry/><entry>cardiovascular injury.</entry></row><row><entry>Human fast twitch</entry><entry>GeneSeq Accession</entry><entry>WO0054770</entry><entry>Troponins are contractile proteins that are</entry><entry>Ability of soluble Troponins to</entry><entry>Anti-angiogenesis</entry></row><row><entry>skeletal muscle</entry><entry>B00135</entry><entry/><entry>thought to inhibit angiogencsis. High</entry><entry>inhibit anglogenesis can be</entry></row><row><entry>Troponin subunit I</entry><entry/><entry/><entry>levels may contribute to the difficulty</entry><entry>determined using assays known in</entry></row><row><entry>Protein</entry><entry/><entry/><entry>encountered in revascularizing the</entry><entry>the art:. Proc Natl Acad Sci USA</entry></row><row><entry/><entry/><entry/><entry>ischemic myocardium after</entry><entry>1999 Mar. 16; 96(6): 2645-50.</entry></row><row><entry/><entry/><entry/><entry>cardiovascular injury.</entry></row><row><entry>Human fast twitch</entry><entry>GeneSeq Accession</entry><entry>WO0054770</entry><entry>Troponins are contractile proteins that are</entry><entry>Ability of soluble Troponins to</entry><entry>Anti-angiogenesis</entry></row><row><entry>skeletal muscle</entry><entry>B00136</entry><entry/><entry>thought to inhibit angiogencsis. High</entry><entry>inhibit anglogenesis can be</entry></row><row><entry>Troponin subunit T</entry><entry/><entry/><entry>levels may contribute to the difficulty</entry><entry>determined using assays known in</entry></row><row><entry/><entry/><entry/><entry>encountered in revascularizing the</entry><entry>the art:. Proc Natl Acad Sci USA</entry></row><row><entry/><entry/><entry/><entry>ischemic myocardium after</entry><entry>1999 Mar. 16; 96(6): 2645-50.</entry></row><row><entry/><entry/><entry/><entry>cardiovascular injury.</entry></row><row><entry>Activator</entry><entry>GeneSeq Accession</entry><entry>WO9013648</entry><entry>PAIs are believed to play a role in cancer,</entry><entry>Methods that measure plasminogen</entry><entry>Anti-angiogenesis;</entry></row><row><entry>Inbibitor-1; PAI-1</entry><entry>R08411</entry><entry/><entry>and cardiovascular disease and blood-</entry><entry>activator inhibitor (PAI) activity are</entry><entry>blood-clotting disorders.</entry></row><row><entry/><entry/><entry/><entry>clotting disorders.</entry><entry>known in the art, for example, assay</entry></row><row><entry/><entry/><entry/><entry/><entry>the ability of PAI to inhibit tissue</entry></row><row><entry/><entry/><entry/><entry/><entry>plasminogen activator (tPA) or</entry></row><row><entry/><entry/><entry/><entry/><entry>urokinase (uPA): J Biochem</entry></row><row><entry/><entry/><entry/><entry/><entry>Biophys Methods 2000 Sep. 11;</entry></row><row><entry/><entry/><entry/><entry/><entry>45(2): 127-40, Breast Cancer Res</entry></row><row><entry/><entry/><entry/><entry/><entry>Treat 1996; 41(2): 141-6. Methods</entry></row><row><entry/><entry/><entry/><entry/><entry>that measure anti-angiogenesis</entry></row><row><entry/><entry/><entry/><entry/><entry>activity are known in the art, for</entry></row><row><entry/><entry/><entry/><entry/><entry>example, Proc Natl Acad Sci USA</entry></row><row><entry/><entry/><entry/><entry/><entry>1999 Mar. 16; 96(6): 2645-50.</entry></row><row><entry>Plasminogen</entry><entry>GeneSeq Accession</entry><entry>DE3722673</entry><entry>PAIs are believed to play a role in cancer,</entry><entry>Methods that measure plasminogen</entry><entry>Anti-angiogenesis;</entry></row><row><entry>Activator</entry><entry>P94160</entry><entry/><entry>and cardiovascular disease and blood-</entry><entry>activator inhibitor (PAI) activity are</entry><entry>blood-clotting disorders.</entry></row><row><entry>Inhibitor-2; PAI-2</entry><entry/><entry/><entry>clotting disorders.</entry><entry>known in the art, for example, assay</entry></row><row><entry/><entry/><entry/><entry/><entry>the ability of PAI to inhibit tissue</entry></row><row><entry/><entry/><entry/><entry/><entry>plasminogen activator (tPA) or</entry></row><row><entry/><entry/><entry/><entry/><entry>urokinase (uPA): J Biochem</entry></row><row><entry/><entry/><entry/><entry/><entry>Biophys Methods 2000 Sep. 11;</entry></row><row><entry/><entry/><entry/><entry/><entry>45(2): 127-40, Breast Cancer Res</entry></row><row><entry/><entry/><entry/><entry/><entry>Treat 1996; 41(2): 141-6. Methods</entry></row><row><entry/><entry/><entry/><entry/><entry>that measure anti-angiogenesis</entry></row><row><entry/><entry/><entry/><entry/><entry>activity are known in the art, for</entry></row><row><entry/><entry/><entry/><entry/><entry>example, Proc Natl Acad Sci USA</entry></row><row><entry/><entry/><entry/><entry/><entry>1999 Mar. 16; 96(6): 2645-50.</entry></row><row><entry>Activator</entry><entry>GeneSeq Accession</entry><entry>WO9102057</entry><entry>PAIs are believed to play a role in cancer,</entry><entry>Methods that measure plasminogen</entry><entry>Anti-angiogenesis;</entry></row><row><entry>Inhibitor-2; PAI-2</entry><entry>R10921</entry><entry/><entry>and cardiovascular disease and blood-</entry><entry>activator inhibitor (PAI) activity are</entry><entry>blood-clotting disorders.</entry></row><row><entry/><entry/><entry/><entry>clotting disorders.</entry><entry>known in the art, for example, assay</entry></row><row><entry/><entry/><entry/><entry/><entry>the ability of PAI to inhibit tissue</entry></row><row><entry/><entry/><entry/><entry/><entry>plasminogen activator (tPA) or</entry></row><row><entry/><entry/><entry/><entry/><entry>urokinase (uPA): J Biochem</entry></row><row><entry/><entry/><entry/><entry/><entry>Biophys Methods 2000 Sep. 11;</entry></row><row><entry/><entry/><entry/><entry/><entry>45(2): 127-40, Breast Cancer Res</entry></row><row><entry/><entry/><entry/><entry/><entry>Treat 1996; 41(2): 141-6. Methods</entry></row><row><entry/><entry/><entry/><entry/><entry>that measure anti-angiogenesis</entry></row><row><entry/><entry/><entry/><entry/><entry>activity are known in the art, for</entry></row><row><entry/><entry/><entry/><entry/><entry>example, Proc Natl Acad Sci USA</entry></row><row><entry/><entry/><entry/><entry/><entry>1999 Mar. 16; 96(6): 2645-50.</entry></row><row><entry>Human PAI-1</entry><entry>GeneSeq Accessions</entry><entry>WO9105048</entry><entry>PAIs are believed to play a role in cancer,</entry><entry>Methods that measure plasminogen</entry><entry>Anti-angiogenesis;</entry></row><row><entry>mutants</entry><entry>R11755, R11756,</entry><entry/><entry>and cardiovascular disease and blood-</entry><entry>activator inhibitor (PAI) activity are</entry><entry>blood-clotting disorders.</entry></row><row><entry/><entry>R11757, R11758,</entry><entry/><entry>clotting disorders.</entry><entry>known in the art, for example, assay</entry></row><row><entry/><entry>R11759, R11760,</entry><entry/><entry/><entry>the ability of PAI to inhibit tissue</entry></row><row><entry/><entry>R11761, R11762</entry><entry/><entry/><entry>plasminogen activator (tPA) or</entry></row><row><entry/><entry>and R11763</entry><entry/><entry/><entry>urokinase (uPA): J Biochem</entry></row><row><entry/><entry/><entry/><entry/><entry>Biophys Methods 2000 Sep. 11;</entry></row><row><entry/><entry/><entry/><entry/><entry>45(2): 127-40, Breast Cancer Res</entry></row><row><entry/><entry/><entry/><entry/><entry>Treat 1996; 41(2): 141-6. Methods</entry></row><row><entry/><entry/><entry/><entry/><entry>that measure anti-angiogenesis</entry></row><row><entry/><entry/><entry/><entry/><entry>activity are known in the art, for</entry></row><row><entry/><entry/><entry/><entry/><entry>example, Proc Natl Acad Sci USA</entry></row><row><entry/><entry/><entry/><entry/><entry>1999 Mar. 16; 96(6): 2645-50.</entry></row><row><entry>CXCR3; CXC</entry><entry>GeneSeq Accession</entry><entry>WO0018431</entry><entry>Chemokines are a family of related small,</entry><entry>Chemokine activities can be</entry><entry>Soluble CXCR3</entry></row><row><entry/><entry>Y79372</entry><entry/><entry>secreted proteins involved in biological</entry><entry>determined using assays known in</entry><entry>polypeptides may be</entry></row><row><entry/><entry/><entry/><entry>processes ranging from hematopoiesis,</entry><entry>the art: Methods in Molecular</entry><entry>useful for inhibiting</entry></row><row><entry/><entry/><entry/><entry>angiogenesis, and leukocyte trafficking.</entry><entry>Biology, 2000, vol. 138: Chemokine</entry><entry>chemokine activities and</entry></row><row><entry/><entry/><entry/><entry>Members of this family are involved in a</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry><entry>viral infection.</entry></row><row><entry/><entry/><entry/><entry>similarly diverse range of pathologies</entry><entry>T. N. C. Wells, and C. A. Power.</entry></row><row><entry/><entry/><entry/><entry>including inflammation, allergy, tissue</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry></row><row><entry/><entry/><entry/><entry>rejection, viral infection, and tumor</entry><entry>Totowa, NJ.</entry></row><row><entry/><entry/><entry/><entry>biology. The chemokines exert their</entry></row><row><entry/><entry/><entry/><entry>effects by acting on a family of seven</entry></row><row><entry/><entry/><entry/><entry>transmembrane G-protein coupled</entry></row><row><entry/><entry/><entry/><entry>receptors. Over 40 human chemokines</entry></row><row><entry/><entry/><entry/><entry>have been described, which bind to ~17</entry></row><row><entry/><entry/><entry/><entry>receptors thus far identified.</entry></row><row><entry>Modified Rantes</entry><entry>GeneSeq Accession</entry><entry>WO9737005</entry><entry>Chemokines are a family of related small,</entry><entry>Chemokine activities can be</entry><entry>Immune disorders.</entry></row><row><entry/><entry>W38129</entry><entry/><entry>secreted proteins involved in biological</entry><entry>determined using assays known in</entry></row><row><entry/><entry/><entry/><entry>processes ranging from hematopoiesis,</entry><entry>the art: Methods in Molecular</entry></row><row><entry/><entry/><entry/><entry>angiogenesis, and leukocyte trafficking.</entry><entry>Biology, 2000, vol. 138: Chemokine</entry></row><row><entry/><entry/><entry/><entry>Members of this family are involved in a</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry></row><row><entry/><entry/><entry/><entry>similarly diverse range of pathologies</entry><entry>T. N. C. Wells, and C. A. Power.</entry></row><row><entry/><entry/><entry/><entry>including inflammation, allergy, tissue</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry></row><row><entry/><entry/><entry/><entry>rejection, viral infection, and tumor</entry><entry>Totowa, NJ.</entry></row><row><entry/><entry/><entry/><entry>biology. The chemokines exert their</entry></row><row><entry/><entry/><entry/><entry>effects by acting on a family of seven</entry></row><row><entry/><entry/><entry/><entry>transmembrane G-protein coupled</entry></row><row><entry/><entry/><entry/><entry>receptors. Over 40 human chemokines</entry></row><row><entry/><entry/><entry/><entry>have been described, which bind to ~17</entry></row><row><entry/><entry/><entry/><entry>receptors thus far identified.</entry></row><row><entry>RANTES</entry><entry>GeneSeq Accession</entry><entry>EP905240</entry><entry>Chemokines are a family of related small,</entry><entry>Chemokine activities can be</entry><entry>Immune disorders.</entry></row><row><entry/><entry>Y05299</entry><entry/><entry>secreted proteins involved in biological</entry><entry>determined using assays known in</entry></row><row><entry/><entry/><entry/><entry>processes ranging from hematopoiesis,</entry><entry>the art: Methods in Molecular</entry></row><row><entry/><entry/><entry/><entry>angiogenesis, and leukocyte trafficking.</entry><entry>Biology, 2000, vol. 138: Chemokine</entry></row><row><entry/><entry/><entry/><entry>Members of this family are involved in a</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry></row><row><entry/><entry/><entry/><entry>similarly diverse range of pathologies</entry><entry>T. N. C. Wells, and C. A. Power.</entry></row><row><entry/><entry/><entry/><entry>including inflammation, allergy, tissue</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry></row><row><entry/><entry/><entry/><entry>rejection, viral infection, and tumor</entry><entry>Totowa, NJ.</entry></row><row><entry/><entry/><entry/><entry>biology. The chemokines exert their</entry></row><row><entry/><entry/><entry/><entry>effects by acting on a family of seven</entry></row><row><entry/><entry/><entry/><entry>transmembrane G-protein coupled</entry></row><row><entry/><entry/><entry/><entry>receptors. Over 40 human chemokines</entry></row><row><entry/><entry/><entry/><entry>have been described, which bind to ~17</entry></row><row><entry/><entry/><entry/><entry>receptors thus far identified.</entry></row><row><entry>MCI-la</entry><entry>GeneSeq Accession</entry><entry>WO9509232</entry><entry>Chemokines are a family of related small,</entry><entry>Chemokine activities can be</entry><entry>Immune disorders.</entry></row><row><entry/><entry>R73914</entry><entry/><entry>secreted proteins involved in biological</entry><entry>determined using assays known in</entry></row><row><entry/><entry/><entry/><entry>processes ranging from hematopoiesis,</entry><entry>the art: Methods in Molecular</entry></row><row><entry/><entry/><entry/><entry>angiogenesis; and leukocyte trafficking.</entry><entry>Biology, 2000, vol. 138: Chemokine</entry></row><row><entry/><entry/><entry/><entry>Members of this family are involved in a</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry></row><row><entry/><entry/><entry/><entry>similarly diverse range of pathologies</entry><entry>T. N. C. Wells, and C. A. Power.</entry></row><row><entry/><entry/><entry/><entry>including inflammation, allergy, tissue</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry></row><row><entry/><entry/><entry/><entry>rejection, viral infection, and tumor</entry><entry>Totowa, NJ.</entry></row><row><entry/><entry/><entry/><entry>biology. The chemokines exert their</entry></row><row><entry/><entry/><entry/><entry>effects by acting on a family of seven</entry></row><row><entry/><entry/><entry/><entry>transmembrane G-protein coupled</entry></row><row><entry/><entry/><entry/><entry>receptors. Over 40 human chemokines</entry></row><row><entry/><entry/><entry/><entry>have been described, which bind to ~17</entry></row><row><entry/><entry/><entry/><entry>receptors thus far identified.</entry></row><row><entry>MCP-lb</entry><entry>GeneSeq Accession</entry><entry>WO9929728</entry><entry>Chemokines are a family of related small,</entry><entry>Chemokine activities can be</entry><entry>Immune disorders.</entry></row><row><entry/><entry>Y26176</entry><entry/><entry>secreted proteins involved in biological</entry><entry>determined using assays known in</entry></row><row><entry/><entry/><entry/><entry>processes ranging from hematopoiesis,</entry><entry>the art: Methods in Molecular</entry></row><row><entry/><entry/><entry/><entry>angiogenesis, and leukocyte trafficking.</entry><entry>Biology, 2000, vol. 138: Chemokine</entry></row><row><entry/><entry/><entry/><entry>Members of this family are involved in a</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry></row><row><entry/><entry/><entry/><entry>similarly diverse range of pathologies</entry><entry>T. N. C. Wells, and C. A. Power.</entry></row><row><entry/><entry/><entry/><entry>including inflammation, allergy, tissue</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry></row><row><entry/><entry/><entry/><entry>rejection, viral infection, and tumor</entry><entry>Totowa, NJ.</entry></row><row><entry/><entry/><entry/><entry>biology. The chemokines exert their</entry></row><row><entry/><entry/><entry/><entry>effects by acting on a family of seven</entry></row><row><entry/><entry/><entry/><entry>transmembrane G-protein coupled</entry></row><row><entry/><entry/><entry/><entry>receptors. Over 40 human chemokines</entry></row><row><entry/><entry/><entry/><entry>have been described, which bind to ~17</entry></row><row><entry/><entry/><entry/><entry>receptors thus far identified.</entry></row><row><entry>MCP-I receptor</entry><entry>GeneSeq Accession</entry><entry>WO9519436</entry><entry>Chemokines are a family of related small,</entry><entry>Chemokine activities can be</entry><entry>Soluble MCP-1 Receptor</entry></row><row><entry/><entry>R79165</entry><entry/><entry>secreted proteins involved in biological</entry><entry>determined using assays known in</entry><entry>polypeptides may be</entry></row><row><entry/><entry/><entry/><entry>processes ranging from hematopoiesis,</entry><entry>the art: Methods in Molecular</entry><entry>useful for inhibiting</entry></row><row><entry/><entry/><entry/><entry>angiogenesis, and leukocyte trafficking.</entry><entry>Biology, 2000, vol. 138: Chemokine</entry><entry>chemokine activities and</entry></row><row><entry/><entry/><entry/><entry>Members of this family are involved in a</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry><entry>viral infection.</entry></row><row><entry/><entry/><entry/><entry>similarly diverse range of pathologies</entry><entry>T. N. C. Wells, and C. A. Power.</entry></row><row><entry/><entry/><entry/><entry>including inflammation, allergy, tissue</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry></row><row><entry/><entry/><entry/><entry>rejection, viral infection, and tumor</entry><entry>Totowa, NJ.</entry></row><row><entry/><entry/><entry/><entry>biology. The chemokines exert their</entry></row><row><entry/><entry/><entry/><entry>effects by acting on a family of seven</entry></row><row><entry/><entry/><entry/><entry>transmembrane G-protein coupled</entry></row><row><entry/><entry/><entry/><entry>receptors. Over 40 human chemokines</entry></row><row><entry/><entry/><entry/><entry>have been described, which bind to ~17</entry></row><row><entry/><entry/><entry/><entry>receptors thus far identified.</entry></row><row><entry>MCP-3</entry><entry>GeneSeq Accession</entry><entry>W09509232</entry><entry>Chemokines are a family of related small,</entry><entry>Chemokine activities can be</entry><entry>Immune disorders.</entry></row><row><entry/><entry>R73915</entry><entry/><entry>secreted proteins involved in biological</entry><entry>determined using assays known in</entry></row><row><entry/><entry/><entry/><entry>processes ranging from hematopoiesis,</entry><entry>the art: Methods in Molecular</entry></row><row><entry/><entry/><entry/><entry>angiogenesis, and leukocyte trafficking.</entry><entry>Biology, 2000, vol. 138: Chemokine</entry></row><row><entry/><entry/><entry/><entry>Members of this family are involved in a</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry></row><row><entry/><entry/><entry/><entry>similarly diverse range of pathologies</entry><entry>T. N. C. Wells, and C. A. Power.</entry></row><row><entry/><entry/><entry/><entry>including inflammation, allergy, tissue</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry></row><row><entry/><entry/><entry/><entry>rejection, viral infection, and tumor</entry><entry>Totowa, NJ.</entry></row><row><entry/><entry/><entry/><entry>biology. The chemokines exert their</entry></row><row><entry/><entry/><entry/><entry>effects by acting on a family of seven</entry></row><row><entry/><entry/><entry/><entry>transmembrane G-protein coupled</entry></row><row><entry/><entry/><entry/><entry>receptors. Over 40 human chemokines</entry></row><row><entry/><entry/><entry/><entry>have been described, which bind to ~17</entry></row><row><entry/><entry/><entry/><entry>receptors thus far identified.</entry></row><row><entry>MCP-4 receptor</entry><entry>GeneSeq Accession</entry><entry>W09809171</entry><entry>Chemokines are a family of related small,</entry><entry>Chemokine activities can be</entry><entry>Soluble MCP-4 Receptor</entry></row><row><entry/><entry>W56689</entry><entry/><entry>secreted proteins involved in biological</entry><entry>determined using assays known in</entry><entry>polypeptides may be</entry></row><row><entry/><entry/><entry/><entry>processes ranging from hematopoiesis,</entry><entry>the art: Methods in Molecular</entry><entry>useful for inhibiting</entry></row><row><entry/><entry/><entry/><entry>angiogenesis, and leukocyte trafficking.</entry><entry>Biology, 2000, vol. 138: Chemokine</entry><entry>chemokine activities and</entry></row><row><entry/><entry/><entry/><entry>Members of this family are involved in a</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry><entry>viral infection.</entry></row><row><entry/><entry/><entry/><entry>similarly diverse range of pathologies</entry><entry>T. N. C. Wells, and C. A. Power.</entry></row><row><entry/><entry/><entry/><entry>including inflammation, allergy, tissue</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry></row><row><entry/><entry/><entry/><entry>rejection, viral infection, and tumor</entry><entry>Totowa, NJ.</entry></row><row><entry/><entry/><entry/><entry>biology. The chemokines exert their</entry></row><row><entry/><entry/><entry/><entry>effects by acting on a family of seven</entry></row><row><entry/><entry/><entry/><entry>transmembrane G-protein coupled</entry></row><row><entry/><entry/><entry/><entry>receptors. Over 40 human chemokines</entry></row><row><entry/><entry/><entry/><entry>have been described, which bind to ~17</entry></row><row><entry/><entry/><entry/><entry>receptors thus far identified.</entry></row><row><entry>RANTES receptor</entry><entry>GeneSeq Accession</entry><entry>U.S. Pat. No. 5,652,133</entry><entry>Chemokines are a family of related small,</entry><entry>Chemokine activities can be</entry><entry>Soluble RANTES</entry></row><row><entry/><entry>W29588</entry><entry/><entry>secreted proteins involved in biological</entry><entry>determined using assays known in</entry><entry>Receptor polypeptides</entry></row><row><entry/><entry/><entry/><entry>processes ranging from hematopoiesis,</entry><entry>the art: Methods in Molecular</entry><entry>may be useful for</entry></row><row><entry/><entry/><entry/><entry>angiogenesis, and leukocyte trafficking.</entry><entry>Biology, 2000, vol. 138: Chemokine</entry><entry>inhibiting chemokine</entry></row><row><entry/><entry/><entry/><entry>Members of this family are involved in a</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry><entry>activities and viral</entry></row><row><entry/><entry/><entry/><entry>similarly diverse range of pathologies</entry><entry>T. N. C. Wells, and C. A. Power.</entry><entry>infection.</entry></row><row><entry/><entry/><entry/><entry>including inflammation, allergy, tissue</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry></row><row><entry/><entry/><entry/><entry>rejection, viral infection, and tumor</entry><entry>Totowa, NJ.</entry></row><row><entry/><entry/><entry/><entry>biology. The chemokines exert their</entry></row><row><entry/><entry/><entry/><entry>effects by acting on a family of seven</entry></row><row><entry/><entry/><entry/><entry>transmembrane G-protein coupled</entry></row><row><entry/><entry/><entry/><entry>receptors. Over 40 human chemokines</entry></row><row><entry/><entry/><entry/><entry>have been described, which bind to ~17</entry></row><row><entry/><entry/><entry/><entry>receptors thus far identified.</entry></row><row><entry>CCR5 variant</entry><entry>GeneSeq Accession</entry><entry>WO9854317</entry><entry>Chemokines are a family of related small,</entry><entry>Chemokine activities can be</entry><entry>Soluble CCR5</entry></row><row><entry/><entry>W88238</entry><entry/><entry>secreted proteins involved in biological</entry><entry>determined using assays known in</entry><entry>polypeptides may be</entry></row><row><entry/><entry/><entry/><entry>processes ranging from hematopoiesis,</entry><entry>the art: Methods in Molecular</entry><entry>useful for inhibiting</entry></row><row><entry/><entry/><entry/><entry>angiogenesis, and leukocyte trafficking.</entry><entry>Biology, 2000, vol. 138: Chemokine</entry><entry>chemokine activities and</entry></row><row><entry/><entry/><entry/><entry>Members of this family are involved in a</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry><entry>viral infection.</entry></row><row><entry/><entry/><entry/><entry>similarly diverse range of pathologies</entry><entry>T. N. C. Wells, and C. A. Power.</entry></row><row><entry/><entry/><entry/><entry>including inflammation, allergy, tissue</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry></row><row><entry/><entry/><entry/><entry>rejection, viral infection, and tumor</entry><entry>Totowa, NJ.</entry></row><row><entry/><entry/><entry/><entry>biology. The chemokines exert their</entry></row><row><entry/><entry/><entry/><entry>effects by acting on a family of seven</entry></row><row><entry/><entry/><entry/><entry>transmembrane G-protein coupled</entry></row><row><entry/><entry/><entry/><entry>receptors. Over 40 human chemokines</entry></row><row><entry/><entry/><entry/><entry>have been described, which bind to ~17</entry></row><row><entry/><entry/><entry/><entry>receptors thus far identified.</entry></row><row><entry>CCR7</entry><entry>GeneSeq Accession</entry><entry>U.S. Pat. No. 6,153,441</entry><entry>Chemokines are a family of related small,</entry><entry>Chemokine activities can be</entry><entry>Soluble CCR7</entry></row><row><entry/><entry>B50859</entry><entry/><entry>secreted proteins involved in biological</entry><entry>determined using assays known in</entry><entry>polypeptides may be</entry></row><row><entry/><entry/><entry/><entry>processes ranging from hematopoiesis,</entry><entry>the art: Methods in Molecular</entry><entry>useful for inhibiting</entry></row><row><entry/><entry/><entry/><entry>angiogenesis, and leukocyte trafficking.</entry><entry>Biology, 2000, vol. 138: Chemokine</entry><entry>chemokine activities and</entry></row><row><entry/><entry/><entry/><entry>Members of this family are involved in a</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry><entry>viral infection.</entry></row><row><entry/><entry/><entry/><entry>similarly diverse range of pathologies</entry><entry>T. N. C. Wells, and C. A. Power.</entry></row><row><entry/><entry/><entry/><entry>including inflammation, allergy, tissue</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry></row><row><entry/><entry/><entry/><entry>rejection, viral infection, and tumor</entry><entry>Totowa, NJ.</entry></row><row><entry/><entry/><entry/><entry>biology. The chemokines exert their</entry></row><row><entry/><entry/><entry/><entry>effects by acting on a family of seven</entry></row><row><entry/><entry/><entry/><entry>transmembrane G-protein coupled</entry></row><row><entry/><entry/><entry/><entry>receptors. Over 40 human chemokines</entry></row><row><entry/><entry/><entry/><entry>have been described, which bind to ~17</entry></row><row><entry/><entry/><entry/><entry>receptors thus far identified.</entry></row><row><entry>CXC3</entry><entry>GeneSeq Accession</entry><entry>WO9727299</entry><entry>Chemokines are a family of related small,</entry><entry>Chemokine activities can be</entry><entry>Immune disorders.</entry></row><row><entry/><entry>W23345</entry><entry/><entry>secreted proteins involved in biological</entry><entry>determined using assays known in</entry></row><row><entry/><entry/><entry/><entry>processes ranging from hematopoiesis,</entry><entry>the art: Methods in Molecular</entry></row><row><entry/><entry/><entry/><entry>angiogenesis, and leukocyte trafficking.</entry><entry>Biology, 2000, vol. 138: Chemokine</entry></row><row><entry/><entry/><entry/><entry>Members of this family are involved in a</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry></row><row><entry/><entry/><entry/><entry>similarly diverse range of pathologies</entry><entry>T. N. C. Wells, and C. A. Power.</entry></row><row><entry/><entry/><entry/><entry>including inflammation, allergy, tissue</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry></row><row><entry/><entry/><entry/><entry>rejection, viral infection, and tumor</entry><entry>Totowa, NJ.</entry></row><row><entry/><entry/><entry/><entry>biology. The chemokines exert their</entry></row><row><entry/><entry/><entry/><entry>effects by acting on a family of seven</entry></row><row><entry/><entry/><entry/><entry>transmembrane G-protein coupled</entry></row><row><entry/><entry/><entry/><entry>receptors. Over 40 human chemokines</entry></row><row><entry/><entry/><entry/><entry>have been described, which bind to ~17</entry></row><row><entry/><entry/><entry/><entry>receptors thus far identified.</entry></row><row><entry>Eotaxin</entry><entry>GeneSeq Accession</entry><entry>WO9700960</entry><entry>Chemokines are a family of related small,</entry><entry>Chemokine activities can be</entry><entry>Immune disorders.</entry></row><row><entry/><entry>W10099</entry><entry/><entry>secreted proteins involved in biological</entry><entry>determined using assays known in</entry></row><row><entry/><entry/><entry/><entry>processes ranging from hematopoiesis,</entry><entry>the art: Methods in Molecular</entry></row><row><entry/><entry/><entry/><entry>angiogenesis, and leukocyte trafficking.</entry><entry>Biology, 2000, vol. 138: Chemokine</entry></row><row><entry/><entry/><entry/><entry>Members of this family are involved in a</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry></row><row><entry/><entry/><entry/><entry>similarly diverse range of pathologies</entry><entry>T. N. C. Wells, and C. A. Power.</entry></row><row><entry/><entry/><entry/><entry>including inflammation, allergy, tissue</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry></row><row><entry/><entry/><entry/><entry>rejection, viral infection, and tumor</entry><entry>Totowa, NJ.</entry></row><row><entry/><entry/><entry/><entry>biology. The chemokines exert their</entry></row><row><entry/><entry/><entry/><entry>effects by acting on a family of seven</entry></row><row><entry/><entry/><entry/><entry>transmembrane G-protein coupled</entry></row><row><entry/><entry/><entry/><entry>receptors. Over 40 human chemokines</entry></row><row><entry/><entry/><entry/><entry>have been described, which bind to ~17</entry></row><row><entry/><entry/><entry/><entry>receptors thus far identified.</entry></row><row><entry>Neurotactin</entry><entry>GeneSeq Accessions</entry><entry>U.S. Pat. No. 6,013,257</entry><entry>Neurotactin may play a role in</entry><entry>Chemotactic leukocyte migration</entry><entry>Immune disorders.</entry></row><row><entry/><entry>Y77537, W34307,</entry><entry>WO9742224</entry><entry>chemotactic leukocyte migration and</entry><entry>assays are known in the art, for</entry></row><row><entry/><entry>Y53259, and,</entry><entry/><entry>brain inflammation processes.</entry><entry>example: J. Immunol. Methods 33,</entry></row><row><entry/><entry>Y77539</entry><entry/><entry/><entry>((1980)); Nature 1997 Jun. 5;</entry></row><row><entry/><entry/><entry/><entry/><entry>387(6633): 611-7.</entry></row><row><entry>Human CKbeta-9</entry><entry>GeneSeq Accession</entry><entry>U.S. Pat. No. 6,153,441</entry><entry>Chemokines are a family of related small,</entry><entry>Chemokine activities can be</entry><entry>Immune disorders.</entry></row><row><entry/><entry>B50860</entry><entry/><entry>secreted proteins involved in biological</entry><entry>determined using assays known in</entry></row><row><entry/><entry/><entry/><entry>processes ranging from hematopoiesis,</entry><entry>the art: Methods in Molecular</entry></row><row><entry/><entry/><entry/><entry>angiogenesis, and leukocyte trafficking.</entry><entry>Biology, 2000, vol. 138: Chemokine</entry></row><row><entry/><entry/><entry/><entry>Members of this family are involved in a</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry></row><row><entry/><entry/><entry/><entry>similarly diverse range of pathologies</entry><entry>T. N. C. Wells, and C. A. Power.</entry></row><row><entry/><entry/><entry/><entry>including inflammation, allergy, tissue</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry></row><row><entry/><entry/><entry/><entry>rejection, viral infection, and tumor</entry><entry>Totowa, NJ.</entry></row><row><entry/><entry/><entry/><entry>biology. The chemokines exert their</entry></row><row><entry/><entry/><entry/><entry>effects by acting on a family of seven</entry></row><row><entry/><entry/><entry/><entry>transmembrane G-protein coupled</entry></row><row><entry/><entry/><entry/><entry>receptors. Over 40 human chemokines</entry></row><row><entry/><entry/><entry/><entry>have been described, which bind to ~17</entry></row><row><entry/><entry/><entry/><entry>receptors thus far identified.</entry></row><row><entry>Lymphotactin</entry><entry>GeneSeq Accession</entry><entry>WO0073320</entry><entry>Chemokines are a family of related small,</entry><entry>Chemokine activities can be</entry><entry>Immune disorders.</entry></row><row><entry/><entry>B50052</entry><entry/><entry>secreted proteins involved in biological</entry><entry>determined using assays known in</entry></row><row><entry/><entry/><entry/><entry>processes ranging from hematopoiesis,</entry><entry>the art: Methods in Molecular</entry></row><row><entry/><entry/><entry/><entry>angiogenesis, and leukocyte trafficking.</entry><entry>Biology, 2000, vol. 138: Chemokine</entry></row><row><entry/><entry/><entry/><entry>Members of this family are involved in a</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry></row><row><entry/><entry/><entry/><entry>similarly diverse range of pathologies</entry><entry>T. N. C. Wells, and C. A. Power.</entry></row><row><entry/><entry/><entry/><entry>including inflammation, allergy, tissue</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry></row><row><entry/><entry/><entry/><entry>rejection, viral infection, and tumor</entry><entry>Totowa, NJ.</entry></row><row><entry/><entry/><entry/><entry>biology. The chemokines exert their</entry></row><row><entry/><entry/><entry/><entry>effects by acting on a family of seven</entry></row><row><entry/><entry/><entry/><entry>transmembrane G.</entry></row><row><entry>MIP-3 alpha</entry><entry>GeneSeq Accession</entry><entry>WO9801557</entry><entry>Chemokines are a family of related small,</entry><entry>Chemokine activities can be</entry><entry>Immune disorders.</entry></row><row><entry/><entry>W44398</entry><entry/><entry>secreted proteins involved in biological</entry><entry>determined using assays known in</entry></row><row><entry/><entry/><entry/><entry>processes ranging from hematopoiesis,</entry><entry>the art: Methods in Molecular</entry></row><row><entry/><entry/><entry/><entry>angiogenesis, and leukocyte trafficking.</entry><entry>Biology, 2000, vol. 138: Chemokine</entry></row><row><entry/><entry/><entry/><entry>Members of this family are involved in a</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry></row><row><entry/><entry/><entry/><entry>similarly diverse range of pathologies</entry><entry>T. N. C. Wells, and C. A. Power.</entry></row><row><entry/><entry/><entry/><entry>including inflammation, allergy, tissue</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry></row><row><entry/><entry/><entry/><entry>rejection, viral infection, and tumor</entry><entry>Totowa, NJ.</entry></row><row><entry/><entry/><entry/><entry>biology. The chemokines exert their</entry></row><row><entry/><entry/><entry/><entry>effects by acting on a family of seven</entry></row><row><entry/><entry/><entry/><entry>transmembrane G.</entry></row><row><entry>MIP-3 beta</entry><entry>GeneSeq Accession</entry><entry>WO9801557</entry><entry>Chemokines are a family of related small,</entry><entry>Chemokine activities can be</entry><entry>Immune disorders.</entry></row><row><entry/><entry>W44399</entry><entry/><entry>secreted proteins involved in biological</entry><entry>determined using assays known in</entry></row><row><entry/><entry/><entry/><entry>processes ranging from hematopoiesis,</entry><entry>the art: Methods in Molecular</entry></row><row><entry/><entry/><entry/><entry>angiogenesis, and leukocyte trafficking.</entry><entry>Biology, 2000, vol. 138: Chemokine</entry></row><row><entry/><entry/><entry/><entry>Members of this family are involved in a</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry></row><row><entry/><entry/><entry/><entry>similarly diverse range of pathologies</entry><entry>T. N. C. Wells, and C. A. Power.</entry></row><row><entry/><entry/><entry/><entry>including inflammation, allergy, tissue</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry></row><row><entry/><entry/><entry/><entry>rejection, viral infection, and tumor</entry><entry>Totowa, NJ.</entry></row><row><entry/><entry/><entry/><entry>biology. The chemokines exert their</entry></row><row><entry/><entry/><entry/><entry>effects by acting on a family of seven</entry></row><row><entry/><entry/><entry/><entry>transmembrane G.</entry></row><row><entry>MIP-Gamma</entry><entry>GeneSeq Accession</entry><entry>WO9504158</entry><entry>Chemokines are a family of related small,</entry><entry>Chemokine activities can be</entry><entry>Immune disorders.</entry></row><row><entry/><entry>R70798</entry><entry/><entry>secreted proteins involved in biological</entry><entry>determined using assays known in</entry></row><row><entry/><entry/><entry/><entry>processes ranging from hematopoiesis,</entry><entry>the art: Methods in Molecular</entry></row><row><entry/><entry/><entry/><entry>angiogenesis, and leukocyte trafficking.</entry><entry>Biology, 2000, vol. 138: Chemokine</entry></row><row><entry/><entry/><entry/><entry>Members of this family are involved in a</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry></row><row><entry/><entry/><entry/><entry>similarly diverse range of pathologies</entry><entry>T. N. C. Wells, and C. A. Power.</entry></row><row><entry/><entry/><entry/><entry>including inflammation, allergy, tissue</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry></row><row><entry/><entry/><entry/><entry>rejection, viral infection, and tumor</entry><entry>Totowa, NJ.</entry></row><row><entry/><entry/><entry/><entry>biology. The chemokines exert their</entry></row><row><entry/><entry/><entry/><entry>effects by acting on a family of seven</entry></row><row><entry/><entry/><entry/><entry>transmembrane G.</entry></row><row><entry>Stem Cell</entry><entry>GeneSeq Accession</entry><entry>WO9104274</entry><entry>Chemokines are a family of related small,</entry><entry>Chemokine activities can be</entry><entry>Hematopoietic growth</entry></row><row><entry>Inhibitory</entry><entry>R11553</entry><entry/><entry>secreted proteins involved in biological</entry><entry>determined using assays known in</entry><entry>factors.</entry></row><row><entry>Factor</entry><entry/><entry/><entry>processes ranging from hematopoiesis,</entry><entry>the art: Methods in Molecular</entry></row><row><entry/><entry/><entry/><entry>angiogenesis, and leukocyte trafficking.</entry><entry>Biology, 2000, vol. 138: Chemokine</entry></row><row><entry/><entry/><entry/><entry>Members of this family are involved in a</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry></row><row><entry/><entry/><entry/><entry>similarly diverse range of pathologies</entry><entry>T. N. C. Wells, and C. A. Power.</entry></row><row><entry/><entry/><entry/><entry>including inflammation, allergy, tissue</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry></row><row><entry/><entry/><entry/><entry>rejection, viral infection, and tumor</entry><entry>Totowa, NJ.</entry></row><row><entry/><entry/><entry/><entry>biology. The chemokines exert their</entry></row><row><entry/><entry/><entry/><entry>effects by acting on a family of seven</entry></row><row><entry/><entry/><entry/><entry>transmembrane G.</entry></row><row><entry>thrombopoietin</entry><entry>GeneSeq Accession</entry><entry>WO9521920</entry><entry>Thrombopoietin is involved in the</entry><entry>Thrombopoietin (TPO) can be</entry><entry>Hematopoietic growth</entry></row><row><entry/><entry>R79905</entry><entry/><entry>regulation of the growth and</entry><entry>assayed to determine regulation of</entry><entry>factors.</entry></row><row><entry/><entry/><entry/><entry>differentiation of megakaryocytes and</entry><entry>growth and differentiation of</entry></row><row><entry/><entry/><entry/><entry>preceptors thereof.</entry><entry>megakaryocytes. Mol Cell Biol</entry></row><row><entry/><entry/><entry/><entry/><entry>2001 April; 21(8): 2659-70; Exp</entry></row><row><entry/><entry/><entry/><entry/><entry>Hematol 2001 January; 29(1): 51-8 and</entry></row><row><entry/><entry/><entry/><entry/><entry>within.</entry></row><row><entry>c-kit ligand;</entry><entry>GeneSeq Accession</entry><entry>EP992579 and</entry><entry>C-kit ligan is thought to stimulate the</entry><entry>Chemokine activities can be</entry><entry>Hematopoietic growth</entry></row><row><entry>SCF; Mast cell</entry><entry>Y53284, R83978</entry><entry>EP676470</entry><entry>proliferation of mast cells, and is able to</entry><entry>determined using assays known in</entry><entry>factors.</entry></row><row><entry>growth factor;</entry><entry>and R83977</entry><entry/><entry>augment the proliferation of both</entry><entry>the art: Methods in Molecular</entry></row><row><entry>MGF;</entry><entry/><entry/><entry>myeloid and lymphoid hematopoietic</entry><entry>Biology, 2000, vol. 138: Chemokine</entry></row><row><entry>Fibrosarcoma-</entry><entry/><entry/><entry>progenitors in bone marrow culture. C-</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry></row><row><entry>derived stem</entry><entry/><entry/><entry>kit ligand is also though to act</entry><entry>T. N. C. Wells, and C. A. Power.</entry></row><row><entry>cell factor</entry><entry/><entry/><entry>synergistically with other cytokines.</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry></row><row><entry/><entry/><entry/><entry/><entry>Totowa, NJ.</entry></row><row><entry>Platelet derived</entry><entry>GeneSeq Accession</entry><entry>WO0066736</entry><entry>Vascular Endothelial Growth Factor</entry><entry>VEGF activity can be determined</entry><entry>Promotion of growth and</entry></row><row><entry>growth factor</entry><entry>B48653</entry><entry/><entry/><entry>using assays known in the art, such</entry><entry>proliferation of cells,</entry></row><row><entry/><entry/><entry/><entry/><entry>as those disclosed in International</entry><entry>such as vascular</entry></row><row><entry/><entry/><entry/><entry/><entry>Publication No. WO0045835, for</entry><entry>endothelial cells.</entry></row><row><entry/><entry/><entry/><entry/><entry>example.</entry><entry>Antagonists may be</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>useful as anti-angiogenic</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>agents, and may be</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>applicable for cancer.</entry></row><row><entry>Melanoma</entry><entry>GeneSeq Accession</entry><entry>WO9503328</entry><entry>Melanoma inhibiting protein has</entry><entry>Tumor suppressor activity of</entry><entry>Cancer; melanoma</entry></row><row><entry>inhibiting protein</entry><entry>R69811</entry><entry/><entry>melanoma-inhibiting activity and can be</entry><entry>melanoma inhibiting protein can be</entry></row><row><entry/><entry/><entry/><entry>used to treat cancer (melanoma,</entry><entry>determined using assays known in</entry></row><row><entry/><entry/><entry/><entry>glioblastoma, neuroblastoma, small cell</entry><entry>the art: Matzuk et al., Nature 1992</entry></row><row><entry/><entry/><entry/><entry>lung cancer, neuroectodermal tumors) or</entry><entry>Nov. 26; 360(6402): 313-9.</entry></row><row><entry/><entry/><entry/><entry>as an immunosuppressant (it inhibits IL-2</entry></row><row><entry/><entry/><entry/><entry>or phytohaemagglutinin induced</entry></row><row><entry/><entry/><entry/><entry>proliferation of peripheral blood</entry></row><row><entry/><entry/><entry/><entry>lymphocytes.</entry></row><row><entry>Glioma-derived</entry><entry>GeneSeq Accession</entry><entry>EP399816</entry><entry>Vascular Endothelial Growth Factor</entry><entry>VEGF activity can be determined</entry><entry>Promotion of growth and</entry></row><row><entry>growth factor</entry><entry>R08120</entry><entry/><entry/><entry>using assays known in the art, such</entry><entry>proliferation of cells,</entry></row><row><entry/><entry/><entry/><entry/><entry>as those disclosed in International</entry><entry>such as vascular</entry></row><row><entry/><entry/><entry/><entry/><entry>Publication No. WO0045835, for</entry><entry>endothelial cells.</entry></row><row><entry/><entry/><entry/><entry/><entry>example.</entry><entry>Antagonists may be</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>useful as anti-angiogenic</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>agents, and may be</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>applicable for cancer.</entry></row><row><entry>Platelet derived</entry><entry>GeneSeq Accession</entry><entry>EP682110</entry><entry>Vascular Endothelial Growth Factor</entry><entry>VEGF activity can be determined</entry><entry>Promotion of growth and</entry></row><row><entry>growth factor</entry><entry>R84759</entry><entry/><entry/><entry>using assays known in the art, such</entry><entry>proliferation of cells,</entry></row><row><entry>precursor A</entry><entry/><entry/><entry/><entry>as those disclosed in International</entry><entry>such as vascular</entry></row><row><entry/><entry/><entry/><entry/><entry>Publication No. WO0045835, for</entry><entry>endothelial cells.</entry></row><row><entry/><entry/><entry/><entry/><entry>example.</entry><entry>Antagonists may be</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>useful as anti-angiogenic</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>agents, and may be</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>applicable for cancer.</entry></row><row><entry>Platelet derived</entry><entry>GeneSeq Accession</entry><entry>EP682110</entry><entry>Vascular Endothelial Growth Factor</entry><entry>VEGF activity can be determined</entry><entry>Promotion of growth and</entry></row><row><entry>growth factor</entry><entry>R84760</entry><entry/><entry/><entry>using assays known in the art, such</entry><entry>proliferation of cells,</entry></row><row><entry>precursor B</entry><entry/><entry/><entry/><entry>as those disclosed in International</entry><entry>such as vascular</entry></row><row><entry/><entry/><entry/><entry/><entry>Publication No. WO0045835, for</entry><entry>endothelial cells.</entry></row><row><entry/><entry/><entry/><entry/><entry>example.</entry><entry>Antagonists may be</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>useful as anti-angiogenic</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>agents, and may be</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>applicable for cancer.</entry></row><row><entry>Platelet derived</entry><entry>GeneSeq Accession</entry><entry>EP282317</entry><entry>Vascular Endothelial Growth Factor</entry><entry>VEGF activity can be determined</entry><entry>Promotion of growth and</entry></row><row><entry>growth factor Bv-</entry><entry>P80595 and</entry><entry/><entry/><entry>using assays known in the art, such</entry><entry>proliferation of cells,</entry></row><row><entry>sis</entry><entry>P80596</entry><entry/><entry/><entry>as those disclosed in International</entry><entry>such as vascular</entry></row><row><entry/><entry/><entry/><entry/><entry>Publication No. WO0045835, for</entry><entry>endothelial cells.</entry></row><row><entry/><entry/><entry/><entry/><entry>example.</entry><entry>Antagonists may be</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>useful as anti-angiogenic</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>agents, and may be</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>applicable for cancer.</entry></row><row><entry>Placental Growth</entry><entry>GeneSeq Accessions</entry><entry>WO9206194</entry><entry>Vascular Endothelial Growth Factor</entry><entry>VEGF activity can be determined</entry><entry>Promotion of growth and</entry></row><row><entry>Factor</entry><entry>R23059 and</entry><entry/><entry/><entry>using assays known in the art, such</entry><entry>proliferation of cells,</entry></row><row><entry/><entry>R23060</entry><entry/><entry/><entry>as those disclosed in International</entry><entry>such as vascular</entry></row><row><entry/><entry/><entry/><entry/><entry>Publication No. WO0045835, for</entry><entry>endothelial cells.</entry></row><row><entry/><entry/><entry/><entry/><entry>example.</entry><entry>Antagonists may be</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>useful as anti-angiogenic</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>agents, and may be</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>applicable for cancer.</entry></row><row><entry>Placental Growth</entry><entry>GeneSeq Accession</entry><entry>DE19748734</entry><entry>Vascular Endothelial Growth Factor</entry><entry>VEGF activity can be determined</entry><entry>Promotion of growth and</entry></row><row><entry>Factor-2</entry><entry>Y08289</entry><entry/><entry/><entry>using assays known in the art, such</entry><entry>proliferation of cells,</entry></row><row><entry/><entry/><entry/><entry/><entry>as those disclosed in International</entry><entry>such as vascular</entry></row><row><entry/><entry/><entry/><entry/><entry>Publication No. WO0045835, for</entry><entry>endothelial cells.</entry></row><row><entry/><entry/><entry/><entry/><entry>example.</entry><entry>Antagonists may be</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>useful as anti-angiogenic</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>agents, and may be</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>applicable for cancer.</entry></row><row><entry>Thrombopoietin</entry><entry>GeneSeq Accession</entry><entry>WO0000612</entry><entry>Thrombopoietin is involved in the</entry><entry>Thrombopoietin (TPO) can be</entry><entry>Thrombocytopenia,</entry></row><row><entry>derivative1</entry><entry>Y77244</entry><entry/><entry>regulation of the growth and</entry><entry>assayed to determine regulation of</entry><entry>cancer.</entry></row><row><entry/><entry/><entry/><entry>differentiation of megakaryocytes and</entry><entry>growth and differentiation of</entry></row><row><entry/><entry/><entry/><entry>preceptors thereof.</entry><entry>megakaryocytes. Mol Cell Biol</entry></row><row><entry/><entry/><entry/><entry/><entry>2001 April; 21(8): 2659-70; Exp</entry></row><row><entry/><entry/><entry/><entry/><entry>Hematol 2001 January; 29(1): 51-8 and</entry></row><row><entry/><entry/><entry/><entry/><entry>within.</entry></row><row><entry>Thrombopoietin</entry><entry>GeneSeq Accession</entry><entry>WO0000612</entry><entry>Thrombopoietin is involved in the</entry><entry>Thrombopoietin (TPO) can be</entry><entry>Thrombocytopenia,</entry></row><row><entry>derivative2</entry><entry>Y77255</entry><entry/><entry>regulation of the growth and</entry><entry>assayed to determine regulation of</entry><entry>cancer.</entry></row><row><entry/><entry/><entry/><entry>differentiation of megakaryocytes and</entry><entry>growth and differentiation of</entry></row><row><entry/><entry/><entry/><entry>preceptors thereof.</entry><entry>megakaryocytes. Mol Cell Biol</entry></row><row><entry/><entry/><entry/><entry/><entry>2001 April; 21(8): 2659-70; Exp</entry></row><row><entry/><entry/><entry/><entry/><entry>Hematol 2001 January; 29(1): 51-8 and</entry></row><row><entry/><entry/><entry/><entry/><entry>within.</entry></row><row><entry>Thrombopoietin</entry><entry>GeneSeq Accession</entry><entry>WO0000612</entry><entry>Thrombopoietin is involved in the</entry><entry>Thrombopoietin (TPO) can be</entry><entry>Thrombocytopenia,</entry></row><row><entry>derivative3</entry><entry>Y77262</entry><entry/><entry>regulation of the growth and</entry><entry>assayed to determine regulation of</entry><entry>cancer.</entry></row><row><entry/><entry/><entry/><entry>differentiation of megakaryocytes and</entry><entry>growth and differentiation of</entry></row><row><entry/><entry/><entry/><entry>preceptors thereof.</entry><entry>megakaryocytes. Mol Cell Biol</entry></row><row><entry/><entry/><entry/><entry/><entry>2001 April; 21(8): 2659-70; Exp</entry></row><row><entry/><entry/><entry/><entry/><entry>Hematol 2001 January; 29(1): 51-8 and</entry></row><row><entry/><entry/><entry/><entry/><entry>within.</entry></row><row><entry>Thrombopoietin</entry><entry>GeneSeq Accession</entry><entry>WO0000612</entry><entry>Thrombopoietin is involved in the</entry><entry>Thrombopoietin (TPO) can be</entry><entry>Thrombocytopenia,</entry></row><row><entry>derivative4</entry><entry>Y77267</entry><entry/><entry>regulation of the growth and</entry><entry>assayed to determine regulation of</entry><entry>cancer.</entry></row><row><entry/><entry/><entry/><entry>differentiation of megakaryocytes and</entry><entry>growth and differentiation of</entry></row><row><entry/><entry/><entry/><entry>preceptors thereof.</entry><entry>megakaryocytes. Mol Cell Biol</entry></row><row><entry/><entry/><entry/><entry/><entry>2001 April; 21(8): 2659-70; Exp</entry></row><row><entry/><entry/><entry/><entry/><entry>Hematol 2001 January; 29(1): 51-8 and</entry></row><row><entry/><entry/><entry/><entry/><entry>within.</entry></row><row><entry>Thrombopoietin</entry><entry>GeneSeq Accession</entry><entry>WO0000612</entry><entry>Thrombopoietin is involved in the</entry><entry>Thrombopoietin (TPO) can be</entry><entry>Thrombocytopenia,</entry></row><row><entry>derivative5</entry><entry>Y77246</entry><entry/><entry>regulation of the growth and</entry><entry>assayed to determine regulation of</entry><entry>cancer.</entry></row><row><entry/><entry/><entry/><entry>differentiation of megakaryocytes and</entry><entry>growth and differentiation of</entry></row><row><entry/><entry/><entry/><entry>preceptors thereof.</entry><entry>megakaryocytes. Mol Cell Biol</entry></row><row><entry/><entry/><entry/><entry/><entry>2001 April; 21(8): 2659-70; Exp</entry></row><row><entry/><entry/><entry/><entry/><entry>Hematol 2001 January; 29(1): 51-8 and</entry></row><row><entry/><entry/><entry/><entry/><entry>within.</entry></row><row><entry>Thrombopoietin</entry><entry>GeneSeq Accession</entry><entry>WO0000612</entry><entry>Thrombopoietin is involved in the</entry><entry>Thrombopoietin (TPO) can be</entry><entry>Thrombocytopenia,</entry></row><row><entry>derivative6</entry><entry>Y77253</entry><entry/><entry>regulation of the growth and</entry><entry>assayed to determine regulation of</entry><entry>cancer.</entry></row><row><entry/><entry/><entry/><entry>differentiation of megakaryocytes and</entry><entry>growth and differentiation of</entry></row><row><entry/><entry/><entry/><entry>preceptors thereof.</entry><entry>megakaryocytes. Mol Cell Biol</entry></row><row><entry/><entry/><entry/><entry/><entry>2001 April; 21(8): 2659-70; Exp</entry></row><row><entry/><entry/><entry/><entry/><entry>Hematol 2001 January; 29(1): 51-8 and</entry></row><row><entry/><entry/><entry/><entry/><entry>within.</entry></row><row><entry>Thrombopoietin</entry><entry>GeneSeq Accession</entry><entry>WO0000612</entry><entry>Thrombopoietin is involved in the</entry><entry>Thrombopoietin (TPO) can be</entry><entry>Thrombocytopenia,</entry></row><row><entry>derivative7</entry><entry>Y77256</entry><entry/><entry>regulation of the growth and</entry><entry>assayed to determine regulation of</entry><entry>cancer.</entry></row><row><entry/><entry/><entry/><entry>differentiation of megakaryocytes and</entry><entry>growth and differentiation of</entry></row><row><entry/><entry/><entry/><entry>preceptors thereof.</entry><entry>megakaryocytes. Mol Cell Biol</entry></row><row><entry/><entry/><entry/><entry/><entry>2001 April; 21(8): 2659-70; Exp</entry></row><row><entry/><entry/><entry/><entry/><entry>Hematol 2001 January; 29(1): 51-8 and</entry></row><row><entry/><entry/><entry/><entry/><entry>within.</entry></row><row><entry>Fractalkine</entry><entry>GeneSeq Accession</entry><entry>U.S. Pat. No. 6,043,086</entry><entry>Fractalkine is believed to play a role in</entry><entry>Fractalkine activity can be</entry><entry>Immune disorders.</entry></row><row><entry/><entry>Y53255</entry><entry/><entry>chemotactic leukocyte migration and</entry><entry>determined using Chemotactic</entry></row><row><entry/><entry/><entry/><entry>neurological disorders.</entry><entry>leukocyte migration assays known in</entry></row><row><entry/><entry/><entry/><entry/><entry>the art, for example: J. Immunol.</entry></row><row><entry/><entry/><entry/><entry/><entry>Methods 33, ((1980)); Nature 1997</entry></row><row><entry/><entry/><entry/><entry/><entry>Jun 5; 387(6633): 611-7.</entry></row><row><entry>CXC3</entry><entry>GeneSeq Accession</entry><entry>WO9757599</entry><entry>Chemokines are a family of related small,</entry><entry>Chemokine activities can be</entry><entry>Immune disorders.</entry></row><row><entry/><entry>W23345</entry><entry/><entry>secreted proteins involved in biological</entry><entry>determined using assays known in</entry></row><row><entry/><entry/><entry/><entry>processes ranging from hematopoiesis,</entry><entry>the art: Methods in Molecular</entry></row><row><entry/><entry/><entry/><entry>angiogenesis, and leukocyte trafficking.</entry><entry>Biology, 2000, vol. 138: Chemokine</entry></row><row><entry/><entry/><entry/><entry>Members of this family are involved in a</entry><entry>Prototols. Edited by: A. E. I. Proudfoot,</entry></row><row><entry/><entry/><entry/><entry>similarly diverse range of pathologies</entry><entry>T. N. C. Wells, and C. A. Power.</entry></row><row><entry/><entry/><entry/><entry>including inflammation, allergy, tissue</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry></row><row><entry/><entry/><entry/><entry>rejection, viral infection, and tumor</entry><entry>Totowa, NJ.</entry></row><row><entry/><entry/><entry/><entry>biology. The chemokines exert their</entry></row><row><entry/><entry/><entry/><entry>effects by acting on a family of seven</entry></row><row><entry/><entry/><entry/><entry>transmembrane G-protein coupled</entry></row><row><entry/><entry/><entry/><entry>receptors. Over 40 human chemokines</entry></row><row><entry/><entry/><entry/><entry>have been described, which bind to ~17</entry></row><row><entry/><entry/><entry/><entry>receptors thus far identified.</entry></row><row><entry>CCR7</entry><entry>GeneSeq Accession</entry><entry>U.S. Pat. No. 6,153,441</entry><entry>Chemokines are a family of related small,</entry><entry>Chemokine activities can be</entry><entry>Soluble CCR7</entry></row><row><entry/><entry>B50859</entry><entry/><entry>secreted proteins involved in biological</entry><entry>determined using assays known in</entry><entry>polypeptides may be</entry></row><row><entry/><entry/><entry/><entry>processes ranging from hematopoiesis,</entry><entry>the art: Methods in Molecular</entry><entry>useful for inhibiting</entry></row><row><entry/><entry/><entry/><entry>angiogenesis, and leukocyte trafficking.</entry><entry>Biology, 2000, vol. 138: Chemokine</entry><entry>chemokine activities and</entry></row><row><entry/><entry/><entry/><entry>Members of this family are involved in a</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry><entry>viral infection.</entry></row><row><entry/><entry/><entry/><entry>similarly diverse range of pathologies</entry><entry>T. N. C. Wells, and C. A. Power.</entry></row><row><entry/><entry/><entry/><entry>including inflammation, allergy, tissue</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry></row><row><entry/><entry/><entry/><entry>rejection, viral infection, and tumor</entry><entry>Totowa, NJ.</entry></row><row><entry/><entry/><entry/><entry>biology. The chemokines exert their</entry></row><row><entry/><entry/><entry/><entry>effects by acting on a family of seven</entry></row><row><entry/><entry/><entry/><entry>transmembrane G-protein coupled</entry></row><row><entry/><entry/><entry/><entry>receptors. Over 40 human chemokines</entry></row><row><entry/><entry/><entry/><entry>have been described, which bind to ~17</entry></row><row><entry/><entry/><entry/><entry>receptors thus far identified.</entry></row><row><entry>Nerve Growth</entry><entry>GeneSeq Accession</entry><entry>EP414151</entry><entry>Nerve Growth Factor</entry><entry>Proliferation assay using NR6R-3T3</entry><entry>Neurological disorders,</entry></row><row><entry>Factor-beta</entry><entry>R11474</entry><entry/><entry/><entry>cells (Rizzino 1988 Cancer Res. 48:</entry><entry>cancer</entry></row><row><entry/><entry/><entry/><entry/><entry>4266)</entry></row><row><entry>Nerve Growth</entry><entry>GeneSeq Accession</entry><entry>EP859056</entry><entry>Nerve Growth Factor</entry><entry>Proliferation assay using NR6R 3T3</entry><entry>Neurological disorders,</entry></row><row><entry>Factor-beta2</entry><entry>W69725</entry><entry/><entry/><entry>cells (Rizzino 1988 Cancer Res. 48:</entry><entry>cancer</entry></row><row><entry/><entry/><entry/><entry/><entry>4266</entry></row><row><entry>Neurotrophin-3</entry><entry>GeneSeq Accession</entry><entry>WO9821234</entry><entry>Neurotrophins regulate neuronal cell</entry><entry>Trk tyrosine kinase activation assays</entry><entry>Neurological disorders,</entry></row><row><entry/><entry>W8889</entry><entry/><entry>survival and synaptic plasticity.</entry><entry>known in the art can be used to assay</entry><entry>cancer</entry></row><row><entry/><entry/><entry/><entry/><entry>for neurotrophin activity, for</entry></row><row><entry/><entry/><entry/><entry/><entry>example, Proc Natl Acad Sci USA</entry></row><row><entry/><entry/><entry/><entry/><entry>2001 Mar. 13; 98(6): 3555-3560.</entry></row><row><entry>Neurotrophin-3</entry><entry>GeneSeq Accession</entry><entry>WO9325684</entry><entry>Neurotrophins regulate neuronal cell</entry><entry>Trk tyrosine kinase activation assays</entry><entry>Neurological disorders,</entry></row><row><entry/><entry>R47100</entry><entry/><entry>survival and synaptic plasticity.</entry><entry>known in the art can be used to assay</entry><entry>cancer</entry></row><row><entry/><entry/><entry/><entry/><entry>for neurotrophin activity, for</entry></row><row><entry/><entry/><entry/><entry/><entry>example, Proc Natl Acad Sci USA</entry></row><row><entry/><entry/><entry/><entry/><entry>2001 Mar. 13; 98(6): 3555-3560.</entry></row><row><entry>Neurotrophin-4a</entry><entry>GeneSeq Accession</entry><entry>WO9325684</entry><entry>Neurotrophins regulate neuronal cell</entry><entry>Trk tyrosine kinase activation assays</entry><entry>Neurological disorders,</entry></row><row><entry/><entry>R47101</entry><entry/><entry>survival and synaptic plasticity.</entry><entry>known in the art can be used to assay</entry><entry>cancer</entry></row><row><entry/><entry/><entry/><entry/><entry>for neurotrophin activity, for</entry></row><row><entry/><entry/><entry/><entry/><entry>example, Proc Natl Acad Sci USA</entry></row><row><entry/><entry/><entry/><entry/><entry>2001 Mar. 13; 98(6): 3555-3560.</entry></row><row><entry/><entry/><entry/><entry/><entry>13; 98(6): 3555-3560</entry></row><row><entry>Neurotrophin-4b</entry><entry>GeneSeq Accession</entry><entry>WO9325684</entry><entry>Neurotrophins regulate neuronal cell</entry><entry>Trk tyrosine kinase activation assays</entry><entry>Neurological disorders,</entry></row><row><entry/><entry>R47102</entry><entry/><entry>survival and synaptic plasticity.</entry><entry>known in the art can be used to assay</entry><entry>cancer</entry></row><row><entry/><entry/><entry/><entry>tyrosine kinases.</entry><entry>for neurotrophin activity, for</entry></row><row><entry/><entry/><entry/><entry/><entry>example, Proc Natl Acad Sci USA</entry></row><row><entry/><entry/><entry/><entry/><entry>2001 Mar. 13; 98(6): 3555-3560.</entry></row><row><entry>Neurotrophin-4c</entry><entry>GeneSeq Accession</entry><entry>WO9325684</entry><entry>Neurotrophins regulate neuronal cell</entry><entry>Trk tyrosine kinase activation assays</entry><entry>Neurological disorders,</entry></row><row><entry/><entry>R47103</entry><entry/><entry>survival and synaptic plasticity.</entry><entry>known in the art can be used to assay</entry><entry>cancer</entry></row><row><entry/><entry/><entry/><entry>tyrosine kinases.</entry><entry>for neurotrophin activity, for</entry></row><row><entry/><entry/><entry/><entry/><entry>example, Proc Natl Acad Sci USA</entry></row><row><entry/><entry/><entry/><entry/><entry>2001 Mar. 13; 98(6): 3555-3560.</entry></row><row><entry>Neurotrophin-4d</entry><entry>GeneSeq Accession</entry><entry>WO9325684</entry><entry>Neurotrophins regulate neuronal cell</entry><entry>Trk tyrosine kinase activation assays</entry><entry>Neurological disorders,</entry></row><row><entry/><entry>R47102</entry><entry/><entry>survival and synaptic plasticity.</entry><entry>known in the art can be used to assay</entry><entry>cancer</entry></row><row><entry/><entry/><entry/><entry>tyrosine kinases.</entry><entry>for neurotrophin activity, for</entry></row><row><entry/><entry/><entry/><entry/><entry>example, Proc Natl Acad Sci USA</entry></row><row><entry/><entry/><entry/><entry/><entry>2001 Mar. 13; 98(6): 3555-3560.</entry></row><row><entry>Platelet-Derived</entry><entry>GeneSeq Accession</entry><entry>U.S. Pat. No. 5,219,739</entry><entry>Vascular Endothelial Growth Factor</entry><entry>VEGF activity can be determined</entry><entry>Promotion of growth and</entry></row><row><entry>Growth Factor</entry><entry>R38918</entry><entry/><entry/><entry>using assays known in the art, such as</entry><entry>proliferation of cells,</entry></row><row><entry>A chain</entry><entry/><entry/><entry/><entry>those disclosed in International</entry><entry>such as vascular</entry></row><row><entry/><entry/><entry/><entry/><entry>Publication No. W00045835, for</entry><entry>endothelial cells.</entry></row><row><entry/><entry/><entry/><entry/><entry>example.</entry><entry>Hematopoietic and</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>immune disorders.</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>Antagonists may be</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>useful as anti-angiogenic</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>agents, and may be</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>applicable for cancer</entry></row><row><entry>Platelet-Derived</entry><entry>GeneSeq Accession</entry><entry>U.S. Pat. No. 5,219,739</entry><entry>Vascular Endothelial Growth Factor</entry><entry>VEGF activity can be determined</entry><entry>Promotion of growth and</entry></row><row><entry>Growth Factor</entry><entry>R38919</entry><entry/><entry/><entry>using assays known in the art, such as</entry><entry>proliferation of cells,</entry></row><row><entry>B chain</entry><entry/><entry/><entry/><entry>those disclosed in International</entry><entry>such as vascular</entry></row><row><entry/><entry/><entry/><entry/><entry>Publication No. W00045835, for</entry><entry>endothelial cells.</entry></row><row><entry/><entry/><entry/><entry/><entry>example.</entry><entry>Hematopoietic and</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>immune disorders.</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>Antagonists may be</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>useful as anti-angiogenic</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>agents, and may be</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>applicable for cancer</entry></row><row><entry>Stromal Derived</entry><entry>GeneSeq Accession</entry><entry>WO9948528</entry><entry>Stromal Growth Factor</entry><entry>Proliferation assay using NR6R-3T3</entry><entry>Hematopoietic, immune</entry></row><row><entry>Factor-1 alpha</entry><entry>Y39995</entry><entry/><entry/><entry>cells (Rizzino 1988 Cancer Res. 48:</entry><entry>disorders, cancer</entry></row><row><entry/><entry/><entry/><entry/><entry>4266)</entry></row><row><entry>Stromal Derived</entry><entry>GeneSeq Accession</entry><entry>CA2117953</entry><entry>Stromal Growth Factor</entry><entry>Proliferation assay using NR6R-3T3</entry><entry>Hematopoietic, immune</entry></row><row><entry>Factor-1 beta</entry><entry>R75420</entry><entry/><entry/><entry>cells (Rizzino 1988 Cancer Res. 48:</entry><entry>disorders, cancer</entry></row><row><entry/><entry/><entry/><entry/><entry>4266)</entry></row><row><entry>Tarc</entry><entry>GeneSeq Accession</entry><entry>WO9711969</entry><entry>Chemotactic for T lymphocytes. May</entry><entry>Chemotactic leukocyte migration</entry><entry>Antiinflammatory.</entry></row><row><entry/><entry>W14917</entry><entry/><entry>play a role in T-cell development.</entry><entry>assays are known in the art, for</entry><entry>Immune disorders,</entry></row><row><entry/><entry/><entry/><entry>Thought to bind CCR8 and CCR4</entry><entry>example: J. Immunol. Methods 33</entry><entry>cancer</entry></row><row><entry/><entry/><entry/><entry/><entry>((1980))</entry></row><row><entry>Prolactin</entry><entry>GeneSeq Accession</entry><entry>WO9521625</entry><entry>Prolactin is involved in immune cell</entry><entry>Immune coil proliferation and</entry><entry>Reproductive system</entry></row><row><entry/><entry>R78691</entry><entry/><entry>proliferation and apoptosis.</entry><entry>suppression of apoptosis by prolactin</entry><entry>disorders, cancer.</entry></row><row><entry/><entry/><entry/><entry/><entry>can be assayed by methods well-</entry></row><row><entry/><entry/><entry/><entry/><entry>known in the art, for example,</entry></row><row><entry/><entry/><entry/><entry/><entry>Buckley, A R and Buckley D J, Ann NY</entry></row><row><entry/><entry/><entry/><entry/><entry>Acad Sci 2000; 917: 522-33, and</entry></row><row><entry/><entry/><entry/><entry/><entry>within.</entry></row><row><entry>Prolactin2</entry><entry>GeneSeq Accession</entry><entry>U.S. Pat. No. 5,955,346</entry><entry>Prolactin is involved in immune cell</entry><entry>Immune coil proliferation and</entry><entry>Reproductive system</entry></row><row><entry/><entry>Y31764</entry><entry/><entry>proliferation and apoptosis.</entry><entry>suppression of apoptosis by prolactin</entry><entry>disorders, cancer.</entry></row><row><entry/><entry/><entry/><entry/><entry>can be assayed by methods well-</entry></row><row><entry/><entry/><entry/><entry/><entry>known in the art, for example,</entry></row><row><entry/><entry/><entry/><entry/><entry>Buckley, A R and Buckley D J, Ann NY</entry></row><row><entry/><entry/><entry/><entry/><entry>Acad Sci 2000; 917: 522-33, and</entry></row><row><entry/><entry/><entry/><entry/><entry>within.</entry></row><row><entry>Follicle</entry><entry>GeneSeq Accession</entry><entry>EP974359</entry><entry>FSH stimulates secretion of interleukin-1</entry><entry>FSH activities can be determined</entry><entry>Reproductive system</entry></row><row><entry>stimulating</entry><entry>Y54160</entry><entry/><entry>by cells isolated from women in the</entry><entry>using assays known in the art; J Gend</entry><entry>disorders, cancer.</entry></row><row><entry>hormone Alpha</entry><entry/><entry/><entry>follicular phase</entry><entry>Specif Med 1999 November-December; 2(6): 30-4;</entry></row><row><entry>subunit</entry><entry/><entry/><entry/><entry>Mol Cell Endocrinol. 1997 Nov.</entry></row><row><entry/><entry/><entry/><entry/><entry>15; 134(2): 109-18.</entry></row><row><entry>Follicle</entry><entry>GeneSeq Accession</entry><entry>EP974359</entry><entry>FSH stimulates secretion of interleukin-1</entry><entry>FSH activities can be determined</entry><entry>Reproductive system</entry></row><row><entry>stimulating</entry><entry>Y54161</entry><entry/><entry>by cells isolated from women in the</entry><entry>using assays known in the art; J Gend</entry><entry>disorders, cancer.</entry></row><row><entry>hormone Beta</entry><entry/><entry/><entry>follicular phase</entry><entry>Specif Med 1999 November-December; 2(6): 30-4;</entry></row><row><entry>subunit</entry><entry/><entry/><entry/><entry>Mol Cell Endocrinol. 1997 Nov.</entry></row><row><entry/><entry/><entry/><entry/><entry>15; 134(2): 109-18.</entry></row><row><entry>Substance P</entry><entry>GeneSeq Accession</entry><entry>WO0054053</entry><entry>Substance P is associated with</entry><entry>Immuneregulation and bone marrow,</entry><entry>diabetes mellitus,</entry></row><row><entry>(tachykinin)</entry><entry>B23027</entry><entry/><entry>immunoregulation.</entry><entry>cell proliferation by substance P can</entry><entry>hypertension, cancer</entry></row><row><entry/><entry/><entry/><entry/><entry>be assayed by methods well-known in</entry></row><row><entry/><entry/><entry/><entry/><entry>the art, for example, Lai et al. Proc</entry></row><row><entry/><entry/><entry/><entry/><entry>Natl Acad Sci USA 2001 Mar. 27;</entry></row><row><entry/><entry/><entry/><entry/><entry>98(7): 3970-5; Jallat-Daloz et al.</entry></row><row><entry/><entry/><entry/><entry/><entry>Allergy Asthma Proc 2001 January-February;</entry></row><row><entry/><entry/><entry/><entry/><entry>22(1): 17-23; Kahler et al. Exp Lung</entry></row><row><entry/><entry/><entry/><entry/><entry>Res 2001 January-February; 27(1): 25-46; and</entry></row><row><entry/><entry/><entry/><entry/><entry>Adamus M A and Dabrowski Z J. J</entry></row><row><entry/><entry/><entry/><entry/><entry>Cell Biochem 2001; 81(3)499-506.</entry></row><row><entry>Ocytocin</entry><entry>GeneSeq Accession</entry><entry>WO0053755</entry><entry>Oxytocin is involved in the induction of</entry><entry>Oxytocin and prostaglandin E(2)</entry><entry>inflammatory disorders</entry></row><row><entry>(Neurophysin I)</entry><entry>B24085 and</entry><entry/><entry>prostaglandin (E2) release as well as an</entry><entry>release and Ocytocin (Ca2+) increase</entry><entry>immunologic disorders,</entry></row><row><entry/><entry>B24086</entry><entry/><entry>increased amount of calcium release by</entry><entry>can be assayed by methods well-</entry><entry>cancer</entry></row><row><entry/><entry/><entry/><entry>smooth muscle cells.</entry><entry>known in the art, for example, Pavan</entry></row><row><entry/><entry/><entry/><entry/><entry>et al., AM J Obset Gynecol 2000 July;</entry></row><row><entry/><entry/><entry/><entry/><entry>183(1): 76-82 and Holda et al., Cell</entry></row><row><entry/><entry/><entry/><entry/><entry>Calcium 1996 July; 20(1): 43 51.</entry></row><row><entry>Vasopressin</entry><entry>GeneSeq Accession</entry><entry>WO0053755</entry><entry>Vasopressinis believed to have a direct</entry><entry>Vasopressin activity can be</entry><entry>inflammatory disorders</entry></row><row><entry>(Neurophysin II)</entry><entry>B24085 and</entry><entry/><entry>antidiuretic action on the kidney, and it is</entry><entry>determined using assays known in the</entry><entry>immunologic disorders,</entry></row><row><entry/><entry>B24086</entry><entry/><entry>thought to cause vasoconstriction of the</entry><entry>art, for example, Endocr Regul 1996</entry><entry>cancer</entry></row><row><entry/><entry/><entry/><entry>peripheral vessels.</entry><entry>March; 30(1): 13-17.</entry></row><row><entry>IL-1</entry><entry>GeneSeq Accession</entry><entry>EP165654</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be determined</entry><entry>inflammatory disorders,</entry></row><row><entry/><entry>P60326</entry><entry/><entry>multifunctional cytokines synthesized by</entry><entry>using assays known in the art:</entry><entry>immunologic disorders,</entry></row><row><entry/><entry/><entry/><entry>lymphocytes, monocytes, and</entry><entry>Matthews et al., in <i>Lymphokines and</i></entry><entry>cancer</entry></row><row><entry/><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Interferens: A Practical Approach</i>,</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune cells</entry><entry>Clemens et al., eds, IRL Press,</entry></row><row><entry/><entry/><entry/><entry>(e.g., T helper cells, B cells, eosinophils,</entry><entry>Washington, D.C. 1987, pp. 221-225;</entry></row><row><entry/><entry/><entry/><entry>and lymphocytes), chemotaxis of</entry><entry>and Orencole &#x26; Dinarclio (1989)</entry></row><row><entry/><entry/><entry/><entry>neutrophils and T lymphocytes, and/or</entry><entry>Cytokine 1, 14-20.</entry></row><row><entry/><entry/><entry/><entry>inhibition of interferons.</entry></row><row><entry>IL-1 mature</entry><entry>GeneSeq Accession</entry><entry>EP456332</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be determined</entry><entry>inflammatory disorders,</entry></row><row><entry/><entry>R14855</entry><entry/><entry>multifunctional cytokines synthesized by</entry><entry>using assays known in the art:</entry><entry>immunologic disorders,</entry></row><row><entry/><entry/><entry/><entry>lymphocytes, monocytes, and</entry><entry>Matthews et al., in <i>Lymphokines and</i></entry><entry>cancer</entry></row><row><entry/><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Interferens: A Practical Approach</i>,</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune cells</entry><entry>Clemens et al., eds, IRL Press,</entry></row><row><entry/><entry/><entry/><entry>(e.g., T helper cells, B cells, eosinophils,</entry><entry>Washington, D.C. 1987, pp. 221-225;</entry></row><row><entry/><entry/><entry/><entry>and lymphocytes), chemotaxis of</entry><entry>and Orencole &#x26; Dinarclio (1989)</entry></row><row><entry/><entry/><entry/><entry>neutrophils and T lymphocytes, and/or</entry><entry>Cytokine 1, 14-20.</entry></row><row><entry/><entry/><entry/><entry>inhibition of interferons.</entry></row><row><entry>IL-1 beta</entry><entry>GeneSeq Accession</entry><entry>WO9922763</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be determined</entry><entry>inflammatory disorders,</entry></row><row><entry/><entry>Y08322</entry><entry/><entry>multifunctional cytokines synthesized by</entry><entry>using assays known in the art:</entry><entry>immunologic disorders,</entry></row><row><entry/><entry/><entry/><entry>lymphocytes, monocytes, and</entry><entry>Matthews et al., in <i>Lymphokines and</i></entry><entry>cancer</entry></row><row><entry/><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Interferens: A Practical Approach</i>,</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune cells</entry><entry>Clemens et al., eds, IRL Press,</entry></row><row><entry/><entry/><entry/><entry>(e.g., T helper cells, B cells, eosinophils,</entry><entry>Washington, D.C. 1987, pp. 221-225;</entry></row><row><entry/><entry/><entry/><entry>and lymphocytes), chemotaxis of</entry><entry>and Orencole &#x26; Dinarclio (1989)</entry></row><row><entry/><entry/><entry/><entry>neutrophils and T lymphocytes, and/or</entry><entry>Cytokine 1, 14-20.</entry></row><row><entry/><entry/><entry/><entry>inhibition of interferons.</entry></row><row><entry>IL-3 variants</entry><entry>GeneSeq Accession</entry><entry>WO8806161</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be determined</entry><entry>inflammatory disorders,</entry></row><row><entry/><entry>P80382, P80383,</entry><entry/><entry>multifunctional cytokines synthesized by</entry><entry>using assays known in the art:</entry><entry>immunologic disorders,</entry></row><row><entry/><entry>P80384, and</entry><entry/><entry>lymphocytes, monocytes, and</entry><entry>Matthews et al., in <i>Lymphokines and</i></entry><entry>cancer</entry></row><row><entry/><entry>P80381</entry><entry/><entry>macrophages. Known functions include</entry><entry><i>Interferens: A Practical Approach</i>,</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune cells</entry><entry>Clemens et al., eds, IRL Press,</entry></row><row><entry/><entry/><entry/><entry>(e.g., T helper cells, B cells, eosinophils,</entry><entry>Washington, D.C. 1987, pp. 221-225;</entry></row><row><entry/><entry/><entry/><entry>and lymphocytes), chemotaxis of</entry><entry>and Kitamura et al (1989) J Cell</entry></row><row><entry/><entry/><entry/><entry>neutrophils and T lymphocytes, and/or</entry><entry>Physiol. 140 323-334.</entry></row><row><entry/><entry/><entry/><entry>inhibition of interferons.</entry></row><row><entry>IL-4</entry><entry>GeneSeq Accession</entry><entry>WO8702990</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be determined</entry><entry>inflammatory disorders,</entry></row><row><entry/><entry>P70615</entry><entry/><entry>multifunctional cytokines synthesized by</entry><entry>using assays known in the art:</entry><entry>immunologic disorders,</entry></row><row><entry/><entry/><entry/><entry>lymphocytes, monocytes, and</entry><entry>Matthews et al., in <i>Lymphokines and</i></entry><entry>cancer</entry></row><row><entry/><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Interferens: A Practical Approach</i>,</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune cells</entry><entry>Clemens et al., eds, IRL Press,</entry></row><row><entry/><entry/><entry/><entry>(e.g., T helper cells, B cells, eosinophils,</entry><entry>Washington, D.C. 1987, pp. 221-225;</entry></row><row><entry/><entry/><entry/><entry>and lymphocytes), chemotaxis of</entry><entry>and Siegel &#x26; Mostowski (1990) J</entry></row><row><entry/><entry/><entry/><entry>neutrophils and T lymphocytes, and/or</entry><entry>Immunol Methods 132, 287-295.</entry></row><row><entry/><entry/><entry/><entry>inhibition of interferons.</entry></row><row><entry>IL-4 muteins</entry><entry>GeneSeq Accession</entry><entry>WO9747744</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be determined</entry><entry>inflammatory disorders,</entry></row><row><entry/><entry>W52151 W52152</entry><entry/><entry>multifunctional cytokines synthesized by</entry><entry>using assays known in the art:</entry><entry>immunologic disorders,</entry></row><row><entry/><entry>W52153 W52154</entry><entry/><entry>lymphocytes, monocytes, and</entry><entry>Matthews et al., in <i>Lymphokines and</i></entry><entry>cancer</entry></row><row><entry/><entry>W52155 W52156</entry><entry/><entry>macrophages. Known functions include</entry><entry><i>Interferens: A Practical Approach</i>,</entry></row><row><entry/><entry>W52157 W52158</entry><entry/><entry>stimulating proliferation of immune cells</entry><entry>Clemens et al., eds, IRL Press,</entry></row><row><entry/><entry>W52159 W52160</entry><entry/><entry>(e.g., T helper cells, B cells, eosinophils,</entry><entry>Washington, D.C. 1987, pp. 221-225;</entry></row><row><entry/><entry>W52161 W52162</entry><entry/><entry>and lymphocytes), chemotaxis of</entry><entry>and Siegel &#x26; Mostowski (1990) J</entry></row><row><entry/><entry>W52163 W52164</entry><entry/><entry>neutrophils and T lymphocytes, and/or</entry><entry>Immunol Methods 132, 287-295.</entry></row><row><entry/><entry>and W52165</entry><entry/><entry>inhibition of interferons.</entry></row><row><entry>IL-1 alpha</entry><entry>GeneSeq Accession</entry><entry>EP324447</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be determined</entry><entry>inflammatory disorders,</entry></row><row><entry/><entry>P90108</entry><entry/><entry>multifunctional cytokines synthesized by</entry><entry>using assays known in the art:</entry><entry>immunologic disorders,</entry></row><row><entry/><entry/><entry/><entry>lymphocytes, monocytes, and</entry><entry>Matthews et al., in <i>Lymphokines and</i></entry><entry>cancer</entry></row><row><entry/><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Interferens: A Practical Approach</i>,</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune cells</entry><entry>Clemens et al., eds, IRL Press,</entry></row><row><entry/><entry/><entry/><entry>(e.g., T helper cells, B cells, eosinophils,</entry><entry>Washington, D.C. 1987, pp. 221-225;</entry></row><row><entry/><entry/><entry/><entry>and lymphocytes), chemotaxis of</entry><entry>and Orencole &#x26; Dinarello (1989)</entry></row><row><entry/><entry/><entry/><entry>neutrophils and T lymphocytes, and/or</entry><entry>Cytokine 1, 14-20.</entry></row><row><entry/><entry/><entry/><entry>inhibition of interferons.</entry></row><row><entry>IL-3 variants</entry><entry>GeneSeq Accession</entry><entry>WO9307171</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be determined</entry><entry>inflammatory disorders,</entry></row><row><entry/><entry>R38561, R38562,</entry><entry/><entry>multifunctional cytokines synthesized by</entry><entry>using assays known in the art:</entry><entry>immunologic disorders,</entry></row><row><entry/><entry>R38563, R38564,</entry><entry/><entry>lymphocytes, monocytes, and</entry><entry>Matthews et al., in <i>Lymphokines and</i></entry><entry>cancer</entry></row><row><entry/><entry>R38565, R38566,</entry><entry/><entry>macrophages. Known functions include</entry><entry><i>Interferens: A Practical Approach</i>,</entry></row><row><entry/><entry>R38567, R38568,</entry><entry/><entry>stimulating proliferation of immune cells</entry><entry>Clemens et al.; eds, IRL Press,</entry></row><row><entry/><entry>R38569, R38570,</entry><entry/><entry>(e.g., T helper cells, B cells, eosinophils,</entry><entry>Washington, D.C. 1987, pp. 221-225;</entry></row><row><entry/><entry>R38571, and</entry><entry/><entry>and lymphocytes), chemotaxis of</entry><entry>and Aarden et al (1987) Eur. J.</entry></row><row><entry/><entry>R38572</entry><entry/><entry>neutrophils and T lymphocytes, and/or</entry><entry>Immunol 17, 1411-16.</entry></row><row><entry/><entry/><entry/><entry>inhibition of interferons.</entry></row><row><entry>IL-6</entry><entry>GeneSeq Accession</entry><entry>WO9402512</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be determined</entry><entry>inflammatory disorders,</entry></row><row><entry/><entry>R45717 and</entry><entry/><entry>multifunctional cytokines synthesized by</entry><entry>using assays known in the art:</entry><entry>immunologic disorders,</entry></row><row><entry/><entry>R45718</entry><entry/><entry>lymphocytes, monocytes, and</entry><entry>Matthews et al., in <i>Lymphokines and</i></entry><entry>cancer</entry></row><row><entry/><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Interferens: A Practical Approach</i>,</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune cells</entry><entry>Clemens et al., eds, IRL Press,</entry></row><row><entry/><entry/><entry/><entry>(e.g., T helper cells, B cells, eosinophils,</entry><entry>Washington, D.C. 1987, pp. 221-225;</entry></row><row><entry/><entry/><entry/><entry>and lymphocytes), chemotaxis of</entry><entry>and Aarden et al (1987) Eur. J.</entry></row><row><entry/><entry/><entry/><entry>neutrophils and T lymphocytes, and/or</entry><entry>Immunol 17, 1411-16.</entry></row><row><entry/><entry/><entry/><entry>inhibition of interferons.</entry></row><row><entry>IL-13</entry><entry>GeneSeq Accession</entry><entry>WO9404680</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be determined</entry><entry>inflammatory disorders,</entry></row><row><entry/><entry>R48624</entry><entry/><entry>multifunctional cytokines synthesized by</entry><entry>using assays known in the art:</entry><entry>immunologic disorders,</entry></row><row><entry/><entry/><entry/><entry>lymphocytes, monocytes, and</entry><entry>Matthews et al., in <i>Lymphokines and</i></entry><entry>cancer</entry></row><row><entry/><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Interferens: A Practical Approach</i>,</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune cells</entry><entry>Clemens et al., eds, IRL Press,</entry></row><row><entry/><entry/><entry/><entry>(e.g., T helper cells, B cells, eosinophils,</entry><entry>Washington, D.C. 1987, pp. 221-225;</entry></row><row><entry/><entry/><entry/><entry>and lymphocytes), chemotaxis of</entry><entry>and Boutelier et al (1995) J.</entry></row><row><entry/><entry/><entry/><entry>neutrophils and T lymphocytes, and/or</entry><entry>Immunol. Methods 181, 29.</entry></row><row><entry/><entry/><entry/><entry>inhibition of interferons.</entry></row><row><entry>IL-4 mutein</entry><entry>GeneSeq Accession</entry><entry>DE4137333</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be determined</entry><entry>inflammatory disorders,</entry></row><row><entry/><entry>R47182</entry><entry/><entry>multifunctional cytokines synthesized by</entry><entry>using assays known in the art:</entry><entry>immunologic disorders,</entry></row><row><entry/><entry/><entry/><entry>lymphocytes, monocytes, and</entry><entry>Matthews et al., in <i>Lymphokines and</i></entry><entry>cancer</entry></row><row><entry/><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Interferens: A Practical Approach</i>,</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune cells</entry><entry>Clemens et al., eds, IRL Press,</entry></row><row><entry/><entry/><entry/><entry>(e.g., T helper cells, B cells, eosinophils,</entry><entry>Washington, D.C. 1987, pp. 221-225;</entry></row><row><entry/><entry/><entry/><entry>and lymphocytes), chemotaxis of</entry><entry>and Siegel &#x26; Mostowski (1990) J</entry></row><row><entry/><entry/><entry/><entry>neutrophils and T lymphocytes, and/or</entry><entry>Immunol Methods 132, 287-295.</entry></row><row><entry/><entry/><entry/><entry>inhibition of interferons.</entry></row><row><entry>IL-4 mutein</entry><entry>GeneSeq Accession</entry><entry>DE4137333</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be determined</entry><entry>inflammatory disorders,</entry></row><row><entry>Y124X</entry><entry>R47183</entry><entry/><entry>multifunctional cytokines synthesized by</entry><entry>using assays known in the art:</entry><entry>immunologic disorders,</entry></row><row><entry/><entry/><entry/><entry>lymphocytes, monocytes, and</entry><entry>Matthews et al., in <i>Lymphokines and</i></entry><entry>cancer</entry></row><row><entry/><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Interferens: A Practical Approach</i>,</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune cells</entry><entry>Clemens et al., eds, IRL Press,</entry></row><row><entry/><entry/><entry/><entry>(e.g., T helper cells, B cells, eosinophils,</entry><entry>Washington, D.C. 1987, pp. 221-225;</entry></row><row><entry/><entry/><entry/><entry>and lymphocytes), chemotaxis of</entry><entry>and Siegel &#x26; Mostowski (1990) J</entry></row><row><entry/><entry/><entry/><entry>neutrophils and T lymphocytes, and/or</entry><entry>Immunol Methods 132, 287-295.</entry></row><row><entry/><entry/><entry/><entry>inhibition of interferons.</entry></row><row><entry>IL-4 mutein</entry><entry>GeneSeq Accession</entry><entry>DE4137333</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be determined</entry><entry>inflammatory disorders,</entry></row><row><entry>Y124G</entry><entry>R47184</entry><entry/><entry>multifunctional cytokines synthesized by</entry><entry>using assays known in the art:</entry><entry>immunologic disorders,</entry></row><row><entry/><entry/><entry/><entry>lymphocytes, monocytes, and</entry><entry>Matthews et al., in <i>Lymphokines and</i></entry><entry>cancer</entry></row><row><entry/><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Interferens: A Practical Approach</i>,</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune cells</entry><entry>Clemens et al., eds, IRL Press,</entry></row><row><entry/><entry/><entry/><entry>(e.g., T helper cells, B cells, eosinophils,</entry><entry>Washington, D.C. 1987, pp. 221-225;</entry></row><row><entry/><entry/><entry/><entry>and lymphocytes), chemotaxis of</entry><entry>and Siegel &#x26; Mostowski (1990) J</entry></row><row><entry/><entry/><entry/><entry>neutrophils and T lymphocytes, and/or</entry><entry>Immunol Methods 132, 287-295.</entry></row><row><entry/><entry/><entry/><entry>inhibition of interferons.</entry></row><row><entry>Human</entry><entry>GeneSeq Accession</entry><entry>WO9317698</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be determined</entry><entry>inflammatory disorders,</entry></row><row><entry>Interleukin-10</entry><entry>R41664</entry><entry/><entry>multifunctional cytokines synthesized by</entry><entry>using assays known in the art:</entry><entry>immunologic disorders,</entry></row><row><entry>(precursor)</entry><entry/><entry/><entry>lymphocytes, monocytes, and</entry><entry>Matthews et al., in <i>Lymphokines and</i></entry><entry>cancer</entry></row><row><entry/><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Interferens: A Practical Approach</i>,</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune cells</entry><entry>Clemens et al., eds, IRL Press,</entry></row><row><entry/><entry/><entry/><entry>(e.g., T helper cells, B cells, eosinophils,</entry><entry>Washington, D.C. 1987, pp. 221-225;</entry></row><row><entry/><entry/><entry/><entry>and lymphocytes), chemotaxis of</entry><entry>and Thompson-Snipes et al (1991) J.</entry></row><row><entry/><entry/><entry/><entry>neutrophils and T lymphocytes, and/or</entry><entry>Exp. Med. 173, 507-510.</entry></row><row><entry/><entry/><entry/><entry>inhibition of interferons.</entry></row><row><entry>Human</entry><entry>GeneSeq Accession</entry><entry>WO9318783-A</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be determined</entry><entry>inflammatory disorders,</entry></row><row><entry>Interleukin-10</entry><entry>R42642</entry><entry/><entry>multifunctional cytokines synthesized by</entry><entry>using assays known in the art:</entry><entry>immunologic disorders,</entry></row><row><entry/><entry/><entry/><entry>lymphocytes, monocytes, and</entry><entry>Matthews et al., in <i>Lymphokines and</i></entry><entry>cancer</entry></row><row><entry/><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Interferens: A Practical Approach</i>,</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune cells</entry><entry>Clemens et al., eds, IRL Press,</entry></row><row><entry/><entry/><entry/><entry>(e.g., T helper cells, B cells, eosinophils,</entry><entry>Washington, D.C. 1987, pp. 221-225;</entry></row><row><entry/><entry/><entry/><entry>and lymphocytes), chemotaxis of</entry><entry>and Thompson-Snipes et al (1991) J.</entry></row><row><entry/><entry/><entry/><entry>neutrophils and T lymphocytes, and/or</entry><entry>Exp. Med. 173, 507-510.</entry></row><row><entry/><entry/><entry/><entry>inhibition of interferons.</entry></row><row><entry>Human</entry><entry>GeneSeq Accession</entry><entry>EP569042</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be determined</entry><entry>inflammatory disorders,</entry></row><row><entry>interleukin-1</entry><entry>R42447</entry><entry/><entry>multifunctional cytokines synthesized by</entry><entry>using assays known in the art:</entry><entry>immunologic disorders,</entry></row><row><entry>beta precursor.</entry><entry/><entry/><entry>lymphocytes, monocytes, and</entry><entry>Matthews et al., in <i>Lymphokines and</i></entry><entry>cancer</entry></row><row><entry/><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Interferens: A Practical Approach</i>,</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune cells</entry><entry>Clemens et al., eds, IRL Press,</entry></row><row><entry/><entry/><entry/><entry>(e.g., T helper cells, B cells, eosinophils,</entry><entry>Washington, D.C. 1987, pp. 221-225;</entry></row><row><entry/><entry/><entry/><entry>and lymphocytes), chemotaxis of</entry><entry>and Orencole &#x26; Dinarello (1989)</entry></row><row><entry/><entry/><entry/><entry>neutrophils and T lymphocytes, and/or</entry><entry>Cytokine 1, 14-20.</entry></row><row><entry/><entry/><entry/><entry>inhibition of interferons.</entry></row><row><entry>Interleukin-</entry><entry>GeneSeq Accession</entry><entry>EP578278</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be determined</entry><entry>inflammatory disorders,</entry></row><row><entry>1alpha</entry><entry>R45364</entry><entry/><entry>multifunctional cytokines synthesized by</entry><entry>using assays known in the art:</entry><entry>immunologic disorders,</entry></row><row><entry/><entry/><entry/><entry>lymphocytes, monocytes, and</entry><entry>Matthews et al., in <i>Lymphokines and</i></entry><entry>cancer</entry></row><row><entry/><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Interferens: A Practical Approach</i>,</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune cells</entry><entry>Clemens et al., eds, IRL Press,</entry></row><row><entry/><entry/><entry/><entry>(e.g., T helper cells, B cells, eosinophils,</entry><entry>Washington, D.C. 1987, pp. 221-225.</entry></row><row><entry/><entry/><entry/><entry>and lymphocytes), chemotaxis of</entry></row><row><entry/><entry/><entry/><entry>neutrophils and T lymphocytes, and/or</entry></row><row><entry/><entry/><entry/><entry>inhibition of interferons.</entry></row><row><entry>Human</entry><entry>GeneSeq Accession</entry><entry>JP04063595</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be determined</entry><entry>inflammatory disorders,</entry></row><row><entry>interleukin-3</entry><entry>R22814</entry><entry/><entry>multifunctional cytokines synthesized by</entry><entry>using assays known in the art:</entry><entry>immunologic disorders,</entry></row><row><entry>variant</entry><entry/><entry/><entry>lymphocytes, monocytes, and</entry><entry>Matthews et al., in <i>Lymphokines and</i></entry><entry>cancer</entry></row><row><entry/><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Interferens: A Practical Approach</i>,</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune cells</entry><entry>Clemens et al., eds, IRL Press,</entry></row><row><entry/><entry/><entry/><entry>(e.g., T helper cells, B cells, eosinophils,</entry><entry>Washington, D.C. 1987, pp. 221-225;</entry></row><row><entry/><entry/><entry/><entry>and lymphocytes), chemotaxis of</entry><entry>and Kitamura et al (1989) J Cell</entry></row><row><entry/><entry/><entry/><entry>neutrophils and T lymphocytes, and/or</entry><entry>Physiol. 140 323-334.</entry></row><row><entry/><entry/><entry/><entry>inhibition of interferons.</entry></row><row><entry>IL-1i fragments</entry><entry>GeneSeq Accession</entry><entry>EP541920</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be determined</entry><entry>inflammatory disorders,</entry></row><row><entry/><entry>R35484 and</entry><entry/><entry>multifunctional cytokines synthesized by</entry><entry>using assays known in the art:</entry><entry>immunologic disorders,</entry></row><row><entry/><entry>R35485</entry><entry/><entry>lymphocytes, monocytes, and</entry><entry>Matthews et al., in <i>Lymphokines and</i></entry><entry>cancer</entry></row><row><entry/><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Interferens: A Practical Approach</i>,</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune cells</entry><entry>Clemens et al., eds, IRL Press,</entry></row><row><entry/><entry/><entry/><entry>(e.g., T helper cells, B cells, eosinophils,</entry><entry>Washington, D.C. 1987, pp. 221-225;</entry></row><row><entry/><entry/><entry/><entry>and lymphocytes), chemotaxis of</entry><entry>and Orencole &#x26; Dinarclio (1989)</entry></row><row><entry/><entry/><entry/><entry>neutrophils and T lymphocytes, and/or</entry><entry>Cytokine 1, 14-20.</entry></row><row><entry/><entry/><entry/><entry>inhibition of interferons.</entry></row><row><entry>IL-1 inhibitor</entry><entry>GeneSeq Accession</entry><entry>EPS541920</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be determined</entry><entry>inflammatory disorders,</entry></row><row><entry>(IL-li)</entry><entry>R35486 and</entry><entry/><entry>multifunctional cytokines synthesized by</entry><entry>using assays known in the art:</entry><entry>immunologic disorders,</entry></row><row><entry/><entry>R35484</entry><entry/><entry>lymphocytes, monocytes, and</entry><entry>Matthews et al., in <i>Lymphokines and</i></entry><entry>cancer</entry></row><row><entry/><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Interferens: A Practical Approach</i>,</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune cells</entry><entry>Clemens et al., eds, IRL Press,</entry></row><row><entry/><entry/><entry/><entry>(e.g., T helper cells, B cells, eosinophils,</entry><entry>Washington, D.C. 1987, pp. 221-225;</entry></row><row><entry/><entry/><entry/><entry>and lymphocytes), chemotaxis of</entry><entry>and Orencole &#x26; Dinarclio (1989)</entry></row><row><entry/><entry/><entry/><entry>neutrophils and T lymphocytes, and/or</entry><entry>Cytokine 1, 14-20.</entry></row><row><entry/><entry/><entry/><entry>inhibition of interferons.</entry></row><row><entry>ICE 22 kD subunit.</entry><entry>GeneSeq Accession</entry><entry>EP533350</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be determined</entry><entry>inflammatory disorders,</entry></row><row><entry/><entry>R33780</entry><entry/><entry>multifunctional cytokines synthesized by</entry><entry>using assays known in the art:</entry><entry>immunologic disorders,</entry></row><row><entry/><entry/><entry/><entry>lymphocytes, monocytes, and</entry><entry>Matthews et al., in <i>Lymphokines and</i></entry><entry>cancer</entry></row><row><entry/><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Interferens: A Practical Approach</i>,</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune cells</entry><entry>Clemens et al., eds, IRL Press,</entry></row><row><entry/><entry/><entry/><entry>(e.g., T helper cells, B cells, eosinophils,</entry><entry>Washington, D.C. 1987, pp. 221-225.</entry></row><row><entry/><entry/><entry/><entry>and lymphocytes), chemotaxis of</entry></row><row><entry/><entry/><entry/><entry>neutrophils and T lymphocytes, and/or</entry></row><row><entry/><entry/><entry/><entry>inhibition of interferons.</entry></row><row><entry>ICE 20 kD subunit.</entry><entry>GeneSeq Accession</entry><entry>EP533350</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be determined</entry><entry>inflammatory disorders,</entry></row><row><entry/><entry>R33781</entry><entry/><entry>multifunctional cytokines synthesized by</entry><entry>using assays known in the art:</entry><entry>immunologic disorders,</entry></row><row><entry/><entry/><entry/><entry>lymphocytes, monocytes, and</entry><entry>Matthews et al., in <i>Lymphokines and</i></entry><entry>cancer</entry></row><row><entry/><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Interferens: A Practical Approach</i>,</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune cells</entry><entry>Clemens et al., eds, IRL Press,</entry></row><row><entry/><entry/><entry/><entry>(e.g., T helper cells, B cells, eosinophils,</entry><entry>Washington, D.C. 1987, pp. 221-225.</entry></row><row><entry/><entry/><entry/><entry>and lymphocytes), chemotaxis of</entry></row><row><entry/><entry/><entry/><entry>neutrophils and T lymphocytes, and/or</entry></row><row><entry/><entry/><entry/><entry>inhibition of interferons.</entry></row><row><entry>ICE 10 kD</entry><entry>GeneSeq Accession</entry><entry>EP533350</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be determined</entry><entry>inflammatory disorders,</entry></row><row><entry>subunit</entry><entry>R33782</entry><entry/><entry>multifunctional cytokines synthesized by</entry><entry>using assays known in the art:</entry><entry>immunologic disorders,</entry></row><row><entry/><entry/><entry/><entry>lymphocytes, monocytes, and</entry><entry>Matthews et al., in <i>Lymphokines and</i></entry><entry>cancer</entry></row><row><entry/><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Interferens: A Practical Approach</i>,</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune cells</entry><entry>Clemens et al., eds, IRL Press,</entry></row><row><entry/><entry/><entry/><entry>(e.g., T helper cells, B cells, eosinophils,</entry><entry>Washington, D.C. 1987, pp. 221-225.</entry></row><row><entry/><entry/><entry/><entry>and lymphocytes), chemotaxis of</entry></row><row><entry/><entry/><entry/><entry>neutrophils and T lymphocytes, and/or</entry></row><row><entry/><entry/><entry/><entry>inhibition of interferons.</entry></row><row><entry>Human</entry><entry>GeneSeq Accession</entry><entry>WO9317698</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be determined</entry><entry>inflammatory disorders,</entry></row><row><entry>Interleukin-10</entry><entry>R41664</entry><entry/><entry>multifunctional cytokines synthesized by</entry><entry>using assays known in the art:</entry><entry>immunologic disorders,</entry></row><row><entry>(precursor)</entry><entry/><entry/><entry>lymphocytes, monocytes, and</entry><entry>Matthews et al., in<i>Lymphokines and</i></entry><entry>cancer</entry></row><row><entry/><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Interferens: A Practical Approach</i>,</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune cells</entry><entry>Clemens et al., eds, IRL Press,</entry></row><row><entry/><entry/><entry/><entry>(e.g., T helper cells, B cells, eosinophils,</entry><entry>Washington, D.C. 1987, pp. 221-225;</entry></row><row><entry/><entry/><entry/><entry>and lymphocytes), chemotaxis of</entry><entry>and Thompson-Snipes et al (1991) J.</entry></row><row><entry/><entry/><entry/><entry>neutrophils and T lymphocytes, and/or</entry><entry>Exp. Med. 173, 507-510.</entry></row><row><entry/><entry/><entry/><entry>inhibition of interferons.</entry></row><row><entry>Human</entry><entry>GeneSeq Accession</entry><entry>WO9318783</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be determined</entry><entry>inflammatory disorders,</entry></row><row><entry>Interleukin-10</entry><entry>R42642</entry><entry/><entry>multifunctional cytokines synthesized by</entry><entry>using assays known in the art:</entry><entry>immunologic disorders,</entry></row><row><entry/><entry/><entry/><entry>lymphocytes, monocytes, and</entry><entry>Matthews et al., in <i>Lymphokines and</i></entry><entry>cancer</entry></row><row><entry/><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Interferens: A Practical Approach</i>,</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune cells</entry><entry>Clemens et al., eds, IRL Press,</entry></row><row><entry/><entry/><entry/><entry>(e.g., T helper cells, B cells, eosinophils,</entry><entry>Washington, D.C. 1987, pp. 221-225;</entry></row><row><entry/><entry/><entry/><entry>and lymphocytes), chemotaxis of</entry><entry>and Thompson-Snipes et al (1991) J.</entry></row><row><entry/><entry/><entry/><entry>neutrophils and T lymphocytes, and/or</entry><entry>Exp. Med. 173, 507-510.</entry></row><row><entry/><entry/><entry/><entry>inhibition of interferons.</entry></row><row><entry>Human</entry><entry>GeneSeq Accession</entry><entry>EP569042</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be determined</entry><entry>inflammatory disorders,</entry></row><row><entry>Interleukin-1</entry><entry>R42447</entry><entry/><entry>multifunctional cytokines synthesized by</entry><entry>using assays known in the art:</entry><entry>immunologic disorders,</entry></row><row><entry>beta precursor</entry><entry/><entry/><entry>lymphocytes, monocytes, and</entry><entry>Matthews et al., in <i>Lymphokines and</i></entry><entry>cancer</entry></row><row><entry/><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Interferens: A Practical Approach</i>,</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune cells</entry><entry>Clemens et al., eds, IRL Press,</entry></row><row><entry/><entry/><entry/><entry>(e.g., T helper cells, B cells, eosinophils,</entry><entry>Washington, D.C. 1987, pp. 221-225;</entry></row><row><entry/><entry/><entry/><entry>and lymphocytes), chemotaxis of</entry><entry>and Kitamura et al (1989) J Cell</entry></row><row><entry/><entry/><entry/><entry>neutrophils and T lymphocytes, and/or</entry><entry>Physiol. 140 323-334.</entry></row><row><entry/><entry/><entry/><entry>inhibition of interferons.</entry></row><row><entry>Human</entry><entry>GeneSeq Accession</entry><entry>WO9403492</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be determined</entry><entry>inflammatory disorders,</entry></row><row><entry>interleukin-6</entry><entry>R49041</entry><entry/><entry>multifunctional cytokines synthesized by</entry><entry>using assays known in the art:</entry><entry>immunologic disorders,</entry></row><row><entry/><entry/><entry/><entry>lymphocytes, monocytes, and</entry><entry>Matthews et al., in <i>Lymphokines and</i></entry><entry>cancer</entry></row><row><entry/><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Interferens: A Practical Approach</i>,</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune cells</entry><entry>Clemens et al., eds, IRL Press,</entry></row><row><entry/><entry/><entry/><entry>(e.g., T helper cells, B cells, eosinophils,</entry><entry>Washington, D.C. 1987, pp. 221-225;</entry></row><row><entry/><entry/><entry/><entry>and lymphocytes), chemotaxis of</entry><entry>and Aarden et al (1987) Eur. J.</entry></row><row><entry/><entry/><entry/><entry>neutrophils and T lymphocytes, and/or</entry><entry>Immunol 17, 1411-16.</entry></row><row><entry/><entry/><entry/><entry>inhibition of interferons.</entry></row><row><entry>Mutant Interleukin 6</entry><entry>GeneSeq Accession</entry><entry>WO9411402</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be determined</entry><entry>inflammatory disorders,</entry></row><row><entry>S176R</entry><entry>R54990</entry><entry/><entry>multifunctional cytokines synthesized by</entry><entry>using assays known in the art:</entry><entry>immunologic disorders,</entry></row><row><entry/><entry/><entry/><entry>lymphocytes, monocytes, and</entry><entry>Matthews et al., in <i>Lymphokines and</i></entry><entry>cancer</entry></row><row><entry/><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Interferens: A Practical Approach</i>,</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune cells</entry><entry>Clemens et al., eds, IRL Press,</entry></row><row><entry/><entry/><entry/><entry>(e.g., T helper cells, B cells, eosinophils,</entry><entry>Washington, D.C. 1987, pp. 221-225;</entry></row><row><entry/><entry/><entry/><entry>and lymphocytes), chemotaxis of</entry><entry>and Aarden et al (1987) Eur. J.</entry></row><row><entry/><entry/><entry/><entry>neutrophils and T lymphocytes, and/or</entry><entry>Immunol 17, 1411-16.</entry></row><row><entry/><entry/><entry/><entry>inhibition of interferons.</entry></row><row><entry>Interleukin 6</entry><entry>GeneSeq Accession</entry><entry>JP06145063</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be determined</entry><entry>inflammatory disorders,</entry></row><row><entry/><entry>R55256</entry><entry/><entry>multifunctional cytokines synthesized by</entry><entry>using assays known in the art:</entry><entry>immunologic disorders,</entry></row><row><entry/><entry/><entry/><entry>lymphocytes, monocytes, and</entry><entry>Matthews et al., in <i>Lymphokines and</i></entry><entry>cancer</entry></row><row><entry/><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Interferens: A Practical Approach</i>,</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune cells</entry><entry>Clemens et al., eds, IRL Press,</entry></row><row><entry/><entry/><entry/><entry>(e.g., T helper cells, B cells, eosinophils,</entry><entry>Washington, D.C. 1987, pp. 221-225;</entry></row><row><entry/><entry/><entry/><entry>and lymphocytes), chemotaxis of</entry><entry>and Aarden et al (1987) Eur. J.</entry></row><row><entry/><entry/><entry/><entry>neutrophils and T lymphocytes, and/or</entry><entry>Immunol 17, 1411-16.</entry></row><row><entry/><entry/><entry/><entry>inhibition of interferons.</entry></row><row><entry>Interleukin 8</entry><entry>GeneSeq Accession</entry><entry>JP06100595</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be determined</entry><entry>Soluble IL-8 receptor</entry></row><row><entry>(IL-8) receptor</entry><entry>R53932</entry><entry/><entry>multifunctional cytokines synthesized by</entry><entry>using assays known in the art:</entry><entry>polypeptides may be</entry></row><row><entry/><entry/><entry/><entry>lymphocytes, monocytes, and</entry><entry>Matthews et al., in <i>Lymphokines and</i></entry><entry>useful for inhibiting</entry></row><row><entry/><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Interferens: A Practical Approach</i>,</entry><entry>interleukin activities.</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune cells</entry><entry>Clemens et al., eds, IRL Press,</entry></row><row><entry/><entry/><entry/><entry>(e.g., T helper cells, B cells, eosinophils,</entry><entry>Washington, D.C. 1987, pp. 221-225;</entry></row><row><entry/><entry/><entry/><entry>and lymphocytes), chemotaxis of</entry><entry>and Holmes et al (1991) Science 253,</entry></row><row><entry/><entry/><entry/><entry>neutrophils and T lymphocytes, and/or</entry><entry>1278-80.</entry></row><row><entry/><entry/><entry/><entry>inhibition of interferons.</entry></row><row><entry>Human</entry><entry>GeneSeq Accession</entry><entry>U.S. Pat. No. 5,328,988</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be determined</entry><entry>inflammatory disorders,</entry></row><row><entry>interleukin-7</entry><entry>R59919</entry><entry/><entry>multifunctional cytokines synthesized by</entry><entry>using assays known in the art:</entry><entry>immunologic disorders,</entry></row><row><entry/><entry/><entry/><entry>lymphocytes, monocytes, and</entry><entry>Matthews et al., in <i>Lymphokines and</i></entry><entry>cancer</entry></row><row><entry/><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Interferens: A Practical Approach</i>,</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune cells</entry><entry>Clemens et al., eds, IRL Press,</entry></row><row><entry/><entry/><entry/><entry>(e.g., T helper cells, B cells, eosinophils,</entry><entry>Washington, D.C. 1987, pp. 221-225;</entry></row><row><entry/><entry/><entry/><entry>and lymphocytes), chemotaxis of</entry><entry>and Park et al (1990) J. Exp. Med.</entry></row><row><entry/><entry/><entry/><entry>neutrophils and T lymphocytes, and/or</entry><entry>171, 1073-79.</entry></row><row><entry/><entry/><entry/><entry>inhibition of interferons.</entry></row><row><entry>IL-3 containing</entry><entry>GeneSeq Accession</entry><entry>WO9521254</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be determined</entry><entry>inflammatory disorders,</entry></row><row><entry>fusion protein.</entry><entry>R79342 and</entry><entry/><entry>multifunctional cytokines synthesized by</entry><entry>using assays known in the art:</entry><entry>immunologic disorders,</entry></row><row><entry/><entry>R79344</entry><entry/><entry>lymphocytes, monocytes, and</entry><entry>Matthews et al., in <i>Lymphokines and</i></entry><entry>cancer</entry></row><row><entry/><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Interferens: A Practical Approach</i>,</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune cells</entry><entry>Clemens et al., eds, IRL Press,</entry></row><row><entry/><entry/><entry/><entry>(e.g., T helper cells, B cells, eosinophils,</entry><entry>Washington, D.C. 1987, pp. 221-225;</entry></row><row><entry/><entry/><entry/><entry>and lymphocytes), chemotaxis of</entry><entry>and Kitamura et al (1989) J Cell</entry></row><row><entry/><entry/><entry/><entry>neutrophils and T lymphocytes, and/or</entry><entry>Physiol. 140 323-334.</entry></row><row><entry/><entry/><entry/><entry>inhibition of interferons.</entry></row><row><entry>IL-3 mutant</entry><entry>GeneSeq Accession</entry><entry>ZA9402636</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be determined</entry><entry>inflammatory disorders,</entry></row><row><entry>proteins</entry><entry>R79254, R79255,</entry><entry/><entry>multifunctional cytokines synthesized by</entry><entry>using assays known in the art:</entry><entry>immunologic disorders,</entry></row><row><entry/><entry>R79256, R79257,</entry><entry/><entry>lymphocytes, monocytes, and</entry><entry>Matthews et al., in <i>Lymphokines and</i></entry><entry>cancer</entry></row><row><entry/><entry>R79258, R79259,</entry><entry/><entry>macrophages. Known functions include</entry><entry><i>Interferens: A Practical Approach</i>,</entry></row><row><entry/><entry>R79260, R79261,</entry><entry/><entry>stimulating proliferation of immune cells</entry><entry>Clemens et al., eds, IRL Press,</entry></row><row><entry/><entry>R79262, R79263,</entry><entry/><entry>(e.g., T helper cells, B cells, eosinophils,</entry><entry>Washington, D.C. 1987, pp. 221-225;</entry></row><row><entry/><entry>R79264, R79265,</entry><entry/><entry>and lymphocytes), chemotaxis of</entry><entry>and Giri et al (1994) EMBO J. 13</entry></row><row><entry/><entry>R79266, R79267,</entry><entry/><entry>neutrophils and T lymphocytes, and/or</entry><entry>2822-2830.</entry></row><row><entry/><entry>R79268, R79269,</entry><entry/><entry>inhibition of interferons.</entry></row><row><entry/><entry>R79270, R79271,</entry></row><row><entry/><entry>R79272, R79273,</entry></row><row><entry/><entry>R79274, R79275,</entry></row><row><entry/><entry>R79276, R79277,</entry></row><row><entry/><entry>R79278, R79279,</entry></row><row><entry/><entry>R79280, R79281,</entry></row><row><entry/><entry>R79282, 879283,</entry></row><row><entry/><entry>R79284, and</entry></row><row><entry/><entry>R79285</entry></row><row><entry>IL-12 p40</entry><entry>GeneSeq Accession</entry><entry>AU9466072</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be determined</entry><entry>inflammatory disorders,</entry></row><row><entry>subunit.</entry><entry>R63018</entry><entry/><entry>multifunctional cytokines synthesized by</entry><entry>using assays known in the art:</entry><entry>immunologic disorders,</entry></row><row><entry/><entry/><entry/><entry>lymphocytes, monocytes, and</entry><entry>Matthews et al., in <i>Lymphokines and</i></entry><entry>cancer</entry></row><row><entry/><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Interferens: A Practical Approach</i>,</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune cells</entry><entry>Clemens et al., eds, IRL Press,</entry></row><row><entry/><entry/><entry/><entry>(e.g., T helper cells, B cells, eosinophils,</entry><entry>Washington, D.C. 1987, pp. 221-225.</entry></row><row><entry/><entry/><entry/><entry>and lymphocytes), chemotaxis of</entry></row><row><entry/><entry/><entry/><entry>neutrophils and T lymphocytes, and/or</entry></row><row><entry/><entry/><entry/><entry>inhibition of interferons.</entry></row><row><entry>AGF</entry><entry>GeneSeq Accession</entry><entry>WO9429344</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be determined</entry><entry>inflammatory disorders,</entry></row><row><entry/><entry>R64240</entry><entry/><entry>multifunctional cytokines synthesized by</entry><entry>using assays known in the art:</entry><entry>immunologic disorders,</entry></row><row><entry/><entry/><entry/><entry>lymphocytes, monocytes, and</entry><entry>Matthews et al., in <i>Lymphokines and</i></entry><entry>cancer</entry></row><row><entry/><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Interferens: A Practical Approach</i>,</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune cells</entry><entry>Clemens et al., eds, IRL Press,</entry></row><row><entry/><entry/><entry/><entry>(e.g., T helper cells, B cells, eosinophils,</entry><entry>Washington, D.C. 1987, pp. 221-225.</entry></row><row><entry/><entry/><entry/><entry>and lymphocytes), chemotaxis of</entry></row><row><entry/><entry/><entry/><entry>neutrophils and T lymphocytes, and/or</entry></row><row><entry/><entry/><entry/><entry>inhibition of interferons.</entry></row><row><entry>Human</entry><entry>GeneSeq Accession</entry><entry>WO9519786</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be determined</entry><entry>inflammatory disorders,</entry></row><row><entry>interlaukin-12 40 kD</entry><entry>R79187</entry><entry/><entry>multifunctional cytokines synthesized by</entry><entry>using assays known in the art:</entry><entry>immunologic disorders,</entry></row><row><entry>subunit</entry><entry/><entry/><entry>lymphocytes, monocytes, and</entry><entry>Matthews et al., in <i>Lymphokines and</i></entry><entry>cancer</entry></row><row><entry/><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Interferens: A Practical Approach</i>,</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune cells</entry><entry>Clemens et al., eds, IRL Press,</entry></row><row><entry/><entry/><entry/><entry>(e.g., T helper cells, B cells, eosinophils,</entry><entry>Washington, D.C. 1987, pp. 221-225;</entry></row><row><entry/><entry/><entry/><entry>and lymphocytes), chemotaxis of</entry><entry>and Hori et al (1987), Blood 70,</entry></row><row><entry/><entry/><entry/><entry>neutrophils and T lymphocytes, and/or</entry><entry>1069-1078.</entry></row><row><entry/><entry/><entry/><entry>inhibition of interferons.</entry></row><row><entry>Human</entry><entry>GeneSeq Accession</entry><entry>WO9530695</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be determined</entry><entry>Soluble IL-8 receptor</entry></row><row><entry>interleukin-15</entry><entry>R90843</entry><entry/><entry>multifunctional cytokines synthesized by</entry><entry>using assays known in the art:</entry><entry>polypeptides may be</entry></row><row><entry>receptor from</entry><entry/><entry/><entry>lymphocytes, monocytes, and</entry><entry>Matthews et al., in <i>Lymphokines and</i></entry><entry>useful for inhibiting</entry></row><row><entry>clone P1</entry><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Interferens: A Practical Approach</i>,</entry><entry>interleukin activities.</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune cells</entry><entry>Clemens et al., eds, IRL Press,</entry></row><row><entry/><entry/><entry/><entry>(e.g., T helper cells, B cells, eosinophils,</entry><entry>Washington, D.C. 1987, pp. 221-225;</entry></row><row><entry/><entry/><entry/><entry>and lymphocytes), chemotaxis of</entry><entry>and Giri et al (1994) EMBO J. 13</entry></row><row><entry/><entry/><entry/><entry>neutrophils and T lymphocytes, and/or</entry><entry>2822-2830.</entry></row><row><entry/><entry/><entry/><entry>inhibition of interferons.</entry></row><row><entry>Human</entry><entry>GeneSeq Accession</entry><entry>WO9604306</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be determined</entry><entry>inflammatory disorders,</entry></row><row><entry>interleukin-7</entry><entry>R92796</entry><entry/><entry>multifunctional cytokines synthesized by</entry><entry>using assays known in the art:</entry><entry>immunologic disorders,</entry></row><row><entry/><entry/><entry/><entry>lymphocytes, monocytes, and</entry><entry>Matthews et al., in <i>Lymphokines and</i></entry><entry>cancer</entry></row><row><entry/><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Interferens: A Practical Approach</i>,</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune cells</entry><entry>Clemens et al., eds, IRL Press,</entry></row><row><entry/><entry/><entry/><entry>(e.g., T helper cells, B cells, eosinophils,</entry><entry>Washington, D.C. 1987, pp. 221-225;</entry></row><row><entry/><entry/><entry/><entry>and lymphocytes), chemotaxis of</entry><entry>and Park et al (1990) J. Exp. Med.</entry></row><row><entry/><entry/><entry/><entry>neutrophils and T lymphocytes, and/or</entry><entry>171, 1073-79.</entry></row><row><entry/><entry/><entry/><entry>inhibition of interferons.</entry></row><row><entry>interleukin-9</entry><entry>GeneSeq Accesion</entry><entry>WO9604306</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be determined</entry><entry>inflammatory disorders,</entry></row><row><entry/><entry>R92797</entry><entry/><entry>multifunctional cytokines synthesized by</entry><entry>using assays known in the art:</entry><entry>immunologic disorders,</entry></row><row><entry/><entry/><entry/><entry>lymphocytes, monocytes, and</entry><entry>Matthews et al., in <i>Lymphokines and</i></entry><entry>cancer</entry></row><row><entry/><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Interferens: A Practical Approach</i>,</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune cells</entry><entry>Clemens et al., eds, IRL Press,</entry></row><row><entry/><entry/><entry/><entry>(e.g., T helper cells, B cells, eosinophils,</entry><entry>Washington, D.C. 1987, pp. 221-225;</entry></row><row><entry/><entry/><entry/><entry>and lymphocytes), chemotaxis of</entry><entry>and Yang et al (1989) Blood 74,</entry></row><row><entry/><entry/><entry/><entry>neutrophils and T lymphocytes, and/or</entry><entry>1880-84.</entry></row><row><entry/><entry/><entry/><entry>inhibition of interferons.</entry></row><row><entry>interleukin-3</entry><entry>GeneSeq Accession</entry><entry>WO9604306</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be determined</entry><entry>inflammatory disorders,</entry></row><row><entry/><entry>R92801</entry><entry/><entry>multifunctional cytokines synthesized by</entry><entry>using assays known in the art:</entry><entry>immunologic disorders,</entry></row><row><entry/><entry/><entry/><entry>lymphocytes, monocytes, and</entry><entry>Matthews et al., in <i>Lymphokines and</i></entry><entry>cancer</entry></row><row><entry/><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Interferens: A Practical Approach</i>,</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune cells</entry><entry>Clemens et al., eds, IRL Press,</entry></row><row><entry/><entry/><entry/><entry>(e.g., T helper cells, B cells, eosinophils,</entry><entry>Washington, D.C. 1987, pp. 221-225;</entry></row><row><entry/><entry/><entry/><entry>and lymphocytes), chemotaxis of</entry><entry>and Kitamura et al (1989) J Cell</entry></row><row><entry/><entry/><entry/><entry>neutrophils and T lymphocytes, and/or</entry><entry>Physiol. 140 323-334.</entry></row><row><entry/><entry/><entry/><entry>inhibition of interferons.</entry></row><row><entry>Human</entry><entry>GeneSeq Accession</entry><entry>WO9604306</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be determined</entry><entry>inflammatory disorders,</entry></row><row><entry>interleukin-5</entry><entry>R92802</entry><entry/><entry>multifunctional cytokines synthesized by</entry><entry>using assays known in the art:</entry><entry>immunologic disorders,</entry></row><row><entry/><entry/><entry/><entry>lymphocytes, monocytes, and</entry><entry>Matthews et al., in <i>Lymphokines and</i></entry><entry>cancer</entry></row><row><entry/><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Interferens: A Practical Approach</i>,</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune cells</entry><entry>Clemens et al., eds, IRL Press,</entry></row><row><entry/><entry/><entry/><entry>(e.g., T helper cells, B cells, eosinophils,</entry><entry>Washington, D.C. 1987, pp. 221-225;</entry></row><row><entry/><entry/><entry/><entry>and lymphocytes), chemotaxis of</entry><entry>and Kitamura et al (1989) J Cell</entry></row><row><entry/><entry/><entry/><entry>neutrophils and T lymphocytes, and/or</entry><entry>Physiol. 140 323-334.</entry></row><row><entry/><entry/><entry/><entry>inhibition of interferons.</entry></row><row><entry>Recombinant</entry><entry>GeneSeq Accession</entry><entry>DE19617202</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be determined</entry><entry>inflammatory disorders,</entry></row><row><entry>interleukin-16</entry><entry>W33373</entry><entry/><entry>multifunctional cytokines synthesized by</entry><entry>using assays known in the art:</entry><entry>immunologic disorders,</entry></row><row><entry/><entry/><entry/><entry>lymphocytes, monocytes, and</entry><entry>Matthews et al., in <i>Lymphokines and</i></entry><entry>cancer</entry></row><row><entry/><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Interferens: A Practical Approach</i>,</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune cells</entry><entry>Clemens et al., eds, IRL Press,</entry></row><row><entry/><entry/><entry/><entry>(e.g., T helper cells, B cells, eosinophils,</entry><entry>Washington, D.C. 1987, pp. 221-225;</entry></row><row><entry/><entry/><entry/><entry>and lymphocytes), chemotaxis of</entry><entry>and Lim et al (1996) J. Immunol. 156,</entry></row><row><entry/><entry/><entry/><entry>neutrophils and T lymphocytes, and/or</entry><entry>2566-70.</entry></row><row><entry/><entry/><entry/><entry>inhibition of interferons.</entry></row><row><entry>Human IL-16</entry><entry>GeneSeq Accession</entry><entry>DE19617202</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be determined</entry><entry>inflammatory disorders,</entry></row><row><entry>protein</entry><entry>W33234</entry><entry/><entry>multifunctional cytokines synthesized by</entry><entry>using assays known in the art:</entry><entry>immunologic disorders,</entry></row><row><entry/><entry/><entry/><entry>lymphocytes, monocytes, and</entry><entry>Matthews et al., in <i>Lymphokines and</i></entry><entry>cancer</entry></row><row><entry/><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Interferens: A Practical Approach</i>,</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune cells</entry><entry>Clemens et al., eds, IRL Press,</entry></row><row><entry/><entry/><entry/><entry>(e.g., T helper cells, B cells, eosinophils,</entry><entry>Washington, D.C. 1987, pp. 221-225;</entry></row><row><entry/><entry/><entry/><entry>and lymphocytes), chemotaxis of</entry><entry>and Lim et al (1996) J. Immunol. 156,</entry></row><row><entry/><entry/><entry/><entry>neutrophils and T lymphocytes, and/or</entry><entry>2566-70.</entry></row><row><entry/><entry/><entry/><entry>inhibition of interferons.</entry></row><row><entry>Thrl 17 human</entry><entry>GeneSeq Accession</entry><entry>WO9708321</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be determined</entry><entry>inflammatory disorders,</entry></row><row><entry>interleukin 9</entry><entry>W27521</entry><entry/><entry>multifunctional cytokines synthesized by</entry><entry>using assays known in the art:</entry><entry>immunologic disorders,</entry></row><row><entry/><entry/><entry/><entry>lymphocytes, monocytes, and</entry><entry>Matthews et al., in <i>Lymphokines and</i></entry><entry>cancer</entry></row><row><entry/><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Interferens: A Practical Approach</i>,</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune cells</entry><entry>Clemens et al., eds, IRL Press,</entry></row><row><entry/><entry/><entry/><entry>(e.g., T helper cells, B cells, eosinophils,</entry><entry>Washington, D.C. 1987, pp. 221-225.</entry></row><row><entry/><entry/><entry/><entry>and lymphocytes), chemotaxis of</entry></row><row><entry/><entry/><entry/><entry>neutrophils and T lymphocytes, and/or</entry></row><row><entry/><entry/><entry/><entry>inhibition of interferons.</entry></row><row><entry>Metl 17 human</entry><entry>GeneSeq Accession</entry><entry>WO9708321</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be determined</entry><entry>inflammatory disorders,</entry></row><row><entry>interleukin 9</entry><entry>W27522</entry><entry/><entry>multifunctional cytokines synthesized by</entry><entry>using assays known in the art:</entry><entry>immunologic disorders,</entry></row><row><entry/><entry/><entry/><entry>lymphocytes, monocytes, and</entry><entry>Matthews et al., in <i>Lymphokines and</i></entry><entry>cancer</entry></row><row><entry/><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Interferens: A Practical Approach</i>,</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune cells</entry><entry>Clemens et al., eds, IRL Press,</entry></row><row><entry/><entry/><entry/><entry>(e.g., T helper cells, B cells, eosinophils,</entry><entry>Washington, D.C. 1987, pp. 221-225;</entry></row><row><entry/><entry/><entry/><entry>and lymphocytes), chemotaxis of</entry><entry>and Yang et al (1989) Blood 74,</entry></row><row><entry/><entry/><entry/><entry>neutrophils and T lymphocytes, and/or</entry><entry>1880-84.</entry></row><row><entry/><entry/><entry/><entry>inhibition of interferons.</entry></row><row><entry>Human</entry><entry>GeneSeq Accession</entry><entry>EP86-4585</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be determined</entry><entry>inflammatory disorders,</entry></row><row><entry>intracellular IL-1</entry><entry>W77158</entry><entry/><entry>multifunctional cytokines synthesized by</entry><entry>using assays known in the art:</entry><entry>immunologic disorders,</entry></row><row><entry>receptor</entry><entry/><entry/><entry>lymphocytes, monocytes, and</entry><entry>Matthews et al., in <i>Lymphokines and</i></entry><entry>cancer</entry></row><row><entry>antagonist.</entry><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Interferens: A Practical Approach</i>,</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune cells</entry><entry>Clemens et al., eds, IRL Press,</entry></row><row><entry/><entry/><entry/><entry>(e.g., T helper cells, B cells, eosinophils,</entry><entry>Washington, D.C. 1987, pp. 221-225;</entry></row><row><entry/><entry/><entry/><entry>and lymphocytes), chemotaxis of</entry><entry>and Orencole &#x26; Dinarello (1989)</entry></row><row><entry/><entry/><entry/><entry>neutrophils and T lymphocytes, and/or</entry><entry>Cytokine 1, 14-20.</entry></row><row><entry/><entry/><entry/><entry>inhibition of interferons.</entry></row><row><entry>Human</entry><entry>GeneSeq Accession</entry><entry>EP864585</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be determined</entry><entry>inflammatory disorders,</entry></row><row><entry>interleukin-18</entry><entry>W77158</entry><entry/><entry>multifunctional cytokines synthesized by</entry><entry>using assays known in the art:</entry><entry>immunologic disorders,</entry></row><row><entry>protein (IL-18)</entry><entry/><entry/><entry>lymphocytes, monocytes, and</entry><entry>Matthews et al., in <i>Lymphokines and</i></entry><entry>cancer</entry></row><row><entry/><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Interferens: A Practical Approach</i>,</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune cells</entry><entry>Clemens et al., eds, IRL Press,</entry></row><row><entry/><entry/><entry/><entry>(e.g., T helper cells, B cells, eosinophils,</entry><entry>Washington, D.C. 1987, pp. 221-225;</entry></row><row><entry/><entry/><entry/><entry>and lymphocytes), chemotaxis of</entry><entry>and USHIO et al (1996) J. Immunol.</entry></row><row><entry/><entry/><entry/><entry>neutrophils and T lymphocytes, and/or</entry><entry>156, 4274-79.</entry></row><row><entry/><entry/><entry/><entry>inhibition of interferons.</entry></row><row><entry>Human</entry><entry>GeneSeq Accession</entry><entry>EP861663</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be determined</entry><entry>inflammatory disorders,</entry></row><row><entry>interleukin-18</entry><entry>W77077</entry><entry/><entry>multifunctional cytokines synthesized by</entry><entry>using assays known in the art:</entry><entry>immunologic disorders,</entry></row><row><entry/><entry/><entry/><entry>lymphocytes, monocytes, and</entry><entry>Matthews et al., in <i>Lymphokines and</i></entry><entry>cancer</entry></row><row><entry/><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Interferens: A Practical Approach</i>,</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune cells</entry><entry>Clemens et al., eds, IRL Press,</entry></row><row><entry/><entry/><entry/><entry>(e.g., T helper cells, B cells, eosinophils,</entry><entry>Washington, D.C. 1987, pp. 221-225;</entry></row><row><entry/><entry/><entry/><entry>and lymphocytes), chemotaxis of</entry><entry>and USHIO et al (1996) J. Immunol.</entry></row><row><entry/><entry/><entry/><entry>neutrophils and T lymphocytes, and/or</entry><entry>156, 4274-79.</entry></row><row><entry/><entry/><entry/><entry>inhibition of interferons.</entry></row><row><entry>Human interleukin</entry><entry>GeneSeq Accessions</entry><entry>EP861663</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be determined</entry><entry>inflammatory disorders,</entry></row><row><entry>18 derivatives</entry><entry>W77083, W77084,</entry><entry/><entry>multifunctional cytokines synthesized by</entry><entry>using assays known in the art:</entry><entry>immunologic disorders,</entry></row><row><entry/><entry>W77085, W77086,</entry><entry/><entry>lymphocytes, monocytes, and</entry><entry>Matthews et al., in <i>Lymphokines and</i></entry><entry>cancer</entry></row><row><entry/><entry>W77087, W77088,</entry><entry/><entry>macrophages. Known functions include</entry><entry><i>Interferons: A Practical Approach</i>,</entry></row><row><entry/><entry>and W77089</entry><entry/><entry>stimulating proliferation of immune cells</entry><entry>Clemens et al., eds, IRL Press,</entry></row><row><entry/><entry/><entry/><entry>(e.g., T helper cells, B cells, eosinophils,</entry><entry>Washington, D.C. 1987, pp. 221-225;</entry></row><row><entry/><entry/><entry/><entry>and lymphocytes), chemotaxis of</entry><entry>and Ushio et al (1996) J. Immunol,</entry></row><row><entry/><entry/><entry/><entry>neutrophils and T lymphocytes, and/or</entry><entry>156, 4274-79.</entry></row><row><entry/><entry/><entry/><entry>inhibition of interferons.</entry></row><row><entry>Interleukin-9</entry><entry>GeneSeq Accession</entry><entry>WO9827997</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be determined</entry><entry>inflammatory disorders,</entry></row><row><entry>(IL-9) mature</entry><entry>W68158</entry><entry/><entry>multifunctional cytokines synthesized by</entry><entry>using assays known in the art:</entry><entry>immunologic disorders,</entry></row><row><entry>protein (Thr117</entry><entry/><entry/><entry>lymphocytes, monocytes, and</entry><entry>Matthews et al., in <i>Lymphokines and</i></entry><entry>cancer</entry></row><row><entry>version).</entry><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Interferons: A Practical Approach</i>,</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune cells</entry><entry>Clemens et al., eds, IRL Press,</entry></row><row><entry/><entry/><entry/><entry>(e.g., T helper cells, B cells, eosinophils,</entry><entry>Washington, D.C. 1987, pp. 221-225;</entry></row><row><entry/><entry/><entry/><entry>and lymphocytes), chemotaxis of</entry><entry>and Yang et al (1989) Blood 74,</entry></row><row><entry/><entry/><entry/><entry>neutrophils and T lymphocytes, and/or</entry><entry>1880-84.</entry></row><row><entry/><entry/><entry/><entry>inhibition of interferons.</entry></row><row><entry>IL-9 mature</entry><entry>GenSeq Accession</entry><entry>WO9827997</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be determined</entry><entry>inflammatory disorders,</entry></row><row><entry>protein variant</entry><entry>W68157</entry><entry/><entry>multifunctional cytokines synthesized by</entry><entry>using assays known in the art:</entry><entry>immunologic disorders,</entry></row><row><entry>(Met117 version)</entry><entry/><entry/><entry>lymphocytes, monocytes, and</entry><entry>Matthews et al., in <i>Lymphokines and</i></entry><entry>cancer</entry></row><row><entry/><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Interferons: A Practical Approach</i>,</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune cells</entry><entry>Clemens et al., eds, IRL Press,</entry></row><row><entry/><entry/><entry/><entry>(e.g., T helper cells, B cells, eosinophils,</entry><entry>Washington, D.C. 1987, pp. 221-225;</entry></row><row><entry/><entry/><entry/><entry>and lymphocytes), chemotaxis of</entry><entry>and Yang et al (1989) Blood 74,</entry></row><row><entry/><entry/><entry/><entry>neutrophils and T lymphocytes, and/or</entry><entry>1880-84.</entry></row><row><entry/><entry/><entry/><entry>inhibition of interferons.</entry></row><row><entry>Human IL-9</entry><entry>GeneSeq Accession</entry><entry>WO9824904</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be determined</entry><entry>inflammatory disorders,</entry></row><row><entry>receptor protein</entry><entry>W64058</entry><entry/><entry>multifunctional cytokines synthesized by</entry><entry>using assays known in the art:</entry><entry>immunologic disorders,</entry></row><row><entry>variant #3.</entry><entry/><entry/><entry>lymphocytes, monocytes, and</entry><entry>Matthews et al., in <i>Lymphokines and</i></entry><entry>cancer</entry></row><row><entry/><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Interferons: A Practical Approach</i>,</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune cells</entry><entry>Clemens et al., eds, IRL Press,</entry></row><row><entry/><entry/><entry/><entry>(e.g., T helper cells, B cells, eosinophils,</entry><entry>Washington, D.C. 1987, pp. 221-225;</entry></row><row><entry/><entry/><entry/><entry>and lymphocytes), chemotaxis of</entry><entry>and Yang et at (1989) Blood 74,</entry></row><row><entry/><entry/><entry/><entry>neutrophils and T lymphocytes, and/or</entry><entry>1880-84.</entry></row><row><entry/><entry/><entry/><entry>inhibition of interferons.</entry></row><row><entry>Human IL-9</entry><entry>GenSeq Accession</entry><entry>WO9824904</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be determined</entry><entry>Soluble IL-9 receptor</entry></row><row><entry>receptor protein</entry><entry>W64060</entry><entry/><entry>multifunctional cytokines synthesized by</entry><entry>using assays known in the art:</entry><entry>polypeptides may be</entry></row><row><entry>variant fragment</entry><entry/><entry/><entry>lymphocytes, monocytes, and</entry><entry>Matthews et al., in <i>Lymphokines and</i></entry><entry>useful for inhibiting</entry></row><row><entry/><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Interferons: A Practical Approach</i>,</entry><entry>interleukin activities.</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune cells</entry><entry>Clemens et al., eds, IRL Press,</entry></row><row><entry/><entry/><entry/><entry>(e.g., T helper cells, B cells, eosinophils,</entry><entry>Washington, D.C. 1987, pp. 221-225;</entry></row><row><entry/><entry/><entry/><entry>and lymphocytes), chemotaxis of</entry><entry>and Yang et al (1989) Blood 74,</entry></row><row><entry/><entry/><entry/><entry>neutrophils and T lymphocytes, and/or</entry><entry>1880-84.</entry></row><row><entry/><entry/><entry/><entry>inhibition of interferons.</entry></row><row><entry>Human IL-9</entry><entry>GeneSeq Accession</entry><entry>WO9824904</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be determined</entry><entry>Soluble IL-9 receptor</entry></row><row><entry>receptor protein</entry><entry>W64061</entry><entry/><entry>multifunctional cytokines synthesized by</entry><entry>using assays known in the art:</entry><entry>polypeptides may be</entry></row><row><entry>variant #3.</entry><entry/><entry/><entry>lymphocytes, monocytes, and</entry><entry>Matthews et al., in <i>Lymphokines and</i></entry><entry>useful for inhibiting</entry></row><row><entry/><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Interferons: A Practical Approach</i>,</entry><entry>interleukin activities.</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune cells</entry><entry>Clemens et al., eds, IRL Press,</entry></row><row><entry/><entry/><entry/><entry>(e.g., T helper cells, B cells, eosinophils,</entry><entry>Washington, D.C. 1987, pp. 221-225;</entry></row><row><entry/><entry/><entry/><entry>and lymphocytes), chemotaxis of</entry><entry>and Yang et at (1989) Blood 74,</entry></row><row><entry/><entry/><entry/><entry>neutrophils and T lymphocytes, and/or</entry><entry>1880-84.</entry></row><row><entry/><entry/><entry/><entry>inhibition of interferons.</entry></row><row><entry>Human</entry><entry>GeneSeq Accession</entry><entry>WO9817689</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be determined</entry><entry>inflammatory disorders,</entry></row><row><entry>Interleukin-12 p40</entry><entry>W51311</entry><entry/><entry>multifunctional cytokines synthesized by</entry><entry>using assays known in the art:</entry><entry>immunologic disorders,</entry></row><row><entry>protein</entry><entry/><entry/><entry>lymphocytes, monocytes, and</entry><entry>Matthews et al., in <i>Lymphokines and</i></entry><entry>cancer</entry></row><row><entry/><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Interferons: A Practical Approach</i>,</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune cells</entry><entry>Clemens et al., eds, IRL Press,</entry></row><row><entry/><entry/><entry/><entry>(e.g., T helper cells, B cells, eosinophils,</entry><entry>Washington, D.C. 1987, pp. 221-225;</entry></row><row><entry/><entry/><entry/><entry>and lymphocytes), chemotaxis of</entry><entry>and Hori et al (1987), Blood 70,</entry></row><row><entry/><entry/><entry/><entry>neutrophils and T lymphocytes, and/or</entry><entry>1069-1078.</entry></row><row><entry/><entry/><entry/><entry>inhibition of interferons.</entry></row><row><entry>Human</entry><entry>GeneSeq Accession</entry><entry>WO9817689</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be determined</entry><entry>inflammatory disorders,</entry></row><row><entry>Interleukin-12 p35</entry><entry>W51312</entry><entry/><entry>multifunctional cytokines synthesized by</entry><entry>using assays known in the art:</entry><entry>immunologic disorders,</entry></row><row><entry>protein</entry><entry/><entry/><entry>lymphocytes, monocytes, and</entry><entry>Matthews et al., in <i>Lymphokines and</i></entry><entry>cancer</entry></row><row><entry/><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Interferons: A Practical Approach</i>,</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune cells</entry><entry>Clemens et al., eds, IRL Press,</entry></row><row><entry/><entry/><entry/><entry>(e.g., T helper cells, B cells, eosinophils,</entry><entry>Washington, D.C. 1987, pp. 221-225;</entry></row><row><entry/><entry/><entry/><entry>and lymphocytes), chemotaxis of</entry><entry>and Hori et al (1987), Blood 70,</entry></row><row><entry/><entry/><entry/><entry>neutrophils and T lymphocytes, and/or</entry><entry>1069-1078.</entry></row><row><entry/><entry/><entry/><entry>inhibition of interferons.</entry></row><row><entry>Human protein</entry><entry>GeneSeq Accession</entry><entry>DE19649233-</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be determined</entry><entry>inflammatory disorders,</entry></row><row><entry>with IL-16 activity</entry><entry>W63753</entry><entry/><entry>multifunctional cytokines synthesized by</entry><entry>using assays known in the art:</entry><entry>immunologic disorders,</entry></row><row><entry/><entry/><entry/><entry>lymphocytes, monocytes, and</entry><entry>Matthews et al., in <i>Lymphokines and</i></entry><entry>cancer</entry></row><row><entry/><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Interferons: A Practical Approach</i>,</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune cells</entry><entry>Clemens et al., eds, IRL Press,</entry></row><row><entry/><entry/><entry/><entry>(e.g., T helper cells, B cells, eosinophils,</entry><entry>Washington, D.C. 1987, pp. 221-225;</entry></row><row><entry/><entry/><entry/><entry>and lymphocytes), chemotaxis of</entry><entry>and Lim et al (1996) J. Immunol. 156,</entry></row><row><entry/><entry/><entry/><entry>neutrophils and T lymphocytes, and/or</entry><entry>2566-70.</entry></row><row><entry/><entry/><entry/><entry>inhibition of interferons.</entry></row><row><entry>Human protein</entry><entry>GeneSeq Accession</entry><entry>DE19649233-</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be determined</entry><entry>inflammatory disorders,</entry></row><row><entry>with IL-16 activity</entry><entry>W59425</entry><entry/><entry>multifunctional cytokines synthesized by</entry><entry>using assays known in the art:</entry><entry>immunologic disorders,</entry></row><row><entry/><entry/><entry/><entry>lymphocytes, monocytes, and</entry><entry>Matthews et al., in <i>Lymphokines and</i></entry><entry>cancer</entry></row><row><entry/><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Interferons: A Practical Approach</i>,</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune cells</entry><entry>Clemens et al., eds, IRL Press,</entry></row><row><entry/><entry/><entry/><entry>(e.g., T helper cells, B cells, eosinophils,</entry><entry>Washington, D.C. 1987, pp. 221-225;</entry></row><row><entry/><entry/><entry/><entry>and lymphocytes), chemotaxis of</entry><entry>and Lim et al (1996) J. Immunol. 156,</entry></row><row><entry/><entry/><entry/><entry>neutrophils and T lymphocytes, and/or</entry><entry>2566-70.</entry></row><row><entry/><entry/><entry/><entry>inhibition of interferons.</entry></row><row><entry>Human</entry><entry>GeneSeq Accession</entry><entry>U.S. Pat. No. 5,747,024</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be determined</entry><entry>inflammatory disorders,</entry></row><row><entry>interleukin-15</entry><entry>W53878</entry><entry/><entry>multifunctional cytokines synthesized by</entry><entry>using assays known in the art:</entry><entry>immunologic disorders,</entry></row><row><entry/><entry/><entry/><entry>lymphocytes, monocytes, and</entry><entry>Matthews et al., in <i>Lymphokines and</i></entry><entry>cancer</entry></row><row><entry/><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Interferons: A Practical Approach</i>,</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune cells</entry><entry>Clemens et al., eds, IRL Press,</entry></row><row><entry/><entry/><entry/><entry>(e.g., T helper cells, B cells, eosinophils,</entry><entry>Washington, D.C. 1987, pp. 221-225;</entry></row><row><entry/><entry/><entry/><entry>and lymphocytes), chemotaxis of</entry><entry>and Giri et al (1994) EMBO J. 13</entry></row><row><entry/><entry/><entry/><entry>neutrophils and T lymphocytes, and/or</entry><entry>2822-2830.</entry></row><row><entry/><entry/><entry/><entry>inhibition of interferons.</entry></row><row><entry>Human wild-type</entry><entry>GeneSeq Accession</entry><entry>WO9747744</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be determined</entry><entry>inflammatory disorders,</entry></row><row><entry>interleukin-4 (hIL-</entry><entry>W52149</entry><entry/><entry>multifunctional cytokines synthesized by</entry><entry>using assays known in the art:</entry><entry>immunologic disorders,</entry></row><row><entry>4) protein</entry><entry/><entry/><entry>lymphocytes, monocytes, and</entry><entry>Matthews et al., in <i>Lymphokines and</i></entry><entry>cancer</entry></row><row><entry/><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Interferons: A Practical Approach</i>,</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune cells</entry><entry>Clemens et al., eds, IRL Press,</entry></row><row><entry/><entry/><entry/><entry>(e.g., T helper cells, B cells, eosinophils,</entry><entry>Washington, D.C. 1987, pp. 221-225;</entry></row><row><entry/><entry/><entry/><entry>and lymphocytes), chemotaxis of</entry><entry>and Siegel &#x26; Mostowski (1990) J</entry></row><row><entry/><entry/><entry/><entry>neutrophils and T lymphocytes, and/or</entry><entry>Immunol Methods 132, 287-295.</entry></row><row><entry/><entry/><entry/><entry>inhibition of interferons.</entry></row><row><entry>interleukin-4</entry><entry>GeneSeq Accessions</entry><entry>WO9747744</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be determined</entry><entry>inflammatory disorders,</entry></row><row><entry>muteins</entry><entry>W52150, W52151,</entry><entry/><entry>multifunctional cytokines synthesized by</entry><entry>using assays known in the art:</entry><entry>immunologic disorders,</entry></row><row><entry/><entry>W52153, W52154,</entry><entry/><entry>lymphocytes, monocytes, and</entry><entry>Matthews et al., in <i>Lymphokines and</i></entry><entry>cancer</entry></row><row><entry/><entry>W52155, W52156,</entry><entry/><entry>macrophages. Known functions include</entry><entry><i>Interferons: A Practical Approach</i>,</entry></row><row><entry/><entry>W52157, W52158,</entry><entry/><entry>stimulating proliferation of immune cells</entry><entry>Clemens et al., eds, IRL Press,</entry></row><row><entry/><entry>W52159, W52160,</entry><entry/><entry>(e.g., T helper cells, B cells, eosinophils,</entry><entry>Washington, D.C. 1987, pp. 221-225;</entry></row><row><entry/><entry>W52161, W52162,</entry><entry/><entry>and lymphocytes), chemotaxis of</entry><entry>and Siegel &#x26; Mostowski (1990) J</entry></row><row><entry/><entry>W52163, W52164,</entry><entry/><entry>neutrophils and T lymphocytes, and/or</entry><entry>Immunol Methods 132, 287-295.</entry></row><row><entry/><entry>W52165, W52166,</entry><entry/><entry>inhibition of interferons.</entry></row><row><entry/><entry>and W52167</entry></row><row><entry>Human interleukin</entry><entry>GeneSeq Accession</entry><entry>WO9935268</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be determined</entry><entry>inflammatory disorders,</entry></row><row><entry>1 delta</entry><entry>Y28408</entry><entry/><entry>multifunctional cytokines synthesized by</entry><entry>using assays known in the art:</entry><entry>immunologic disorders,</entry></row><row><entry/><entry/><entry/><entry>lymphocytes, monocytes, and</entry><entry>Matthews et al., in <i>Lymphokines and</i></entry><entry>cancer</entry></row><row><entry/><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Interferons: A Practical Approach</i>,</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune cells</entry><entry>Clemens et al., eds, IRL Press,</entry></row><row><entry/><entry/><entry/><entry>(e.g., T helper cells, B cells, eosinophils,</entry><entry>Washington, D.C. 1987, pp. 221-225;</entry></row><row><entry/><entry/><entry/><entry>and lymphocytes), chemotaxis of</entry><entry>and Orencole &#x26; Dinarello (1989)</entry></row><row><entry/><entry/><entry/><entry>neutrophils and T lymphocytes, and/or</entry><entry>Cytokine 1, 14-20.</entry></row><row><entry/><entry/><entry/><entry>inhibition of interferons.</entry></row><row><entry>Human</entry><entry>GeneSeq Accession</entry><entry>WO9935268</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be determined</entry><entry>inflammatory disorders,</entry></row><row><entry>interleukin-1</entry><entry>Y24395</entry><entry/><entry>multifunctional cytokines synthesized by</entry><entry>using assays known in the art:</entry><entry>immunologic disorders,</entry></row><row><entry>receptor antagonist</entry><entry/><entry/><entry>lymphocytes, monocytes, and</entry><entry>Matthews et al., in <i>Lymphokines and</i></entry><entry>cancer</entry></row><row><entry>beta</entry><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Interferons: A Practical Approach</i>,</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune cells</entry><entry>Clemens et al., eds, IRL, Press,</entry></row><row><entry/><entry/><entry/><entry>(e.g., T helper cells, B cells, eosinophils,</entry><entry>Washington, D.C. 1987, pp. 221-225;</entry></row><row><entry/><entry/><entry/><entry>and lymphocytes), chemotaxis of</entry><entry>and Orencole &#x26; Dinarello (1989)</entry></row><row><entry/><entry/><entry/><entry>neutrophils and T lymphocytes, and/or</entry><entry>Cytokine 1, 14-20.</entry></row><row><entry/><entry/><entry/><entry>inhibition of interferons.</entry></row><row><entry>Human EDIRF II</entry><entry>GeneSeq Accession</entry><entry>WO9932632</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be determined</entry><entry>inflammatory disorders,</entry></row><row><entry>protein sequence</entry><entry>Y22199</entry><entry/><entry>multifunctional cytokines synthesized by</entry><entry>using assays known in the art:</entry><entry>immunologic disorders,</entry></row><row><entry/><entry/><entry/><entry>lymphocytes, monocytes, and</entry><entry>Matthews et al., in <i>Lymphokines and</i></entry><entry>cancer</entry></row><row><entry/><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Interferons: A Practical Approach</i>,</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune cells</entry><entry>Clemens et al., eds, IRL Press,</entry></row><row><entry/><entry/><entry/><entry>(e.g., T helper cells, B cells, eosinophils,</entry><entry>Washington, D.C. 1987, pp. 221-225.</entry></row><row><entry/><entry/><entry/><entry>and lymphocytes), chemotaxis of</entry></row><row><entry/><entry/><entry/><entry>neutrophils and T lymphocytes, and/or</entry></row><row><entry/><entry/><entry/><entry>inhibition of interferons.</entry></row><row><entry>Human EDIRF I</entry><entry>GeneSeq Accession</entry><entry>WO9932632</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be determined</entry><entry>inflammatory disorders,</entry></row><row><entry>protein sequence</entry><entry>Y22197</entry><entry/><entry>multifunctional cytokines synthesized by</entry><entry>using assays known in the art:</entry><entry>immunologic disorders,</entry></row><row><entry/><entry/><entry/><entry>lymphocytes, monocytes, and</entry><entry>Matthews et al., in <i>Lymphokines and</i></entry><entry>cancer</entry></row><row><entry/><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Interferons: A Practical Approach</i>,</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune cells</entry><entry>Clemens et al., eds, IRL Press,</entry></row><row><entry/><entry/><entry/><entry>(e.g., T helper cell, B cells, eosinophils,</entry><entry>Washington, D.C. 1987, pp. 221-225.</entry></row><row><entry/><entry/><entry/><entry>and lymphocytes), chemotaxis of</entry></row><row><entry/><entry/><entry/><entry>neutrophils and T lymphocytes, and/or</entry></row><row><entry/><entry/><entry/><entry>inhibition of interferons.</entry></row><row><entry>Human IL-1RD10</entry><entry>GeneSeq Accession</entry><entry>WO9919480</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be determined</entry><entry>Soluble IL-1RD10</entry></row><row><entry>protein sequence</entry><entry>Y14131</entry><entry/><entry>multifunctional cytokines synthesized by</entry><entry>using assays known in the art:</entry><entry>receptor polypeptides</entry></row><row><entry/><entry/><entry/><entry>lymphocytes, monocytes, and</entry><entry>Matthews et al., in <i>Lymphokines and</i></entry><entry>may be useful for</entry></row><row><entry/><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Interferons: A Practical Approach</i>,</entry><entry>inhibiting interleukin</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune cells</entry><entry>Clemens et al., eds, IRL Press,</entry><entry>activites.</entry></row><row><entry/><entry/><entry/><entry>(e.g., T helper cells, B cells, eosinophils,</entry><entry>Washington, D.C. 1987, pp. 221-225;</entry></row><row><entry/><entry/><entry/><entry>and lymphocytes), chemotaxis of</entry><entry>and Orencole &#x26; Dinarello (1989)</entry></row><row><entry/><entry/><entry/><entry>neutrophils and T lymphocytes, and/or</entry><entry>Cytokine 1, 14-20.</entry></row><row><entry/><entry/><entry/><entry>inhibition of interferons.</entry></row><row><entry>Human IL-1RD9</entry><entry>GeneSeq Accession</entry><entry>WO9919480</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be determined</entry><entry>Soluble IL-1RD10</entry></row><row><entry/><entry>Y14122</entry><entry/><entry>multifunctional cytokines synthesized by</entry><entry>using assays known in the art:</entry><entry>receptor polypeptides</entry></row><row><entry/><entry/><entry/><entry>lymphocytes, monocytes, and</entry><entry>Matthews et al., in <i>Lymphokines and</i></entry><entry>may be useful for</entry></row><row><entry/><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Interferons: A Practical Approach</i>,</entry><entry>inhibiting interleukin</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune cells</entry><entry>Clemens et al., eds, IRL Press,</entry><entry>activites.</entry></row><row><entry/><entry/><entry/><entry>(e.g., T helper cells, B cells, eosinophils,</entry><entry>Washington, D.C. 1987, pp. 221-225;</entry></row><row><entry/><entry/><entry/><entry>and lymphocytes), chemotaxis of</entry><entry>and Orencole &#x26; Dinarello (1989)</entry></row><row><entry/><entry/><entry/><entry>neutrophils and T lymphocytes, and/or</entry><entry>Cytokine 1, 14-20.</entry></row><row><entry/><entry/><entry/><entry>inhibition of interferons.</entry></row><row><entry>Human DNAX</entry><entry>GeneSeq Accession</entry><entry>WO9919491</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be determined</entry><entry>inflammatory disorders,</entry></row><row><entry>interleukin-40</entry><entry>Y09196</entry><entry/><entry>multifunctional cytokines synthesized by</entry><entry>using assays known in the art:</entry><entry>immunologic disorders,</entry></row><row><entry/><entry/><entry/><entry>lymphocytes, monocytes, and</entry><entry>Matthews et al., in <i>Lymphokines and</i></entry><entry>cancer</entry></row><row><entry/><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Interferons: A Practical Approach</i>,</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune cells</entry><entry>Clemens et al., eds, IRL Press,</entry></row><row><entry/><entry/><entry/><entry>(e.g., T helper cells, B cells, eosinophils,</entry><entry>Washington, D.C. 1987, pp. 221-225.</entry></row><row><entry/><entry/><entry/><entry>and lymphocytes), chemotaxis of</entry></row><row><entry/><entry/><entry/><entry>neutrophils and T lymphocytes, and/or</entry></row><row><entry/><entry/><entry/><entry>inhibition of interferons.</entry></row><row><entry>(DIL-40)</entry><entry>GeneSeq Accession</entry><entry>WO9919491</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be determined</entry><entry>inflammatory disorders,</entry></row><row><entry>alternative</entry><entry>Y09197</entry><entry/><entry>multifunctional cytokines synthesized by</entry><entry>using assays known in the art:</entry><entry>immunologic disorders,</entry></row><row><entry>sequence</entry><entry/><entry/><entry>lymphocytes, monocytes, and</entry><entry>Matthews et al., in <i>Lymphokines and</i></entry><entry>cancer</entry></row><row><entry/><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Interferons: A Practical Approach</i>,</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune cells</entry><entry>Clemens et al., eds, IRL Press,</entry></row><row><entry/><entry/><entry/><entry>(e.g., T helper cells, B cells, eosinophils,</entry><entry>Washington, D.C. 1987, pp. 221-225.</entry></row><row><entry/><entry/><entry/><entry>and lymphocytes), chemotaxis of</entry></row><row><entry/><entry/><entry/><entry>neutrophils and T lymphocytes, and/or</entry></row><row><entry/><entry/><entry/><entry>inhibition of interferons.</entry></row><row><entry>IL-11</entry><entry>GeneSeq Accession</entry><entry>WO9405318</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be determined</entry><entry>inflammatory disorders,</entry></row><row><entry/><entry>R50176</entry><entry/><entry>multifunctional cytokines synthesized by</entry><entry>using assays known in the art:</entry><entry>immunologic disorders,</entry></row><row><entry/><entry/><entry/><entry>lymphocytes, monocytes, and</entry><entry>Matthews et al., in <i>Lymphokines and</i></entry><entry>cancer</entry></row><row><entry/><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Interferons: A Practical Approach</i>,</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune cells</entry><entry>Clemens et al., eds, IRL Press,</entry></row><row><entry/><entry/><entry/><entry>(e.g., T helper cells, B cells, eosinophils,</entry><entry>Washington, D.C. 1987, pp. 221-225;</entry></row><row><entry/><entry/><entry/><entry>and lymphocytes), chemotaxis of</entry><entry>and Lu et al (1994) J immunol.</entry></row><row><entry/><entry/><entry/><entry>neutrophils and T lymphocytes, and/or</entry><entry>Methods 173, 19.</entry></row><row><entry/><entry/><entry/><entry>inhibition of interferons.</entry></row><row><entry>Human</entry><entry>GeneSeq Accession</entry><entry>EP566410</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be determined</entry><entry>inflammatory disorders,</entry></row><row><entry>adipogenesis</entry><entry>R43260</entry><entry/><entry>multifunctional cytokines synthesized by</entry><entry>using assays known in the art:</entry><entry>immunologic disorders,</entry></row><row><entry>inhibitory factor</entry><entry/><entry/><entry>lymphocytes, monocytes, and</entry><entry>Matthews et al., in <i>Lymphokines and</i></entry><entry>cancer</entry></row><row><entry/><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Interferons: A Practical Approach</i>,</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune cells</entry><entry>Clemens et al., eds, IRL Press,</entry></row><row><entry/><entry/><entry/><entry>(e.g., T helper cells, B cells, eosinophils,</entry><entry>Washington, D.C. 1987, pp. 221-225.</entry></row><row><entry/><entry/><entry/><entry>and lymphocytes), chemotaxis of</entry></row><row><entry/><entry/><entry/><entry>neutrophils and T lymphocytes, and/or</entry></row><row><entry/><entry/><entry/><entry>inhibition of interferons.</entry></row><row><entry>IL-11</entry><entry>GeneSeq Accession</entry><entry>JP08127539</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be determined</entry><entry>inflammatory disorders,</entry></row><row><entry/><entry>W02202</entry><entry/><entry>multifunctional cytokines synthesized by</entry><entry>using assays known in the art:</entry><entry>immunologic disorders,</entry></row><row><entry/><entry/><entry/><entry>lymphocytes, monocytes, and</entry><entry>Matthews et al., in <i>Lymphokines and</i></entry><entry>cancer</entry></row><row><entry/><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Interferons: A Practical Approach</i>,</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune cells</entry><entry>Clemens et al., eds, IRL Press,</entry></row><row><entry/><entry/><entry/><entry>(e.g., T helper cells, B cells, eosinophils,</entry><entry>Washington, D.C. 1987, pp. 221-225;</entry></row><row><entry/><entry/><entry/><entry>and lymphocytes), chemotaxis of</entry><entry>and Lu et al (1994) J immunol.</entry></row><row><entry/><entry/><entry/><entry>neutrophils and T lymphocytes, and/or</entry><entry>Methods 173, 19.</entry></row><row><entry/><entry/><entry/><entry>inhibition of interferons.</entry></row><row><entry>IL-14</entry><entry>GeneSeq Accession</entry><entry>WO9416074</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be determined</entry><entry>inflammatory disorders,</entry></row><row><entry/><entry>R55800</entry><entry/><entry>multifunctional cytokines synthesized by</entry><entry>using assays known in the art:</entry><entry>immunologic disorders,</entry></row><row><entry/><entry/><entry/><entry>lymphocytes, monocytes, and</entry><entry>Matthews et al., in <i>Lymphokines and</i></entry><entry>cancer</entry></row><row><entry/><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Interferons: A Practical Approach</i>,</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune cells</entry><entry>Clemens et al., eds, IRL Press,</entry></row><row><entry/><entry/><entry/><entry>(e.g., T helper cells, B cells, eosinophils,</entry><entry>Washington, D.C. 1987, pp. 221-225;</entry></row><row><entry/><entry/><entry/><entry>and lymphocytes), chemotaxis of</entry><entry>and Ambrus et al (1993) PNAS 90,</entry></row><row><entry/><entry/><entry/><entry>neutrophils and T lymphocytes, and/or</entry><entry>63330-34.</entry></row><row><entry/><entry/><entry/><entry>inhibition of interferons.</entry></row><row><entry>IL-17 receptor</entry><entry>GeneSeq Accession</entry><entry>U.S. Pat. No. 6,072,033</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be determined</entry><entry>Soluble IL-17 receptor</entry></row><row><entry/><entry>B03807</entry><entry/><entry>multifunctional cytokines synthesized by</entry><entry>using assays known in the art:</entry><entry>polypeptides may be</entry></row><row><entry/><entry/><entry/><entry>lymphocytes, monocytes, and</entry><entry>Matthews et al., in <i>Lymphokines and</i></entry><entry>useful for inhibiting</entry></row><row><entry/><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Interferons: A Practical Approach</i>,</entry><entry>interleukin activities.</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune cells</entry><entry>Clemens et al., eds, IRL Press,</entry></row><row><entry/><entry/><entry/><entry>(e.g., T helper cells, B cells, eosinophils,</entry><entry>Washington, D.C. 1987, pp. 221-225;</entry></row><row><entry/><entry/><entry/><entry>and lymphocytes), chemotaxis of</entry><entry>and Yao et al (1995) J. Immunol. 155,</entry></row><row><entry/><entry/><entry/><entry>neutrophils and T lymphocytes, and/or</entry><entry>5483-86.</entry></row><row><entry/><entry/><entry/><entry>inhibition of interferons.</entry></row><row><entry>IL-17</entry><entry>GeneSeq Accession</entry><entry>WO9518826</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be determined</entry><entry>inflammatory disorders,</entry></row><row><entry/><entry>R76573</entry><entry/><entry>multifunctional cytokines synthesized by</entry><entry>using assays known in the art:</entry><entry>immunologic disorders,</entry></row><row><entry/><entry/><entry/><entry>lymphocytes, monocytes, and</entry><entry>Matthews et al., in <i>Lymphokines and</i></entry><entry>cancer</entry></row><row><entry/><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Interferons: A Practical Approach</i>,</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune cells</entry><entry>Clemens et al., eds, IRL Press,</entry></row><row><entry/><entry/><entry/><entry>(e.g., T helper cells, B cells, eosinophils,</entry><entry>Washington, D.C. 1987, pp. 221-225;</entry></row><row><entry/><entry/><entry/><entry>and lymphocytes), chemotaxis of</entry><entry>and Yao et al (1995) J. Immunol. 155,</entry></row><row><entry/><entry/><entry/><entry>neutrophils and T lymphocytes, and/or</entry><entry>5483-86.</entry></row><row><entry/><entry/><entry/><entry>inhibition of interferons.</entry></row><row><entry>CTLA-8</entry><entry>GeneSeq Accession</entry><entry>WO9704097</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be determined</entry><entry>inflammatory disorders,</entry></row><row><entry/><entry>W13651</entry><entry/><entry>multifunctional cytokines synthesized by</entry><entry>using assays known in the art:</entry><entry>immunologic disorders,</entry></row><row><entry/><entry/><entry/><entry>lymphocytes, monocytes, and</entry><entry>Matthews et al., in <i>Lymphokines and</i></entry><entry>cancer</entry></row><row><entry/><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Interferons: A Practical Approach</i>,</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune cells</entry><entry>Clemens et al., eds, IRL Press,</entry></row><row><entry/><entry/><entry/><entry>(e.g., T helper cells, B cells, eosinophils,</entry><entry>Washington, D.C. 1987, pp. 221-225.</entry></row><row><entry/><entry/><entry/><entry>and lymphocytes), chemotaxis of</entry></row><row><entry/><entry/><entry/><entry>neutrophils and T lymphocytes, and/or</entry></row><row><entry/><entry/><entry/><entry>inhibition of interferons.</entry></row><row><entry>IL-19</entry><entry>GeneSeq Accession</entry><entry>WO9808870</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be determined</entry><entry>inflammatory disorders,</entry></row><row><entry/><entry>W37935</entry><entry/><entry>multifunctional cytokines synthesized by</entry><entry>using assays known in the art:</entry><entry>immunologic disorders,</entry></row><row><entry/><entry/><entry/><entry>lymphocytes, monocytes, and</entry><entry>Matthews et al., in <i>Lymphokines and</i></entry><entry>cancer</entry></row><row><entry/><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Interferons: A Practical Approach</i>,</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune cells</entry><entry>Clemens et al., eds, IRL Press,</entry></row><row><entry/><entry/><entry/><entry>(e.g., T helper cells, B cells, eosinophils,</entry><entry>Washington, D.C. 1987, pp. 221-225;</entry></row><row><entry/><entry/><entry/><entry>and lymphocytes), chemotaxis of</entry><entry>and Gallagher et al (2000) Genes</entry></row><row><entry/><entry/><entry/><entry>neutrophils and T lymphocytes, and/or</entry><entry>Immun. 1, 442-50.</entry></row><row><entry/><entry/><entry/><entry>inhibition of interferons.</entry></row><row><entry>IL-21 (TIF)</entry><entry>GeneSeq Accession</entry><entry>WO0024758</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be determined</entry><entry>inflammatory disorders,</entry></row><row><entry/><entry>Y92879</entry><entry/><entry>multifunctional cytokines synthesized by</entry><entry>using assays known in the art:</entry><entry>immunologic disorders,</entry></row><row><entry/><entry/><entry/><entry>lymphocytes, monocytes, and</entry><entry>Matthews et al., in <i>Lymphokines and</i></entry><entry>cancer</entry></row><row><entry/><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Interferons: A Practical Approach</i>,</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune cells</entry><entry>Clemens et al., eds, IRL Press,</entry></row><row><entry/><entry/><entry/><entry>(e.g., T helper cells, B cells, eosinophils,</entry><entry>Washington, D.C. 1987, pp. 221-225;</entry></row><row><entry/><entry/><entry/><entry>and lymphocytes), chemotaxis of</entry><entry>and Parrish-Novak et al (2000)</entry></row><row><entry/><entry/><entry/><entry>neutrophils and T lymphocytes, and/or</entry><entry>Nature 408, 57-63.</entry></row><row><entry/><entry/><entry/><entry>inhibition of interferons.</entry></row><row><entry>IL-8 receptor</entry><entry>GeneSeq Accession</entry><entry>WO9306229</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be determined</entry><entry>Soluble IL-8 receptor</entry></row><row><entry/><entry>R33420</entry><entry/><entry>multifunctional cytokines synthesized by</entry><entry>using assays known in the art:</entry><entry>polypeptides may be</entry></row><row><entry/><entry/><entry/><entry>lymphocytes, monocytes, and</entry><entry>Matthews et al., in <i>Lymphokines and</i></entry><entry>useful for inhibiting</entry></row><row><entry/><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Interferons: A Practical Approach</i>,</entry><entry>interleukin activities.</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune cells</entry><entry>Clemens et al., eds, IRL Press,</entry></row><row><entry/><entry/><entry/><entry>(e.g., T helper cells, B cells, eosinophils,</entry><entry>Washington, D.C. 1987, pp. 221-225;</entry></row><row><entry/><entry/><entry/><entry>and lymphocytes), chemotaxis of</entry><entry>and Holmes et al (1991) Science 253,</entry></row><row><entry/><entry/><entry/><entry>neutrophils and T lymphocytes, and/or</entry><entry>1278-80.</entry></row><row><entry/><entry/><entry/><entry>inhibition of interferons.</entry></row><row><entry>Human type II</entry><entry>GeneSeq Accession</entry><entry>U.S. Pat. No. 5,464,937</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be determined</entry><entry>Soluble type II</entry></row><row><entry>interleukin-1</entry><entry>R85480</entry><entry/><entry>multifunctional cytokines synthesized by</entry><entry>using assays known in the art:</entry><entry>interleukin-1 receptor</entry></row><row><entry>receptor</entry><entry/><entry/><entry>lymphocytes, monocytes, and</entry><entry>Matthews et al., in <i>Lymphokines and</i></entry><entry>polypeptides may be</entry></row><row><entry/><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Interferons: A Practical Approach</i>,</entry><entry>useful for inhibiting</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune cells</entry><entry>Clemens et al., eds. IRL Press,</entry><entry>interleukin activities.</entry></row><row><entry/><entry/><entry/><entry>(e.g., T helper cells, B cells, eosinophils,</entry><entry>Washington, D.C. 1987, pp. 221-225;</entry></row><row><entry/><entry/><entry/><entry>and lymphocytes), chemotaxis of</entry><entry>and Orencole &#x26; Dinarello (1989)</entry></row><row><entry/><entry/><entry/><entry>neutrophils and T lymphocytes, and/or</entry><entry>Cytokine 1, 14-20.</entry></row><row><entry/><entry/><entry/><entry>inhibition of interferons.</entry></row><row><entry>Human</entry><entry>GeneSeq Accession</entry><entry>EP638644</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be determined</entry><entry>Soluble IL-12 receptor</entry></row><row><entry>interleukin-12</entry><entry>R69632</entry><entry/><entry>multifunctional cytokines synthesized by</entry><entry>using assays known in the art:</entry><entry>polypeptides may be</entry></row><row><entry>receptor</entry><entry/><entry/><entry>lymphocytes, monocytes, and</entry><entry>Matthews et al., in <i>Lymphokines and</i></entry><entry>useful for inhibiting</entry></row><row><entry/><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Interferons: A Practical Approach</i>,</entry><entry>interleukin activities.</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune cells</entry><entry>Clemens et al., eds, IRL Press,</entry></row><row><entry/><entry/><entry/><entry>(e.g., T helper cells, B cells, eosinophils,</entry><entry>Washington, D.C. 1987, pp. 221-225;</entry></row><row><entry/><entry/><entry/><entry>and lymphocytes), chemotaxis of</entry><entry>and Hori et al (1987), Blood 70,</entry></row><row><entry/><entry/><entry/><entry>neutrophils and T lymphocytes, and/or</entry><entry>1069-1078.</entry></row><row><entry/><entry/><entry/><entry>inhibition of interferons.</entry></row><row><entry>Interleukin 8</entry><entry>GeneSeq Accession</entry><entry>U.S. Pat. No. 5,440,021</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be determined</entry><entry>Soluble IL-8 receptor B</entry></row><row><entry>receptor B</entry><entry>R80758</entry><entry/><entry>multifunctional cytokines synthesized by</entry><entry>using assays known in the art:</entry><entry>polypeptides may be</entry></row><row><entry/><entry/><entry/><entry>lymphocytes, monocytes, and</entry><entry>Matthews et al., in <i>Lymphokines and</i></entry><entry>useful for inhibiting</entry></row><row><entry/><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Interferons: A Practical Approach</i>,</entry><entry>interleukin activities.</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune cells</entry><entry>Clemens et al., eds, IRL Press,</entry></row><row><entry/><entry/><entry/><entry>(e.g., T helper cells, B cells, eosinophils,</entry><entry>Washington, D.C. 1987, pp. 221-225;</entry></row><row><entry/><entry/><entry/><entry>and lymphocytes), chemotaxis of</entry><entry>and Holmes et al (1991) Science 253,</entry></row><row><entry/><entry/><entry/><entry>neutrophils and T lymphocytes, and/or</entry><entry>1278-80.</entry></row><row><entry/><entry/><entry/><entry>inhibition of interferons.</entry></row><row><entry>Human IL-8</entry><entry>GeneSeq Accession</entry><entry>JP08103276</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be determined</entry><entry>Soluble IL-8 receptor A</entry></row><row><entry>receptor protein</entry><entry>B09989</entry><entry/><entry>multifunctional cytokines synthesized by</entry><entry>using assays known in the art:</entry><entry>polypeptides may be</entry></row><row><entry>hIL8RA</entry><entry/><entry/><entry>lymphocytes, monocytes, and</entry><entry>Matthews et al., in <i>Lymphokines and</i></entry><entry>useful for inhibiting</entry></row><row><entry/><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Interferons: A Practical Approach</i>,</entry><entry>interleukin activities.</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune cells</entry><entry>Clemens et al., eds, IRL Press,</entry></row><row><entry/><entry/><entry/><entry>(e.g., T helper cells, B cells, eosinophils,</entry><entry>Washington, D.C. 1987, pp. 221-225;</entry></row><row><entry/><entry/><entry/><entry>and lymphocytes), chemotaxis of</entry><entry>and Holmes et al (1991) Science 253,</entry></row><row><entry/><entry/><entry/><entry>neutrophils and T lymphocytes, and/or</entry><entry>1278-80.</entry></row><row><entry/><entry/><entry/><entry>inhibition of interferons.</entry></row><row><entry>Human IL-8</entry><entry>GeneSeq Accession</entry><entry>JP08103276</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be</entry><entry>Soluble IL-8 receptor</entry></row><row><entry>receptor protein</entry><entry>B09990</entry><entry/><entry>multifunctional cytokines synthesized</entry><entry>determined using asays known in the</entry><entry>polypeptides may be</entry></row><row><entry>hIL8R</entry><entry/><entry/><entry>by lymphocytes, monocytes, and</entry><entry>art: Matthews et al., in <i>Lymphokines</i></entry><entry>useful for inhibiting</entry></row><row><entry/><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>and Interferons: A Practical</i></entry><entry>interleukin activities.</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune</entry><entry><i>Approach</i>, Clemens et al., eds, IRL</entry></row><row><entry/><entry/><entry/><entry>cells (e.g., T helper cells, B cells,</entry><entry>Press, Washington, D.C. 1987, pp.</entry></row><row><entry/><entry/><entry/><entry>eosinophils, and lymphocytes),</entry><entry>221-225; and Holmes et al (1991)</entry></row><row><entry/><entry/><entry/><entry>chemotaxis of neutrophils and T</entry><entry>Science 253, 1278-80.</entry></row><row><entry/><entry/><entry/><entry>lymphocytes, and/or inhibition of</entry></row><row><entry/><entry/><entry/><entry>interferons.</entry></row><row><entry>Interleukin-2</entry><entry>GeneSeq Accession</entry><entry>WO9621732</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be</entry><entry>Soluble IL-2 receptor</entry></row><row><entry>receptor associated</entry><entry>R97569</entry><entry/><entry>multifunctional cytokines synthesized</entry><entry>determined using assays known in</entry><entry>polypeptides may be</entry></row><row><entry>protein p43</entry><entry/><entry/><entry>by lymphocytes, monocytes, and</entry><entry>the art: Matthews et al., in</entry><entry>useful for inhibiting</entry></row><row><entry/><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Lymphokines and Interferons: A</i></entry><entry>interleukin activities.</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune</entry><entry><i>Practical Approach</i>, Clemens et al.,</entry></row><row><entry/><entry/><entry/><entry>cells (e.g., T helper cells, B cells,</entry><entry>eds, IRL Press, Washington, D.C.</entry></row><row><entry/><entry/><entry/><entry>eosinophils, and lymphocytes),</entry><entry>1987, pp. 221-225; and Gillis et al</entry></row><row><entry/><entry/><entry/><entry>chemotaxis of neutrophils and T</entry><entry>(1978) J. Immunol. 120, 2027.</entry></row><row><entry/><entry/><entry/><entry>lymphocytes, and/or inhibition of</entry></row><row><entry/><entry/><entry/><entry>interferons.</entry></row><row><entry>Human</entry><entry>GeneSeq Accession</entry><entry>WO9629408</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be</entry><entry>Soluble IL-17 receptor</entry></row><row><entry>interleukin-17</entry><entry>W04185</entry><entry/><entry>multifunctional cytokines synthesized</entry><entry>determined using assays known in</entry><entry>polypeptides may be</entry></row><row><entry>receptor</entry><entry/><entry/><entry>by lymphocytes, monocytes, and</entry><entry>the art: Matthews et al., in</entry><entry>useful for inhibiting</entry></row><row><entry/><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Lymphokines and Interferons: A</i></entry><entry>interleukin activities.</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune</entry><entry><i>Practical Approach</i>, Clemens et al.,</entry></row><row><entry/><entry/><entry/><entry>cells (e.g., T helper cells, B cells,</entry><entry>eds, IRL Press, Washington, D.C.</entry></row><row><entry/><entry/><entry/><entry>eosinophils, and lymphocytes),</entry><entry>1987, pp. 221-225; and Yao et al</entry></row><row><entry/><entry/><entry/><entry>chemotaxis of neutrophils and T</entry><entry>(1995) J. Immunol. 155, 5483-86.</entry></row><row><entry/><entry/><entry/><entry>lymphocytes, and/or inhibition of</entry></row><row><entry/><entry/><entry/><entry>interferons.</entry></row><row><entry>Human</entry><entry>GeneSeq Accession</entry><entry>WO9619574</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be</entry><entry>Soluble IL-11 receptor</entry></row><row><entry>interleukin-11</entry><entry>R99090</entry><entry/><entry>multifunctional cytokines synthesized</entry><entry>determined using assays known in</entry><entry>polypeptides may be</entry></row><row><entry>receptor</entry><entry/><entry/><entry>by lymphocytes, monocytes, and</entry><entry>the art: Matthews et al., in</entry><entry>useful for inhibiting</entry></row><row><entry/><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Lymphokines and Interferons: A</i></entry><entry>interleukin activities.</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune</entry><entry><i>Practical Approach</i>, Clemens et al.,</entry></row><row><entry/><entry/><entry/><entry>cells (e.g., T helper cells, B cells,</entry><entry>eds, IRL Press, Washington, D.C.</entry></row><row><entry/><entry/><entry/><entry>eosinophils, and lymphocytes),</entry><entry>1987, pp. 221-225; and Lu et al</entry></row><row><entry/><entry/><entry/><entry>chemotaxis of neutrophils and T</entry><entry>(1994) J immunol. Methods 173, 19.</entry></row><row><entry/><entry/><entry/><entry>lymphocytes, and/or inhibition of</entry></row><row><entry/><entry/><entry/><entry>interferons.</entry></row><row><entry>Human</entry><entry>GeneSeq Accession</entry><entry>WO9623067</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be</entry><entry>Inflammatory disorders,</entry></row><row><entry>interleukin-1</entry><entry>W01911</entry><entry/><entry>multifunctional cytokines synthesized</entry><entry>determined using assays known in</entry><entry>immunologic disorders,</entry></row><row><entry>receptor accessory</entry><entry/><entry/><entry>by lymphocytes, monocytes, and</entry><entry>the art: Matthews et al., in</entry><entry>cancer</entry></row><row><entry>protein</entry><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Lymphokines and Interferons: A</i></entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune</entry><entry><i>Practical Approach</i>, Clemens et al.,</entry></row><row><entry/><entry/><entry/><entry>cells (e.g., T helper cells, B cells,</entry><entry>eds, IRL Press, Washington, D.C.</entry></row><row><entry/><entry/><entry/><entry>eosinophils, and lymphocytes),</entry><entry>1987, pp. 221-225; and Orencole &#x26;</entry></row><row><entry/><entry/><entry/><entry>chemotaxis of neutrophils and T</entry><entry>Dinarello (1989) Cytokine 1, 14-20.</entry></row><row><entry/><entry/><entry/><entry>lymphocytes, and/or inhibition of</entry></row><row><entry/><entry/><entry/><entry>interferons.</entry></row><row><entry>AGF Protein</entry><entry>GeneSeq Accession</entry><entry>U.S. Pat. No. 5,488,032</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be</entry><entry>Inflammatory disorders,</entry></row><row><entry/><entry>R92749</entry><entry/><entry>multifunctional cytokines synthesized</entry><entry>determined using assays known in</entry><entry>immunologic disorders,</entry></row><row><entry/><entry/><entry/><entry>by lymphocytes, monocytes, and</entry><entry>the art: Matthews et al., in</entry><entry>cancer</entry></row><row><entry/><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Lymphokines and Interferons: A</i></entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune</entry><entry><i>Practical Approach</i>, Clemens et al.,</entry></row><row><entry/><entry/><entry/><entry>cells (e.g., T helper cells, B cells,</entry><entry>eds, IRL Press, Washington, D.C.</entry></row><row><entry/><entry/><entry/><entry>eosinophils, and lymphocytes),</entry><entry>1987, pp. 221-225.</entry></row><row><entry/><entry/><entry/><entry>chemotaxis of neutrophils and T</entry></row><row><entry/><entry/><entry/><entry>lymphocytes, and/or inhibition of</entry></row><row><entry/><entry/><entry/><entry>interferons.</entry></row><row><entry>Human</entry><entry>GeneSeq Accession</entry><entry>W09607739</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be</entry><entry>Soluble IL-type-3</entry></row><row><entry>interleukin-1 type-</entry><entry>R91064</entry><entry/><entry>multifunctional cytokines synthesized</entry><entry>determined using assays known in</entry><entry>receptor polypeptides</entry></row><row><entry>3 receptor</entry><entry/><entry/><entry>by lymphocytes, monocytes, and</entry><entry>the art: Matthews et al., in</entry><entry>may be useful for</entry></row><row><entry/><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Lymphokines and Interferons: A</i></entry><entry>inhibiting interleukin</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune</entry><entry><i>Practical Approach</i>, Clemens et al.,</entry><entry>activities</entry></row><row><entry/><entry/><entry/><entry>cells (e.g., T helper cells, B cells,</entry><entry>eds, IRL Press, Washington, D.C.</entry></row><row><entry/><entry/><entry/><entry>eosinophils, and lymphocytes),</entry><entry>1987, pp. 221-225; and Orencole &#x26;</entry></row><row><entry/><entry/><entry/><entry>chemotaxis of neutrophils and T</entry><entry>Dinarello (1989) Cytokine 1, 14-20.</entry></row><row><entry/><entry/><entry/><entry>lymphocytes, and/or inhibition of</entry></row><row><entry/><entry/><entry/><entry>interferons.</entry></row><row><entry>Human</entry><entry>GeneSeq Accession</entry><entry>WO9720926</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be</entry><entry>Soluble IL-13 beta</entry></row><row><entry>interleukin-13 beta</entry><entry>W24972</entry><entry/><entry>multifunctional cytokines synthesized</entry><entry>determined using assays known in</entry><entry>receptor polypeptides</entry></row><row><entry>receptor</entry><entry/><entry/><entry>by lymphocytes, monocytes, and</entry><entry>the art: Matthews et al., in</entry><entry>may be useful for</entry></row><row><entry/><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Lymphokines and Interferons: A</i></entry><entry>inhibiting interleukin</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune</entry><entry><i>Practical Approach</i>, Clemens et al.,</entry><entry>activities.</entry></row><row><entry/><entry/><entry/><entry>cells (e.g., T helper cells, B cells,</entry><entry>eds, IRL Press, Washington, D.C.</entry></row><row><entry/><entry/><entry/><entry>eosinophils, and lymphocytes),</entry><entry>1987, pp. 221-225; and Boutelier et</entry></row><row><entry/><entry/><entry/><entry>chemotaxis of neutrophils and T</entry><entry>al (1995) J. Immunol. Methods</entry></row><row><entry/><entry/><entry/><entry>lymphocytes, and/or inhibition of</entry><entry>181, 29.</entry></row><row><entry/><entry/><entry/><entry>interferons.</entry></row><row><entry>Human</entry><entry>GeneSeq Accession</entry><entry>WO9720926</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be</entry><entry>Soluble IL-13 alpha</entry></row><row><entry>interleukin-13</entry><entry>W24973</entry><entry/><entry>multifunctional cytokines synthesized</entry><entry>determined using assays known in</entry><entry>receptor polypeptides</entry></row><row><entry>alpha receptor</entry><entry/><entry/><entry>by lymphocytes, monocytes, and</entry><entry>the art: Matthews et al., in</entry><entry>may be useful for</entry></row><row><entry/><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Lymphokines and Interferons: A</i></entry><entry>inhibiting interleukin</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune</entry><entry><i>Practical Approach</i>, Clemens et al.,</entry><entry>activities.</entry></row><row><entry/><entry/><entry/><entry>cells (e.g., T helper cells, B cells,</entry><entry>eds, IRL Press, Washington, D.C.</entry></row><row><entry/><entry/><entry/><entry>eosinophils, and lymphocytes),</entry><entry>1987, pp. 221-225; and Boutelier et</entry></row><row><entry/><entry/><entry/><entry>chemotaxis of neutrophils and T</entry><entry>al (1995) J. Immunol. Methods</entry></row><row><entry/><entry/><entry/><entry>lymphocytes, and/or inhibition of</entry><entry>181, 29.</entry></row><row><entry/><entry/><entry/><entry>interferons.</entry></row><row><entry>Human</entry><entry>GeneSeq Accession</entry><entry>U.S. Pat. No. 5,599,905</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be</entry><entry>Soluble IL-4 receptor</entry></row><row><entry>interleukin-4</entry><entry>W13499</entry><entry/><entry>multifunctional cytokines synthesized</entry><entry>determined using assays known in</entry><entry>polypeptides may be</entry></row><row><entry>receptor</entry><entry/><entry/><entry>by lymphocytes, monocytes, and</entry><entry>the art: Matthews et al., in</entry><entry>useful for inhibiting</entry></row><row><entry/><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Lymphokines and Interferons: A</i></entry><entry>interleukin activities.</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune</entry><entry><i>Practical Approach</i>, Clemens et al.,</entry></row><row><entry/><entry/><entry/><entry>cells (e.g., T helper cells, B cells,</entry><entry>eds, IRL Press, Washington, D.C.</entry></row><row><entry/><entry/><entry/><entry>eosinophils, and lymphocytes),</entry><entry>1987, pp. 221-225; and Siegel &#x26;</entry></row><row><entry/><entry/><entry/><entry>chemotaxis of neutrophils and T</entry><entry>Mostowski (1990) J Immunol</entry></row><row><entry/><entry/><entry/><entry>lymphocytes, and/or inhibition of</entry><entry>Methods 132, 287-295.</entry></row><row><entry/><entry/><entry/><entry>interferons.</entry></row><row><entry>Human</entry><entry>GeneSeq Accession</entry><entry>EP759466</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be</entry><entry>Soluble IL-12 beta-2</entry></row><row><entry>interleukin-12</entry><entry>W12771</entry><entry/><entry>multifunctional cytokines synthesized</entry><entry>determined using assays known in</entry><entry>receptor polypeptides</entry></row><row><entry>beta-2 receptor</entry><entry/><entry/><entry>by lymphocytes, monocytes, and</entry><entry>the art: Matthews et al., in</entry><entry>may be useful for</entry></row><row><entry/><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Lymphokines and Interferons: A</i></entry><entry>inhibiting interleukin</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune</entry><entry><i>Practical Approach</i>, Clemens et al.,</entry><entry>activities.</entry></row><row><entry/><entry/><entry/><entry>cells (e.g., T helper cells, B cells,</entry><entry>eds, IRL Press, Washington, D.C.</entry></row><row><entry/><entry/><entry/><entry>eosinophils, and lymphocytes),</entry><entry>1987, pp. 221-225; and Hori et al</entry></row><row><entry/><entry/><entry/><entry>chemotaxis of neutrophils and T</entry><entry>(1987), Blood 70, 1069-1078.</entry></row><row><entry/><entry/><entry/><entry>lymphocytes, and/or inhibition of</entry></row><row><entry/><entry/><entry/><entry>interferons.</entry></row><row><entry>Human</entry><entry>GeneSeq Accession</entry><entry>EP759466</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be</entry><entry>Soluble IL-12 beta-1</entry></row><row><entry>interleukin-12</entry><entry>W12772</entry><entry/><entry>multifunctional cytokines synthesized</entry><entry>determined using assays known in</entry><entry>receptor polypeptides</entry></row><row><entry>beta-1 receptor.</entry><entry/><entry/><entry>by lymphocytes, monocytes, and</entry><entry>the art: Matthews et al., in</entry><entry>may be useful for</entry></row><row><entry/><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Lymphokines and Interferons: A</i></entry><entry>inhibiting interleukin</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune</entry><entry><i>Practical Approach</i>, Clemens et al.,</entry><entry>activities.</entry></row><row><entry/><entry/><entry/><entry>cells (e.g., T helper cells, B cells,</entry><entry>eds, IRL Press, Washington, D.C.</entry></row><row><entry/><entry/><entry/><entry>eosinophils, and lymphocytes),</entry><entry>1987, pp. 221-225; and Hori et at</entry></row><row><entry/><entry/><entry/><entry>chemotaxis of neutrophils and T</entry><entry>(1987), Blood 70, 1069-1078.</entry></row><row><entry/><entry/><entry/><entry>lymphocytes, and/or inhibition of</entry></row><row><entry/><entry/><entry/><entry>interferons.</entry></row><row><entry>Human IL-9</entry><entry>GeneSeq Accessions</entry><entry>WO9824904</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be</entry><entry>Soluble IL-9 receptor</entry></row><row><entry>receptor protein</entry><entry>W64055, W64056,</entry><entry/><entry>multifunctional cytokines synthesized</entry><entry>determined using assays known in</entry><entry>polypeptides may be</entry></row><row><entry/><entry>and W64057</entry><entry/><entry>by lymphocytes, monocytes, and</entry><entry>the art: Matthews et al., in</entry><entry>useful for inhibiting</entry></row><row><entry/><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Lymphokines and Interferons: A</i></entry><entry>interleukin activities.</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune</entry><entry><i>Practical Approach</i>, Clemens et al.,</entry></row><row><entry/><entry/><entry/><entry>cells (e.g., T helper cells, B cells,</entry><entry>eds, IRL Press, Washington, D.C.</entry></row><row><entry/><entry/><entry/><entry>eosinophils, and lymphocytes),</entry><entry>1987, pp. 221-225; and Yang et al</entry></row><row><entry/><entry/><entry/><entry>chemotaxis of neutrophils and T</entry><entry>(1989), Blood 74, 1880-84..</entry></row><row><entry/><entry/><entry/><entry>lymphocytes, and/or inhibition of</entry></row><row><entry/><entry/><entry/><entry>interferons.</entry></row><row><entry>IL-10 receptor</entry><entry>GeneSeq Accession</entry><entry>U.S. Pat. No. 5,716,804</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be</entry><entry>Soluble IL-10 receptor</entry></row><row><entry/><entry>W41804</entry><entry/><entry>multifunctional cytokines synthesized</entry><entry>determined using assays known in</entry><entry>polypeptides may be</entry></row><row><entry/><entry/><entry/><entry>by lymphocytes, monocytes, and</entry><entry>the art: Matthews et al., in</entry><entry>useful for inhibiting</entry></row><row><entry/><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Lymphokines and Interferons: A</i></entry><entry>interleukin activities.</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune</entry><entry><i>Practical Approach</i>, Clemens et al.,</entry></row><row><entry/><entry/><entry/><entry>cells (e.g., T helper cells, B cells,</entry><entry>eds, IRL Press, Washington, D.C.</entry></row><row><entry/><entry/><entry/><entry>eosinophils, and lymphocytes),</entry><entry>1987, pp. 221-225; and Thompson-</entry></row><row><entry/><entry/><entry/><entry>chemotaxis of neutrophils and T</entry><entry>Snipes et al (1991) J. Exp. Med. 173,</entry></row><row><entry/><entry/><entry/><entry>lymphocytes, and/or inhibition of</entry><entry>507-510.</entry></row><row><entry/><entry/><entry/><entry>interferons.</entry></row><row><entry>Human IL-6</entry><entry>GeneSeq Accession</entry><entry>JP11196867</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be</entry><entry>Soluble IL-6 receptor</entry></row><row><entry>receptor</entry><entry>Y30938</entry><entry/><entry>multifunctional cytokines synthesized</entry><entry>determined using assays known in</entry><entry>polypeptides may be</entry></row><row><entry/><entry/><entry/><entry>by lymphocytes, monocytes, and</entry><entry>the art: Matthews et al., in</entry><entry>useful for inhibiting</entry></row><row><entry/><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Lymphokines and Interferons: A</i></entry><entry>interleukin activities.</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune</entry><entry><i>Practical Approach</i>, Clemens et al.,</entry></row><row><entry/><entry/><entry/><entry>cells (e.g., T helper cells, B cells,</entry><entry>eds, IRL Press, Washington, D.C.</entry></row><row><entry/><entry/><entry/><entry>eosinophils, and lymphocytes),</entry><entry>1987, pp. 221-225; and Aarden et al</entry></row><row><entry/><entry/><entry/><entry>chemotaxis of neutrophils and T</entry><entry>(1987) Eur. J. Immunol 17, 1411-16.</entry></row><row><entry/><entry/><entry/><entry>lymphocytes, and/or inhibition of</entry></row><row><entry/><entry/><entry/><entry>interferons.</entry></row><row><entry>Il-17 receptor</entry><entry>GeneSeq Accession</entry><entry>U.S. Pat. No. 6,096,305</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be</entry><entry>Soluble IL-17 receptor</entry></row><row><entry/><entry>Y97181</entry><entry/><entry>multifunctional cytokines synthesized</entry><entry>determined using assays known in</entry><entry>polypeptides may be</entry></row><row><entry/><entry/><entry/><entry>by lymphocytes, monocytes, and</entry><entry>the art: Matthews et al., in</entry><entry>useful for inhibiting</entry></row><row><entry/><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Lymphokines and Interferons: A</i></entry><entry>interleukin activities.</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune</entry><entry><i>Practical Approach</i>, Clemens et al.,</entry></row><row><entry/><entry/><entry/><entry>cells (e.g., T helper cells, B cells,</entry><entry>eds, IRL Press, Washington, D.C.</entry></row><row><entry/><entry/><entry/><entry>eosinophils, and lymphocytes),</entry><entry>1987, pp. 221-225; and Yao et al</entry></row><row><entry/><entry/><entry/><entry>chemotaxis of neutrophils and T</entry><entry>(1995) J. Immunol. 155, 5483-86.</entry></row><row><entry/><entry/><entry/><entry>lymphocytes, and/or inhibition of</entry></row><row><entry/><entry/><entry/><entry>interferons.</entry></row><row><entry>Il-17 receptor</entry><entry>GeneSeq Accession</entry><entry>U.S. Pat. No. 6,100,235</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be</entry><entry>Soluble IL-17 receptor</entry></row><row><entry/><entry>Y97131</entry><entry/><entry>multifunctional cytokines synthesized</entry><entry>determined using assays known in</entry><entry>polypeptides may be</entry></row><row><entry/><entry/><entry/><entry>by lymphocytes, monocytes, and</entry><entry>the art: Matthews et al., in</entry><entry>useful for inhibiting</entry></row><row><entry/><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Lymphokines and Interferons: A</i></entry><entry>interleukin activities.</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune</entry><entry><i>Practical Approach</i>, Clemens et al.,</entry></row><row><entry/><entry/><entry/><entry>cells (e.g., T helper cells, B cells,</entry><entry>eds, IRL Press, Washington, D.C.</entry></row><row><entry/><entry/><entry/><entry>eosinophils, and lymphocytes),</entry><entry>1987, pp. 221-225; and Yao et al</entry></row><row><entry/><entry/><entry/><entry>chemotaxis of neutrophils and T</entry><entry>(1995) J. Immunol. 155, 5483-86.</entry></row><row><entry/><entry/><entry/><entry>lymphocytes, and/or inhibition of</entry></row><row><entry/><entry/><entry/><entry>interferons.</entry></row><row><entry>Human</entry><entry>GeneSeq Accession</entry><entry>EP509826</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be</entry><entry>Soluble IL-3 receptor</entry></row><row><entry>interleukin-3</entry><entry>R25300</entry><entry/><entry>multifunctional cytokines synthesized</entry><entry>determined using assays known in</entry><entry>polypeptides may be</entry></row><row><entry>receptor</entry><entry/><entry/><entry>by lymphocytes, monocytes, and</entry><entry>the art: Matthews et al., in</entry><entry>useful for inhibiting</entry></row><row><entry/><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Lymphokines and Interferons: A</i></entry><entry>interleukin activities.</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune</entry><entry><i>Practical Approach</i>, Clemens et al.,</entry></row><row><entry/><entry/><entry/><entry>cells (e.g., T helper cells, B cells,</entry><entry>eds, IRL, Press, Washington, D.C.</entry></row><row><entry/><entry/><entry/><entry>eosinophils, and lymphocytes),</entry><entry>1987, pp. 221-225; and Kitamura et</entry></row><row><entry/><entry/><entry/><entry>chemotaxis of neutrophils and T</entry><entry>al (1989) J Cell Physiol. 140 323-334.</entry></row><row><entry/><entry/><entry/><entry>lymphocytes, and/or inhibition of</entry></row><row><entry/><entry/><entry/><entry>interferons.</entry></row><row><entry>Human GM-CSF</entry><entry>GeneSeq Accession</entry><entry>WO9102063</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be</entry><entry>Soluble GM-CSF</entry></row><row><entry>receptor</entry><entry>R10919</entry><entry/><entry>multifunctional cytokines synthesized</entry><entry>determined using assays known in</entry><entry>receptor polypeptides</entry></row><row><entry/><entry/><entry/><entry>by lymphocytes, monocytes, and</entry><entry>the art: Matthews et al., in</entry><entry>may be useful for</entry></row><row><entry/><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Lymphokines and Interferons: A</i></entry><entry>inhibiting interleukin</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune</entry><entry><i>Practical Approach</i>, Clemens et al.,</entry><entry>activities.</entry></row><row><entry/><entry/><entry/><entry>cells (e.g., T helper cells, B cells,</entry><entry>eds, IRL Press, Washington, D.C.</entry></row><row><entry/><entry/><entry/><entry>eosinophils, and lymphocytes),</entry><entry>1987, pp. 221-225.</entry></row><row><entry/><entry/><entry/><entry>chemotaxis of neutrophils and T</entry></row><row><entry/><entry/><entry/><entry>lymphocytes, and/or inhibition of</entry></row><row><entry/><entry/><entry/><entry>interferons.</entry></row><row><entry>Human IL-5</entry><entry>GeneSeq Accession</entry><entry>EP492214</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be</entry><entry>Soluble IL-5 receptor</entry></row><row><entry>receptor alpha</entry><entry>R25064</entry><entry/><entry>multifunctional cytokines synthesized</entry><entry>determined using assays known in</entry><entry>alpha polypeptides may</entry></row><row><entry>chain</entry><entry/><entry/><entry>by lymphocytes, monocytes, and</entry><entry>the art: Matthews et al., in</entry><entry>be useful for inhibiting</entry></row><row><entry/><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Lymphokines and Interferons: A</i></entry><entry>interleukin activities.</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune</entry><entry><i>Practical Approach</i>, Clemens et al.,</entry></row><row><entry/><entry/><entry/><entry>cells (e.g., T helper cells, B cells,</entry><entry>eds, IRL Press, Washington, D.C.</entry></row><row><entry/><entry/><entry/><entry>eosinophils, and lymphocytes),</entry><entry>1987, pp. 221-225; and Kitamura et</entry></row><row><entry/><entry/><entry/><entry>chemotaxis of neutrophils and T</entry><entry>al (1989) J Cell Physiol. 140, 323-334.</entry></row><row><entry/><entry/><entry/><entry>lymphocytes, and/or inhibition of</entry></row><row><entry/><entry/><entry/><entry>interferons.</entry></row><row><entry>Il-5 receptor</entry><entry>GeneSeq Accession</entry><entry>WO9847923</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be</entry><entry>Soluble IL-5 receptor</entry></row><row><entry/><entry>W82842</entry><entry/><entry>multifunctional cytokines synthesized</entry><entry>determined using assays known in</entry><entry>polypeptides may be</entry></row><row><entry/><entry/><entry/><entry>by lymphocytes, monocytes, and</entry><entry>the art: Matthews et al., in</entry><entry>useful for inhibiting</entry></row><row><entry/><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Lymphokines and Interferons: A</i></entry><entry>interleukin activities.</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune</entry><entry><i>Practical Approach</i>, Clemens et al.,</entry></row><row><entry/><entry/><entry/><entry>cells (e.g., T helper cells, B cells,</entry><entry>eds, IRL Press, Washington, D.C.</entry></row><row><entry/><entry/><entry/><entry>eosinophils, and lymphocytes),</entry><entry>1987, pp. 221-225; and Kitamura et</entry></row><row><entry/><entry/><entry/><entry>chemotaxis of neutrophils and T</entry><entry>al (1989) J Cell Physiol. 140, 323-334.</entry></row><row><entry/><entry/><entry/><entry>lymphocytes, and/or inhibition of</entry></row><row><entry/><entry/><entry/><entry>interferons.</entry></row><row><entry>Il-6 receptor</entry><entry>GeneSeq Accession</entry><entry>JP05091892</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be</entry><entry>Soluble IL-6 receptor</entry></row><row><entry/><entry>R37215</entry><entry/><entry>multifunctional cytokines synthesized</entry><entry>determined using assays known in</entry><entry>polypeptides may be</entry></row><row><entry/><entry/><entry/><entry>by lymphocytes, monocytes, and</entry><entry>the art: Matthews et al., in</entry><entry>useful for inhibiting</entry></row><row><entry/><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Lymphokines and Interferons: A</i></entry><entry>interleukin activities.</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune</entry><entry><i>Practical Approach</i>, Clemens et al.,</entry></row><row><entry/><entry/><entry/><entry>cells (e.g., T helper cells, B cells,</entry><entry>eds, IRL Press, Washington, D.C.</entry></row><row><entry/><entry/><entry/><entry>eosinophils, and lymphocytes),</entry><entry>1987, pp. 221-225; and Aarden et al</entry></row><row><entry/><entry/><entry/><entry>chemotaxis of neutrophils and T</entry><entry>(1987) Eur. J. Immunol 17, 1411-16.</entry></row><row><entry/><entry/><entry/><entry>lymphocytes, and/or inhibition of</entry></row><row><entry/><entry/><entry/><entry>interferons.</entry></row><row><entry>Human B cell</entry><entry>GeneSeq Accession</entry><entry>AU8928720</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be</entry><entry>Soluble B cell</entry></row><row><entry>stimulating factor-</entry><entry>P90525</entry><entry/><entry>multifunctional cytokines synthesized</entry><entry>determined using assays known in</entry><entry>stimulating factor-2</entry></row><row><entry>2 receptor</entry><entry/><entry/><entry>by lymphocytes, monocytes, and</entry><entry>the art: Matthews et al., in</entry><entry>receptor polypeptides</entry></row><row><entry/><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Lymphokines and Interferons: A</i></entry><entry>may be useful for</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune</entry><entry><i>Practical Approach</i>, Clemens et al.,</entry><entry>inhibiting interleukin</entry></row><row><entry/><entry/><entry/><entry>cells (e.g., T helper cells, B cells,</entry><entry>eds, IRL Press, Washington, D.C.</entry><entry>activities.</entry></row><row><entry/><entry/><entry/><entry>eosinophils, and lymphocytes),</entry><entry>1987, pp. 221-225.</entry></row><row><entry/><entry/><entry/><entry>chemotaxis of neutrophils and T</entry></row><row><entry/><entry/><entry/><entry>lymphocytes, and/or inhibition of</entry></row><row><entry/><entry/><entry/><entry>interferons.</entry></row><row><entry>IL-7 receptor clone</entry><entry>GeneSeq Accession</entry><entry>EP403114</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be</entry><entry>Soluble IL-7 receptor</entry></row><row><entry/><entry>R08330</entry><entry/><entry>multifunctional cytokines synthesized</entry><entry>determined using assays known in</entry><entry>polypeptides may be</entry></row><row><entry/><entry/><entry/><entry>by lymphocytes, monocytes, and</entry><entry>the art: Matthews et al., in</entry><entry>useful for inhibiting</entry></row><row><entry/><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Lymphokines and Interferons: A</i></entry><entry>interleukin activities.</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune</entry><entry><i>Practical Approach</i>, Clemens et al.,</entry></row><row><entry/><entry/><entry/><entry>cells (e.g., T helper cells, B cells,</entry><entry>eds, IRL Press, Washington, D.C.</entry></row><row><entry/><entry/><entry/><entry>eosinophils, and lymphocytes),</entry><entry>1987, pp. 221-225; and Park et al</entry></row><row><entry/><entry/><entry/><entry>chemotaxis of neutrophils and T</entry><entry>(1990) J. Exp. Med. 171, 1073-79.</entry></row><row><entry/><entry/><entry/><entry>lymphocytes, and/or inhibition of</entry></row><row><entry/><entry/><entry/><entry>interferons.</entry></row><row><entry>EPO receptor;</entry><entry>GeneSeq Accession</entry><entry>WO9008822</entry><entry>EPO Receptor is involved in the</entry><entry>EPO Receptor activity can be</entry><entry>Inflammatory disorders,</entry></row><row><entry>EPOR</entry><entry>R06512</entry><entry/><entry>proliferation and differentiation of</entry><entry>determined using assays known in</entry><entry>immunologic disorders,</entry></row><row><entry/><entry/><entry/><entry>erythroblasts.</entry><entry>the art, such as, J Biol Chem 2001</entry><entry>cancer, erythroblast</entry></row><row><entry/><entry/><entry/><entry/><entry>Mar. 23; 276(12: 8995-9002; JAK2</entry><entry>proliferation and</entry></row><row><entry/><entry/><entry/><entry/><entry>protein tyrosine kinase activity:</entry><entry>differentiation</entry></row><row><entry/><entry/><entry/><entry/><entry>Blood 1994 Sep. 1; 84(5): 1501-7 and</entry></row><row><entry/><entry/><entry/><entry/><entry>Mol Cell Biol. 1994</entry></row><row><entry/><entry/><entry/><entry/><entry>October; 14(10: 6506-14.</entry></row><row><entry>IL-15 receptor</entry><entry>GeneSeq Accession</entry><entry>WO9530695</entry><entry>Interleukins are a group of</entry><entry>Interleukin activity can be</entry><entry>Soluble IL-15 receptor</entry></row><row><entry/><entry>R90843</entry><entry/><entry>multifunctional cytokines synthesized</entry><entry>determined using assays known in</entry><entry>polypeptides may be</entry></row><row><entry/><entry/><entry/><entry>by lymphocytes, monocytes, and</entry><entry>the art: Matthews et al., in</entry><entry>useful for inhibiting</entry></row><row><entry/><entry/><entry/><entry>macrophages. Known functions include</entry><entry><i>Lymphokines and Interferons: A</i></entry><entry>interleukin activities.</entry></row><row><entry/><entry/><entry/><entry>stimulating proliferation of immune</entry><entry><i>Practical Approach</i>, Clemens et al.,</entry></row><row><entry/><entry/><entry/><entry>cells (e.g., T helper cells, B cells,</entry><entry>eds, IRL Press, Washington, D.C.</entry></row><row><entry/><entry/><entry/><entry>eosinophils, and lymphocytes),</entry><entry>1987, pp. 221-225; and Giri et al</entry></row><row><entry/><entry/><entry/><entry>chemotaxis of neutrophils and T</entry><entry>(1994) EMBO J. 13 2822-2830.</entry></row><row><entry/><entry/><entry/><entry>lymphocytes, and/or inhibition of</entry></row><row><entry/><entry/><entry/><entry>interferons.</entry></row><row><entry>CD137; 4-1BB</entry><entry>GeneSeq Accession</entry><entry>WO9507984</entry><entry>Activities associated with apoptosis,</entry><entry>Apoptosis activity, NF-kB</entry><entry>Soluble 4-1BB receptor</entry></row><row><entry>Receptor Protein</entry><entry>R70977</entry><entry/><entry>NF-kB activation, and co-stimulation of</entry><entry>activation, and B and T cell co-</entry><entry>polypeptides may be</entry></row><row><entry/><entry/><entry/><entry>immune cells such as T and B cells.</entry><entry>stimulation can be determined using</entry><entry>useful for inhibiting</entry></row><row><entry/><entry/><entry/><entry/><entry>assays known in the art: Moore et</entry><entry>apoptosis, NF-kB</entry></row><row><entry/><entry/><entry/><entry/><entry>al., 1999, Science, 285(5425): 260-3;</entry><entry>activation, and/or co-</entry></row><row><entry/><entry/><entry/><entry/><entry>Song H Y et al., 1997 Proc Natl Acad</entry><entry>stimulation of immune</entry></row><row><entry/><entry/><entry/><entry/><entry>Sci USA 94(18): 9792-6; Epsevik</entry><entry>cells such as B and T</entry></row><row><entry/><entry/><entry/><entry/><entry>and Nissen-Meyer, 1986, J.</entry><entry>cells.</entry></row><row><entry/><entry/><entry/><entry/><entry>Immunol. Methods.</entry></row><row><entry>BCMA</entry><entry>GeneSeq Accession</entry><entry>WO0068378</entry><entry>Activities associated with apoptosis,</entry><entry>Apoptosis activity, NF-kB</entry><entry>Soluble BCMA receptor</entry></row><row><entry/><entry>Y71979</entry><entry/><entry>NF-kB activation, and co-stimulation of</entry><entry>activation, and B and T cell co-</entry><entry>polypeptides may be</entry></row><row><entry/><entry/><entry/><entry>immune cells such as T and B cells.</entry><entry>stimulation can be determined using</entry><entry>useful for inhibiting</entry></row><row><entry/><entry/><entry/><entry/><entry>assays known in the art: Moore et</entry><entry>apoptosis, NF-kB</entry></row><row><entry/><entry/><entry/><entry/><entry>al., 1999, Science, 285(5425): 260-3;</entry><entry>activation, and/or co-</entry></row><row><entry/><entry/><entry/><entry/><entry>Song H Y et al., 1997 Proc Natl Acad</entry><entry>stimulation of immune</entry></row><row><entry/><entry/><entry/><entry/><entry>Sci USA 94(18): 9792-6; Epsevik</entry><entry>cells such as B and T</entry></row><row><entry/><entry/><entry/><entry/><entry>and Nissen-Meyer, 1986, J.</entry><entry>cells.</entry></row><row><entry/><entry/><entry/><entry/><entry>Immunol. Methods.</entry></row><row><entry>CD27</entry><entry>GeneSeq Accession</entry><entry>WO9201049</entry><entry>Activities associated with apoptosis,</entry><entry>Apoptosis activity, NF-kB</entry><entry>Soluble CD27</entry></row><row><entry/><entry>R20814</entry><entry/><entry>NF-kB activation, and co-stimulation of</entry><entry>activation, and B and T cell co-</entry><entry>polypeptides may be</entry></row><row><entry/><entry/><entry/><entry>immune cells such as T and B cells.</entry><entry>stimulation can be determined using</entry><entry>useful for inhibiting</entry></row><row><entry/><entry/><entry/><entry/><entry>assays known in the art: Moore et</entry><entry>apoptosis, NF-kB</entry></row><row><entry/><entry/><entry/><entry/><entry>al., 1999, Science, 285(5425): 260-3;</entry><entry>activation, and/or co-</entry></row><row><entry/><entry/><entry/><entry/><entry>Song H Y et al., 1997 Proc Natl Acad</entry><entry>stimulation of immune</entry></row><row><entry/><entry/><entry/><entry/><entry>Sci USA 94(18): 9792-6; Epsevik</entry><entry>cells such as B and T</entry></row><row><entry/><entry/><entry/><entry/><entry>and Nissen-Meyer, 1986, J.</entry><entry>cells.</entry></row><row><entry/><entry/><entry/><entry/><entry>Immunol. Methods.</entry></row><row><entry>CD30</entry><entry>GeneSeq Accession</entry><entry>DE4200043</entry><entry>Activities associated with apoptosis,</entry><entry>Apoptosis activity, NF-kB</entry><entry>Soluble CD30</entry></row><row><entry/><entry>R35478</entry><entry/><entry>NF-kB activation, and co-stimulation of</entry><entry>activation, and B and T cell co-</entry><entry>polypeptides may be</entry></row><row><entry/><entry/><entry/><entry>immune cells such as T and B cells.</entry><entry>stimulation can be determined using</entry><entry>useful for inhibiting</entry></row><row><entry/><entry/><entry/><entry/><entry>assays known in the art: Moore et</entry><entry>apoptosis, NF-kB</entry></row><row><entry/><entry/><entry/><entry/><entry>al., 1999, Science, 285(5425): 260-3;</entry><entry>activation, and/or co-</entry></row><row><entry/><entry/><entry/><entry/><entry>Song H Y et al., 1997 Proc Natl Acad</entry><entry>stimulation of immune</entry></row><row><entry/><entry/><entry/><entry/><entry>Sci USA 94(18): 9792-6; Epsevik</entry><entry>cells such as B and T</entry></row><row><entry/><entry/><entry/><entry/><entry>and Nissen-Meyer, 1986, J.</entry><entry>cells.</entry></row><row><entry/><entry/><entry/><entry/><entry>Immunol. Methods.</entry></row><row><entry>CD40</entry><entry>GeneSeq Accession</entry><entry>WO9945944</entry><entry>Activities associated with apoptosis,</entry><entry>Apoptosis activity, NF-kB</entry><entry>Soluble CD40</entry></row><row><entry/><entry>Y33499</entry><entry/><entry>NF-kB activation, and co-stimulation of</entry><entry>activation, and B and T cell</entry><entry>polypeptides may be</entry></row><row><entry/><entry/><entry/><entry>immune cells such as T and B cells.</entry><entry>co-stimulation can be determined</entry><entry>useful for inhibiting</entry></row><row><entry/><entry/><entry/><entry/><entry>using assays known in the art:</entry><entry>apoptosis, NF-kB</entry></row><row><entry/><entry/><entry/><entry/><entry>Moore et al., 1999, Science</entry><entry>activation, and/or co-</entry></row><row><entry/><entry/><entry/><entry/><entry>285(5425): 260-3; Song H Y et al.,</entry><entry>stimulation of immune</entry></row><row><entry/><entry/><entry/><entry/><entry>1997 Proc Natl Acad Sci USA</entry><entry>cells such as B and T</entry></row><row><entry/><entry/><entry/><entry/><entry>94(18): 9792-6; Epsevik and</entry><entry>cells.</entry></row><row><entry/><entry/><entry/><entry/><entry>Nissen-Meyer, 1986, J. Immunol.</entry></row><row><entry/><entry/><entry/><entry/><entry>Methods.</entry></row><row><entry>EDAR</entry><entry>Genbank Accession</entry><entry/><entry>Activities associated with apoptosis,</entry><entry>Apoptosis activity, NF-kB activation,</entry><entry>Immune Disorders,</entry></row><row><entry/><entry>AAD50077</entry><entry/><entry>NF-kB activation, and co-stimulation of</entry><entry>and B and T cell co-stimulation can</entry><entry>Lymphomas, X-linked</entry></row><row><entry/><entry/><entry/><entry>immune cells such as T and B cells.</entry><entry>be determined using assays known in</entry><entry>hypohidrotic ectodermal</entry></row><row><entry/><entry/><entry/><entry/><entry>the art: Moore et al., 1999, Science,</entry><entry>dysplasia</entry></row><row><entry/><entry/><entry/><entry/><entry>285(5425): 260-3; Song H Y et al.,</entry></row><row><entry/><entry/><entry/><entry/><entry>1997 Proc Natl Acad Sci USA</entry></row><row><entry/><entry/><entry/><entry/><entry>94(18): 9792-6; Epsevik and Nissen-</entry></row><row><entry/><entry/><entry/><entry/><entry>Meyer, 1986, J. Immunol. Methods.</entry></row><row><entry>OX40; ACT-4</entry><entry>GeneSeq Accession</entry><entry>WO9512673</entry><entry>Activities associated with apoptosis,</entry><entry>Apoptosis activity, NF-kB activation,</entry><entry>Immune Disorders,</entry></row><row><entry/><entry>R74737</entry><entry/><entry>NF-kB activation, and co-stimulation of</entry><entry>and B and T cell co-stimulation can</entry><entry>Lymphomas, T cell</entry></row><row><entry/><entry/><entry/><entry>immune cells such as T and B cells.</entry><entry>be determined using assays known in</entry><entry>disorders</entry></row><row><entry/><entry/><entry/><entry/><entry>the art: Moore et al., 1999, Science,</entry></row><row><entry/><entry/><entry/><entry/><entry>285(5425): 260-3; Song H Y et al.,</entry></row><row><entry/><entry/><entry/><entry/><entry>1997 Proc Natl Acad Sci USA</entry></row><row><entry/><entry/><entry/><entry/><entry>94(18): 9792-6; Epsevik and Nissen-</entry></row><row><entry/><entry/><entry/><entry/><entry>Meyer, 1986, J. Immunol. Methods.</entry></row><row><entry>TACI</entry><entry>GeneSeq Accession</entry><entry>WO9839361</entry><entry>Activities associated with apoptosis,</entry><entry>Apoptosis activity, NF-kB activation,</entry><entry>Soluble TACI receptor</entry></row><row><entry/><entry>W75783</entry><entry/><entry>NF-kB activation, and co-stimulation of</entry><entry>and B and T cell co-stimulation can</entry><entry>polypeptides may be</entry></row><row><entry/><entry/><entry/><entry>immune cells such as T and B cells.</entry><entry>be determined using assays known in</entry><entry>useful for inhibiting</entry></row><row><entry/><entry/><entry/><entry/><entry>the art: Moore et al., 1999, Science,</entry><entry>apoptosis, NF-kB</entry></row><row><entry/><entry/><entry/><entry/><entry>285(5425): 260-3; Song H Y et al.,</entry><entry>activation, and/or co-</entry></row><row><entry/><entry/><entry/><entry/><entry>1997 Proc Natl Acad Sci USA</entry><entry>stimulation of immune</entry></row><row><entry/><entry/><entry/><entry/><entry>94(18): 9792-6; Epsevik and Nissen-</entry><entry>cells such as B and T</entry></row><row><entry/><entry/><entry/><entry/><entry>Meyer, 1986, J. Immunol. Methods.</entry><entry>cells.</entry></row><row><entry>TNF-R</entry><entry>GeneSeq Accession</entry><entry>AU9058976</entry><entry>Activities associates with apoptosis,</entry><entry>Apoptosis activity, NF-kB</entry><entry>Soluble TNF-R receptor</entry></row><row><entry/><entry>R10986</entry><entry/><entry>NF-kB activation, and co-stimulation of</entry><entry>activation, and B and T cell co-</entry><entry>polypeptides may be</entry></row><row><entry/><entry/><entry/><entry>immune cells such as T and B cells.</entry><entry>stimulation can be determined using</entry><entry>useful for inhibiting</entry></row><row><entry/><entry/><entry/><entry/><entry>assays known in the art: Moore et al.,</entry><entry>apoptosis, NF-kB</entry></row><row><entry/><entry/><entry/><entry/><entry>1999, Science, 285(5425): 260-3;</entry><entry>activation, and/or co-</entry></row><row><entry/><entry/><entry/><entry/><entry>Song H Y et al., 1997 Proc Natl Acad</entry><entry>stimulation of immune</entry></row><row><entry/><entry/><entry/><entry/><entry>Sci USA 94(18): 9792-6; Epsevik</entry><entry>cells such as B and T</entry></row><row><entry/><entry/><entry/><entry/><entry>and Nissen-Meyer, 1986, J. Immunol.</entry><entry>cells.</entry></row><row><entry/><entry/><entry/><entry/><entry>Methods.</entry></row><row><entry>TNF-RII; TNF</entry><entry>GeneSeq Accession</entry><entry>EP418014</entry><entry>Activities associated with apoptosis,</entry><entry>Apoptosis activity, NF-kB activation,</entry><entry>Soluble TNFR-II</entry></row><row><entry>p75 receptor;</entry><entry>R11141</entry><entry/><entry>NF-kB activation, and co-stimulation of</entry><entry>and B and T cell co-stimulation can</entry><entry>receptor polypeptides</entry></row><row><entry>Death Receptor</entry><entry/><entry/><entry>immune cells such as T and B cells.</entry><entry>be determined using assays known in</entry><entry>may be useful for</entry></row><row><entry/><entry/><entry/><entry/><entry>the art: Moore et al., 1999, Science,</entry><entry>inhibiting apoptosis,</entry></row><row><entry/><entry/><entry/><entry/><entry>285(5425): 260-3; Song H Y et al.,</entry><entry>NF-kB activation,</entry></row><row><entry/><entry/><entry/><entry/><entry>1997 Proc Natl Acad Sci USA</entry><entry>and/or co-stimulation of</entry></row><row><entry/><entry/><entry/><entry/><entry>94(18)9792-6; Epsevik and Nissen-</entry><entry>immune cells such as B</entry></row><row><entry/><entry/><entry/><entry/><entry>Meyer, 1986, J. Immunol. Methods.</entry><entry>and T cells.</entry></row><row><entry>hAPO-4; TROY</entry><entry>GeneSeq Accession</entry><entry>WO9911791</entry><entry>Activities associated with apoptosis,</entry><entry>Apoptosis activity, NF-kB activation,</entry><entry>Immune Disorders,</entry></row><row><entry/><entry>W93581</entry><entry/><entry>NF-kB activation, and co-stimulation of</entry><entry>and B and T cell co-stimulation can</entry><entry>Cancers</entry></row><row><entry/><entry/><entry/><entry>immune cells such as T and B cells.</entry><entry>be determined using assays known in</entry></row><row><entry/><entry/><entry/><entry/><entry>the art: Moore et al., 1999, Science,</entry></row><row><entry/><entry/><entry/><entry/><entry>285(5425): 260-3; Song H Y et al.,</entry></row><row><entry/><entry/><entry/><entry/><entry>1997 Proc Natl Acad Sci USA</entry></row><row><entry/><entry/><entry/><entry/><entry>94(18): 9792-6; Epsevik and Nissen-</entry></row><row><entry/><entry/><entry/><entry/><entry>Meyer, 1986, J. Immunol. Methods.</entry></row><row><entry>TNF-alpha</entry><entry>GeneSeq Accession</entry><entry>EP205038</entry><entry>Activities associated with apoptosis,</entry><entry>Apoptosis activity, NF-kB activation,</entry><entry>Inflammatory disorders,</entry></row><row><entry>precursor</entry><entry>P60074</entry><entry/><entry>NF-kB activation, and co-stimulation of</entry><entry>and B and T cell co-stimulation can</entry><entry>immunologic disorders,</entry></row><row><entry/><entry/><entry/><entry>immune cells such as T and B cells.</entry><entry>be determined using assays known in</entry><entry>cancer</entry></row><row><entry/><entry/><entry/><entry/><entry>the art: Moore et al., 1999, Science,</entry></row><row><entry/><entry/><entry/><entry/><entry>285(5425): 260-3; Song H Y et al.,</entry></row><row><entry/><entry/><entry/><entry/><entry>1997 Proc Natl Acad Sci USA</entry></row><row><entry/><entry/><entry/><entry/><entry>94(18): 9792-6; Epsevik and Nissen-</entry></row><row><entry/><entry/><entry/><entry/><entry>Meyer, 1986, J. Immunol. Methods.</entry></row><row><entry>Human TNF-</entry><entry>GeneSeq Accession</entry><entry>EP619372</entry><entry>Activities associated with apoptosis,</entry><entry>Apoptosis activity, NF-kB activation,</entry><entry>Inflammatory disorders,</entry></row><row><entry>alpha</entry><entry>R62463</entry><entry/><entry>NF-kB activation, and co-stimulation of</entry><entry>and B and T cell co-stimulation can</entry><entry>immunologic disorders,</entry></row><row><entry/><entry/><entry/><entry>immune cells such as T and B cells</entry><entry>be determined using assays known in</entry><entry>cancer</entry></row><row><entry/><entry/><entry/><entry/><entry>the art: Moore et al., 1999, Science,</entry></row><row><entry/><entry/><entry/><entry/><entry>285(5425): 260-3; Song H Y et al.,</entry></row><row><entry/><entry/><entry/><entry/><entry>1997 Proc Natl Acad Sci USA</entry></row><row><entry/><entry/><entry/><entry/><entry>94(18): 9792-6; Epsevik and Nissen-</entry></row><row><entry/><entry/><entry/><entry/><entry>Meyer, 1986, J. Immunol. Methods.</entry></row><row><entry>Human TNF-</entry><entry>GeneSeq Accession</entry><entry>EP563714</entry><entry>Activities associated with apoptosis,</entry><entry>Apoptosis activity, NF-kB activation,</entry><entry>Inflammatory disorders,</entry></row><row><entry>alpha</entry><entry>R42679</entry><entry/><entry>NF-kB activation, and co-stimulation of</entry><entry>and B and T cell co-stimulation can</entry><entry>immunologic disorders,</entry></row><row><entry/><entry/><entry/><entry>immune cells such as T and B cells.</entry><entry>be determined using assays known in</entry><entry>cancer</entry></row><row><entry/><entry/><entry/><entry/><entry>the art: Moore et al., 1999, Science,</entry></row><row><entry/><entry/><entry/><entry/><entry>285(5425): 260-3; Song H Y et al.,</entry></row><row><entry/><entry/><entry/><entry/><entry>1997 Proc Natl Acad Sci USA</entry></row><row><entry/><entry/><entry/><entry/><entry>94(18): 9792-6; Epsevik and Nissen-</entry></row><row><entry/><entry/><entry/><entry/><entry>Meyer, 1986, J. Immunol. Methods.</entry></row><row><entry>Human TNF-</entry><entry>GeneSeq Accession</entry><entry>WO0064479</entry><entry>Activities associated with apoptosis,</entry><entry>Apoptosis activity, NF-kB activation,</entry><entry>Inflammatory disorders,</entry></row><row><entry>beta (LT-alpha)</entry><entry>B37799</entry><entry/><entry>NF-kB activation, and co-stimulation of</entry><entry>and B and T cell co-stimulation can</entry><entry>immunologic disorders,</entry></row><row><entry/><entry/><entry/><entry>immune cells such as T and B cells.</entry><entry>be determined using assays known in</entry><entry>cancer</entry></row><row><entry/><entry/><entry/><entry/><entry>the art: Moore et al., 1999, Science,</entry></row><row><entry/><entry/><entry/><entry/><entry>285(5425): 260-3; Song H Y et al.,</entry></row><row><entry/><entry/><entry/><entry/><entry>1997 Proc Natl Acad Sci USA</entry></row><row><entry/><entry/><entry/><entry/><entry>94(18): 9792-6; Epsevik and Nissen-</entry></row><row><entry/><entry/><entry/><entry/><entry>Meyer, 1986, J. Immunol. Methods.</entry></row><row><entry>LT-alpha</entry><entry>GeneSeq Accession</entry><entry>EP250000</entry><entry>Activities associated with apoptosis,</entry><entry>Apoptosis activity, NF-kB activation,</entry><entry>Inflammatory disorders,</entry></row><row><entry/><entry>P70107</entry><entry/><entry>NF-kB activation, and co-stimulation of</entry><entry>and B and T cell co-stimulation can</entry><entry>immunologic disorders,</entry></row><row><entry/><entry/><entry/><entry>immune cells such as T and B cells.</entry><entry>be determined using assays known in</entry><entry>cancer</entry></row><row><entry/><entry/><entry/><entry/><entry>the art: Moore et al., 1999, Science,</entry></row><row><entry/><entry/><entry/><entry/><entry>285(5425): 260-3; Song H Y et al.,</entry></row><row><entry/><entry/><entry/><entry/><entry>1997 Proc Natl Acad Sci USA</entry></row><row><entry/><entry/><entry/><entry/><entry>94(18): 9792-6; Epsevik and Nissen-</entry></row><row><entry/><entry/><entry/><entry/><entry>Meyer, 1986, J. Immunol. Methods.</entry></row><row><entry>LT-beta</entry><entry>GeneSeq Accession</entry><entry>WO9413808</entry><entry>Activities associated with apoptosis,</entry><entry>Apoptosis activity, NF-kB activation,</entry><entry>Inflammatory disorders,</entry></row><row><entry/><entry>R56869</entry><entry/><entry>NF-kB activation, and co-stimulation of</entry><entry>and B and T cell co-stimulation can</entry><entry>immunologic disorders,</entry></row><row><entry/><entry/><entry/><entry>immune cells such as T and B cells.</entry><entry>be determined using assays known in</entry><entry>cancer</entry></row><row><entry/><entry/><entry/><entry/><entry>the art: Moore et al., 1999, Science,</entry></row><row><entry/><entry/><entry/><entry/><entry>285(5425): 260-3; Song H Y et al.,</entry></row><row><entry/><entry/><entry/><entry/><entry>1997 Proc Natl Acad Sci USA</entry></row><row><entry/><entry/><entry/><entry/><entry>94(18)9792-6; Epsevik and Nissen-</entry></row><row><entry/><entry/><entry/><entry/><entry>Meyer, 1986, J. Immunol. Methods.</entry></row><row><entry>OPGL</entry><entry>GeneSeq Accession</entry><entry>WO9846751</entry><entry>Activities associated with apoptosis,</entry><entry>Apoptosis activity, NF-kB activation,</entry><entry>Inflammatory disorders,</entry></row><row><entry/><entry>W83195</entry><entry/><entry>NF-kB activation, and co-stimulation of</entry><entry>and B and T cell co-stimulation can</entry><entry>immunologic disorders,</entry></row><row><entry/><entry/><entry/><entry>immune cells such as T and B cells.</entry><entry>be determined using assays known in</entry><entry>cancer, loss of bone</entry></row><row><entry/><entry/><entry/><entry/><entry>the art: Moore et al., 1999, Science,</entry><entry>mass</entry></row><row><entry/><entry/><entry/><entry/><entry>285(5425): 260-3; Song H Y et al.,</entry></row><row><entry/><entry/><entry/><entry/><entry>1997 Proc Natl Acad Sci USA</entry></row><row><entry/><entry/><entry/><entry/><entry>94(18)9792-6; Epsevik and Nissen-</entry></row><row><entry/><entry/><entry/><entry/><entry>Meyer, 1986, J. Immunol. Methods.</entry></row><row><entry>FasL</entry><entry>GeneSeq Accession</entry><entry>WO9903999</entry><entry>Activities associated with apoptosis,</entry><entry>Apoptosis activity, NF-kB activation,</entry><entry>Inflammatory disorders,</entry></row><row><entry/><entry>W98071</entry><entry/><entry>NF-kB activation, and co-stimulation of</entry><entry>and B and T cell co-stimulation can</entry><entry>immunologic disorders,</entry></row><row><entry/><entry/><entry/><entry>immune cells such as T and B cells.</entry><entry>be determined using assays known in</entry><entry>cancer</entry></row><row><entry/><entry/><entry/><entry/><entry>the art: Moore, et al., 1999, Science,</entry></row><row><entry/><entry/><entry/><entry/><entry>285(5425): 260-3; Song H Y et al.,</entry></row><row><entry/><entry/><entry/><entry/><entry>1997 Proc Natl Acad Sci USA</entry></row><row><entry/><entry/><entry/><entry/><entry>94(18)9792-6; Epsevik and Nissen-</entry></row><row><entry/><entry/><entry/><entry/><entry>Meyer, 1986, J. Immunol. Methods.</entry></row><row><entry>FasL</entry><entry>GeneSeq Accession</entry><entry>WO9903998</entry><entry>Activities associated with apoptosis,</entry><entry>Apoptosis activity, NF-kB activation,</entry><entry>Inflammatory disorders,</entry></row><row><entry/><entry>W95041</entry><entry/><entry>NF-kB activation, and co-stimulation of</entry><entry>and B and T cell co-stimulation can</entry><entry>imunologic disorders,</entry></row><row><entry/><entry/><entry/><entry>immune cells such as T and B cells.</entry><entry>be determined using assays known in</entry><entry>cancer</entry></row><row><entry/><entry/><entry/><entry/><entry>the art: Moore et al., 1999, Science,</entry></row><row><entry/><entry/><entry/><entry/><entry>285(5425): 260-3; Song H Y et al.,</entry></row><row><entry/><entry/><entry/><entry/><entry>1997 Proc Natl Acad Sci USA</entry></row><row><entry/><entry/><entry/><entry/><entry>94(18): 9792-6; Epsevik and Nissen-</entry></row><row><entry/><entry/><entry/><entry/><entry>Meyer, 1986, J. Immunol. Methods.</entry></row><row><entry>CD27L</entry><entry>GeneSeq Accession</entry><entry>WO9405691</entry><entry>Activities associated with apoptosis,</entry><entry>Apoptosis activity, NF-kB activation,</entry><entry>Inflammatory disorders,</entry></row><row><entry/><entry>R50121</entry><entry/><entry>NF-kB activation, and co-stimulation of</entry><entry>and B and T cell co-stimulation can</entry><entry>immunologic disorders,</entry></row><row><entry/><entry/><entry/><entry>immune cells such as T and B cells.</entry><entry>be determined using assays known in</entry><entry>cancer</entry></row><row><entry/><entry/><entry/><entry/><entry>the art: Moore et al., 1999, Science,</entry></row><row><entry/><entry/><entry/><entry/><entry>285(5425): 260-3; Song H Y et al.,</entry></row><row><entry/><entry/><entry/><entry/><entry>1997 Proc Natl Acad Sci USA</entry></row><row><entry/><entry/><entry/><entry/><entry>94(18): 9792-6; Epsevik and Nissen-</entry></row><row><entry/><entry/><entry/><entry/><entry>Meyer, 1986, J. Immunol. Methods.</entry></row><row><entry>CD30 ligand</entry><entry>GeneSeq Accession</entry><entry>WO9324135</entry><entry>Activities associated with apoptosis,</entry><entry>Apoptosis activity, NF-kB activation,</entry><entry>Inflammatory disorders,</entry></row><row><entry/><entry>R45007</entry><entry/><entry>NF-kB activation, and co-stimulation of</entry><entry>and B and T cell co-stimulation can</entry><entry>immunologic disorders,</entry></row><row><entry/><entry/><entry/><entry>immune cells such as T and B cells.</entry><entry>be determined using assays known in</entry><entry>cancer</entry></row><row><entry/><entry/><entry/><entry/><entry>the art: Moore et al., 1999, Science,</entry></row><row><entry/><entry/><entry/><entry/><entry>285(5425): 260-3; Song H Y et al.,</entry></row><row><entry/><entry/><entry/><entry/><entry>1997 Proc Natl Acad Sci USA</entry></row><row><entry/><entry/><entry/><entry/><entry>94(18): 9792-6; Epsevik and Nissen-</entry></row><row><entry/><entry/><entry/><entry/><entry>Meyer, 1986, J. Immunol. Methods.</entry></row><row><entry>CD40L</entry><entry>GeneSeq Accession</entry><entry>WO9529935</entry><entry>Activities associated with apoptosis,</entry><entry>Apoptosis activity, NF-kB activation,</entry><entry>Inflammatory disorders,</entry></row><row><entry/><entry>R85486</entry><entry/><entry>NF-kB activation, and co-stimulation of</entry><entry>and B and T cell co-stimulation can</entry><entry>immunologic disorders,</entry></row><row><entry/><entry/><entry/><entry>immune cells such as T and B cells.</entry><entry>be determined using assays known in</entry><entry>cancer</entry></row><row><entry/><entry/><entry/><entry/><entry>the art: Moore, et al., 1999, Science,</entry></row><row><entry/><entry/><entry/><entry/><entry>285(5425): 260-3; Song H Y et al.,</entry></row><row><entry/><entry/><entry/><entry/><entry>1997 Proc Natl Acad Sci USA</entry></row><row><entry/><entry/><entry/><entry/><entry>94(18): 9792-6; Epsevik and Nissen-</entry></row><row><entry/><entry/><entry/><entry/><entry>Meyer, 1986, J. Immunol. Methods.</entry></row><row><entry>4-1BB ligand</entry><entry>GeneSeq Accession</entry><entry>U.S. Pat. No. 5,674,704</entry><entry>Activities associated with apoptosis,</entry><entry>Apoptosis activity, NF-kB activation,</entry><entry>Inflammatory disorders,</entry></row><row><entry/><entry>W26657</entry><entry/><entry>NF-kB activation, and co-stimulation of</entry><entry>and B and T cell co-stimulation can</entry><entry>immunologic disorders,</entry></row><row><entry/><entry/><entry/><entry>immune cells such as T and B cells.</entry><entry>be determined using assays known in</entry><entry>cancer</entry></row><row><entry/><entry/><entry/><entry/><entry>the art: Moore et al., 1999, Science,</entry></row><row><entry/><entry/><entry/><entry/><entry>285(5425): 260-3; Song H Y et al.,</entry></row><row><entry/><entry/><entry/><entry/><entry>1997 Proc Natl Acad Sci USA</entry></row><row><entry/><entry/><entry/><entry/><entry>94(18): 9792-6; Epsevik and Nissen-</entry></row><row><entry/><entry/><entry/><entry/><entry>Meyer, 1986, J. Immunol. Methods.</entry></row><row><entry>FAS Ligand</entry><entry>GeneSeq Accession</entry><entry>WO0058465</entry><entry>Activities associated with apoptosis,</entry><entry>Apoptosis activity, NF-kB activation,</entry><entry>Soluble DcR3</entry></row><row><entry>Inhibitory</entry><entry>B19335</entry><entry/><entry>NF-kB activation, and co-stimulation of</entry><entry>and B and T cell co-stimulation can</entry><entry>polypeptides may be</entry></row><row><entry>Protein (DcR3)</entry><entry/><entry/><entry>immune cells such as T and B cells.</entry><entry>be determined using assays known in</entry><entry>useful for inhibiting</entry></row><row><entry/><entry/><entry/><entry/><entry>the art: Moore et al., 1999, Science,</entry><entry>apoptosis, NF-kB</entry></row><row><entry/><entry/><entry/><entry/><entry>285(5425): 260-3; Song H Y et al.,</entry><entry>activation, and/or co-</entry></row><row><entry/><entry/><entry/><entry/><entry>1997 Proc Natl Acad Sci USA</entry><entry>stimulation of immune</entry></row><row><entry/><entry/><entry/><entry/><entry>94(18): 9792-6; Epsevik and Nissen-</entry><entry>cells such as B and T</entry></row><row><entry/><entry/><entry/><entry/><entry>Meyer, 1986, J. Immunol. Methods</entry><entry>cells.</entry></row><row><entry>OX40L</entry><entry>GeneSeq Accession</entry><entry>WO9521915</entry><entry>Activities associated with apoptosis,</entry><entry>Apoptosis activity, NF-kB activation,</entry><entry>Inflammatory disorders,</entry></row><row><entry/><entry>R79903</entry><entry/><entry>NF-kB activation, and co-stimulation of</entry><entry>and B and T cell co-stimulation can</entry><entry>immunologic disorders,</entry></row><row><entry/><entry/><entry/><entry>immune cells such as T and B cells.</entry><entry>be determined using assays known in</entry><entry>cancer</entry></row><row><entry/><entry/><entry/><entry/><entry>the art: Moore et al., 1999, Science,</entry></row><row><entry/><entry/><entry/><entry/><entry>285(5425): 260-3; Song H Y et al.,</entry></row><row><entry/><entry/><entry/><entry/><entry>1997 Proc Natl Acad Sci USA</entry></row><row><entry/><entry/><entry/><entry/><entry>94(18): 9792-6; Epsevik and Nissen-</entry></row><row><entry/><entry/><entry/><entry/><entry>Meyer, 1986, J. Immunol. Methods.</entry></row><row><entry>Protease</entry><entry>GeneSeq Accessions</entry><entry>WO9106561</entry><entry>Peptides that inhibit the function/binding</entry><entry>HIV protease activities are known in</entry><entry>HIV, inflammatory</entry></row><row><entry>inhibitor</entry><entry>R12435, R12436,</entry><entry/><entry>of HIV</entry><entry>the art: HIV protease assays:</entry><entry>disorders, immunologic</entry></row><row><entry>peptides</entry><entry>R12437, R12438,</entry><entry/><entry/><entry>EP0387231. One can modify the</entry><entry>disorders, cancer, viral</entry></row><row><entry/><entry>R12439, R12440,</entry><entry/><entry/><entry>assay to look for inhibition using any</entry><entry>infections</entry></row><row><entry/><entry>and R1244</entry><entry/><entry/><entry>of the disclosed protease inhibitor</entry></row><row><entry/><entry/><entry/><entry/><entry>polypeptides.</entry></row><row><entry>Retroviral protease</entry><entry>GeneSeq Accessions</entry><entry>EP387231</entry><entry>Peptides that inhibit the function/binding</entry><entry>HIV protease activities are known in</entry><entry>HIV, inflammatory</entry></row><row><entry>inhibitors</entry><entry>R06660, R06661,</entry><entry/><entry>of HIV</entry><entry>the art: HIV protease assays:</entry><entry>disorders, immunologic</entry></row><row><entry/><entry>R06662, R06663,</entry><entry/><entry/><entry>EP0387231. One can modify the</entry><entry>disorders, cancer, viral</entry></row><row><entry/><entry>R06664, R06665,</entry><entry/><entry/><entry>assay to look for inhibition using any</entry><entry>infections</entry></row><row><entry/><entry>R06666, R06667,</entry><entry/><entry/><entry>of the disclosed protease inhibitor</entry></row><row><entry/><entry>R06668, R06669,</entry><entry/><entry/><entry>polypeptides.</entry></row><row><entry/><entry>R06670, R06671,</entry></row><row><entry/><entry>R06672, R06673,</entry></row><row><entry/><entry>R06674, R06675,</entry></row><row><entry/><entry>and R06676</entry></row><row><entry>HIV protease</entry><entry>GeneSeq Accessions</entry><entry>WO9301828</entry><entry>Peptides that inhibit the function/binding of</entry><entry>HIV protease activities are known in the</entry><entry>HIV, inflammatory</entry></row><row><entry>inhibiting</entry><entry>R59293, R59294,</entry><entry/><entry>HIV</entry><entry>art: HIV protease assays: EP0387231.</entry><entry>disorders, immunologic</entry></row><row><entry>peptides</entry><entry>R59295, R59296,</entry><entry/><entry/><entry>One can modify, the assay to look for</entry><entry>disorders, cancer, viral</entry></row><row><entry/><entry>R59297, R59298,</entry><entry/><entry/><entry>inhibition using any of the disclosed</entry><entry>infections</entry></row><row><entry/><entry>R59299, R592300,</entry><entry/><entry/><entry>protease inhibitor polypeptides.</entry></row><row><entry/><entry>R59301, R59302,</entry></row><row><entry/><entry>R59301, R59302,</entry></row><row><entry/><entry>R59303, R59304,</entry></row><row><entry/><entry>R59305, R59306,</entry></row><row><entry/><entry>R59307, R59308,</entry></row><row><entry/><entry>R59309, R59310,</entry></row><row><entry/><entry>R59311, R59312,</entry></row><row><entry/><entry>R59313, R59314,</entry></row><row><entry/><entry>R59315, R59316,</entry></row><row><entry/><entry>R59317 R59318,</entry></row><row><entry/><entry>R59319, R59320,</entry></row><row><entry/><entry>R59321, R59322,</entry></row><row><entry/><entry>R59323, R59324,</entry></row><row><entry/><entry>R59325, R59326,</entry></row><row><entry/><entry>R59327, R59328,</entry></row><row><entry/><entry>R59329, R59330,</entry></row><row><entry/><entry>R59331, R59332,</entry></row><row><entry/><entry>R59333, R59334,</entry></row><row><entry/><entry>R59335, R59336,</entry></row><row><entry/><entry>R59337, R59338,</entry></row><row><entry/><entry>R59339, R59340,</entry></row><row><entry/><entry>R59341, R59342,</entry></row><row><entry/><entry>R59343, R59344,</entry></row><row><entry/><entry>R59345, R59346,</entry></row><row><entry/><entry>R59347, R59348,</entry></row><row><entry/><entry>R59349, and</entry></row><row><entry/><entry>R59350</entry></row><row><entry>HIV-1 protease</entry><entry>GeneSeq Accessions</entry><entry>DE4412174</entry><entry>Peptides that inhibit the function/binding of</entry><entry>HIV protease activities are known in the</entry><entry>HIV, inflammatory</entry></row><row><entry>hinibitors</entry><entry>R86326, R86327,</entry><entry/><entry>HIV</entry><entry>art: HIV protease assays: EP0387231.</entry><entry>disorders, immunologic</entry></row><row><entry/><entry>R86328, R86329,</entry><entry/><entry/><entry>One can modify the assay to look for</entry><entry>disorders, cancer, viral</entry></row><row><entry/><entry>R86330, R86331,</entry><entry/><entry/><entry>inhibition using any of the disclosed</entry><entry>infections</entry></row><row><entry/><entry>R86332, R86333,</entry><entry/><entry/><entry>protease inhibitor polypeptides.</entry></row><row><entry/><entry>R86334, R86335,</entry></row><row><entry/><entry>R86336, R86337,</entry></row><row><entry/><entry>R86338, R86339,</entry></row><row><entry/><entry>R86340, R86341,</entry></row><row><entry/><entry>R86342, R86343,</entry></row><row><entry/><entry>R86344, R86345,</entry></row><row><entry/><entry>R86346, R86347,</entry></row><row><entry/><entry>R86348, R86349,</entry></row><row><entry/><entry>R86350, R86351,</entry></row><row><entry/><entry>R86352, R86353,</entry></row><row><entry/><entry>R86354, R86355,</entry></row><row><entry/><entry>R86356, R86357,</entry></row><row><entry/><entry>R86358, R86359,</entry></row><row><entry/><entry>R86360, R86361,</entry></row><row><entry/><entry>R86362, R86363,</entry></row><row><entry/><entry>R86364, R86365,</entry></row><row><entry/><entry>R86366, R86367,</entry></row><row><entry/><entry>R86368, R86369,</entry></row><row><entry/><entry>R86370, and</entry></row><row><entry/><entry>R86371</entry></row><row><entry>HIV Inhibitor</entry><entry>GeneSeq Accession</entry><entry>WO9959615</entry><entry>Peptides that inhibit the function/binding</entry><entry>HIV protease activities are known in</entry><entry>HIV, inflammatory</entry></row><row><entry>Peptide</entry><entry>Y89687</entry><entry/><entry>of HIV</entry><entry>the art: HIV protease assays:</entry><entry>disorders, immunologic</entry></row><row><entry/><entry/><entry/><entry/><entry>EP0387231. One can modify the</entry><entry>disorders, cancer, viral</entry></row><row><entry/><entry/><entry/><entry/><entry>assay to look for inhibition using any</entry><entry>infections</entry></row><row><entry/><entry/><entry/><entry/><entry>of the disclosed protease inhibitor</entry></row><row><entry/><entry/><entry/><entry/><entry>polypeptides.</entry></row><row><entry>HIV Inhibitor</entry><entry>GenSeq Accession</entry><entry>WO9948513</entry><entry>Peptides that inhibit the function/binding</entry><entry>HIV Protease activities are known in</entry><entry>HIV, inflammatory</entry></row><row><entry>Peptide</entry><entry>Y31955</entry><entry/><entry>of HIV</entry><entry>the art; HIV protease assays:</entry><entry>disorders, immunologic</entry></row><row><entry/><entry/><entry/><entry/><entry>EP0387231. One can modify the</entry><entry>disorders, cancer, viral</entry></row><row><entry/><entry/><entry/><entry/><entry>assay to look for inhibition using any</entry><entry>infections.</entry></row><row><entry/><entry/><entry/><entry/><entry>of the disclosed protease inhibitor</entry></row><row><entry/><entry/><entry/><entry/><entry>polypeptides.</entry></row><row><entry>HIV Inhibitor</entry><entry>www.sciencexpress.org;</entry><entry/><entry>Peptides that inhibit the function/binding</entry><entry>HIV protease activities are known in</entry><entry>HIV, inflammatory</entry></row><row><entry>Peptide</entry><entry>Published online</entry><entry/><entry>of HIV</entry><entry>the art: HIV protease assays:</entry><entry>disorders, immunologic</entry></row><row><entry/><entry>12 Jan. 2001;</entry><entry/><entry/><entry>EP0387231: One can modify the</entry><entry>disorders, cancer, viral</entry></row><row><entry/><entry>10.1126/science.1057453</entry><entry/><entry/><entry>assay to look for inhibition using any</entry><entry>infections</entry></row><row><entry/><entry/><entry/><entry/><entry>of the disclosed protease inhibitor</entry></row><row><entry/><entry/><entry/><entry/><entry>polypeptides.</entry></row><row><entry>Human monocyte</entry><entry>GeneSeq Accession</entry><entry>WO9509232</entry><entry>Chemokines are a family of small,</entry><entry>Chemokine activities can be</entry><entry>Immune disorders,</entry></row><row><entry>chemoattractant</entry><entry>R73915</entry><entry/><entry>secreted proteins involved in biological</entry><entry>determined using assays known in</entry><entry>particularly useful for</entry></row><row><entry>factor hMCP-3</entry><entry/><entry/><entry>processes ranging from hematopoiesis,</entry><entry>the art: Methods in Molecular</entry><entry>treating bacterial and/or</entry></row><row><entry/><entry/><entry/><entry>angiogenesis, and leukocyte trafficking.</entry><entry>Biology, 2000, vol. 138: Chemokine</entry><entry>viral menigitis</entry></row><row><entry/><entry/><entry/><entry>Members of this family are involved in a</entry><entry>Protocols, Edited by: A. E. I. Proudfoot,</entry></row><row><entry/><entry/><entry/><entry>similarly diverse range of pathologies</entry><entry>T. N. C. Wells, and C. A. Power.</entry></row><row><entry/><entry/><entry/><entry>including inflammation, allergy, tissue</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry></row><row><entry/><entry/><entry/><entry>rejection, viral infection, and tumor</entry><entry>Totowa, NJ</entry></row><row><entry/><entry/><entry/><entry>biology. The chemokines exert their</entry></row><row><entry/><entry/><entry/><entry>effects by acting on a family of seven</entry></row><row><entry/><entry/><entry/><entry>transmembrane G-protein-coupled</entry></row><row><entry/><entry/><entry/><entry>receptors. Over 40 human chemokines</entry></row><row><entry/><entry/><entry/><entry>have been described, which bind to &#x2212;17</entry></row><row><entry/><entry/><entry/><entry>receptors thus far identified.</entry></row><row><entry>Human monocyte</entry><entry>GeneSeq Accession</entry><entry>WO9509232</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Immune disorders,</entry></row><row><entry>chemoattractant</entry><entry>R73914</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in</entry><entry>particularly useful for</entry></row><row><entry>factor hMCP-1</entry><entry/><entry/><entry>biological processes ranging from</entry><entry>the art: Methods in Molecular</entry><entry>treating bacterial and/or</entry></row><row><entry/><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>Biology, 2000, vol. 138: Chemokine</entry><entry>viral menigitis</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power.</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>Totowa, NJ</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to &#x2212;17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Human gro-beta</entry><entry>GeneSeq Accessions</entry><entry>WO9429341</entry><entry>Chemokines are a family of small,</entry><entry>Chemokine activities can be</entry><entry>immune disorders,</entry></row><row><entry>chemokine</entry><entry>R66699 and</entry><entry/><entry>secreted proteins involved in biological</entry><entry>determined using assays known in</entry><entry>inflammatory disorders,</entry></row><row><entry/><entry>W17671</entry><entry/><entry>processes ranging from hematopoiesis,</entry><entry>the art: Methods in Molecular</entry><entry>blood-related disorders,</entry></row><row><entry/><entry/><entry/><entry>angiogenesis, and leukocyte trafficking.</entry><entry>Biology, 2000, vol. 138: Chemokine</entry><entry>stem cell</entry></row><row><entry/><entry/><entry/><entry>Members of this family are involved in a</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry><entry>transplantation, cancer</entry></row><row><entry/><entry/><entry/><entry>similarly diverse range of pathologies</entry><entry>T. N. C. Wells, and C. A. Power.</entry></row><row><entry/><entry/><entry/><entry>including inflammation, allergy, tissue</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry></row><row><entry/><entry/><entry/><entry>rejection, viral infection, and tumor</entry><entry>Totowa, NJ.</entry></row><row><entry/><entry/><entry/><entry>biology. The chemokines exert their</entry></row><row><entry/><entry/><entry/><entry>effects by acting on a family of seven</entry></row><row><entry/><entry/><entry/><entry>transmembrane G-protein-coupled</entry></row><row><entry/><entry/><entry/><entry>receptors. Over 40 human chemokines</entry></row><row><entry/><entry/><entry/><entry>have been described, which bind to &#x2212;17</entry></row><row><entry/><entry/><entry/><entry>receptors thus far identified.</entry></row><row><entry>Human gro-</entry><entry>GeneSeq Accessions</entry><entry>WO9429341</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Immune disorders,</entry></row><row><entry>gamma chemokine</entry><entry>R66700 and</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in</entry><entry>inflammatory disorders,</entry></row><row><entry/><entry>W17672</entry><entry/><entry>biological processes ranging from</entry><entry>the art: Methods in Molecular</entry><entry>blood-related disorders,</entry></row><row><entry/><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>Biology, 2000, vol. 138: Chemokine</entry><entry>stem cell</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry><entry>transplantation, cancer</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power.</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>Totowa, NJ</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to &#x2212;17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified</entry></row><row><entry>Human gro-alpha</entry><entry>GeneSeq Accessions</entry><entry>WO9429341</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Immune disorders,</entry></row><row><entry>chemokine</entry><entry>R66698 and</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in</entry><entry>inflammatory disorders,</entry></row><row><entry/><entry>W18024</entry><entry/><entry>biological processes ranging from</entry><entry>the art: Methods in Molecular</entry><entry>blood-related disorders,</entry></row><row><entry/><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>Biology, 2000, vol. 138: Chemokine</entry><entry>stem cell</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry><entry>transplantation, cancer</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power.</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>Totowa, NJ</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to &#x2212;17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified</entry></row><row><entry>Human eosinophil-</entry><entry>GeneSeq Accession</entry><entry>WO9632481</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Immune disorders,</entry></row><row><entry>expressed</entry><entry>W05186</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in</entry><entry>particularly treatment of</entry></row><row><entry>chemokine (EEC)</entry><entry/><entry/><entry>biological processes ranging from</entry><entry>the art: Methods in Molecular</entry><entry>eosinophilia,</entry></row><row><entry/><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>Biology, 2000, vol. 138: Chemokine</entry><entry>inflammation, allergies,</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry><entry>asthma, leukaemia and</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power.</entry><entry>lymphoma</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>Totowa, NJ</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to &#x2212;17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified</entry></row><row><entry>Chemokine-like</entry><entry>GeneSeq Accessions</entry><entry>WO9613587</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Cancer and blood-</entry></row><row><entry>protein PF4-414</entry><entry>R92318 and</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in</entry><entry>related disorders,</entry></row><row><entry>Full-Length and</entry><entry>R99809</entry><entry/><entry>biological processes ranging from</entry><entry>the art: Methods in Molecular</entry><entry>particularly</entry></row><row><entry>Mature</entry><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>Biology, 2000, vol. 138: Chemokine</entry><entry>myelosuppression</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power.</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>Totowa, NJ</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to &#x2212;17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified</entry></row><row><entry>Chemokine-like</entry><entry>GeneSeq Accession</entry><entry>WO9613587</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Cancer and blood-</entry></row><row><entry>protein IL-8M3</entry><entry>R99812</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in</entry><entry>related disorders,</entry></row><row><entry/><entry/><entry/><entry>biological processes ranging from</entry><entry>the art: Methods in Molecular</entry><entry>particularly</entry></row><row><entry/><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>Biology, 2000, vol. 138: Chemokine</entry><entry>myelosuppression</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power.</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>Totowa, NJ; and Holmes et al (1991)</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry><entry>Science 253, 1278-80.</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to &#x2212;17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified</entry></row><row><entry>Human</entry><entry>GeneSeq Accession</entry><entry>WO9613587</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Cancer and blood-</entry></row><row><entry>interleukin-8</entry><entry>R99814</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in</entry><entry>related disorders,</entry></row><row><entry>(IL-8)</entry><entry/><entry/><entry>biological processes ranging from</entry><entry>the art: Methods in Molecular</entry><entry>particularly</entry></row><row><entry/><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>Biology, 2000, vol. 138: Chemokine</entry><entry>myelosuppression</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power.</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>Totowa, NJ; and Holmes et al (1991)</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry><entry>Science 253, 1278-80.</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to &#x2212;17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified</entry></row><row><entry>Chemokine-like</entry><entry>GeneSeq Accessions</entry><entry>WO9613587</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Cancer and blood-</entry></row><row><entry>protein IL-8M1</entry><entry>R99815 and</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in</entry><entry>related disorders,</entry></row><row><entry>Full-Length and</entry><entry>R99803</entry><entry/><entry>biological processes ranging from</entry><entry>the art: Methods in Molecular</entry><entry>particularly</entry></row><row><entry>Mature</entry><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>Biology, 2000, vol. 138: Chemokine</entry><entry>myelosuppression</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power.</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>Totowa, NJ; and Holmes et al (1991)</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry><entry>Science 253, 1278-80.</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to &#x2212;17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified</entry></row><row><entry>Chemokine-like</entry><entry>GeneSeq Accessions</entry><entry>WO9613587</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Cancer and blood-</entry></row><row><entry>protein IL-8M8</entry><entry>R99816 and</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assasys known in</entry><entry>related disorders,</entry></row><row><entry>Full-Length and</entry><entry>R99805</entry><entry/><entry>biological processes ranging from</entry><entry>the art: Methods in Molecular</entry><entry>particularly</entry></row><row><entry>Mature</entry><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>Biology, 2000, vol. 138: Chemokine</entry><entry>myelosuppression.</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Protocols. Edited by: A. E. I. Proudfoot;</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power.</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>Totowa, NJ; and Holmes et al (1991)</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry><entry>Science 253, 1278-80.</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Chemokine-like</entry><entry>GeneSeq Accessions</entry><entry>WO9613587</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Cancer and blood-</entry></row><row><entry>protein IL-8M8</entry><entry>R99817 and</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assasys known in</entry><entry>related disorders,</entry></row><row><entry>Full-Length and</entry><entry>R99806</entry><entry/><entry>biological processes ranging from</entry><entry>the art: Methods in Molecular</entry><entry>particularly</entry></row><row><entry>Mature</entry><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>Biology, 2000, vol. 138: Chemokine</entry><entry>myelosuppression.</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Protocols. Edited by: A. E. I. Proudfoot;</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power.</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>Totowa, NJ; and Holmes et al (1991)</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry><entry>Science 253, 1278-80.</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Chemokine-like</entry><entry>GeneSeq Accessions</entry><entry>WO9613587</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Cancer and blood-</entry></row><row><entry>protein IL-8M8</entry><entry>R99818 and</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assasys known in</entry><entry>related disorders,</entry></row><row><entry>Full-Length and</entry><entry>R99804</entry><entry/><entry>biological processes ranging from</entry><entry>the art: Methods in Molecular</entry><entry>particularly</entry></row><row><entry>Mature</entry><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>Biology, 2000, vol. 138: Chemokine</entry><entry>myelosuppression.</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Protocols. Edited by: A. E. I. Proudfoot;</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power.</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>Totowa, NJ; and Holmes et al (1991)</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry><entry>Science 253, 1278-80.</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Chemokine-like</entry><entry>GeneSeq Accessions</entry><entry>WO9613587</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Cancer and blood-</entry></row><row><entry>protein IL-8M8</entry><entry>R99819 and</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assasys known in</entry><entry>related disorders,</entry></row><row><entry>Full-Length and</entry><entry>R99807</entry><entry/><entry>biological processes ranging from</entry><entry>the art: Methods in Molecular</entry><entry>particularly</entry></row><row><entry>Mature</entry><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>Biology, 2000, vol. 138: Chemokine</entry><entry>myelosuppression.</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Protocols. Edited by: A. E. I. Proudfoot;</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power.</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>Totowa, NJ</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Chemokine-like</entry><entry>GeneSeq Accessions</entry><entry>WO9613587</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Cancer and blood-</entry></row><row><entry>protein IL-8M8</entry><entry>R99822 and</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assasys known in</entry><entry>related disorders,</entry></row><row><entry>Full-Length and</entry><entry>R9807</entry><entry/><entry>biological processes ranging from</entry><entry>the art: Methods in Molecular</entry><entry>particularly</entry></row><row><entry>Mature</entry><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>Biology, 2000, vol. 138: Chemokine</entry><entry>myelosuppression.</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Protocols. Edited by: A. E. I. Proudfoot;</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power.</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>Totowa, NJ</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Human foetal</entry><entry>GeneSeq Accession</entry><entry>WO9622374</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Immune disorders</entry></row><row><entry>spleen expressed</entry><entry>R98499</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assasys known in</entry></row><row><entry>chemokine, FSEC</entry><entry/><entry/><entry>biological processes ranging from</entry><entry>the art: Methods in Molecular</entry></row><row><entry/><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>Biology, 2000, vol. 138: Chemokine</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Protocols. Edited by: A. E. I. Proudfoot;</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power.</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>Totowa, NJ</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Liver expressed</entry><entry>GeneSeq Accession</entry><entry>WO9616979</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Inflammation of the</entry></row><row><entry>chemokine-</entry><entry>R95689</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assasys known in</entry><entry>liver</entry></row><row><entry>1(LVEC-1)</entry><entry/><entry/><entry>biological processes ranging from</entry><entry>the art: Methods in Molecular</entry></row><row><entry/><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>Biology, 2000, vol. 138: Chemokine</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Protocols. Edited by: A. E. I. Proudfoot;</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power.</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>Totowa, NJ</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Liver expressed</entry><entry>GeneSeq Accession</entry><entry>WO9616979</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Inflammation of the</entry></row><row><entry>chemokine-</entry><entry>R95690</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assasys known in</entry><entry>liver</entry></row><row><entry>2(LVEC-2)</entry><entry/><entry/><entry>biological processes ranging from</entry><entry>the art: Methods in Molecular</entry></row><row><entry/><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>Biology, 2000, vol. 138: Chemokine</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Protocols. Edited by: A. E. I. Proudfoot;</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power.</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>Totowa, NJ</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Pituitary expressed</entry><entry>GeneSeq Accession</entry><entry>WO9616979</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Inflammation,</entry></row><row><entry>chemokine</entry><entry>R95691</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assasys known in</entry><entry>particularly of the liver</entry></row><row><entry>(PGEC)</entry><entry/><entry/><entry>biological processes ranging from</entry><entry>the art: Methods in Molecular</entry></row><row><entry/><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>Biology, 2000, vol. 138: Chemokine</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Protocols. Edited by: A. E. I. Proudfoot;</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power.</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>Totowa, NJ</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines liave been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Adenoid-expressed</entry><entry>GeneSeq Accession</entry><entry>WO9617868</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Inflammation,</entry></row><row><entry>chemokine</entry><entry>R97664</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assasys known in</entry><entry>angiogenesis,</entry></row><row><entry>(ADEC)</entry><entry/><entry/><entry>biological processes ranging from</entry><entry>the art: Methods in Molecular</entry><entry>tumorigenesis,</entry></row><row><entry/><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>Biology, 2000, vol. 138: Chemokine</entry><entry>musculoskeletal</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Protocols. Edited by: A. E. I. Proudfoot;</entry><entry>disorders</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power.</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>Totowa, NJ</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Human</entry><entry>GeneSeq Accession</entry><entry/><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Immune disorders, cell</entry></row><row><entry>chemokineCC-2</entry><entry>W38170</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in</entry><entry>migration, proliferation,</entry></row><row><entry/><entry/><entry/><entry>biological processes ranging from</entry><entry>the art: Methods in Molecular</entry><entry>and differentiation,</entry></row><row><entry/><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>Biology, 2000, vol. 138; Chemokine</entry><entry>disorders</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>protocols. Edited by: A. E. I. Proudfoot,</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power.</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc.</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>Totowa, NJ</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane</entry></row><row><entry/><entry/><entry/><entry>G-protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Human</entry><entry>GeneSeq Accession</entry><entry>WO9741230</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Immune disorders, cell</entry></row><row><entry>chemokine</entry><entry>W38171</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in the</entry><entry>migration, proliferation,</entry></row><row><entry>HCC-1</entry><entry/><entry/><entry>biological processes ranging from</entry><entry>art: Methods in molecular Biology</entry><entry>and differentiation</entry></row><row><entry/><entry/><entry/><entry>hematopiesis, anglogenesis and</entry><entry>2000, vol. 138: Chemokine</entry><entry>disorders</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Protocols. Edited by A. E. I. Proudfoot,</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells and C. A. Power</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc., Totowa,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>NJ</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane</entry></row><row><entry/><entry/><entry/><entry>G-protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Human</entry><entry>GeneSeq Accession</entry><entry>WO9741230</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Immune disorders, cell</entry></row><row><entry>chemokine CC-3</entry><entry>W38172</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in the</entry><entry>migration, proliferation</entry></row><row><entry/><entry/><entry/><entry>biological processes ranging from</entry><entry>art: Methods in molecular Biology,</entry><entry>and differentiation</entry></row><row><entry/><entry/><entry/><entry>hemotopoiesis, anglogenesis, and</entry><entry>2000, vol. 138: Chemokine</entry><entry>disorders</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Protocols, Edited by A. E. I. Proudfoot,</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc., Totowa,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>NJ</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Novel</entry><entry>GeneSeq Accession</entry><entry>WO9739126</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Immune disorders,</entry></row><row><entry>betachemokine</entry><entry>W27271</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in the</entry><entry>vascular disorders,</entry></row><row><entry>designated PTEC</entry><entry/><entry/><entry>biological processes ranging from</entry><entry>art: Methods in molecular Biology,</entry><entry>cancer</entry></row><row><entry/><entry/><entry/><entry>hemotopoiesis, anglogenesis, and</entry><entry>2000, vol. 138: Chemokine</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Protocols, Edited by A. E. I. Proudfoot,</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc., Totowa,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>NJ</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Human CX3C</entry><entry>GeneSeq Accession</entry><entry>WO9727299</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Immune disorders,</entry></row><row><entry>111 amino acid</entry><entry>W23344</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in the</entry><entry>inflammatory diseases,</entry></row><row><entry>chemokine</entry><entry/><entry/><entry>biological processes ranging from</entry><entry>art: Methods in molecular Biology,</entry><entry>abnormal proliferation,</entry></row><row><entry/><entry/><entry/><entry>hemotopoiesis, anglogenesis, and</entry><entry>2000, vol. 138: Chemokine</entry><entry>regeneration,</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Protocols, Edited by A. E. I. Proudfoot,</entry><entry>degeneration, and</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power</entry><entry>atrophy</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc., Totowa,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>NJ</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Human CCF18</entry><entry>GeneSeq Accession</entry><entry>WO9721812</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Abnormal physiology</entry></row><row><entry>chemokine</entry><entry>W25942</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in the</entry><entry>and development</entry></row><row><entry/><entry/><entry/><entry>biological processes ranging from</entry><entry>art: Methods in molecular Biology,</entry><entry>disorders, can also be</entry></row><row><entry/><entry/><entry/><entry>hemotopoiesis, anglogenesis, and</entry><entry>2000, vol. 138: Chemokine</entry><entry>used as an anti-viral</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Protocols, Edited by A. E. I. Proudfoot,</entry><entry>agent</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc., Totowa,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>NJ</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Human beta-</entry><entry>GeneSeq Accession</entry><entry>WO9725427</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Chemotaxis,</entry></row><row><entry>chemokine</entry><entry>W26655</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in the</entry><entry>blood-related disorders,</entry></row><row><entry>H1305 (MCP-2)</entry><entry/><entry/><entry>biological processes ranging from</entry><entry>art: Methods in molecular Biology,</entry><entry>viral infection, HIV,</entry></row><row><entry/><entry/><entry/><entry>hemotopoiesis, anglogenesis, and</entry><entry>2000, vol. 138: Chemokine</entry><entry>wound healing, cancer</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Protocols, Edited by A. E. I. Proudfoot,</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc., Totowa,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>NJ</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Human</entry><entry>GeneSeq Accession</entry><entry>WO9712914</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Inflammatory and</entry></row><row><entry>eosinocyte CC</entry><entry>W14990</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in the</entry><entry>immune disorders</entry></row><row><entry>type chemokine</entry><entry/><entry/><entry>biological processes ranging from</entry><entry>art: Methods in molecular Biology,</entry></row><row><entry>eotaxin</entry><entry/><entry/><entry>hemotopoiesis, anglogenesis, and</entry><entry>2000, vol. 138: Chemokine</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Protocols, Edited by A. E. I. Proudfoot,</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc., Totowa,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>NJ</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Human thymus</entry><entry>GeneSeq Accession</entry><entry>WO9711969</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Inflammatory and</entry></row><row><entry>and activation</entry><entry>W14018</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in the</entry><entry>immune disorders</entry></row><row><entry>regulated</entry><entry/><entry/><entry>biological processes ranging from</entry><entry>art: Methods in molecular Biology,</entry></row><row><entry>cytokine</entry><entry/><entry/><entry>hemotopoiesis, anglogenesis, and</entry><entry>2000, vol. 138: Chemokine</entry></row><row><entry>(TARC)</entry><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Protocols, Edited by A. E. I. Proudfoot,</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc., Totowa,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>NJ</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Human</entry><entry>GeneSeq Accession</entry><entry>WO9712041</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Cancer, would healing,</entry></row><row><entry>chemokine beta-</entry><entry>W16315</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in the</entry><entry>immune disorders</entry></row><row><entry>8 short forms</entry><entry/><entry/><entry>biological processes ranging from</entry><entry>art: Methods in molecular Biology,</entry></row><row><entry/><entry/><entry/><entry>hemotopoiesis, anglogenesis, and</entry><entry>2000, vol. 138: Chemokine</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Protocols, Edited by A. E. I. Proudfoot,</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc., Totowa,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>NJ</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Microphage</entry><entry>GeneSeq Accession</entry><entry>WO9640923</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Inflammatory</entry></row><row><entry>derived</entry><entry>W20058</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in</entry><entry>diseases, wound</entry></row><row><entry>chemokine, MDC</entry><entry/><entry/><entry>biological processes ranging from</entry><entry>the art: Methods in Molecular</entry><entry>healin,</entry></row><row><entry/><entry/><entry/><entry>hermaatopoiesis, angiogenesis, and</entry><entry>Biology, 2000, vol. 138: Chemokine</entry><entry>angiogenesis</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power.</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>Totowa, NJ</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Human chemokine</entry><entry>GeneSeq Accession</entry><entry>WO9844117</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Inflammatory and</entry></row><row><entry>ZSIG-35</entry><entry>W30565</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in</entry><entry>immune diseases</entry></row><row><entry/><entry/><entry/><entry>biological processes ranging from</entry><entry>the art: Methods in Molecular</entry></row><row><entry/><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>Biology, 2000, vol. 138: Chemokine</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power.</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>Totowa, NJ</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Primate CC</entry><entry>GeneSeq Accesssion</entry><entry>WO98328658</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Immune and</entry></row><row><entry>chemokine</entry><entry>W69990</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in</entry><entry>inflammatory</entry></row><row><entry>&#x201c;ILINCK&#x201d;</entry><entry/><entry/><entry>biological processes ranging from</entry><entry>the art: Methods in Molecular</entry><entry>disorders,</entry></row><row><entry/><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>Biology, 2000, vol. 138: Chemokine</entry><entry>abnormal</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking.</entry><entry>Protocols. Edited by: A. E. I. Prodfoot,</entry><entry>proliferation,</entry></row><row><entry/><entry/><entry/><entry/><entry>T. N. C. Wells, and C. A. Power.</entry><entry>regeneration,</entry></row><row><entry/><entry/><entry/><entry/><entry>&#x2009;&#xa9;Humana Press Inc.,</entry><entry>generation and</entry></row><row><entry/><entry/><entry/><entry/><entry>Totowa, NJ</entry><entry>atrophy disorders</entry></row><row><entry>Primate CXC</entry><entry>GeneSeq Accession</entry><entry>WO9832858</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Immune and</entry></row><row><entry>chemokine</entry><entry>W69989</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in</entry><entry>inflammatory</entry></row><row><entry>&#x201c;IBICK&#x201d;</entry><entry/><entry/><entry>biological processes ranging from</entry><entry>the art: Methods in Molecular</entry><entry>disorders,</entry></row><row><entry/><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>Biology, 2000, vol. 138: Chemokine</entry><entry>abnormal</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Protocols. Editd by: A. E. I. Proudfoot,</entry><entry>proliferation,</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power.</entry><entry>regeneration,</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry><entry>generation and</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>Totowa, NJ</entry><entry>atrophy disorders</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Human CC-type</entry><entry>GeneSeq Accession</entry><entry>WO9831809</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Immune,</entry></row><row><entry>chemokine protein</entry><entry>W69163</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in</entry><entry>inflammatory, and</entry></row><row><entry>designated SLC</entry><entry/><entry/><entry>biological processes ranging from</entry><entry>the art: Methods in Molecular</entry><entry>infectious</entry></row><row><entry>(secondary</entry><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>Biology, 2000, vol. 138: Chemokine</entry><entry>disorders, cancer</entry></row><row><entry>lymphoid</entry><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry></row><row><entry>chemokine)</entry><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power.</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>Totowa, NJ</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Human CC</entry><entry>GeneSeq Accession</entry><entry>WO9826071</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Cancer and</entry></row><row><entry>chemokine ELC</entry><entry>W62542</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in</entry><entry>infectious</entry></row><row><entry>protein</entry><entry/><entry/><entry>biological processes ranging from</entry><entry>the art: Methods in Molecular</entry><entry>diseases,</entry></row><row><entry/><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>Biology, 2000, vol. 138: Chemokine</entry><entry>particularly</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry><entry>herpes virus</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power.</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>Totowa, NJ</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Human DVic-1</entry><entry>GeneSeq Accession</entry><entry>Wo9823750</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Abnormal</entry></row><row><entry>C-C chemokine</entry><entry>W60649</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in</entry><entry>proliferation,</entry></row><row><entry/><entry/><entry/><entry>biological processes ranging from</entry><entry>the art: Methods in Molecular</entry><entry>regeneration,</entry></row><row><entry/><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>Biology, 2000, vol. 138: Chemokine</entry><entry>degeneration, and</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry><entry>atrophy disorders,</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power.</entry><entry>including cancer</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>Totowa, NJ</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Human C-C</entry><entry>GeneSeq Accession</entry><entry>WO9823750</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Immune</entry></row><row><entry>chemokine</entry><entry>W60650</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in</entry><entry>disorders, cell</entry></row><row><entry>DGWCC</entry><entry/><entry/><entry>biological processes ranging from</entry><entry>the art: Methods in Molecular</entry><entry>proliferation</entry></row><row><entry/><entry/><entry/><entry>hematophoiesis, angiogenesis, and</entry><entry>Biology, 2000, vol. 138: Chemokine</entry><entry>disorders, cancer</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power.</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>Totowa, NJ</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identifed.</entry></row><row><entry>Human STCP-1</entry><entry>GeneSeq Accession</entry><entry>WO9824907</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Immune</entry></row><row><entry/><entry>W62783</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in</entry><entry>disorders,</entry></row><row><entry/><entry/><entry/><entry>biological processes ranging from</entry><entry>the art: Methods in Molecular</entry><entry>particularly T cell</entry></row><row><entry/><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>Biology, 2000, vol. 138: Chemokine</entry><entry>related disorders,</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry><entry>viral infection,</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power.</entry><entry>and inflammation,</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry><entry>especially joint</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>Totowa, NJ</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Exodua protein</entry><entry>GeneSeq Accession</entry><entry>WO9821330</entry><entry>Chamokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Immune and</entry></row><row><entry/><entry>W61279</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in</entry><entry>inflammatory</entry></row><row><entry/><entry/><entry/><entry>biological processes ranging from</entry><entry>the art: Methods in Molecular</entry><entry>disorders,</entry></row><row><entry/><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>Biology, 2000, vol. 138: Chemokine</entry><entry>angiogenesis,</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry><entry>cancer, and</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power.</entry><entry>proliferation</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry><entry>disorders,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>Totowa, NJ</entry><entry>particularly</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry><entry/><entry>myeloproliferative</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry><entry/><entry>diseases</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Human</entry><entry>GeneSeq Acession</entry><entry>WO9814581</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Cancer and degenerative</entry></row><row><entry>Chr19Kine</entry><entry>W50887</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in</entry><entry>disorders</entry></row><row><entry>protein</entry><entry/><entry/><entry>biological processes ranging from</entry><entry>the art: Methods in Molecular</entry></row><row><entry/><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>Biology, 2000, vol. 138:</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Chemokine Protocols, Edited by:</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>A. E. I. Proudfoot, T. N. C. Wells, and</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>C. A. Power. &#x2009;&#xa9;Humana Press Inc.,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>Totowa, NJ</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Human T cell</entry><entry>GeneSeq Accession</entry><entry>U.S. Pat. No. 5,780,268</entry><entry>Chemokines area family of related</entry><entry>Chemokine activities can be</entry><entry>Immune, inflammatory,</entry></row><row><entry>mixed</entry><entry>W58703</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in the</entry><entry>and infectious disorders,</entry></row><row><entry>lymphocyte</entry><entry/><entry/><entry>biological processes ranging from</entry><entry>art: Mehtods of Molecular Biology,</entry><entry>cancer</entry></row><row><entry>reaction</entry><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>2000, vol. 138: Chemokine</entry></row><row><entry>expressed</entry><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry></row><row><entry>chemokine</entry><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power</entry></row><row><entry>(TMEC)</entry><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc., Totowa,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>NJ</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Human 6CKine</entry><entry>GeneSeq Accession</entry><entry>W09814581</entry><entry>Chemokines area family of related</entry><entry>Chemokine activities can be</entry><entry>Cancer and degenerative</entry></row><row><entry>protein</entry><entry>W50885</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in the</entry><entry>disorders</entry></row><row><entry/><entry/><entry/><entry>biological processes ranging from</entry><entry>art: Mehtods of Molecular Biology,</entry></row><row><entry/><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>2000, vol. 138: Chemokine</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc., Totowa,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>NJ</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>human liver and</entry><entry>GeneSeq Accession</entry><entry>WO9817800</entry><entry>Chemokines area family of related</entry><entry>Chemokine activities can be</entry><entry>Immune, inflammatory,</entry></row><row><entry>activation</entry><entry>W57475</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in the</entry><entry>and infectious disorders,</entry></row><row><entry>regulated</entry><entry/><entry/><entry>biological processes ranging from</entry><entry>art: Mehtods of Molecular Biology,</entry><entry>cancer</entry></row><row><entry>chemokine</entry><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>2000, vol. 138: Chemokine</entry></row><row><entry>(LARC)</entry><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc., Totowa,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>NJ</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>RANTES</entry><entry>GeneSeq Accession</entry><entry>WO9744462</entry><entry>Chemokines area family of related</entry><entry>Chemokine activities can be</entry><entry>Infectious diseases,</entry></row><row><entry>peptide</entry><entry>W29538</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in the</entry><entry>particularly HIV</entry></row><row><entry/><entry/><entry/><entry>biological processes ranging from</entry><entry>art: Mehtods of Molecular Biology,</entry></row><row><entry/><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>2000, vol. 138: Chemokine</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc., Totowa,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>NJ</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>RANTES 8-68</entry><entry>GeneSeq Accession</entry><entry>WO9744462</entry><entry>Chemokines area family of related</entry><entry>Chemokine activities can be</entry><entry>Infectious diseases,</entry></row><row><entry/><entry>W29529</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in the</entry><entry>particularly HIV</entry></row><row><entry/><entry/><entry/><entry>biological processes ranging from</entry><entry>art: Mehtods of Molecular Biology,</entry></row><row><entry/><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>2000, vol. 138: Chemokine</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc., Totowa,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>NJ</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>RANTES 9-68</entry><entry>GeneSeq Accession</entry><entry>WO9744462</entry><entry>Chemokines area family of related</entry><entry>Chemokine activities can be</entry><entry>Infectious diseases,</entry></row><row><entry/><entry>W29528</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in the</entry><entry>particularly HIV</entry></row><row><entry/><entry/><entry/><entry>biological processes ranging from</entry><entry>art: Mehtods of Molecular Biology,</entry></row><row><entry/><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>2000, vol. 138: Chemokine</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc., Totowa,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>NJ</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Human</entry><entry>GeneSeq Accession</entry><entry>WO9811226</entry><entry>Chemokines area family of related</entry><entry>Chemokine activities can be</entry><entry>Abnormal proliferation,</entry></row><row><entry>chemokine</entry><entry>W59433</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in the</entry><entry>regeneration,</entry></row><row><entry>protein 331D5</entry><entry/><entry/><entry>biological processes ranging from</entry><entry>art: Mehtods of Molecular Biology,</entry><entry>degeneration or atrophy,</entry></row><row><entry/><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>2000, vol. 138: Chemokine</entry><entry>including cancer</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc., Totowa,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>NJ</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Human</entry><entry>GeneSeq Accession</entry><entry>WO9811226</entry><entry>Chemokines area family of related</entry><entry>Chemokine activities can be</entry><entry>Abnormal proliferation,</entry></row><row><entry>chemokine</entry><entry>W59430</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in the</entry><entry>regeneration,</entry></row><row><entry>protein 61164</entry><entry/><entry/><entry>biological processes ranging from</entry><entry>art: Mehtods of Molecular Biology,</entry><entry>degeneration or atrophy,</entry></row><row><entry/><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>2000, vol. 138: Chemokine</entry><entry>including cancer</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc., Totowa,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>NJ</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Chemokine</entry><entry>GeneSeq Accession</entry><entry>WO9809171</entry><entry>Chemokines area family of related</entry><entry>Chemokine activities can be</entry><entry>Immune, Inflammatory,</entry></row><row><entry>MCP-4</entry><entry>W56690</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in the</entry><entry>and infectious diseases</entry></row><row><entry/><entry/><entry/><entry>biological processes ranging from</entry><entry>art: Mehtods of Molecular Biology,</entry></row><row><entry/><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>2000, vol. 138: Chemokine</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc., Totowa,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>NJ</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Human stromal</entry><entry>GeneSeq Accession</entry><entry>FR2751658</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>HIV infections</entry></row><row><entry>cell-derived</entry><entry>W50766</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in</entry></row><row><entry>chemokine, SDF-1</entry><entry/><entry/><entry>biological processes ranging from</entry><entry>the art: Methods in Molecular</entry></row><row><entry/><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>Biology, 2000, vol. 138: Chemokine</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power.</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>Totowa, NJ</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Thymus expressed</entry><entry>GeneSeq Accession</entry><entry>WO9801557</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Immune and</entry></row><row><entry>chemokine</entry><entry>W44397</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in the</entry><entry>inflammatory disorders</entry></row><row><entry>(TECK)</entry><entry/><entry/><entry>biological processes ranging from</entry><entry>art: Methods in Molecular Biology,</entry></row><row><entry/><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>2000, vol. 138: Chemokine Protocols.</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Edited by: A. E. I. Proudfoot, T. N. C. Wells,</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>and C. A. Power. &#x2009;&#xa9;Humana</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>Press Inc., Totowa, NJ</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Human chemokine</entry><entry>GeneSeq Accession</entry><entry>WO9801557</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Immune and</entry></row><row><entry>MIP-3alpha</entry><entry>W44398</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in the</entry><entry>inflammatory disorders</entry></row><row><entry/><entry/><entry/><entry>biological processes ranging from</entry><entry>art: Methods in Molecular Biology,</entry></row><row><entry/><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>2000, vol. 138: Chemokine Protocols.</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Edited by: A. E. I. Proudfoot, T. N. C. Wells,</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>and C. A. Power. &#x2009;&#xa9;Humana</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>Press Inc., Totowa, NJ</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Human chemokine</entry><entry>GeneSeq Accession</entry><entry>WO9801557</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Immune and</entry></row><row><entry>MIP-3beta</entry><entry>W44399</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in the</entry><entry>inflammatory disorders</entry></row><row><entry/><entry/><entry/><entry>biological processes ranging from</entry><entry>art: Methods in Molecular Biology,</entry></row><row><entry/><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>2000, vol. 138: Chemokine Protocols.</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Edited by: A. E. I. Proudfoot, T. N. C. Wells,</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>and C. A. Power. &#x2009;&#xa9;Humana</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>Press Inc., Totowa, NJ</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Human monocyte</entry><entry>GeneSeq Accession</entry><entry>WO9802459</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Immune disorders,</entry></row><row><entry>chemotactic</entry><entry>W42072</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in the</entry><entry>respiratory disorders,</entry></row><row><entry>proprotein (MCPP)</entry><entry/><entry/><entry>biological processes ranging from</entry><entry>art: Methods in Molecular Biology,</entry><entry>cancer</entry></row><row><entry>sequence</entry><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>2000, vol. 138: Chemokine Protocols.</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Edited by: A. E. I. Proudfoot, T. N. C. Wells,</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>and C. A. Power. &#x2009;&#xa9;Humana</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>Press Inc., Totowa, NJ</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Macrophage-</entry><entry>GeneSeq Accessions</entry><entry>U.S. Pat. No. 5,688,927/</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Immune, and</entry></row><row><entry>derived chemokine</entry><entry>W40811 and</entry><entry>U.S. Pat. No. 5,932,703</entry><entry>small, secreted proteins involved in</entry><entry>determined using assays known in the</entry><entry>inflammatory disorders,</entry></row><row><entry>(MDC)</entry><entry>Y24414</entry><entry/><entry>biological processes ranging from</entry><entry>art: Methods in Molecular Biology,</entry><entry>cancer</entry></row><row><entry/><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>2000, vol. 138: Chemokine Protocols.</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Edited by: A. E. I. Proudfoot, T. N. C. Wells,</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>and C. A. Power. &#x2009;&#xa9;Humana</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>Press Inc., Totowa, NJ</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Macrophage</entry><entry>GeneSeq Accession</entry><entry>U.S. Pat. No. 5,932,703</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Immune and</entry></row><row><entry>derived chemokine</entry><entry>Y24416</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in the</entry><entry>inflammatory disorders</entry></row><row><entry>analogue MDC-</entry><entry/><entry/><entry>biological processes ranging from</entry><entry>art: Methods in Molecular Biology,</entry></row><row><entry>eyfy</entry><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>2000, vol. 138: Chemokine Protocols.</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Edited by: A. E. I. Proudfoot, T. N. C. Wells,</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>and C. A. Power. &#x2009;&#xa9;Humana</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>Press Inc., Totowa, NJ</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Macrophage</entry><entry>GeneSeq Accession</entry><entry>U.S. Pat. No. 5,932,703</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Immune and</entry></row><row><entry>derived chemokine</entry><entry>Y24413</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in the</entry><entry>inflammatory disorders</entry></row><row><entry>analogue MDC</entry><entry/><entry/><entry>biological processes ranging from</entry><entry>art: Methods in Molecular Biology,</entry></row><row><entry>(n + 1)</entry><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>2000, vol. 138: Chemokine Protocols.</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Edited by: A. E. I. Proudfoot, T. N. C. Wells,</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>and C. A. Power. &#x2009;&#xa9;Humana</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>Press Inc., Totowa, NJ</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Macrophage</entry><entry>GeneSeq Accession</entry><entry>U.S. Pat. No. 5,932,703</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Immune and</entry></row><row><entry>derived chemokine</entry><entry>Y24415</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in the</entry><entry>inflammatory disorders</entry></row><row><entry>analogue MDC-yl</entry><entry/><entry/><entry>biological processes ranging from</entry><entry>art: Methods in Molecular Biology,</entry></row><row><entry/><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>2000, vol. 138: Chemokine Protocols.</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Edited by: A. E. I. Proudfoot, T. N. C. Wells,</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>and C. A. Power. &#x2009;&#xa9;Humana</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>Press Inc., Totowa, NJ</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Human type CC</entry><entry>GeneSeq Accession</entry><entry>JP11243960</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Allergic diseases and</entry></row><row><entry>chemokine eotaxin</entry><entry>Y43178</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in the</entry><entry>HIV infection</entry></row><row><entry>3 protein sequence</entry><entry/><entry/><entry>biological processes ranging from</entry><entry>art: Methods in Molecular Biology,</entry></row><row><entry/><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>2000, vol. 138: Chemokine Protocols.</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Edited by: A. E. I. Proudfoot, T. N. C. Wells,</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>and C. A. Power. &#x2009;&#xa9;Humana</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>Press Inc., Totowa, NJ</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Human MCP-3</entry><entry>GeneSeq Acession</entry><entry>WO9946392</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Cancer and immune</entry></row><row><entry>and human Muc-1</entry><entry>Y29893</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in</entry><entry>disorders, particularly</entry></row><row><entry>core epitope</entry><entry/><entry/><entry>biological processes ranging from</entry><entry>the art: Methods in Molecular</entry><entry>HIV infection</entry></row><row><entry>(VNT) fusion</entry><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>Biology, 2000, vol. 138: Chemokine</entry></row><row><entry>protein</entry><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarily</entry><entry>T. N. C. Wells, and C. A. Power.</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>Totowa, NJ</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Human IP-10 and</entry><entry>GeneSeq Accession</entry><entry>WO9946392</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Cancer and immune</entry></row><row><entry>human Muc-1 core</entry><entry>Y29894</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in the</entry><entry>disorders, particularly</entry></row><row><entry>epitope (VNT)</entry><entry/><entry/><entry>biological processes ranging from</entry><entry>art: Methods in Molecular Biology,</entry><entry>HIV infection</entry></row><row><entry>fusion protein</entry><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>2000, vol. 138: Chemokine Protocols.</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Edited by: A. E. I. Proudfoot, T. N. C. Wells,</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarily</entry><entry>and C. A. Power. &#x2009;&#xa9;Humana</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>Press Inc., Totowa, NJ</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Human IP-10 and</entry><entry>GeneSeq Accession</entry><entry>W09946392</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Cancer and immune</entry></row><row><entry>HIV-1 gp 120</entry><entry>Y29897</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in the</entry><entry>disorders, particularly</entry></row><row><entry>hypervariable</entry><entry/><entry/><entry>biological processes ranging from</entry><entry>art: Methods in Molecular Biology,</entry><entry>HIV infection</entry></row><row><entry>region fusion</entry><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>2000, vol. 138: Chemokine Protocols.</entry></row><row><entry>protein</entry><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Edited by: A. E. I. Proudfoot, T. N. C. Wells,</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarily</entry><entry>and C. A. Power. &#x2009;&#xa9;Humana</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>Press Inc., Totowa, NJ</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Human mammary</entry><entry>GeneSeq Accessions</entry><entry>WO9936540</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Breast disease,</entry></row><row><entry>associated</entry><entry>Y29092 and</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in the</entry><entry>including cancer</entry></row><row><entry>chemokine</entry><entry>Y29093</entry><entry/><entry>biological processes ranging from</entry><entry>art: Methods in Molecular Biology,</entry></row><row><entry>(MACK) protein</entry><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>2000, vol. 138: Chemokine Protocols.</entry></row><row><entry>Full-Length and</entry><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Edited by: A. E. I. Proudfoot, T. N. C. Wells,</entry></row><row><entry>Mature</entry><entry/><entry/><entry>family are involved in a similarily</entry><entry>and C. A. Power. &#x2009;&#xa9;Humana</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>Press Inc., Totowa, NJ</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Tim-1 protein</entry><entry>GeneSeq Accession</entry><entry>WO9933990</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Inflammation due to</entry></row><row><entry/><entry>Y28290</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in the</entry><entry>stimuli such as heart</entry></row><row><entry/><entry/><entry/><entry>biological processes ranging from</entry><entry>art: Methods in Molecular Biology,</entry><entry>attacks and stroke,</entry></row><row><entry/><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>2000, vol. 138: Chemokine Protocols.</entry><entry>infection, physical</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Edited by: A. E. I. Proudfoot, T. N. C. Wells,</entry><entry>trauma, UV or ionizing</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarily</entry><entry>and C. A. Power. &#x2009;&#xa9;Humana</entry><entry>radiation, burns,</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>Press Inc., Totowa, NJ</entry><entry>frostbite or corrosive</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry/><entry>chemicals</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Human Lkn-1</entry><entry>GeneSeq Accessions</entry><entry>WO9928473 and</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>HIV infection and</entry></row><row><entry>Full-Length and</entry><entry>Y17280, Y17274,</entry><entry>WO9928472</entry><entry>small, secreted proteins involved in</entry><entry>determined using assays known in the</entry><entry>cancer, particularly</entry></row><row><entry>Mature protein</entry><entry>Y17281, and</entry><entry/><entry>biological processes ranging from</entry><entry>art: Methods in Molecular Biology,</entry><entry>leukemia</entry></row><row><entry/><entry>Y17275</entry><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>2000, vol. 138: Chemokine Protocols.</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Edited by: A. E. I. Proudfoot, T. N. C. Wells,</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarily</entry><entry>and C. A. Power. &#x2009;&#xa9;Humana</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>Press Inc., Totowa, NJ</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>N-terminal</entry><entry>GeneSeq Accession</entry><entry>WO9920759</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Inhibit or stimulate</entry></row><row><entry>modified</entry><entry>Y05818</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in the</entry><entry>angiogenesis, inhibit the</entry></row><row><entry>chemokine met-</entry><entry/><entry/><entry>biological processes ranging from</entry><entry>art: Methods in Molecular Biology,</entry><entry>binding of HIV</entry></row><row><entry>hSDF-1 alpha</entry><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>2000, vol. 138: Chemokine Protocols.</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Edited by: A. E. I. Proudfoot, T. N. C. Wells,</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarily</entry><entry>and C. A. Power. &#x2009;&#xa9;Humana</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>Press Inc., Totowa, NJ</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>N-terminal</entry><entry>GeneSeq Accession</entry><entry>WO9920759</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Inhibit or stimulate</entry></row><row><entry>modified</entry><entry>Y05819</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in the</entry><entry>angiogenesis, inhibit the</entry></row><row><entry>chemokine met-</entry><entry/><entry/><entry>biological processes ranging from</entry><entry>art: Methods in Molecular Biology,</entry><entry>binding of HIV,</entry></row><row><entry>hSDF-1 beta</entry><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>2000, vol. 138: Chemokine Protocols.</entry><entry>antiinflammatory;</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Edited by: A. E. I. Proudfoot, T. N. C. Wells,</entry><entry>immunosuppressant</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarily</entry><entry>and C. A. Power. &#x2009;&#xa9;Humana</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>Press Inc., Totowa, NJ</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>N-terminal</entry><entry>GeneSeq Accession</entry><entry>WO9920759</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Inhibit or stimulate</entry></row><row><entry>modified</entry><entry>Y05820</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in the</entry><entry>angiogenesis, inhibit the</entry></row><row><entry>chemokine</entry><entry/><entry/><entry>biological processes ranging from</entry><entry>art: Methods in Molecular Biology,</entry><entry>binding of HIV,</entry></row><row><entry>GroHEK/hSDF-</entry><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>2000, vol. 138: Chemokine Protocols.</entry><entry>antiinflammatory;</entry></row><row><entry>1alpha</entry><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Edited by: A. E. I. Proudfoot, T. N. C. Wells,</entry><entry>immunosuppressant</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarily</entry><entry>and C. A. Power. &#x2009;&#xa9;Humana</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>Press Inc., Totowa, NJ</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>N-terminal</entry><entry>GeneSeq Accession</entry><entry>WO9920759</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Inhibit or stimulate</entry></row><row><entry>modified</entry><entry>Y05821</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in the</entry><entry>angiogenesis, inhibit the</entry></row><row><entry>chemokine</entry><entry/><entry/><entry>biological processes ranging from</entry><entry>art: Methods in Molecular Biology,</entry><entry>binding of HIV,</entry></row><row><entry>GroHEK/hSDF-</entry><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>2000, vol. 138: Chemokine Protocols.</entry><entry>antiinflammatory;</entry></row><row><entry>1beta.</entry><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Edited by: A. E. I. Proudfoot, T. N. C. Wells,</entry><entry>immunosuppressant</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarily</entry><entry>and C. A. Power. &#x2009;&#xa9;Humana</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>Press Inc., Totowa, NJ</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Chemokine</entry><entry>GeneSeq Accession</entry><entry>WO9912968</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Increase or enhance an</entry></row><row><entry>Eotaxin</entry><entry>Y14230</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in</entry><entry>inflammatory response,</entry></row><row><entry/><entry/><entry/><entry>biological processes ranging from</entry><entry>the art: Methods in Molecular</entry><entry>an immune response</entry></row><row><entry/><entry/><entry/><entry>hematopoiesis, agiogenesis, and</entry><entry>Bilogy, 2000, vol. 138: Chemokine</entry><entry>orhaematopoietic cell-</entry></row><row><entry/><entry/><entry/><entry>leukocye trafficking. Members of this</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry><entry>associated activity; treat</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power.</entry><entry>a vascular indication;</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry><entry>Cancer; enhance wound</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>Totowa, NJ</entry><entry>healing, to prevent or</entry></row><row><entry/><entry/><entry/><entry>viralk infection, and tumor biology. The</entry><entry/><entry>treat asthma, organ</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry><entry/><entry>transplant rejction,</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry><entry/><entry>rheumatoid arthritis or</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry><entry/><entry>allergy</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Chemokine</entry><entry>GeneSeq Accession</entry><entry>WO9912968</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Immune disorders,</entry></row><row><entry>hMCP1a</entry><entry>Y14225</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in</entry><entry>Vascular disorders,</entry></row><row><entry/><entry/><entry/><entry>biological processes ranging from</entry><entry>the art: Methods in Molecular</entry><entry>Wound healing, cancer,</entry></row><row><entry/><entry/><entry/><entry>hematopoiesis, agiogenesis, and</entry><entry>Bilogy, 2000, vol. 138: Chemokine</entry><entry>prevent organ transplant</entry></row><row><entry/><entry/><entry/><entry>leukocye trafficking. Members of this</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry><entry>rejection, Increase or</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power.</entry><entry>enhance an</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry><entry>inflammatory response,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>Totowa, NJ</entry></row><row><entry/><entry/><entry/><entry>viralk infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Chemokine</entry><entry>GeneSeq Accession</entry><entry>WO9912968</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Immune disorders,</entry></row><row><entry>hMCP1b</entry><entry>Y14226</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in</entry><entry>Vascular disorders,</entry></row><row><entry/><entry/><entry/><entry>biological processes ranging from</entry><entry>the art: Methods in Molecular</entry><entry>Wound healing, cancer,</entry></row><row><entry/><entry/><entry/><entry>hematopoiesis, agiogenesis, and</entry><entry>Bilogy, 2000, vol. 138: Chemokine</entry><entry>prevent organ transplant</entry></row><row><entry/><entry/><entry/><entry>leukocye trafficking: Members of this</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry><entry>rejection, Increase or</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power.</entry><entry>enhance an</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry><entry>inflammatory response,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>Totowa, NJ</entry></row><row><entry/><entry/><entry/><entry>viralk infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Chemokine</entry><entry>GeneSeq Accession</entry><entry>WO9912968</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Immune disorders,</entry></row><row><entry>hSDF1b</entry><entry>Y14228</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in</entry><entry>Vascular disorders,</entry></row><row><entry/><entry/><entry/><entry>biological processes ranging from</entry><entry>the art: Methods in Molecular</entry><entry>Wound healing, cancer,</entry></row><row><entry/><entry/><entry/><entry>hematopoiesis, agiogenesis, and</entry><entry>Bilogy, 2000, vol. 138: Chemokine</entry><entry>prevent organ transplant</entry></row><row><entry/><entry/><entry/><entry>leukocye trafficking. Members of this</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry><entry>rejection, Increase or</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power.</entry><entry>enhance an</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry><entry>inflammatory response,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>Totowa, NJ</entry></row><row><entry/><entry/><entry/><entry>viralk infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Chemokine</entry><entry>GeneSeq Accession</entry><entry>WO9912968</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Immune disorders,</entry></row><row><entry>hIL-8</entry><entry>Y14229</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in</entry><entry>Vascular disorders,</entry></row><row><entry/><entry/><entry/><entry>biological processes ranging from</entry><entry>the art: Methods in Molecular</entry><entry>Wound healing, cancer,</entry></row><row><entry/><entry/><entry/><entry>hematopoiesis, agiogenesis, and</entry><entry>Bilogy, 2000, vol. 138: Chemokine</entry><entry>prevent organ transplant</entry></row><row><entry/><entry/><entry/><entry>leukocye trafficking. Members of this</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry><entry>rejection, Increase or</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power.</entry><entry>enhance an</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry><entry>inflammatory response,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>Totowa, NJ; and Holmes et al (1991)</entry></row><row><entry/><entry/><entry/><entry>viralk infection, and tumor biology. The</entry><entry>Science 253, 1278-80.</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Chemokine</entry><entry>GeneSeq Accession</entry><entry>WO9912968</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Immune disorders,</entry></row><row><entry>hMCP1</entry><entry>Y14222</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in</entry><entry>Vascular disorders,</entry></row><row><entry/><entry/><entry/><entry>biological processes ranging from</entry><entry>the art: Methods in Molecular</entry><entry>Wound healing, cancer,</entry></row><row><entry/><entry/><entry/><entry>hematopoiesis, agiogenesis, and</entry><entry>Bilogy, 2000, vol. 138: Chemokine</entry><entry>prevent organ transplant</entry></row><row><entry/><entry/><entry/><entry>leukocye trafficking. Members of this</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry><entry>rejection, Increase or</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power.</entry><entry>enhance an</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry><entry>inflammatory response,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>Totowa, NJ</entry></row><row><entry/><entry/><entry/><entry>viralk infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Chemokine</entry><entry>GeneSeq Accession</entry><entry>WO9912968</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Immune disorders,</entry></row><row><entry>hMCP2</entry><entry>Y14223</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in</entry><entry>Vascular disorders,</entry></row><row><entry/><entry/><entry/><entry>biological processes ranging from</entry><entry>the art: Methods in Molecular</entry><entry>Wound healing, cancer,</entry></row><row><entry/><entry/><entry/><entry>hematopoiesis, agiogenesis, and</entry><entry>Bilogy, 2000, vol. 138: Chemokine</entry><entry>prevent organ transplant</entry></row><row><entry/><entry/><entry/><entry>leukocye trafficking. Members of this</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry><entry>rejection, Increase or</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power.</entry><entry>enhance an</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry><entry>inflammatory response,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>Totowa, NJ</entry></row><row><entry/><entry/><entry/><entry>viralk infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Chemokine</entry><entry>GeneSeq Accession</entry><entry>WO9912968</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Immune disorders,</entry></row><row><entry>hMCP3</entry><entry>Y14224</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in</entry><entry>Vascular disorders,</entry></row><row><entry/><entry/><entry/><entry>biological processes ranging from</entry><entry>the art: Methods in Molecular</entry><entry>Wound healing, cancer,</entry></row><row><entry/><entry/><entry/><entry>hematopoiesis, agiogenesis, and</entry><entry>Bilogy, 2000, vol. 138: Chemokine</entry><entry>prevent organ transplant</entry></row><row><entry/><entry/><entry/><entry>leukocye trafficking. Members of this</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry><entry>rejection, Increase or</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power.</entry><entry>enhance an</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry><entry>inflammatory response,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>Totowa, NJ</entry></row><row><entry/><entry/><entry/><entry>viralk infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>C-C chemokine,</entry><entry>GeneSeq Accession</entry><entry>EP905240</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Inflammatory, Immune</entry></row><row><entry>MCP2</entry><entry>Y05300</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in</entry><entry>and infectious diseases;</entry></row><row><entry/><entry/><entry/><entry>biological processes ranging from</entry><entry>the art: Methods in Molecular</entry><entry>pulmonary diseases and</entry></row><row><entry/><entry/><entry/><entry>hematopoiesis, agiogenesis, and</entry><entry>Bilogy, 2000, vol. 138: Chemokine</entry><entry>skin disorders; tumours,</entry></row><row><entry/><entry/><entry/><entry>leukocye trafficking. Members of this</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry><entry>and angiogenesis-and</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power.</entry><entry>haematopoiesis-related</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry><entry>diseases</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>Totowa, NJ</entry></row><row><entry/><entry/><entry/><entry>viralk infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Wild type</entry><entry>GeneSeq Accession</entry><entry>EP906954</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Inflammatory, Immume</entry></row><row><entry>monocyte</entry><entry>Y07233</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in</entry><entry>and infectious diseases;</entry></row><row><entry>chemotactic</entry><entry/><entry/><entry>biological processes ranging from</entry><entry>the art: Methods in Molecular</entry><entry>pulmonary diseases and</entry></row><row><entry>protein 2</entry><entry/><entry/><entry>hematopoiesis, agiogenesis, and</entry><entry>Bilogy, 2000, vol. 138: Chemokine</entry><entry>skin disorders; tumours,</entry></row><row><entry/><entry/><entry/><entry>leukocye trafficking. Members of this</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry><entry>and angiogenesis-and</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power.</entry><entry>haematopoiesis-related</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry><entry>diseases</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>Totowa, NJ</entry></row><row><entry/><entry/><entry/><entry>viralk infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Truncated</entry><entry>GeneSeq Accession</entry><entry>EP906954</entry><entry>Chemokines area family of related small,</entry><entry>Chemokines activities can be</entry><entry>Inflammatory, immune</entry></row><row><entry>monocyte</entry><entry>Y07234</entry><entry/><entry>secreted proteins involved in biological</entry><entry>determined using assays known in the</entry><entry>and infectious diseases;</entry></row><row><entry>chemotactic</entry><entry/><entry/><entry>processes ranging from hematopoiesis,</entry><entry>art: Methods in Molecular Biology,</entry><entry>pulmonry diseases and</entry></row><row><entry>protein 2 (6-76)</entry><entry/><entry/><entry>angiogenesis, and leukocyte trafficking.</entry><entry>2000, vol. 138: Chemokine</entry><entry>skin disorders; tumours,</entry></row><row><entry/><entry/><entry/><entry>Members of this family are involved in a</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry><entry>and angiogenesis-and</entry></row><row><entry/><entry/><entry/><entry>similarly diverse range of pathologies</entry><entry>T. N. C. Wells, and C. A. Power,</entry><entry>haematopoiesis-related</entry></row><row><entry/><entry/><entry/><entry>including inflammation, allergy, tissue</entry><entry>Humana Press Inc., Totowa,</entry><entry>diseases</entry></row><row><entry/><entry/><entry/><entry>rejection, viral infection, and tumor</entry><entry>NJ</entry></row><row><entry/><entry/><entry/><entry>biology. The chemokines exert their</entry></row><row><entry/><entry/><entry/><entry>effects by acting on a fmaily of seven</entry></row><row><entry/><entry/><entry/><entry>transmembrane G-protein-coupled</entry></row><row><entry/><entry/><entry/><entry>receptors. Over 40 human chemokines</entry></row><row><entry/><entry/><entry/><entry>have been described, which bind to ~17</entry></row><row><entry/><entry/><entry/><entry>receptors thus far identified.</entry></row><row><entry>Truncated</entry><entry>GeneSeq Accessions</entry><entry>EP905241;</entry><entry>Chemokines area family of related small,</entry><entry>Chemokines activities can be</entry><entry>Inflammatory, immune</entry></row><row><entry>RANTES</entry><entry>Y07236 and</entry><entry>EP906954</entry><entry>secreted proteins involved in biological</entry><entry>determined using assays known in the</entry><entry>and infectious diseases;</entry></row><row><entry>protein (3-68)</entry><entry>Y07232</entry><entry/><entry>processes ranging from hematopoiesis,</entry><entry>art: Methods in Molecular Biology,</entry><entry>pulmonry diseases and</entry></row><row><entry/><entry/><entry/><entry>angiogenesis, and leukocyte trafficking.</entry><entry>2000, vol. 138: Chemokine</entry><entry>skin disorders; tumours,</entry></row><row><entry/><entry/><entry/><entry>Members of this family are involved in a</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry><entry>and angiogenesis-and</entry></row><row><entry/><entry/><entry/><entry>similarly diverse range of pathologies</entry><entry>T. N. C. Wells, and C. A. Power,</entry><entry>haematopoiesis-related</entry></row><row><entry/><entry/><entry/><entry>including inflammation, allergy, tissue</entry><entry>Humana Press Inc., Totowa,</entry><entry>diseases</entry></row><row><entry/><entry/><entry/><entry>rejection, viral infection, and tumor</entry><entry>NJ</entry></row><row><entry/><entry/><entry/><entry>biology. The chemokines exert their</entry></row><row><entry/><entry/><entry/><entry>effects by acting on a fmaily of seven</entry></row><row><entry/><entry/><entry/><entry>transmembrane G-protein-coupled</entry></row><row><entry/><entry/><entry/><entry>receptors. Over 40 human chemokines</entry></row><row><entry/><entry/><entry/><entry>have been described, which bind to ~17</entry></row><row><entry/><entry/><entry/><entry>receptors thus far identified.</entry></row><row><entry>Wild type</entry><entry>GeneSeq Accession</entry><entry>EP905241</entry><entry>Chemokines area family of related small,</entry><entry>Chemokines activities can be</entry><entry>Inflammatory, immune</entry></row><row><entry>monocyte</entry><entry>Y07237</entry><entry/><entry>secreted proteins involved in biological</entry><entry>determined using assays known in the</entry><entry>and infectious diseases;</entry></row><row><entry>chemotactic</entry><entry/><entry/><entry>processes ranging from hematopoiesis,</entry><entry>art: Methods in Molecular Biology,</entry><entry>pulmonry diseases and</entry></row><row><entry>protein 2</entry><entry/><entry/><entry>angiogenesis, and leukocyte trafficking.</entry><entry>2000, vol. 138: Chemokine</entry><entry>skin disorders; tumours,</entry></row><row><entry/><entry/><entry/><entry>Members of this family are involved in a</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry><entry>and angiogenesis-and</entry></row><row><entry/><entry/><entry/><entry>similarly diverse range of pathologies</entry><entry>T. N. C. Wells, and C. A. Power,</entry><entry>haematopoiesis-related</entry></row><row><entry/><entry/><entry/><entry>including inflammation, allergy, tissue</entry><entry>Humana Press Inc., Totowa,</entry><entry>diseases</entry></row><row><entry/><entry/><entry/><entry>rejection, viral infection, and tumor</entry><entry>NJ</entry></row><row><entry/><entry/><entry/><entry>biology. The chemokines exert their</entry></row><row><entry/><entry/><entry/><entry>effects by acting on a fmaily of seven</entry></row><row><entry/><entry/><entry/><entry>transmembrane G-protein-coupled</entry></row><row><entry/><entry/><entry/><entry>receptors. Over 40 human chemokines</entry></row><row><entry/><entry/><entry/><entry>have been described, which bind to ~17</entry></row><row><entry/><entry/><entry/><entry>receptors thus far identified.</entry></row><row><entry>Truncated</entry><entry>GeneSeq Accession</entry><entry>EP905241</entry><entry>Chemokines area family of related small,</entry><entry>Chemokines activities can be</entry><entry>Inflammatory, immune</entry></row><row><entry>monocyte</entry><entry>Y07238</entry><entry/><entry>secreted proteins involved in biological</entry><entry>determined using assays known in the</entry><entry>and infectious diseases;</entry></row><row><entry>chemotactic</entry><entry/><entry/><entry>processes ranging from hematopoiesis,</entry><entry>art: Methods in Molecular Biology,</entry><entry>pulmonry diseases and</entry></row><row><entry>protein 2 (6-76)</entry><entry/><entry/><entry>angiogenesis, and leukocyte trafficking.</entry><entry>2000, vol. 138: Chemokine</entry><entry>skin disorders; tumours,</entry></row><row><entry/><entry/><entry/><entry>Members of this family are involved in a</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry><entry>and angiogenesis-and</entry></row><row><entry/><entry/><entry/><entry>similarly diverse range of pathologies</entry><entry>T. N. C. Wells, and C. A. Power,</entry><entry>haematopoiesis-related</entry></row><row><entry/><entry/><entry/><entry>including inflammation, allergy, tissue</entry><entry>Humana Press Inc., Totowa,</entry><entry>diseases</entry></row><row><entry/><entry/><entry/><entry>rejection, viral infection, and tumor</entry><entry>NJ</entry></row><row><entry/><entry/><entry/><entry>biology. The chemokines exert their</entry></row><row><entry/><entry/><entry/><entry>effects by acting on a fmaily of seven</entry></row><row><entry/><entry/><entry/><entry>transmembrane G-protein-coupled</entry></row><row><entry/><entry/><entry/><entry>receptors. Over 40 human chemokines</entry></row><row><entry/><entry/><entry/><entry>have been described, which bind to ~17</entry></row><row><entry/><entry/><entry/><entry>receptors thus far identified.</entry></row><row><entry>A partial</entry><entry>GeneSeq Accession</entry><entry>EP897980</entry><entry>Chemokines area family of related small,</entry><entry>Chemokines activities can be</entry><entry>Soluble CXCR4B</entry></row><row><entry>CXCR4B</entry><entry>W97363</entry><entry/><entry>secreted proteins involved in biological</entry><entry>determined using assays known in the</entry><entry>receptor polypeptides</entry></row><row><entry>protein</entry><entry/><entry/><entry>processes ranging from hematopoiesis,</entry><entry>art: Methods in Molecular Biology,</entry><entry>may be useful for</entry></row><row><entry/><entry/><entry/><entry>angiogenesis, and leukocyte trafficking.</entry><entry>2000, vol. 138: Chemokine</entry><entry>inhibiting chemokine</entry></row><row><entry/><entry/><entry/><entry>Members of this family are involved in a</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry><entry>activities and viral</entry></row><row><entry/><entry/><entry/><entry>similarly diverse range of pathologies</entry><entry>T. N. C. Wells, and C. A. Power,</entry><entry>infection.</entry></row><row><entry/><entry/><entry/><entry>including inflammation, allergy, tissue</entry><entry>Humana Press Inc., Totowa,</entry></row><row><entry/><entry/><entry/><entry>rejection, viral infection, and tumor</entry><entry>NJ</entry></row><row><entry/><entry/><entry/><entry>biology. The chemokines exert their</entry></row><row><entry/><entry/><entry/><entry>effects by acting on a family of seven</entry></row><row><entry/><entry/><entry/><entry>transmembrane G-protein-coupled</entry></row><row><entry/><entry/><entry/><entry>receptors. Over 40 human chemokines</entry></row><row><entry/><entry/><entry/><entry>have been described, which bind to ~17</entry></row><row><entry/><entry/><entry/><entry>receptors thus far identified.</entry></row><row><entry>Interferon</entry><entry>GeneSeq Accession</entry><entry>U.S. Pat. No. 5,871,723</entry><entry>Chemokines area family of related small,</entry><entry>Chemokines activities can be</entry><entry>Angiogenesis, Cancer,</entry></row><row><entry>gamma-</entry><entry>W96709</entry><entry/><entry>secreted proteins involved in biological</entry><entry>determined using assays known in the</entry><entry>Inflammatory and</entry></row><row><entry>inducible</entry><entry/><entry/><entry>processes ranging from hematopoiesis,</entry><entry>art: Methods in Molecular Biology,</entry><entry>Immune disorders,</entry></row><row><entry>protein (IP-10)</entry><entry/><entry/><entry>angiogenesis, and leukocyte trafficking.</entry><entry>2000, vol. 138: Chemokine</entry><entry>Cardio-Vascular</entry></row><row><entry/><entry/><entry/><entry>Members of this family are involved in a</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry><entry>discorders, Musco-</entry></row><row><entry/><entry/><entry/><entry>similarly diverse range of pathologies</entry><entry>T. N. C. Wells, and C. A. Power,</entry><entry>skeletal disorders</entry></row><row><entry/><entry/><entry/><entry>including inflammation, allergy, tissue</entry><entry>Humana Press Inc., Totowa,</entry></row><row><entry/><entry/><entry/><entry>rejection, viral infection, and tumor</entry><entry>NJ</entry></row><row><entry/><entry/><entry/><entry>biology. The chemokines exert their</entry></row><row><entry/><entry/><entry/><entry>effects by acting on a fmaily of seven</entry></row><row><entry/><entry/><entry/><entry>transmembrane G-protein-coupled</entry></row><row><entry/><entry/><entry/><entry>receptors. Over 40 human chemokines</entry></row><row><entry/><entry/><entry/><entry>have been described, which bind to ~17</entry></row><row><entry/><entry/><entry/><entry>receptors thus far identified.</entry></row><row><entry>A monokine</entry><entry>GeneSeq Accession</entry><entry>U.S. Pat. No. 5,871,723</entry><entry>Chemokines area family of related small,</entry><entry>Chemokines activities can be</entry><entry>Angiogenesis, Cancer,</entry></row><row><entry>induced by</entry><entry>W96710</entry><entry/><entry>secreted proteins involved in biological</entry><entry>determined using assays known in the</entry><entry>Inflammatory and</entry></row><row><entry>gamma-</entry><entry/><entry/><entry>processes ranging from hematopoiesis,</entry><entry>art: Methods in Molecular Biology,</entry><entry>Immune disorders,</entry></row><row><entry>interferon</entry><entry/><entry/><entry>angiogenesis, and leukocyte trafficking.</entry><entry>2000, vol. 138: Chemokine</entry><entry>Cardio-Vascular</entry></row><row><entry>(MIG)</entry><entry/><entry/><entry>Members of this family are involved in a</entry><entry>Protocols. Edited by: A. E. I. Prougfoot;</entry><entry>discorders, Musco-</entry></row><row><entry/><entry/><entry/><entry>similarly diverse range of pathologies</entry><entry>T. N. C. Wells, and C. A. Power,</entry><entry>skeletal disorders</entry></row><row><entry/><entry/><entry/><entry>including inflammation, allergy, tissue</entry><entry>Humana Press Inc., Totowa,</entry></row><row><entry/><entry/><entry/><entry>rejection, viral infection, and tumor</entry><entry>NJ</entry></row><row><entry/><entry/><entry/><entry>biology. The chemokines exert their</entry></row><row><entry/><entry/><entry/><entry>effects by acting on a fmaily of seven</entry></row><row><entry/><entry/><entry/><entry>transmembrane G-protein-coupled</entry></row><row><entry/><entry/><entry/><entry>receptors. Over 40 human chemokines</entry></row><row><entry/><entry/><entry/><entry>have been described, which bind to ~17</entry></row><row><entry/><entry/><entry/><entry>receptors thus far identified.</entry></row><row><entry>Interleukin-8</entry><entry>GeneSeq Accession</entry><entry>U.S. Pat. No. 5,871,723</entry><entry>Chemokines area family of related small,</entry><entry>Chemokines activities can be</entry><entry>Angiogenesis, Cancer,</entry></row><row><entry>(IL-8) protein.</entry><entry>W96711</entry><entry/><entry>secreted proteins involved in biological</entry><entry>determined using assays known in the</entry><entry>Inflammatory and</entry></row><row><entry/><entry/><entry/><entry>processes ranging from hematopoiesis,</entry><entry>art: Methods in Molecular Biology,</entry><entry>Immune disorders,</entry></row><row><entry/><entry/><entry/><entry>angiogenesis, and leukocyte trafficking.</entry><entry>2000, vol. 138: Chemokine</entry><entry>Cardio-Vascular</entry></row><row><entry/><entry/><entry/><entry>Members of this family are involved in a</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry><entry>discorders, Musco-</entry></row><row><entry/><entry/><entry/><entry>similarly diverse range of pathologies</entry><entry>T. N. C. Wells, and C. A. Power,</entry><entry>skeletal disorders</entry></row><row><entry/><entry/><entry/><entry>including inflammation, allergy, tissue</entry><entry>Humana Press Inc., Totowa,</entry></row><row><entry/><entry/><entry/><entry>rejection, viral infection, and tumor</entry><entry>NJ; and Holmes et al (1991) Science</entry></row><row><entry/><entry/><entry/><entry>biology. The chemokines exert their</entry><entry>253, 1278-80.</entry></row><row><entry/><entry/><entry/><entry>effects by acting on a fmaily of seven</entry></row><row><entry/><entry/><entry/><entry>transmembrane G-protein-coupled</entry></row><row><entry/><entry/><entry/><entry>receptors. Over 40 human chemokines</entry></row><row><entry/><entry/><entry/><entry>have been described, which bind to ~17</entry></row><row><entry/><entry/><entry/><entry>receptors thus far identified.</entry></row><row><entry>Epithelial</entry><entry>GeneSeq Accession</entry><entry>U.S. Pat. No. 5,871,723</entry><entry>Chemokines area family of related small,</entry><entry>Chemokines activities can be</entry><entry>Angiogenesis, Cancer,</entry></row><row><entry>neutrophil</entry><entry>W96712</entry><entry/><entry>secreted proteins involved in biological</entry><entry>determined using assays known in the</entry><entry>Inflammatory and</entry></row><row><entry>activating</entry><entry/><entry/><entry>processes ranging from hematopoiesis,</entry><entry>art: Methods in Molecular Biology,</entry><entry>Immune disorders,</entry></row><row><entry>protein-78</entry><entry/><entry/><entry>angiogenesis, and leukocyte trafficking.</entry><entry>2000, vol. 138: Chemokine</entry><entry>Cardio-Vascular</entry></row><row><entry>(ENA-78)</entry><entry/><entry/><entry>Members of this family are involved in a</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry><entry>discorders, Musco-</entry></row><row><entry/><entry/><entry/><entry>similarly diverse range of pathologies</entry><entry>T. N. C. Wells, and C. A. Power,</entry><entry>skeletal disorders</entry></row><row><entry/><entry/><entry/><entry>including inflammation, allergy, tissue</entry><entry>Humana Press Inc., Totowa,</entry></row><row><entry/><entry/><entry/><entry>rejection, viral infection, and tumor</entry><entry>NJ</entry></row><row><entry/><entry/><entry/><entry>biology. The chemokines exert their</entry></row><row><entry/><entry/><entry/><entry>effects by acting on a fmaily of seven</entry></row><row><entry/><entry/><entry/><entry>transmembrane G-protein-coupled</entry></row><row><entry/><entry/><entry/><entry>receptors. Over 40 human chemokines</entry></row><row><entry/><entry/><entry/><entry>have been described, which bind to ~17</entry></row><row><entry/><entry/><entry/><entry>receptors thus far identified.</entry></row><row><entry>Growth related</entry><entry>GeneSeq Accession</entry><entry>U.S. Pat. No. 5,871,723</entry><entry>Chemokines area family of related small,</entry><entry>Chemokines activities can be</entry><entry>Angiogenesis, Cancer,</entry></row><row><entry>oncogene-alpha</entry><entry>W96713</entry><entry/><entry>secreted proteins involved in biological</entry><entry>determined using assays known in the</entry><entry>Inflammatory and</entry></row><row><entry>(GRO-alpha).</entry><entry/><entry/><entry>processes ranging from hematopoiesis,</entry><entry>art: Methods in Molecular Biology,</entry><entry>Immune disorders,</entry></row><row><entry/><entry/><entry/><entry>angiogenesis, and leukocyte trafficking.</entry><entry>2000, vol. 138: Chemokine</entry><entry>Cardio-Vascular</entry></row><row><entry/><entry/><entry/><entry>Members of this family are involved in a</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry><entry>discorders, Musco-</entry></row><row><entry/><entry/><entry/><entry>similarly diverse range of pathologies</entry><entry>T. N. C. Wells, and C. A. Power,</entry><entry>skeletal disorders</entry></row><row><entry/><entry/><entry/><entry>including inflammation, allergy, tissue</entry><entry>Humana Press Inc., Totowa,</entry></row><row><entry/><entry/><entry/><entry>rejection, viral infection, and tumor</entry><entry>NJ</entry></row><row><entry/><entry/><entry/><entry>biology. The chemokines exert their</entry></row><row><entry/><entry/><entry/><entry>effects by acting on a fmaily of seven</entry></row><row><entry/><entry/><entry/><entry>transmembrane G-protein-coupled</entry></row><row><entry/><entry/><entry/><entry>receptors. Over 40 human chemokines</entry></row><row><entry/><entry/><entry/><entry>have been described, which bind to ~17</entry></row><row><entry/><entry/><entry/><entry>receptors thus far identified.</entry></row><row><entry>Growth related</entry><entry>GeneSeq Accession</entry><entry>U.S. Pat. No. 5,871,723</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Angiogenesis, Cancer,</entry></row><row><entry>oncogene-beta</entry><entry>W96714</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in</entry><entry>Inflammatory and</entry></row><row><entry>(GRO-beta).</entry><entry/><entry/><entry>biological processes ranging from</entry><entry>the art: Methods in Molecular</entry><entry>Immune disorders,</entry></row><row><entry/><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>Biology, 2000, vol. 138: Chemokine</entry><entry>Cardio-Vascular</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry><entry>disorders, Musco-</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power,</entry><entry>skeletal disorders</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>Totowa, NJ</entry></row><row><entry/><entry/><entry/><entry>viral infection and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified</entry></row><row><entry>Growth related</entry><entry>GeneSeq Accession</entry><entry>U.S. Pat. No. 5,871,723</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Angiogenesis, Cancer,</entry></row><row><entry>oncogene-gamma</entry><entry>W96715</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in</entry><entry>Inflammatory and</entry></row><row><entry>(GRO-gamma)</entry><entry/><entry/><entry>biological processes ranging from</entry><entry>the art: Methods in Molecular</entry><entry>Immune disorders,</entry></row><row><entry/><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>Biology, 2000, vol. 138: Chemokine</entry><entry>Cardio-Vascular</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry><entry>disorders, Musco-</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power,</entry><entry>skeletal disorders</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>Totowa, NJ</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>A platelet basic</entry><entry>GeneSeq Accession</entry><entry>U.S. Pat. No. 5,871,723</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Angiogenesis, Cancer,</entry></row><row><entry>protein (PBP)</entry><entry>W96716</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in</entry><entry>Inflammatory and</entry></row><row><entry/><entry/><entry/><entry>biological processes ranging from</entry><entry>the art: Methods in Molecular</entry><entry>Immune disorders,</entry></row><row><entry/><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>Biology, 2000, vol. 138: Chemokine</entry><entry>Cardio-Vascular</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry><entry>disorders, Musco-</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power,</entry><entry>skeletal disorders</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>Totowa, NJ</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Connective tissue</entry><entry>GeneSeqAccession</entry><entry>U.S. Pat. No. 5,871,723</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Angiogenesis, Cancer,</entry></row><row><entry>activating protein-</entry><entry>S96717</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in</entry><entry>Inflammatory and</entry></row><row><entry>III (CTAP-III)</entry><entry/><entry/><entry>biological processes ranging from</entry><entry>the art: Methods in Molecular</entry><entry>Immune disorders,</entry></row><row><entry/><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>Biology, 2000, vol. 138: Chemokine</entry><entry>Cardio-Vascular</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry><entry>disorders, Musco-</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power,</entry><entry>skeletal disorders</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>Totowa, NJ</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Beta-</entry><entry>GeneSeq Accession</entry><entry>U.S. Pat. No. 5,871,723</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Angiogenesis, Cancer,</entry></row><row><entry>thromboglobulin</entry><entry>W96718</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in</entry><entry>Inflammatory and</entry></row><row><entry>protein (beta-TG)</entry><entry/><entry/><entry>biological processes ranging from</entry><entry>the art: Methods in Molecular</entry><entry>Immune disorders,</entry></row><row><entry/><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>Biology, 2000, vol. 138: Chemokine</entry><entry>Cardio-Vascular</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry><entry>disorders, Musco-</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power,</entry><entry>skeletal disorders</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>Totowa, NJ</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Neutrophil</entry><entry>GeneSeq Accession</entry><entry>U.S. Pat. No. 5,871,723</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Angiogenesis, Cancer,</entry></row><row><entry>activating peptide-</entry><entry>W96719</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in</entry><entry>Inflammatory and</entry></row><row><entry>2 (NAP-2)</entry><entry/><entry/><entry>biological processes ranging from</entry><entry>the art: Methods in Molecular</entry><entry>Immune disorders,</entry></row><row><entry/><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>Biology, 2000, vol. 138: Chemokine</entry><entry>Cardio-Vascular</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry><entry>disorders, Musco-</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power,</entry><entry>skeletal disorders</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>Totowa, NJ</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Granulocyte</entry><entry>GeneSeq Accession</entry><entry>U.S. Pat. No. 5,871,723</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Angiogenesis, Cancer,</entry></row><row><entry>chemotactic</entry><entry>W96720</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in</entry><entry>Inflammatory and</entry></row><row><entry>protein-2 (GCP-2)</entry><entry/><entry/><entry>biological processes ranging from</entry><entry>the art: Methods in Molecular</entry><entry>Immune disorders,</entry></row><row><entry/><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>Biology, 2000, vol. 138: Chemokine</entry><entry>Cardio-Vascular</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry><entry>disorders, Musco-</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power,</entry><entry>skeletal disorders</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>Totowa, NJ</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Human chemokine</entry><entry>GeneSeq Accession</entry><entry>EP887409</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Immune disorders, viral,</entry></row><row><entry>MIG-beta protein</entry><entry>W90124</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in</entry><entry>parasitic, fungal or</entry></row><row><entry/><entry/><entry/><entry>biological processes ranging from</entry><entry>the art: Methods in Molecular</entry><entry>bacterial infections,</entry></row><row><entry/><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>Biology, 2000, vol. 138: Chemokine</entry><entry>Cancer; autoimmune</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry><entry>diseases or transplant</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power,</entry><entry>rejection</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>Totowa, NJ</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Human ZCHEMO-8</entry><entry>GeneSeq Accession</entry><entry>WO9854326</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Immune disorders,</entry></row><row><entry/><entry>W82716</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in</entry><entry>cancer, myelopoietic</entry></row><row><entry/><entry/><entry/><entry>biological processes ranging from</entry><entry>the art: Methods in Molecular</entry><entry>disorders, autoimmune</entry></row><row><entry/><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>Biology, 2000, vol. 138: Chemokine</entry><entry>disorders and</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry><entry>immunodeficiencies,</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power,</entry><entry>Inflammatory and</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry><entry>infectious diseases,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>Totowa, NJ</entry><entry>Vascular disorders,</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry><entry/><entry>wound healing</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Human Act-2</entry><entry>GeneSeq Accession</entry><entry>WO9854326</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Immune disorders,</entry></row><row><entry>protein</entry><entry>W82717</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in</entry><entry>cancer, myelopoietic</entry></row><row><entry/><entry/><entry/><entry>biological processes ranging from</entry><entry>the art: Methods in Molecular</entry><entry>disorders, autoimmune</entry></row><row><entry/><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>Biology, 2000, vol. 138: Chemokine</entry><entry>disorders and</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry><entry>immunodeficiencies,</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power,</entry><entry>Inflammatory and</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry><entry>infectious diseases,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>Totowa, NJ</entry><entry>Vascular disorders,</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry><entry/><entry>wound healing</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Human SISD</entry><entry>GeneSeq Acession</entry><entry>WO9854326</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Immune disorders,</entry></row><row><entry>protein</entry><entry>W82720</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in</entry><entry>cancer, myelopoietic</entry></row><row><entry/><entry/><entry/><entry>biological processes ranging from</entry><entry>the art: Methods in Molecular</entry><entry>disorders, autoimmune</entry></row><row><entry/><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>Biology, 2000, vol. 138:</entry><entry>disorders and</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Chemokine Protocols, Edited by:</entry><entry>immunodeficiencies,</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>A. E. I. Proudfoot, T. N. C. Wells, and</entry><entry>Inflammatory and</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>C. A. Power. &#x2009;&#xa9;Humana Press Inc.,</entry><entry>infectious diseases,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>Totowa, NJ</entry><entry>Vascular disorders,</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry><entry/><entry>wound healing</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Human M110</entry><entry>GeneSeq Accession</entry><entry>WO9854326</entry><entry>Chemokines area family of related</entry><entry>Chemokine activities can be</entry><entry>Immune disorders,</entry></row><row><entry>protein</entry><entry>W82721</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in the</entry><entry>cancer, myelopoietic</entry></row><row><entry/><entry/><entry/><entry>biological processes ranging from</entry><entry>art: Mehtods of Molecular Biology,</entry><entry>disorders, autoimmune</entry></row><row><entry/><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>2000, vol. 138: Chemokine</entry><entry>disorders and</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry><entry>immunodeficiencies,</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power</entry><entry>Inflammatory and</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc., Totowa,</entry><entry>infectious diseases,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>NJ</entry><entry>Vascular disorders,</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry><entry/><entry>wound healing</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Human M11A</entry><entry>GeneSeq Accession</entry><entry>WO9854326</entry><entry>Chemokines area family of related</entry><entry>Chemokine activities can be</entry><entry>Immune disorders,</entry></row><row><entry>protein</entry><entry>W82722</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in the</entry><entry>cancer, myelopoietic</entry></row><row><entry/><entry/><entry/><entry>biological processes ranging from</entry><entry>art: Mehtods of Molecular Biology,</entry><entry>disorders, autoimmune</entry></row><row><entry/><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>2000, vol. 138: Chemokine</entry><entry>disorders and</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry><entry>immunodeficiencies,</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power</entry><entry>Inflammatory and</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc., Totowa,</entry><entry>infectious diseases,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>NJ</entry><entry>Vascular disorders,</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry><entry/><entry>wound healing</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Human CCC3</entry><entry>GeneSeq Accession</entry><entry>WO9854326</entry><entry>Chemokines area family of related</entry><entry>Chemokine activities can be</entry><entry>Immune disorders,</entry></row><row><entry>protein</entry><entry>W82723</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in the</entry><entry>cancer, myelopoietic</entry></row><row><entry/><entry/><entry/><entry>biological processes ranging from</entry><entry>art: Mehtods of Molecular Biology,</entry><entry>disorders, autoimmune</entry></row><row><entry/><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>2000, vol. 138: Chemokine</entry><entry>disorders and</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry><entry>immunodeficiencies,</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power</entry><entry>Inflammatory and</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc., Totowa,</entry><entry>infectious diseases,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>NJ</entry><entry>Vascular disorders,</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry><entry/><entry>wound healing</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>A human L105</entry><entry>GeneSeq Accession</entry><entry>WO9856818</entry><entry>Chemokines area family of related</entry><entry>Chemokine activities can be</entry><entry>Cancer, wound healing</entry></row><row><entry>chemokine</entry><entry>W87588</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in the</entry></row><row><entry>designated</entry><entry/><entry/><entry>biological processes ranging from</entry><entry>art: Mehtods of Molecular Biology,</entry></row><row><entry>huL105_3.</entry><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>2000, vol. 138: Chemokine</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc., Totowa,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>NJ</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>A human L105</entry><entry>GeneSeq Accession</entry><entry>WO9856818</entry><entry>Chemokines area family of related</entry><entry>Chemokine activities can be</entry><entry>Cancer, wound healing</entry></row><row><entry>chemokine</entry><entry>W87589</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in the</entry></row><row><entry>designated</entry><entry/><entry/><entry>biological processes ranging from</entry><entry>art: Mehtods of Molecular Biology,</entry></row><row><entry>huL105_7.</entry><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>2000, vol. 138: Chemokine</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc., Totowa,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>NJ</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Human mature</entry><entry>GeneSeq Accession</entry><entry>WO9848828</entry><entry>Chemokines area family of related</entry><entry>Chemokine activities can be</entry><entry>Infectious diseases,</entry></row><row><entry>gro-alpha</entry><entry>W81498</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in the</entry><entry>sepsis</entry></row><row><entry>polypeptide</entry><entry/><entry/><entry>biological processes ranging from</entry><entry>art: Mehtods of Molecular Biology,</entry></row><row><entry>used to treat</entry><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>2000, vol. 138: Chemokine</entry></row><row><entry>sepsis</entry><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc., Totowa,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>NJ</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Human mature</entry><entry>GeneSeq Accession</entry><entry>WO9848828</entry><entry>Chemokines area family of related</entry><entry>Chemokine activities can be</entry><entry>Infectious diseases,</entry></row><row><entry>gro-gamma</entry><entry>W81500</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in the</entry><entry>sepsis</entry></row><row><entry>polypeptide</entry><entry/><entry/><entry>biological processes ranging from</entry><entry>art: Mehtods of Molecular Biology,</entry></row><row><entry>used to treat</entry><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>2000, vol. 138: Chemokine</entry></row><row><entry>sepsis</entry><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc., Totowa,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>NJ</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Human thymus</entry><entry>GeneSeq Accessions</entry><entry>WO0053635</entry><entry>Chemokines area family of related</entry><entry>Chemokine activities can be</entry><entry>Inflammatory disorders,</entry></row><row><entry>expressed</entry><entry>B19607 and</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in the</entry><entry>cancer, Immune and</entry></row><row><entry>chemokine</entry><entry>B19608</entry><entry/><entry>biological processes ranging from</entry><entry>art: Mehtods of Molecular Biology,</entry><entry>vascular disorders</entry></row><row><entry>TECK and</entry><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>2000, vol. 138: Chemokine</entry></row><row><entry>TECK variant</entry><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc., Totowa,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>NJ</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Human</entry><entry>GeneSeq Accession</entry><entry>WO0042071</entry><entry>Chemokines area family of related</entry><entry>Chemokine activities can be</entry><entry>Autoimmune disorders,</entry></row><row><entry>chemokine</entry><entry>B15791</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in the</entry><entry>Immune, Vascular and</entry></row><row><entry>SDF1alpha</entry><entry/><entry/><entry>biological processes ranging from</entry><entry>art: Mehtods of Molecular Biology,</entry><entry>Inflammatory disorders</entry></row><row><entry/><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>2000, vol. 138: Chemokine</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc., Totowa,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>NJ</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Human chemokine</entry><entry>GeneSeq Accession</entry><entry>WO0042071</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Autoimmune disorders,</entry></row><row><entry>GROalpha</entry><entry>B15793</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assasys known in</entry><entry>Immune, Vascular and</entry></row><row><entry/><entry/><entry/><entry>biological processes ranging from</entry><entry>the art: Methods in Molecular</entry><entry>Inflammatory diorders</entry></row><row><entry/><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>Biology, 2000, vol. 138: Chemokine</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Protocols. Edited by: A. E. I. Proudfoot;</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power.</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>Totowa, NJ</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Human chemokine</entry><entry>GeneSeq Accession</entry><entry>WO0042071</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Autoimmune disorders,</entry></row><row><entry>eotaxin</entry><entry>B15794</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assasys known in</entry><entry>Immune, Vascular and</entry></row><row><entry/><entry/><entry/><entry>biological processes ranging from</entry><entry>the art: Methods in Molecular</entry><entry>Inflammatory disorders</entry></row><row><entry/><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>Biology, 2000, vol. 138: Chemokine</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Protocols. Edited by: A. E. I. Proudfoot;</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power.</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>Totowa, NJ</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Human chemokine</entry><entry>GeneSeq Accession</entry><entry>WO0042071</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Autoimmune disorders,</entry></row><row><entry>MIG</entry><entry>B15803</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assasys known in</entry><entry>Immune, Vascular and</entry></row><row><entry/><entry/><entry/><entry>biological processes ranging from</entry><entry>the art: Methods in Molecular</entry><entry>Inflammatory disorders</entry></row><row><entry/><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>Biology, 2000, vol. 138: Chemokine</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Protocols. Edited by: A. E. I. Proudfoot;</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power.</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>Totowa, NJ</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Human chemokine</entry><entry>GeneSeq Accession</entry><entry>WO0042071</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Autoimmune disorders,</entry></row><row><entry>PF4</entry><entry>B15804</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assasys known in</entry><entry>Immune, Vascular and</entry></row><row><entry/><entry/><entry/><entry>biological processes ranging from</entry><entry>the art: Methods in Molecular</entry><entry>Inflammatory disorders</entry></row><row><entry/><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>Biology, 2000, vol. 138: Chemokine</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Protocols. Edited by: A. E. I. Proudfoot;</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power.</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>Totowa, NJ</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Human chemokine</entry><entry>GeneSeq Accession</entry><entry>WO0042071</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Autoimmune disorders,</entry></row><row><entry>I-309</entry><entry>B15805</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assasys known in</entry><entry>Immune, Vascular and</entry></row><row><entry/><entry/><entry/><entry>biological processes ranging from</entry><entry>the art: Methods in Molecular</entry><entry>Inflammatory disorders</entry></row><row><entry/><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>Biology, 2000, vol. 138: Chemokine</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Protocols. Edited by: A. E. I. Proudfoot;</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power.</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>Totowa, NJ</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Human chemokine</entry><entry>GeneSeq Accession</entry><entry>WO0042071</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Autoimmune disorders,</entry></row><row><entry>HCC-1</entry><entry>B15806</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assasys known in</entry><entry>Immune, Vascular and</entry></row><row><entry/><entry/><entry/><entry>biological processes ranging from</entry><entry>the art: Methods in Molecular</entry><entry>Inflammatory disorders</entry></row><row><entry/><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>Biology, 2000, vol. 138: Chemokine</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Protocols. Edited by: A. E. I. Proudfoot;</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power.</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>Totowa, NJ</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Human chemokine</entry><entry>GeneSeq Accession</entry><entry>WO0042071</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Autoimmune disorders,</entry></row><row><entry>C10</entry><entry>B15807</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assasys known in</entry><entry>Immune, Vascular and</entry></row><row><entry/><entry/><entry/><entry>biological processes ranging from</entry><entry>the art: Methods in Molecular</entry><entry>Inflammatory disorders</entry></row><row><entry/><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>Biology, 2000, vol. 138: Chemokine</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Protocols. Edited by: A. E. I. Proudfoot;</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power.</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>Totowa, NJ</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Human chemokine</entry><entry>GeneSeq Accession</entry><entry>WO0042071</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Autoimmune disorders,</entry></row><row><entry>CCR-2</entry><entry>B15808</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assasys known in</entry><entry>Immune, Vascular and</entry></row><row><entry/><entry/><entry/><entry>biological processes ranging from</entry><entry>the art: Methods in Molecular</entry><entry>Inflammatory disorders</entry></row><row><entry/><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>Biology, 2000, vol. 138: Chemokine</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Protocols. Edited by: A. E. I. Proudfoot;</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power.</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>Totowa, NJ</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Human chemokine</entry><entry>GeneSeq Accession</entry><entry>WO0042071</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Autoimmune disorders,</entry></row><row><entry>ENA-78</entry><entry>B15809</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assasys known in</entry><entry>Immune, Vascular and</entry></row><row><entry/><entry/><entry/><entry>biological processes ranging from</entry><entry>the art: Methods in Molecular</entry><entry>Inflammatory disorders</entry></row><row><entry/><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>Biology, 2000, vol. 138: Chemokine</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Protocols. Edited by: A. E. I. Proudfoot;</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power.</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>Totowa, NJ</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Human chemokine</entry><entry>GeneSeq Accession</entry><entry>WO0042071</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Autoimmune disorders,</entry></row><row><entry>GRObeta</entry><entry>B15810</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assasys known in</entry><entry>Immune, Vascular and</entry></row><row><entry/><entry/><entry/><entry>biological processes ranging from</entry><entry>the art: Methods in Molecular</entry><entry>Inflammatory disorders</entry></row><row><entry/><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>Biology, 2000, vol. 138: Chemokine</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Protocols. Edited by: A. E. I. Proudfoot;</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power.</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>Totowa, NJ</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Human chemokine</entry><entry>GeneSeq Accession</entry><entry>WO0042071</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Autoimmune disorders,</entry></row><row><entry>IP-10</entry><entry>B15811</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in</entry><entry>Immune, Vascular and</entry></row><row><entry/><entry/><entry/><entry>biological processes ranging from</entry><entry>the art: Methods in Molecular</entry><entry>Inflammatory disorders</entry></row><row><entry/><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>Biology, 2000, vol. 138: Chemokine</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power.</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>Totowa, NJ</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Human chemokine</entry><entry>GeneSeq Accession</entry><entry>WO0042071</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Autoimmune disorders,</entry></row><row><entry>SDF1beta</entry><entry>B15812</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in</entry><entry>Immune, Vascular and</entry></row><row><entry/><entry/><entry/><entry>biological processes ranging from</entry><entry>the art: Methods in Molecular</entry><entry>Inflammatory disorders</entry></row><row><entry/><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>Biology, 2000, vol. 138: Chemokine</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power.</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>Totowa, NJ</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Human chemokine</entry><entry>GeneSeq Accession</entry><entry>WO0042071</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Autoimmune disorders,</entry></row><row><entry>GRO alpha</entry><entry>B15813</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in</entry><entry>Immune, Vascular and</entry></row><row><entry/><entry/><entry/><entry>biological processes ranging from</entry><entry>the art: Methods in Molecular</entry><entry>Inflammatory disorders</entry></row><row><entry/><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>Biology, 2000, vol. 138: Chemokine</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power.</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>Totowa, NJ</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Human chemokine</entry><entry>GeneSeq Accession</entry><entry>WO0042071</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Autoimmune disorders,</entry></row><row><entry>MIP1beta</entry><entry>B15831</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in</entry><entry>Immune, Vascular and</entry></row><row><entry/><entry/><entry/><entry>biological processes ranging from</entry><entry>the art: Methods in Molecular</entry><entry>Inflammatory disorders</entry></row><row><entry/><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>Biology, 2000, vol. 138: Chemokine</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power.</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>Totowa, NJ</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>A human C-C</entry><entry>GeneSeq Accession</entry><entry>U.S. Pat. No. 6,096,300</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Cancer</entry></row><row><entry>chemokine</entry><entry>B07939</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in</entry></row><row><entry>designated exodus</entry><entry/><entry/><entry>biological processes ranging from</entry><entry>the art: Methods in Molecular</entry></row><row><entry/><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>Biology, 2000, vol. 138: Chemokine</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power.</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>Totowa, NJ</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Human chemokine</entry><entry>GeneSeq Accession</entry><entry>U.S. Pat. No. 6,084,071</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Chemotaxis, Gene</entry></row><row><entry>L105_7</entry><entry>Y96922</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in</entry><entry>Therapy, Wound</entry></row><row><entry/><entry/><entry/><entry>biological processes ranging from</entry><entry>the art: Methods in Molecular</entry><entry>healing</entry></row><row><entry/><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>Biology, 2000, vol. 138: Chemokine</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power.</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>Totowa, NJ</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Human chemokine</entry><entry>GeneSeq Accession</entry><entry>U.S. Pat. No. 6,084,071</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Chemotaxis, Gene</entry></row><row><entry>L105_3</entry><entry>Y96923</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in</entry><entry>Therapy, Wound</entry></row><row><entry/><entry/><entry/><entry>biological processes ranging from</entry><entry>the art: Methods in Molecular</entry><entry>healing</entry></row><row><entry/><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>Biology, 2000, vol. 138: Chemokine</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power.</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>Totowa, NJ</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Human secondary</entry><entry>GeneSeq Accession</entry><entry>WO0038706</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Cancer, Vascular and</entry></row><row><entry>lymphoid</entry><entry>B01434</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in</entry><entry>Immune disorders</entry></row><row><entry>chemokine (SLC)</entry><entry/><entry/><entry>biological processes ranging from</entry><entry>the art: Methods in Molecular</entry></row><row><entry/><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>Biology, 2000, vol. 138: Chemokine</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power.</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>Totowa, NJ</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Human non-ELR</entry><entry>GeneSeq Accession</entry><entry>WO0029439</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Immune and</entry></row><row><entry>CXC chemokine</entry><entry>Y96310</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in</entry><entry>Inflammatory disorders,</entry></row><row><entry>H174</entry><entry/><entry/><entry>biological processes ranging from</entry><entry>the art: Methods in Molecular</entry><entry>Cancer, Haemostatic</entry></row><row><entry/><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>Biology, 2000, vol. 138: Chemokine</entry><entry>and thrombolytic</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry><entry>activity</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power.</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>Totowa, NJ</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Human non-ELR</entry><entry>GeneSeq Accession</entry><entry>WO0029439</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Immune and</entry></row><row><entry>CXC chemokine</entry><entry>Y96311</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in</entry><entry>Inflammatory disorders,</entry></row><row><entry>IP10</entry><entry/><entry/><entry>biological processes ranging from</entry><entry>the art: Methods in Molecular</entry><entry>Cancer, haemostatic and</entry></row><row><entry/><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>Biology, 2000, vol. 138: Chemokine</entry><entry>thrombolytic activity</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power.</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>Totowa, NJ</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to ~17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Human non-ELR</entry><entry>GeneSeq Accession</entry><entry>WO0029439</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Immune and</entry></row><row><entry>CXC chemokine</entry><entry>Y96313</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in</entry><entry>Inflammatory disorders,</entry></row><row><entry>Mig</entry><entry/><entry/><entry>biological processes ranging from</entry><entry>the art: Methods in Molecular</entry><entry>Cancer, haemostatic and</entry></row><row><entry/><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>Biology, 2000, vol. 138: Chemokine</entry><entry>thrombolytic activity</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power.</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>Totowa, NJ</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to <sup>~</sup>17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Human chemokine</entry><entry>GeneSeq Accession</entry><entry>WO0028035</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Cancer, wound healing,</entry></row><row><entry>Ckbeta-7</entry><entry>Y96280</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in</entry><entry>inflammatory and</entry></row><row><entry/><entry/><entry/><entry>biological processes ranging from</entry><entry>the art: Methods in Molecular</entry><entry>immunoregulatory</entry></row><row><entry/><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>Biology, 2000, vol. 138: Chemokine</entry><entry>disorders</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power.</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>Totowa, NJ</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to <sup>~</sup>17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Human chemokine</entry><entry>GeneSeq Accession</entry><entry>WO0028035</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Cancer, wound healing,</entry></row><row><entry>MIP-1alpha</entry><entry>Y96281</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in</entry><entry>inflammatory and</entry></row><row><entry/><entry/><entry/><entry>biological processes ranging from</entry><entry>the art: Methods in Molecular</entry><entry>immunoregulatory</entry></row><row><entry/><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>Biology, 2000, vol. 138: Chemokine</entry><entry>disorders</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power.</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>Totowa, NJ</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to <sup>~</sup>17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Human mature</entry><entry>GenSeq Accession</entry><entry>WO0028035</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Cancer, wound healing,</entry></row><row><entry>chemokine</entry><entry>Y96282</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in</entry><entry>inflammatory and</entry></row><row><entry>Ckbeta-7</entry><entry/><entry/><entry>biological processes ranging from</entry><entry>the art: Methods in Molecular</entry><entry>immunoregulatory</entry></row><row><entry>(optionally</entry><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>Biology, 2000, vol. 138: Chemokine</entry><entry>disorders</entry></row><row><entry>truncated)</entry><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power.</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>Totowa, NJ</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to <sup>~</sup>17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Human chemokine</entry><entry>GeneSeq Accession</entry><entry>WO0018431</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Soluble CXCR3</entry></row><row><entry>receptor CXCR3</entry><entry>Y79372</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in</entry><entry>polypeptides may be</entry></row><row><entry/><entry/><entry/><entry>biological processes ranging from</entry><entry>the art: Methods in Molecular</entry><entry>useful for inhibiting</entry></row><row><entry/><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>Biology, 2000, vol. 138: Chemokine</entry><entry>chemokine activities</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry><entry>and viral infection.</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power.</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>Totowa, NJ</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to <sup>~</sup>17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Human neurotactin</entry><entry>GeneSeq Accession</entry><entry>U.S. Pat. No. 6,043,086</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Neurological disorders,</entry></row><row><entry>chemokine like</entry><entry>Y53259</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in</entry><entry>Immune and respiratory</entry></row><row><entry>domain</entry><entry/><entry/><entry>biological processes ranging from</entry><entry>the art: Methods in Molecular</entry><entry>disorders</entry></row><row><entry/><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>Biology, 2000, vol. 138: Chemokine</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power.</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>Totowa, NJ</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to <sup>~</sup>17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified.</entry></row><row><entry>Human CC type</entry><entry>GeneSeq Accession</entry><entry>JP11302298</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Cancer and infectious</entry></row><row><entry>chemokine</entry><entry>Y57771</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in</entry><entry>diseases</entry></row><row><entry>interleukin C</entry><entry/><entry/><entry>biological processes ranging from</entry><entry>the art: Methods in Molecular</entry></row><row><entry/><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>Biology, 2000, vol. 138: Chemokine</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power.</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>Totowa, NJ</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to <sup>~</sup>17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified</entry></row><row><entry>Human CKbeta-9</entry><entry>GeneSeq Accession</entry><entry>U.S. Pat. No. 6,153,441</entry><entry>Chemokines are a family of related</entry><entry>Chemokine activities can be</entry><entry>Cancer, Auto-immune</entry></row><row><entry/><entry>B50860</entry><entry/><entry>small, secreted proteins involved in</entry><entry>determined using assays known in</entry><entry>and inflammatory</entry></row><row><entry/><entry/><entry/><entry>biological processes ranging from</entry><entry>the art: Methods in Molecular</entry><entry>disorders,</entry></row><row><entry/><entry/><entry/><entry>hematopoiesis, angiogenesis, and</entry><entry>Biology, 2000, vol. 138: Chemokine</entry><entry>Cardiovascular</entry></row><row><entry/><entry/><entry/><entry>leukocyte trafficking. Members of this</entry><entry>Protocols. Edited by: A. E. I. Proudfoot,</entry><entry>disorders</entry></row><row><entry/><entry/><entry/><entry>family are involved in a similarly</entry><entry>T. N. C. Wells, and C. A. Power.</entry></row><row><entry/><entry/><entry/><entry>diverse range of pathologies including</entry><entry>&#x2009;&#xa9;Humana Press Inc.,</entry></row><row><entry/><entry/><entry/><entry>inflammation, allergy, tissue rejection,</entry><entry>Totowa, NJ</entry></row><row><entry/><entry/><entry/><entry>viral infection, and tumor biology. The</entry></row><row><entry/><entry/><entry/><entry>chemokines exert their effects by acting</entry></row><row><entry/><entry/><entry/><entry>on a family of seven transmembrane G-</entry></row><row><entry/><entry/><entry/><entry>protein-coupled receptors. Over 40</entry></row><row><entry/><entry/><entry/><entry>human chemokines have been described,</entry></row><row><entry/><entry/><entry/><entry>which bind to <sup>~</sup>17 receptors thus far</entry></row><row><entry/><entry/><entry/><entry>identified</entry></row><row><entry>Preproapolipoprotein</entry><entry>GeneSeq Accession</entry><entry>WO9637608</entry><entry>Apoa-1 participates in the reverse</entry><entry>Lipid binding activity can be</entry><entry>Useful for</entry></row><row><entry>&#x201c;paris&#x201d; variant</entry><entry>W08602</entry><entry/><entry>transport of cholesterol from tissues to</entry><entry>determined using assays known in</entry><entry>cardiovascular</entry></row><row><entry/><entry/><entry/><entry>the liver for excretion by promoting</entry><entry>the art, such as, for example, the</entry><entry>disorders, cholesterol</entry></row><row><entry/><entry/><entry/><entry>cholesterol efflux from tissues and by</entry><entry>Cholesterol Efflux Assays of</entry><entry>disorders, and</entry></row><row><entry/><entry/><entry/><entry>acting as a cofactor for the lecithin</entry><entry>Takahaski et al., P.N.A.S., Vol. 96,</entry><entry>Hyperlipidaemia</entry></row><row><entry/><entry/><entry/><entry>cholesterol acyltransferase (lcat).</entry><entry>Issue 20, 11358-11363, Sep.</entry></row><row><entry/><entry/><entry/><entry/><entry>28, 1999.</entry></row><row><entry>Preproapolipoprotein</entry><entry/><entry>5,721,114</entry><entry>Apoa-1 participates in the reverse</entry><entry>Lipid binding activity can be</entry><entry>Useful for</entry></row><row><entry>&#x201c;milano&#x201d; variant</entry><entry/><entry/><entry>transport of cholesterol from tissues to</entry><entry>determined using assays known in</entry><entry>cardiovascular</entry></row><row><entry/><entry/><entry/><entry>the liver for excretion by promoting</entry><entry>the art, such as, for example, the</entry><entry>disorders, cholesterol</entry></row><row><entry/><entry/><entry/><entry>cholesterol efflux from tissues and by</entry><entry>Cholesterol Efflux Assays of</entry><entry>disorders, and</entry></row><row><entry/><entry/><entry/><entry>acting as a cofactor for the lecithin</entry><entry>Takahaski et al., P.N.A.S., Vol. 96,</entry><entry>Hyperlipidaemia</entry></row><row><entry/><entry/><entry/><entry>cholesterol acyltransferase (lcat).</entry><entry>Issue 20, 11358-11363, Sep.</entry></row><row><entry/><entry/><entry/><entry/><entry>28, 1999.</entry></row><row><entry>Glycodelin-A;</entry><entry>GeneSeq Accession</entry><entry>WO9628169</entry><entry>Naturally produced female contraceptive</entry><entry>Glycodelin-A activity can be</entry><entry>Naturally derived</entry></row><row><entry>Progesterone-</entry><entry>W00289</entry><entry/><entry>that is removed rapidly from the body</entry><entry>determined using the hemizona</entry><entry>contraceptive useful for</entry></row><row><entry>associated</entry><entry/><entry/><entry>following 2-3 days production. Uses</entry><entry>assay as described in Oehninger, S.,</entry><entry>the prevention of</entry></row><row><entry>endometrial</entry><entry/><entry/><entry>include contraception</entry><entry>Coddington, C. C., Hodgen, G. D.,</entry><entry>pregnancy.</entry></row><row><entry>protein</entry><entry/><entry/><entry/><entry>and Seppala, M (1995) Fertil. Steril.</entry></row><row><entry/><entry/><entry/><entry/><entry>63, 377-383.</entry></row><row><entry>NOGO-A</entry><entry>Genbank Accession</entry><entry/><entry>NOGO polypeptides are potent</entry><entry>Inhibition of Neurite outgrowth.</entry><entry>NOGO-A polypeptide</entry></row><row><entry/><entry>CAB99248</entry><entry/><entry>inhibitors of neurite growth.</entry><entry>Antagonists to NOGO polypeptides</entry><entry>antagonists are useful</entry></row><row><entry/><entry/><entry/><entry/><entry>may promote the outgrowth of</entry><entry>for the promotion of</entry></row><row><entry/><entry/><entry/><entry/><entry>neurites, thus inducing regeneration</entry><entry>neural growth, which</entry></row><row><entry/><entry/><entry/><entry/><entry>of neurons.</entry><entry>could be useful in the</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>treatment of neural</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>disorders and</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>dysfunction due to</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>degenerative diseases or</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>trauma; useful in the</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>treatment of neoplastic</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>diseases of the CNS;</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>induce regeneration of</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>neurons or to promote</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>the structural plasticity</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>of the CNS.</entry></row><row><entry>NOGO-B</entry><entry>Genbank Accession</entry><entry/><entry>NOGO polypeptides are potent</entry><entry>Inhibition of Neurite outgrowth.</entry><entry>NOGO-B polypeptide</entry></row><row><entry/><entry>CAB99249</entry><entry/><entry>inhibitors of neurite growth.</entry><entry>Antagonists to NOGO polypeptides</entry><entry>antagonists are useful</entry></row><row><entry/><entry/><entry/><entry/><entry>may promote the outgrowth of</entry><entry>for the promotion of</entry></row><row><entry/><entry/><entry/><entry/><entry>neurites, thus inducing regeneration</entry><entry>neural growth, which</entry></row><row><entry/><entry/><entry/><entry/><entry>of neurons.</entry><entry>could be useful in the</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>treatment of neural</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>disorders and</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>dysfunction due to</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>degenerative diseases or</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>trauma; useful in the</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>treatment of neoplastic</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>diseases of the CNS;</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>induce regeneration of</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>neurons or to promote</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>the structural plasticity</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>of the CNS.</entry></row><row><entry>NOGO-C</entry><entry>Genbank Accession</entry><entry/><entry>NOGO polypeptides are potent</entry><entry>Inhibition of Neurite outgrowth.</entry><entry>NOGO-C polypeptide</entry></row><row><entry/><entry>CAB99250</entry><entry/><entry>inhibitors of neurite growth.</entry><entry>Antagonists to NOGO polypeptides</entry><entry>antagonists are useful</entry></row><row><entry/><entry/><entry/><entry/><entry>may promote the outgrowth of</entry><entry>for the promotion of</entry></row><row><entry/><entry/><entry/><entry/><entry>neurites, thus inducing regeneration</entry><entry>neural growth, which</entry></row><row><entry/><entry/><entry/><entry/><entry>of neurons.</entry><entry>could be useful in the</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>treatment of neural</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>disorders and</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>dysfunction due to</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>degenerative diseases or</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>trauma; useful in the</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>treatment of neoplastic</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>diseases of the CNS;</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>induce regeneration of</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>neurons or to promote</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>the structural plasticity</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>of the CNS.</entry></row><row><entry>NOGO-66</entry><entry>Genbank Accession</entry><entry/><entry>NOGO polypeptides are potent</entry><entry>Inhibition of Neurite outgrowth by</entry><entry>NOGO-66 receptor</entry></row><row><entry>Receptor</entry><entry>AAG53612</entry><entry/><entry>inhibitors of neurite growth, and are</entry><entry>mediating the biological effects of</entry><entry>polypeptides are useful</entry></row><row><entry/><entry/><entry/><entry>thought to mediate their effects through</entry><entry>NOGO polypeptides. Soluble</entry><entry>for the promotion of</entry></row><row><entry/><entry/><entry/><entry>the NOGO-66 Receptor.</entry><entry>NOGO-66 receptor polypeptides</entry><entry>neural growth, which</entry></row><row><entry/><entry/><entry/><entry/><entry>may promote the outgrowth of</entry><entry>could be useful in the</entry></row><row><entry/><entry/><entry/><entry/><entry>neurites, thus inducing regeneration</entry><entry>treatment of neural</entry></row><row><entry/><entry/><entry/><entry/><entry>of neurons.</entry><entry>disorders and</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>dysfunction due to</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>degenerative diseases or</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>trauma; useful in the</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>treatment of neoplastic</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>diseases of the CNS;</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>induce regeneration of</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>neurons or to promote</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>the structural plasticity</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>of the CNS.</entry></row><row><entry>Antibodies specific</entry><entry/><entry>U.S. Pat. No. 5,416,197</entry><entry>These antibodies are useful for the</entry><entry>Collapsin activity, which is thought</entry><entry>Useful for the</entry></row><row><entry>for collapsin</entry><entry/><entry/><entry>promotion of neurite outgrowth</entry><entry>to inhibit the outgrowth of neurites,</entry><entry>promotion of neural</entry></row><row><entry/><entry/><entry/><entry/><entry>can be assayed in the presence of</entry><entry>growth, which could be</entry></row><row><entry/><entry/><entry/><entry/><entry>antibodies specific for collapsing</entry><entry>useful in the treatment</entry></row><row><entry/><entry/><entry/><entry/><entry>using assays known in the art, such</entry><entry>of neural disorders and</entry></row><row><entry/><entry/><entry/><entry/><entry>as, for example, the collapse assay</entry><entry>dysfunction due to</entry></row><row><entry/><entry/><entry/><entry/><entry>disclosed by Luo et al., Cell 1993</entry><entry>degenerative diseases or</entry></row><row><entry/><entry/><entry/><entry/><entry>Oct. 22; 75(2): 217-27</entry><entry>trauma.</entry></row><row><entry>Humanized Anti-</entry><entry/><entry>WO9845331</entry><entry>These agents have anti-inflammatory</entry><entry>VEGF activity can be determined</entry><entry>Promotion of growth</entry></row><row><entry>VEGF Antibodies,</entry><entry/><entry/><entry>and anti-cancer applications</entry><entry>using assays known in the art, such</entry><entry>and proliferation of</entry></row><row><entry>and fragments</entry><entry/><entry/><entry/><entry>as those disclosed in International</entry><entry>cells, such as vascular</entry></row><row><entry>thereof</entry><entry/><entry/><entry/><entry>Publication No. WO0045835, for</entry><entry>endothelial cells.</entry></row><row><entry/><entry/><entry/><entry/><entry>example.</entry><entry>Antagonists may be</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>useful as anti-</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>angiogenic agents, and</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>may be applicable for</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>cancer</entry></row><row><entry>Humanized Anti-</entry><entry/><entry>WO0029584</entry><entry>These agents have anti-inflammatory</entry><entry>VEGF activity can be determined</entry><entry>Promotion of growth</entry></row><row><entry>VEGF Antibodies,</entry><entry/><entry/><entry>and anti-cancer applications</entry><entry>using assays known in the art, such</entry><entry>and proliferation of</entry></row><row><entry>and fragments</entry><entry/><entry/><entry/><entry>as those disclosed in International</entry><entry>cells, such as vascular</entry></row><row><entry>thereof</entry><entry/><entry/><entry/><entry>Publication No. WO0045835, for</entry><entry>endothelial cells.</entry></row><row><entry/><entry/><entry/><entry/><entry>example.</entry><entry>Antagonists may be</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>useful as anti-</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>angiogenic agents, and</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>may be applicable for</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>cancer</entry></row><row><entry>Membrane bound</entry><entry>GeneSeq. Accession</entry><entry>WO9963088</entry><entry>Cancer, Immune Disorders</entry><entry>These proteins can be used for</entry><entry>Activities can be</entry></row><row><entry>proteins</entry><entry>Y66631-Y66765</entry><entry/><entry/><entry>linking bioactive molecules to cells</entry><entry>determined using assay</entry></row><row><entry/><entry/><entry/><entry/><entry>and for modulating biological</entry><entry>known in the art,</entry></row><row><entry/><entry/><entry/><entry/><entry>activities of cells, using the</entry><entry>suchas, for example, the</entry></row><row><entry/><entry/><entry/><entry/><entry>polypeptides for specific targeting.</entry><entry>assays disclosed in</entry></row><row><entry/><entry/><entry/><entry/><entry>The polypeptide targeting can be</entry><entry>International</entry></row><row><entry/><entry/><entry/><entry/><entry>used to kill the target cells, e.g. for</entry><entry>Publication No.</entry></row><row><entry/><entry/><entry/><entry/><entry>the treatment of cancers. These</entry><entry>WO0121658.</entry></row><row><entry/><entry/><entry/><entry/><entry>proteins are useful for the treatment</entry></row><row><entry/><entry/><entry/><entry/><entry>of immune system disorders.</entry></row><row><entry>Secreted and</entry><entry>GenSeq Accession</entry><entry>WO0053756</entry><entry>Cancer, Immune Disorders</entry><entry>These proteins can be used for</entry><entry>Activities can be</entry></row><row><entry>Transmembrane</entry><entry>B44241-B44334</entry><entry/><entry/><entry>linking bioactive molecules to cells</entry><entry>determined using assay</entry></row><row><entry>polypeptides</entry><entry/><entry/><entry/><entry>and for modulating biological</entry><entry>known in the art,</entry></row><row><entry/><entry/><entry/><entry/><entry>activities of cells, using the</entry><entry>suchas, for example, the</entry></row><row><entry/><entry/><entry/><entry/><entry>polypeptides for specific targeting.</entry><entry>assays disclosed in</entry></row><row><entry/><entry/><entry/><entry/><entry>The polypeptide targeting can be</entry><entry>International</entry></row><row><entry/><entry/><entry/><entry/><entry>used to kill the target cells, e.g. for</entry><entry>Publication No.</entry></row><row><entry/><entry/><entry/><entry/><entry>the treatment of cancers. These</entry><entry>WO0121658</entry></row><row><entry/><entry/><entry/><entry/><entry>proteins are useful for the treatment</entry></row><row><entry/><entry/><entry/><entry/><entry>of immune system disorders.</entry></row><row><entry>Secreted and</entry><entry>GeneSeq Accession</entry><entry>WO9946281</entry><entry>Cancer, Immune Disorders</entry><entry>These proteins can be used for</entry><entry>Activities can be</entry></row><row><entry>Transmembrane</entry><entry>Y41685-Y41774</entry><entry/><entry/><entry>linking bioactive molecules to cells</entry><entry>determined using assay</entry></row><row><entry>polypeptides</entry><entry/><entry/><entry/><entry>and for modulating biological</entry><entry>known in the art,</entry></row><row><entry/><entry/><entry/><entry/><entry>activities of cells, using the</entry><entry>suchas, for example, the</entry></row><row><entry/><entry/><entry/><entry/><entry>polypeptides for specific targeting.</entry><entry>assays disclosed in</entry></row><row><entry/><entry/><entry/><entry/><entry>The polypeptide targeting can be</entry><entry>International</entry></row><row><entry/><entry/><entry/><entry/><entry>used to kill the target cells, e.g. for</entry><entry>Publication No.</entry></row><row><entry/><entry/><entry/><entry/><entry>the treatment of cancers. These</entry><entry>WO0121658</entry></row><row><entry/><entry/><entry/><entry/><entry>proteins are useful for the treatment</entry></row><row><entry/><entry/><entry/><entry/><entry>of immune system disorders.</entry></row><row><entry namest="1" nameend="6" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><heading id="h-0013" level="2">Conjugation and Coupling</heading><p id="p-0142" num="0151">The present invention provides therapeutic agents comprising an ELP component and a therapeutic component, such as therapeutic proteins listed in Table 1, as well as a GLP-1 receptor agonists, insulin, Factor VII/VIIa, and functional analogs as described. Such agents may be prepared by recombinant technology and/or chemical coupling (e.g., conjugation).</p><p id="p-0143" num="0152">A recombinantly-produced ELP fusion protein, in accordance with certain embodiments of the invention, includes the ELP component and the therapeutic component associated with one another by genetic fusion. For example, the fusion protein may be generated by translation of a polynucleotide encoding the therapeutic component cloned in-frame with the ELP component (or vice versa). Such an ELP fusion protein may contain one or more copies of the therapeutic component attached to the N-terminus and/or the C-terminus of the ELP component. In some embodiments, the therapeutic proteinacious component is attached to both the N- and C-terminus of the ELP component and the fusion protein may contain one or more equivalents of the therapeutic component on either or both ends of the ELP component.</p><p id="p-0144" num="0153">In certain embodiments, the ELP component and the therapeutic components can be fused using a linker peptide of various lengths to provide greater physical separation and allow more spatial mobility between the fused portions, and thus maximize the accessibility of the therapeutic component, for instance, for binding to its cognate receptor. The linker peptide may consist of amino acids that are flexible or more rigid. For example, a flexible linker may include amino acids having relatively small side chains, and which may be hydrophilic. Without limitation, the flexible linker may contain a stretch of glycine and/or serine residues. More rigid linkers may contain, for example, more sterically hindering amino acid side chains, such as (without limitation) tyrosine or histidine. The linker may be less than about 50, 40, 30, 20, 10, or 5 amino acid residues. The linker can be covalently linked to and between an ELP component and a therapeutic component, for example, via recombinant fusion.</p><p id="p-0145" num="0154">The linker or peptide spacer may be protease-cleavable or non-cleavable. By way of example, cleavable peptide spacers include, without limitation, a peptide sequence recognized by proteases (in vitro or in vivo) of varying type, such as Tev, thrombin, factor Xa, plasmin (blood proteases), metalloproteases, cathepsins (e.g., GFLG, etc.), and proteases found in other corporeal compartments. In some embodiments employing cleavable linkers, the fusion protein (&#x201c;the therapeutic agent&#x201d;) may be inactive, less active, or less potent as a fusion, which is then activated upon cleavage of the spacer in vivo. Alternatively, where the therapeutic agent is sufficiently active as a fusion, a non-cleavable spacer may be employed. The non-cleavable spacer may be of any suitable type, including, for example, non-cleavable spacer moieties having the formula [(Gly)n-Ser]m (SEQ ID NO.: 22) where n is from 1 to 4, inclusive, and m is from 1 to 4, inclusive. Alternatively, a short ELP sequence different than the backbone ELP could be employed instead of a linker or spacer, while accomplishing the necessary effect.</p><p id="p-0146" num="0155">In still other embodiments, the therapeutic agent is a recombinant fusion having a therapeutic component flanked on each terminus by an ELP component. At least one of said ELP components may be attached via a cleavable spacer, such that the therapeutic component is inactive, but activated in vivo by proteolytic removal of a single ELP component. The resulting single ELP fusion being active, and having an enhanced half-life (or other property described herein) in vivo.</p><p id="p-0147" num="0156">In other embodiments, the present invention provides chemical conjugates of the ELP component and the therapeutic component. The conjugates can be made by chemically coupling an ELP component to a therapeutic component by any number of methods well known in the art (See e.g. Nilsson et al., 2005<i>, Ann Rev Biophys Bio Structure </i>34: 91-118). In some embodiments, the chemical conjugate can be formed by covalently linking the therapeutic component to the ELP component, directly or through a short or long linker moiety, through one or more functional groups on the therapeutic proteinacious component, e. g., amine, carboxyl, phenyl, thiol or hydroxyl groups, to form a covalent conjugate. Various conventional linkers can be used, e. g., diisocyanates, diisothiocyanates, carbodiimides, bis (hydroxysuccinimide) esters, maleimide-hydroxysuccinimide esters, glutaraldehyde and the like.</p><p id="p-0148" num="0157">Non-peptide chemical spacers can additionally be of any suitable type, including for example, by functional linkers described in Bioconjugate Techniques, Greg T. Hermanson, published by Academic Press, Inc., 1995, and those specified in the Cross-Linking Reagents Technical Handbook, available from Pierce Biotechnology, Inc. (Rockford, Ill.), the disclosures of which are hereby incorporated by reference, in their respective entireties. Illustrative chemical spacers include homobifunctional linkers that can attach to amine groups of Lys, as well as heterobifunctional linkers that can attach to Cys at one terminus, and to Lys at the other terminus.</p><p id="p-0149" num="0158">In certain embodiments, relatively small ELP components (e.g., ELP components of less than about 30 kDa, 25 kDa, 20 kDa, 15 kDa, or 10 kDa), that do not transition at room temperature (or human body temperature, e.g., Tt &#x3e;37&#xb0; C.), are chemically coupled or crosslinked. For example, two relatively small ELP components, having the same or different properties, may be chemically coupled. Such coupling, in some embodiments, may take place in vivo, by the addition of a single cysteine residue at or around the C-terminus of the ELP. Such ELP components may each be fused to one or more therapeutic components, so as to increase activity or avidity at the target.</p><heading id="h-0014" level="2">Polynucleotides, Vectors, and Host Cells</heading><p id="p-0150" num="0159">In another aspect, the invention provides polynucleotides comprising a nucleotide sequence encoding the therapeutic agent of the invention. Such polynucleotides further comprise, in addition to sequences encoding the ELP and therapeutic components, one or more expression control elements. For example, the polynucleotide, may comprise one or more promoters or transcriptional enhancers, ribosomal binding sites, transcription termination signals, and polyadenylation signals, as expression control elements. The polynucleotide may be inserted within any suitable vector, which may be contained within any suitable host cell for expression.</p><p id="p-0151" num="0160">A vector comprising the polynucleotide can be introduced into a cell for expression of the therapeutic agent. The vector can remain episomal or become chromosomally integrated, as long as the insert encoding the therapeutic agent can be transcribed. Vectors can be constructed by standard recombinant DNA technology. Vectors can be plasmids, phages, cosmids, phagemids, viruses, or any other types known in the art, which are used for replication and expression in prokaryotic or eukaryotic cells. It will be appreciated by one of skill in the art that a wide variety of components known in the art (such as expression control elements) may be included in such vectors, including a wide variety of transcription signals, such as promoters and other sequences that regulate the binding of RNA polymerase onto the promoter. Any promoter known to be effective in the cells in which the vector will be expressed can be used to initiate expression of the therapeutic agent. Suitable promoters may be inducible or constitutive. Examples of suitable promoters include the SV40 early promoter region, the promoter contained in the 3&#x2032; long terminal repeat of Rous sarcoma virus, the HSV-1 (herpes simplex virus-1) thymidine kinase promoter, the regulatory sequences of the metallothionein gene, etc., as well as the following animal transcriptional control regions, which exhibit tissue specificity and have been utilized in transgenic animals: elastase I gene control region which is active in pancreatic acinar cells; insulin gene control region which is active in pancreatic beta cells, immunoglobulin gene control region which is active in lymphoid cells, mouse mammary tumor virus control region which is active in testicular, breast, lymphoid and mast cells, albumin gene control region which is active in liver, alpha-fetoprotein gene control region which is active in liver, alpha 1-antitrypsin gene control region which is active in the liver, beta-globin gene control region which is active in erythroid cells, myelin basic protein gene control region which is active in oligodendrocyte cells in the brain, myosin light chain-2 gene control region which is active in skeletal muscle, and gonadotropin releasing hormone gene control region which is active in the hypothalamus.</p><heading id="h-0015" level="2">Pharmaceutical Compositions</heading><p id="p-0152" num="0161">The present invention further provides pharmaceutical compositions comprising the therapeutic agents of the invention (as described above) together with a pharmaceutically acceptable carrier or excipient. Such pharmaceutical compositions may be employed in the methods of treatment as described above, for each of the therapeutic proteins, e.g., the therapeutic proteins listed in Table 1, GLP-1 receptor agonists, insulin, and Factor VII/VIIa embodiments.</p><p id="p-0153" num="0162">The therapeutic agents of the invention may overcome certain deficiencies of peptide agents when administered (e.g., parenterally), including in some embodiments, the limitation that such peptides may be easily metabolized by plasma proteases or cleared from circulation by kidney filtration. Traditionally, the oral route of administration of peptide agents may also be problematic, because in addition to proteolysis in the stomach, the high acidity of the stomach destroys such peptide agents before they reach their intended target tissue. Peptides and peptide fragments produced by the action of gastric and pancreatic enzymes are cleaved by exo and endopeptidases in the intestinal brush border membrane to yield di- and tripeptides, and even if proteolysis by pancreatic enzymes is avoided, polypeptides are subject to degradation by brush border peptidases. Any of the peptide agents that survive passage through the stomach are further subjected to metabolism in the intestinal mucosa where a penetration barrier prevents entry into the cells. In certain embodiments, the therapeutic agents of the invention may overcome such deficiencies, and provide compositional forms having enhanced efficacy, bioavailability, therapeutic half-life, persistence, degradation assistance, etc. The therapeutic agents of the invention thus include oral and parenteral dose forms, as well as various other dose forms, by which peptide agents can be utilized in a highly effective manner. For example, in some embodiments, such agents may achieve high mucosal absorption, and the concomitant ability to use lower doses to elicit an optimum therapeutic effect.</p><p id="p-0154" num="0163">The therapeutic agents of the present invention may be administered in smaller doses and/or less frequently than unfused or unconjugated counterparts. While one of skill in the art can determine the desirable dose in each case, a suitable dose of the therapeutic agent for achievement of therapeutic benefit, may, for example, be in a range of about 1 microgram (&#x3bc;g) to about 100 milligrams (mg) per kilogram body weight of the recipient per day, preferably in a range of about 10 &#x3bc;g to about 50 mg per kilogram body weight per day and most preferably in a range of about 10 &#x3bc;g to about 50 mg per kilogram body weight per day. The desired dose may be presented as one dose or two or more sub-doses administered at appropriate intervals throughout the day. These sub-doses can be administered in unit dosage forms, for example, containing from about 10 &#x3bc;g to about 1000 mg, preferably from about 50 &#x3bc;g to about 500 mg, and most preferably from about 50 &#x3bc;g to about 250 mg of active ingredient per unit dosage form. Alternatively, if the condition of the recipient so requires, the doses may be administered as a continuous infusion.</p><p id="p-0155" num="0164">The mode of administration and dosage forms will of course affect the therapeutic amount of the peptide active therapeutic agent that is desirable and efficacious for a given treatment application. For example, orally administered dosages can be at least twice, e.g., 2-10 times, the dosage levels used in parenteral administration methods.</p><p id="p-0156" num="0165">The therapeutic agents of the invention may be administered per se as well as in various forms including pharmaceutically acceptable esters, salts, and other physiologically functional derivatives thereof. The present invention also contemplates pharmaceutical formulations, both for veterinary and for human medical use, which include therapeutic agents of the invention. In such pharmaceutical and medicament formulations, the therapeutic agents can be used together with one or more pharmaceutically acceptable carrier(s) therefore and optionally any other therapeutic ingredients. The carrier(s) must be pharmaceutically acceptable in the sense of being compatible with the other ingredients of the formulation and not unduly deleterious to the recipient thereof. The therapeutic agents are provided in an amount effective to achieve the desired pharmacological effect, as described above, and in a quantity appropriate to achieve the desired daily dose.</p><p id="p-0157" num="0166">The formulations of the therapeutic agent include those suitable for parenteral as well as non-parenteral administration, and specific administration modalities include oral, rectal, buccal, topical, nasal, ophthalmic, subcutaneous, intramuscular, intravenous, transdermal, intrathecal, intra-articular, intra-arterial, sub-arachnoid, bronchial, lymphatic, vaginal, and intra-uterine administration. Formulations suitable for oral and parenteral administration are preferred.</p><p id="p-0158" num="0167">When the therapeutic agent is used in a formulation including a liquid solution, the formulation advantageously can be administered orally or parenterally. When the therapeutic agent is employed in a liquid suspension formulation or as a powder in a biocompatible carrier formulation, the formulation may be advantageously administered orally, rectally, or bronchially.</p><p id="p-0159" num="0168">When the therapeutic agent is used directly in the form of a powdered solid, the active agent can be advantageously administered orally. Alternatively, it may be administered bronchially, via nebulization of the powder in a carrier gas, to form a gaseous dispersion of the powder which is inspired by the patient from a breathing circuit comprising a suitable nebulizer device.</p><p id="p-0160" num="0169">The formulations comprising the therapeutic agent of the present invention may conveniently be presented in unit dosage forms and may be prepared by any of the methods well known in the art of pharmacy. Such methods generally include the step of bringing the therapeutic agents into association with a carrier which constitutes one or more accessory ingredients. Typically, the formulations are prepared by uniformly and intimately bringing the therapeutic agent into association with a liquid carrier, a finely divided solid carrier, or both, and then, if necessary, shaping the product into dosage forms of the desired formulation.</p><p id="p-0161" num="0170">Formulations suitable for oral administration may be presented as discrete units such as capsules, cachets, tablets, or lozenges, each containing a predetermined amount of the active ingredient as a powder or granules; or a suspension in an aqueous liquor or a non-aqueous liquid, such as a syrup, an elixir, an emulsion, or a draught.</p><p id="p-0162" num="0171">A tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine, with the therapeutic agent being in a free-flowing form such as a powder or granules which optionally is mixed with a binder, disintegrant, lubricant, inert diluent, surface active agent, or discharging agent. Molded tablets comprised of a mixture of the powdered peptide active therapeutic agent-ELP construct(s) with a suitable carrier may be made by molding in a suitable machine.</p><p id="p-0163" num="0172">A syrup may be made by adding the peptide active therapeutic agent-ELP construct(s) to a concentrated aqueous solution of a sugar, for example sucrose, to which may also be added any accessory ingredient(s). Such accessory ingredient(s) may include flavorings, suitable preservative, agents to retard crystallization of the sugar, and agents to increase the solubility of any other ingredient, such as a polyhydroxy alcohol, for example glycerol or sorbitol.</p><p id="p-0164" num="0173">Formulations suitable for parenteral administration conveniently comprise a sterile aqueous preparation of the therapeutic agent, which preferably is isotonic with the blood of the recipient (e.g., physiological saline solution). Such formulations may include suspending agents and thickening agents or other microparticulate systems which are designed to target the peptide active therapeutic agent to blood components or one or more organs. The formulations may be presented in unit-dose or multi-dose form.</p><p id="p-0165" num="0174">Nasal spray formulations comprise purified aqueous solutions of the therapeutic agent with preservative agents and isotonic agents. Such formulations are preferably adjusted to a pH and isotonic state compatible with the nasal mucus membranes.</p><p id="p-0166" num="0175">Formulations for rectal administration may be presented as a suppository with a suitable carrier such as cocoa butter, hydrogenated fats, or hydrogenated fatty carboxylic acid.</p><p id="p-0167" num="0176">Topical formulations comprise the therapeutic agent dissolved or suspended in one or more media, such as mineral oil, petroleum, polyhydroxy alcohols, or other bases used for topical pharmaceutical formulations.</p><p id="p-0168" num="0177">In addition to the aforementioned ingredients, the formulations of this invention may further include one or more accessory ingredient(s) selected from diluents, buffers, flavoring agents, disintegrants, surface active agents, thickeners, lubricants, preservatives (including antioxidants), and the like.</p><p id="p-0169" num="0178">The features and advantages of the present invention are more fully shown with respect to the following non-limiting examples.</p><heading id="h-0016" level="1">EXAMPLES</heading><heading id="h-0017" level="1">Example 1: Construction of Various ELP Component Constructs</heading><p id="p-0170" num="0179">Cloning steps were conducted in <i>Escherichia coli </i>strain XL1-Blue (rec A1, endA1, gyrA96, thi-1, hsdR17 (r<sub>k</sub><sup>&#x2212;</sup>, m<sub>k</sub>+), supE44, relA1, lac[F&#x2032;, proAB, l&#x3b1;cl<sup>q</sup>Z&#x394;M15, Tn10 (Tet<sup>r</sup>)] (Stratagene La Jolla, Calif.). pUC19 (NEB, Beverly, Mass.) was used as the cloning vector for the ELP construction (Meyer and Chilkoti, <i>Nat. Biotechnol., </i>17(11):1112-5, 1999). Modified forms of pET15b and pET24d vectors (Novagen) were used to express ELP and ELP-fusion proteins in BL21 Star (DE3) strain (F<sup>&#x2212;</sup>, ompT, hsdS<sub>B </sub>(r<sub>B</sub><sup>&#x2212;</sup> m<sub>B</sub><sup>&#x2212;</sup>), gal, dcm, rne131, (DE3)) (Invitrogen Carlsbed, Calif.) or BLR(DE3) (F<sup>&#x2212;</sup>, ompT, hsdS<sub>B </sub>(r<sub>B</sub><sup>&#x2212;</sup> m<sub>B</sub><sup>&#x2212;</sup>), gal, dcm, &#x394;(srl-recA) 306::Tn10(TcR)(DE3)) (Novagen Madison, Wis.). Synthetic DNA oligos were purchased from Integrated DNA Technologies, Coralville, Iowa. All vector constructs were made using standard molecular biology protocols (e.g., <i>Current Protocols in Molecular Biology</i>, ed. Ausubel, et al., 1995).</p><p id="p-0171" num="0000">Construction of ELP1 [V<sub>5</sub>A<sub>2</sub>G<sub>3</sub>] Gene Series</p><p id="p-0172" num="0180">The ELP1 [V<sub>5</sub>A<sub>2</sub>G<sub>3</sub>] series designate polypeptides containing multiple repeating units of the pentapeptide VPGXG (SEQ ID NO: 3), where X is valine, alanine, and glycine at a relative ratio of 5:2:3.</p><p id="p-0173" num="0181">The ELP1 [V<sub>5</sub>A<sub>2</sub>G<sub>3</sub>] series monomer, ELP1 [V<sub>5</sub>A<sub>2</sub>G<sub>3</sub>-10], was created by annealing four 5&#x2032; phosphorylated, PAGE purified synthetic oligos to form double stranded DNA with EcoRI and HindIII compatible ends (Meyer and Chilkoti, <i>Nat. Biotechnol., </i>17(11):1112-5, 1999). The oligos were annealed in a 1 &#x3bc;M mixture of the four oligos in 50 &#x3bc;l IX ligase buffer (Invitrogen) to 95&#xb0; C. in a heating block than the block was allowed to cool slowly to room temperature. The ELP1 [V<sub>5</sub>A<sub>2</sub>G<sub>3</sub>-10]/EcoRI-HindIII DNA segment was ligated into a pUC19 vector digested with EcoRI and HindIII and CIAP dephosphorylated (Invitrogen) to form pUC19-ELP1 [V<sub>5</sub>A<sub>2</sub>G<sub>3</sub>-10]. Building of the ELP1 [V<sub>5</sub>A<sub>2</sub>G<sub>3</sub>] series library began by inserting ELP1 [V<sub>5</sub>A<sub>2</sub>G<sub>3</sub>-10] PflMI/BglI fragment from pUC19-ELP1 [V<sub>5</sub>A<sub>2</sub>G<sub>3</sub>-10] into pUC19-ELP1 [V<sub>5</sub>A<sub>2</sub>G<sub>3</sub>-10] linearized with PflMI and dephosphorylated with CIAP to create pUC19-ELP1 [V<sub>5</sub>A<sub>2</sub>G<sub>3</sub>-20]. pUC19-ELP1 [V<sub>5</sub>A<sub>2</sub>G<sub>3</sub>-20] was then built up to pUC19-ELP1 [V<sub>5</sub>A<sub>2</sub>G<sub>3</sub>-30] and pUC19-ELP1 [V<sub>5</sub>A<sub>2</sub>G<sub>3</sub>-40] by ligating ELP1 [V<sub>5</sub>A<sub>2</sub>G<sub>3</sub>-10] or ELP1 [V<sub>5</sub>A<sub>2</sub>G<sub>3</sub>-20] PflMI/BglI fragments respectively into PflMI digested pUC 19-ELP1 [V<sub>5</sub>A<sub>2</sub>G<sub>3</sub>-20]. This procedure was used to expand the ELP1 [V<sub>5</sub>A<sub>2</sub>G<sub>3</sub>] series to create pUC19-ELP1 [V<sub>5</sub>A<sub>2</sub>G<sub>3</sub>-60], pUC19-ELP1 [V<sub>5</sub>A<sub>2</sub>G<sub>3</sub>-90] and pUC19-ELP1 [V<sub>5</sub>A<sub>2</sub>G<sub>3</sub>-180] genes.</p><p id="p-0174" num="0000">Construction of ELP1 [K<sub>1</sub>V<sub>2</sub>F<sub>1</sub>] Gene Series</p><p id="p-0175" num="0182">The ELP1 [K<sub>1</sub>V<sub>2</sub>F<sub>1</sub>] series designate polypeptides containing multiple repeating units of the pentapeptide VPGXG (SEQ ID NO: 3), where X is lysine, valine, and phenylalanine at a relative ratio of 1:2:1.</p><p id="p-0176" num="0183">The ELP1 [K<sub>1</sub>V<sub>2</sub>F<sub>1</sub>] series monomer, ELP1 [K<sub>1</sub>V<sub>2</sub>F<sub>1</sub>-4], was created by annealing two 5&#x2032; phosphorylated, PAGE purified synthetic oligos to form double stranded DNA with EcoRI and HindIII compatible ends (Meyer and Chilkoti, 1999). The oligos were annealed in a 1 &#x3bc;M mixture of the four oligos in 50 &#x3bc;l 1&#xd7; ligase buffer (Invitrogen) to 95&#xb0; C. in a heating block then the block was allowed to cool slowly to room temperature. The ELP1 [K<sub>1</sub>V<sub>2</sub>F<sub>1</sub>-4]/EcoRI-HindIII DNA segment was ligated into a pUC19 vector digested with EcoRI and HindIII and CIAP dephosphorylated (Invitrogen) to form pUC19-ELP1 [K<sub>1</sub>V<sub>2</sub>F<sub>1</sub>-4]. Building of the ELP1 [K<sub>1</sub>V<sub>2</sub>F<sub>1</sub>] series library began by inserting ELP1 [K<sub>1</sub>V<sub>2</sub>F<sub>1</sub>-4] PflMI/Bgl1 fragment from pUC19-ELP1 [K<sub>1</sub>V<sub>2</sub>F<sub>1</sub>-4] into pUC19-ELP1 [K<sub>1</sub>V<sub>2</sub>F<sub>1</sub>-4] linearized with PflM1 and dephosphorylated with CIAP to create pUC19-ELP1 [K<sub>1</sub>V<sub>2</sub>F<sub>1</sub>-8]. Using the same procedure the ELP1 [K<sub>1</sub>V<sub>2</sub>F<sub>1</sub>] series was doubled at each ligation to form pUC19-ELP1 [K<sub>1</sub>V<sub>2</sub>F<sub>1</sub>-16], pUC19-ELP1 [K<sub>1</sub>V<sub>2</sub>F<sub>1</sub>-32], pUC19-ELP1 [K<sub>1</sub>V<sub>2</sub>F<sub>1</sub>-64] and pUC19-ELP1 [K<sub>1</sub>V<sub>2</sub>F<sub>1</sub>-128].</p><p id="p-0177" num="0000">Construction of ELP1 [K<sub>1</sub>V<sub>7</sub>F<sub>1</sub>] Gene Series</p><p id="p-0178" num="0184">The ELP1 [K<sub>1</sub>V<sub>7</sub>F<sub>1</sub>] series designate polypeptides containing multiple repeating units of the pentapeptide VPGXG (SEQ ID NO: 3), where X is lysine, valine, and phenylalanine at a relative ratio of 1:7:1.</p><p id="p-0179" num="0185">The ELP1 [K<sub>1</sub>V<sub>7</sub>F<sub>1</sub>] series monomer, ELP1 [K<sub>1</sub>V<sub>7</sub>F<sub>1</sub>-9], was created by annealing four 5&#x2032; phosphorylated, PAGE purified synthetic oligos to form double stranded DNA with PflMI and HindIII compatible ends. The ELP1 [K<sub>1</sub>V<sub>7</sub>F<sub>1</sub>-9] DNA segment was than ligated into PflM1/HindIII dephosphorylated PUC19-ELP1 [V<sub>5</sub>A<sub>2</sub>G<sub>3</sub>-180] vector thereby substituting ELP1 [V<sub>5</sub>A<sub>2</sub>G<sub>3</sub>-180] for ELP1 [K<sub>1</sub>V<sub>7</sub>F<sub>1</sub>-9] to create the pUC19-ELP1 [K<sub>1</sub>V<sub>7</sub>F<sub>1</sub>-9] monomer. The ELP1 [K<sub>1</sub>V<sub>7</sub>F<sub>1</sub>] series was expanded in the same manner as the ELP1 [K<sub>1</sub>V<sub>2</sub>F<sub>1</sub>] series to create pUC19-ELP1 [K<sub>1</sub>V<sub>7</sub>F<sub>1</sub>-18], PUC19-ELP1 [K<sub>1</sub>V<sub>7</sub>F<sub>1</sub>-36], pUC19-ELP1 [K<sub>1</sub>V<sub>7</sub>F<sub>1</sub>-72] and pUC19-ELP1 [K<sub>1</sub>V<sub>7</sub>F<sub>1</sub>-144].</p><heading id="h-0018" level="2">Construction of ELP1 M Gene Series</heading><p id="p-0180" num="0186">The ELP1 [V] series designate polypeptides containing multiple repeating units of the pentapeptide VPGXG (SEQ ID NO: 3), where X is exclusively valine.</p><p id="p-0181" num="0187">The ELP1 [V] series monomer, ELP1 [V-5], was created by annealing two 5&#x2032; phosphorylated, PAGE purified synthetic oligos to form double stranded DNA with EcoRI and HindIII compatible ends. The ELP1 [V-5] DNA segment was than ligated into EcoRI/HindIII dephosphorylated pUC19 vector to create the pUC19-ELP1 [V-5] monomer. The ELP1 [V] series was created in the same manner as the ELP1 [V<sub>5</sub>A<sub>2</sub>G<sub>3</sub>] series, ultimately expanding pUC19-ELP1 [V-5] to pUC19-ELP1 [V-60] and pUC19-ELP1 [V-120].</p><heading id="h-0019" level="2">Construction of ELP2 Gene Series</heading><p id="p-0182" num="0188">The ELP2 series designate polypeptides containing multiple repeating units of the pentapeptide AVGVP.</p><p id="p-0183" num="0189">The ELP2 series monomer, ELP2 [5], was created by annealing two 5&#x2032; phosphorylated, PAGE purified synthetic oligos to form double stranded DNA with EcoRI and HindIII compatible ends. The ELP2 [5] DNA segment was than ligated into EcoRI/HindIII dephosphorylated pUC19 vector to create the pUC19-ELP2[5] monomer. The ELP2 series was expanded in the same manner as the ELP1 [K<sub>1</sub>V<sub>2</sub>F<sub>1</sub>] series to create pUC19-ELP2[10], pUC19-ELP2 [30], pUC 19-ELP2 [60] and pUC 19-ELP2 [120].</p><heading id="h-0020" level="2">Construction of ELP3 M Gene Series</heading><p id="p-0184" num="0190">The ELP3 [V] series designate polypeptides containing multiple repeating units of the pentapeptide IPGXG (SEQ ID NO: 5), where X is exclusively valine.</p><p id="p-0185" num="0191">The ELP3 [V] series monomer, ELP3 [V-5], was created by annealing two 5&#x2032; phosphorylated, PAGE purified synthetic oligos to form double stranded DNA with PfLM1 amino terminal and GGC carboxyl terminal compatible ends due to the lack of a convenient carboxyl terminal restriction site but still enable seamless addition of the monomer. The ELP3 [V-5] DNA segment was then ligated into PflM1/BglI dephosphorylated pUC19-ELP4[V-5], thereby substituting ELP4 [V-5] for ELP3 [V-5] to create the pUC19-ELP3 [V-5] monomer. The ELP3 [V] series was expanded by ligating the annealed ELP3 oligos into pUC19-ELP3[V-5] digested with PflMI. Each ligation expands the ELP3 [V] series by 5 to create ELP3 [V-10], ELP3 [V-15], etc.</p><heading id="h-0021" level="2">Construction of the ELP4 M Gene Series</heading><p id="p-0186" num="0192">The ELP4 [V] series designate polypeptides containing multiple repeating units of the pentapeptide LPGXG (SEQ ID NO: 7), where X is exclusively valine.</p><p id="p-0187" num="0193">The ELP4 [V] series monomer, ELP4 [V-5], was created by annealing two 5&#x2032; phosphorylated, PAGE purified synthetic oligos to form double stranded DNA with EcoRI and HindIII compatible ends. The ELP4 [V-5] DNA segment was than ligated into EcoRI/HindIII dephosphorylated pUC19 vector to create the pUC19-ELP4[V-5] monomer. The ELP4 [V] series was expanded in the same manner as the ELP1 [K<sub>1</sub>V<sub>2</sub>F<sub>1</sub>] series to create pUC19-ELP4[V-10], pUC19-ELP4[V-30], pUC19-ELP4[V-60] and pUC19-ELP4[V-120].</p><p id="p-0188" num="0194">The ELP genes were also inserted into other vectors such as pET15b-SD0, pET15b-SD3, pET15b-SD5, pET15b-SD6, and pET24d-SD21. The pET vector series are available from Novagen, San Diego, Calif.</p><p id="p-0189" num="0195">The pET15b-SD0 vector was formed by modifying the pET15b vector using SD0 double-stranded DNA segment containing the multicloning restriction site (SacI-NdeI-NcoI-XhoI-SnaBI-BamHI). The SD0 double-stranded DNA segment had XbaI and BamHI compatible ends and was ligated into XbaI/BamHI linearized and 5-dephosphorylated pET15b to form the pet15b-SD0 vector.</p><p id="p-0190" num="0196">The pET15b-SD3 vector was formed by modifying the pET15b-SD0 vector using SD3 double-stranded DNA segment containing a SfiI restriction site upstream of a hinge region-thrombin cleavage site followed by the multicloning site (NdeI-NcoI-XhoI-SnaBI-BamHI). The SD3 double-stranded DNA segment had SacI and NdeI compatible ends and was ligated into SacI/NdeI linearized and 5-dephosphorylated pET15b-SD0 to form the pET15b-SD3 vector.</p><p id="p-0191" num="0197">The pET15b-SD5 vector was formed by modifying the pET15b-SD3 vector using the SD5 double-stranded DNA segment containing a SfiI restriction site upstream of a thrombin cleavage site followed by a hinge and the multicloning site (NdeI-NcoI-XhoI-SnaBI-BamHI). The SD5 double-stranded DNA segment had SfiI and NdeI compatible ends and was ligated into SfiI/NdeI linearized and 5-dephosphorylated pET15b-SD3 to form the pET15b-SD5 vector.</p><p id="p-0192" num="0198">The pET15b-SD6 vector was formed by modifying the pET15b-SD3 vector using the SD6 double-stranded DNA segment containing a SfiI restriction site upstream of a linker region-TEV cleavage site followed by the multicloning site (NdeI-NcoI-XhoI-SnaBI-BamH&#xcf;). The SD6 double-stranded DNA segment had SfiI and NheI compatible ends and was ligated into SfiI/NdeI linearized and 5-dephosphorylated pET15b-SD3 to form the pET15b-SD6 vector.</p><p id="p-0193" num="0199">The pET24d-SD21 vector was formed by modifying the pET24d vector using the SD21 double-stranded DNA segment with NcoI and NheI compatible ends. The SD21 double-stranded DNA segment was ligated into NcoI/NheI linearized and 5&#x2032; dephosphorylated pET24d to create the pET24d-SD21 vector, which contained a new multi-cloning site NcoI-SfiI-NheI-BamHI-EcoRI-SacI-San-HindIII-NotI-XhoI with two stop codons directly after the SfiI site for insertion and expression of ELP with the minimum number of extra amino acids.</p><p id="p-0194" num="0200">The pUC19-ELP1 [V<sub>5</sub>A<sub>2</sub>G<sub>3</sub>-60], pUC19-ELP1 [V<sub>5</sub>A<sub>2</sub>G<sub>3</sub>-90], and pUC19-ELP1 [V<sub>5</sub>A<sub>2</sub>G<sub>3</sub>-180] plasmids produced in XL1-Blue were digested with PflMI and BglI, and the ELP-containing fragments were ligated into the SfiI site of the pET15b-SD3 expression vector as described hereinabove to create pET15b-SD3-ELP1 [V<sub>5</sub>A<sub>2</sub>G<sub>3</sub>-60], pET15b-SD5-ELP1 [V<sub>5</sub>A<sub>2</sub>G<sub>3</sub>-90] and pET15b-SD5-ELP1 [V<sub>5</sub>A<sub>2</sub>G<sub>3</sub>-180], respectively.</p><p id="p-0195" num="0201">The pUC19-ELP1 [V<sub>5</sub>A<sub>2</sub>G<sub>3</sub>-90], pUC19-ELP1 [V<sub>5</sub>A<sub>2</sub>G<sub>3</sub>-180], pUC19-ELP1 [V-60] and pUC19-ELP1 [V-120] plasmids produced in XL1-Blue were digested with PflMI and BglI, and the ELP-containing fragments were ligated into the SfiI site of the pET15b-SD5 expression vector as described hereinabove to create pET15b-SD5-ELP1 [V<sub>5</sub>A<sub>2</sub>G<sub>3</sub>-90], pET15b-SD5-ELP1 [V<sub>5</sub>A<sub>2</sub>G<sub>3</sub>-180], pET15b-SD5-ELP1 [V-60] and pET15b-SD5-ELP1 [V-120], respectively.</p><p id="p-0196" num="0202">The pUC19-ELP1 [V<sub>5</sub>A<sub>2</sub>G<sub>3</sub>-90] plasmid produced in XL1-Blue was digested with PflMI and BglI, and the ELP-containing fragment was ligated into the SfiI site of the pET15b-SD6 expression vector as described hereinabove to create pET15b-SD6-ELP1 [V<sub>5</sub>A<sub>2</sub>G<sub>3</sub>-90].</p><p id="p-0197" num="0203">The pUC19-ELP1 [K<sub>1</sub>V<sub>2</sub>F<sub>1</sub>-64], and pUC19-ELP1 [K<sub>1</sub>V<sub>2</sub>F<sub>1</sub>-128] plasmids produced in XL1-Blue were digested with PflMI and BglI, and the ELP-containing fragments were ligated into the SfiI site of the pET24d-SD21 expression vector as described hereinabove to create pET24d-SD21-ELP1 [K<sub>1</sub>V<sub>2</sub>F<sub>1</sub>-64] and pET24d-SD21-ELP1 [K<sub>1</sub>V<sub>2</sub>F<sub>1</sub>-128], respectively.</p><p id="p-0198" num="0204">The pUC19-ELP1 [K<sub>1</sub>V<sub>7</sub>F<sub>1</sub>-72] and pUC19-ELP1 [K<sub>1</sub>V<sub>7</sub>F<sub>1</sub>-144] plasmids produced in XL1-Blue were digested with PflMI and BglI, and the ELP-containing fragments were ligated into the SfiI site of the pET24d-SD21 expression vector as described hereinabove to create pET24d-SD21-ELP1 [K<sub>1</sub>V<sub>7</sub>F<sub>1</sub>-72], pET24d-SD21-ELP1 [K<sub>1</sub>V<sub>7</sub>F<sub>1</sub>-144], respectively.</p><p id="p-0199" num="0205">The pUC19-ELP2[60] and pUC19-ELP2[120] plasmids produced in XL1-Blue were digested with NcoI and HindIII, and the ELP-containing fragments were ligated into the NcoI and HindIII sites of the pET24d-SD21 expression vector as described hereinabove to create pET24d-SD21-ELP2[60], pET24d-SD21-ELP2[120], respectively.</p><p id="p-0200" num="0206">The pUC19-ELP4[V-60] and pUC19-ELP4[V-120] plasmids produced in XL1-Blue were digested with NcoI and HindIII, and the ELP-containing fragments were ligated into the NcoI and HindIII sites of the pET24d-SD21 expression vector as described hereinabove to create pET24d-SD21-ELP4[V-60], pET24d-SD21-ELP4[V-120], respectively.</p><heading id="h-0022" level="1">Example 2: Isolation and Purification of Fusion Proteins Containing Insulin a Peptide (Insa)</heading><p id="p-0201" num="0207">ELP-InsA fusion proteins included the following:</p><p id="p-0202" num="0208">Insulin A peptide and ELP1 [V-60] polypeptide with an enterokinase protease cleavage site therebetween.</p><p id="p-0203" num="0209">Insulin A peptide and ELP1 [V<sub>5</sub>A<sub>2</sub>G<sub>3</sub>-90] polypeptide with an enterokinase protease cleavage site therebetween.</p><p id="p-0204" num="0210">Insulin A peptide and ELP1 [V-120] polypeptide with an enterokinase protease cleavage site therebetween.</p><p id="p-0205" num="0211">Insulin A peptide and ELP1 [V<sub>5</sub>A<sub>2</sub>G<sub>3</sub>-180] polypeptide with an enterokinase protease cleavage site therebetween.</p><p id="p-0206" num="0212">A single colony of <i>E. coli </i>strain BLR (DE3) (Novagen) containing the respective ELP-InsA fusion protein was inoculated into 5 ml CircleGrow (Q-BIOgene, San Diego, Calif.) supplemented with 100 &#x3bc;g/ml ampicillin (Sigma) and grown at 37&#xb0; C. with shaking at 250 rpm for 5 hours. The 5 ml culture was then inoculated into a 500 ml culture and allowed to grow at 25&#xb0; C. for 16 hours before inducing with 1 mM IPTG for 4 hours at 25&#xb0; C. The culture was harvested and suspended in 40 ml 20 mM Tris-HCl pH 7.4, 50 mM NaCl, 1 mM DTT and 1 Complete EDTA free Protease inhibitor pellet (Roche, Indianapolis, Ind.). Cells were lysed by ultrasonic disruption on ice for 3 minutes, which consisted of 10 seconds bursts at 35% power separated by 30 second cooling down intervals. Cell debris was removed by centrifugation at 20,000 g, 4&#xb0; C. for 30 minutes.</p><p id="p-0207" num="0213">Inverse phase transition was induced by adding NaCl to the cell lysate at room temperature to achieve a final concentration of 1.0 M therein, followed by centrifugation at 20,000 g for 15 minutes at room temperature. The resulting pellet contained the respective ELP-InsA fusion protein and non-specifically NaCl precipitated proteins.</p><p id="p-0208" num="0214">The pellet was re-suspended in 40 ml ice-cold ml 20 mM Tris-HCl pH 7.4, 50 mM NaCl, 1 mM DTT and re-centrifuged at 20,000 g, 4&#xb0; C. for 15 minutes to remove the non-specifically NaCl precipitated proteins. The inverse transition cycle was repeated two additional times to increase the purity of the respective ELP-InsA fusion protein and reduce the final volume to 0.5 ml.</p><heading id="h-0023" level="1">Example 3: Half-Life of ELP1</heading><p id="p-0209" num="0215">The pharmacokinetics of ELP1 were determined by intravenously administering [<sup>14</sup>C]ELP1 to nude mice (Balb/c nu/nu) bearing a leg/flank FaDu xenograft and collecting blood samples at various time intervals after administration. The blood pharmacokinetics exhibited a characteristic distribution and elimination response for large macromolecules, which was well described by a bi-exponential process.</p><p id="p-0210" num="0216">The plasma concentration time-course curve was fit to the analytical solution of a two-compartment model to approximate both an elimination and distribution response. Certain pharmakinetic parameters are shown in Table 1 below. The distribution volume of the ELP (1.338 &#x3bc;l) was nearly identical to the hypothetical plasma volume of 1.363 &#x3bc;l (Barbee, R. W., et al., <i>Am. J. Physio. </i>263(3) (1992) R728-R733), indicating that the ELP did not rapidly distribute or bind to specific organs and tissues directly after administration. The AUC is a measure of the cumulative exposure to ELP in the central compartment or the blood plasma. The body clearance is defined as the rate of ELP elimination in the body relative to its plasma concentration and is the summation of clearance through all organs including the kidney, liver and others.</p><p id="p-0211" num="0000"><tables id="TABLE-US-00003" num="00003"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 1</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Pharmacokinetic parameters calculated for [<sup>14</sup>C]ELP1</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="7"><colspec colname="offset" colwidth="42pt" align="left"/><colspec colname="1" colwidth="21pt" align="center"/><colspec colname="2" colwidth="28pt" align="center"/><colspec colname="3" colwidth="21pt" align="center"/><colspec colname="4" colwidth="21pt" align="center"/><colspec colname="5" colwidth="56pt" align="center"/><colspec colname="6" colwidth="28pt" align="center"/><tbody valign="top"><row><entry/><entry>k<sub>1</sub></entry><entry>k<sub>2</sub></entry><entry>k<sub>e</sub></entry><entry>V<sub>d</sub></entry><entry>AUC</entry><entry>Cl<sub>B</sub></entry></row><row><entry/><entry>(hr<sup>&#x2212;1</sup>)</entry><entry>(hr<sup>&#x2212;1</sup>)</entry><entry>(hr<sup>&#x2212;1</sup>)</entry><entry>(&#x3bc;L)</entry><entry>(mg ELP hr/ml)</entry><entry>(&#x3bc;L/hr)</entry></row><row><entry/><entry namest="offset" nameend="6" align="center" rowsep="1"/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="7"><colspec colname="1" colwidth="42pt" align="left"/><colspec colname="2" colwidth="21pt" align="center"/><colspec colname="3" colwidth="28pt" align="center"/><colspec colname="4" colwidth="21pt" align="center"/><colspec colname="5" colwidth="21pt" align="center"/><colspec colname="6" colwidth="56pt" align="center"/><colspec colname="7" colwidth="28pt" align="center"/><tbody valign="top"><row><entry>ELP1-150</entry><entry>3.54</entry><entry>1.99</entry><entry>0.24</entry><entry>1,338</entry><entry>7.1</entry><entry>317</entry></row><row><entry namest="1" nameend="7" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0212" num="0217">The mass transfer rate constants are from a standard two-compartment model (k<sub>1</sub>; from central to peripheral compartment; k<sub>2</sub>, from peripheral to central compartment; and k<sub>e</sub>, elimination from central compartment). The distribution volume (V<sub>d</sub>), central compartment concentration time-course area under the curve (AUC) and body clearance (Cl<sub>B</sub>) are displayed. Data are shown as the mean values (n=5, except V<sub>d </sub>and initial plasma concentration (C<sub>O</sub>) was calculated from a similar cohort with n=3).</p><heading id="h-0024" level="1">Example 4: Biodistribution of ELPs in Nude Mice</heading><p id="p-0213" num="0218"><sup>14</sup>C Labeled ELP1-150 and/or <sup>14</sup>C Labeled ELP2-160</p><p id="p-0214" num="0219"><sup>14</sup>C labeled ELP1-150 and/or <sup>14</sup>C labeled ELP2-160 were administered to nude mice with a FaDu tumor (mean+/&#x2212;SD, n=6). The tumor was heated post administration of the ELP in a water bath at 41.5&#xb0; C. The distribution was highest to the organs with the highest blood content: liver, kidneys, spleen, and lungs.</p><p id="p-0215" num="0000"><sup>14</sup>C Labeled ELP2-[V<sub>1</sub>A<sub>8</sub>G<sub>7</sub>-160]</p><p id="p-0216" num="0220"><sup>14</sup>C labeled ELP2-[V<sub>1</sub>A<sub>8</sub>G<sub>7</sub>-160] (T<sub>t</sub>&#x3e;60&#xb0; C.) was administered to nude mice for a plasma concentration of 15 &#x3bc;M. ELP concentrations were determined following 1 hour of heating (41&#xb0; C.) of an implanted FaDu tumor, located in the right hind leg of the nude mouse. Data are shown as the mean, plus the 95% confidence interval. N=6.</p><p id="p-0217" num="0221">ELP concentration was measured 1.5 hours following systemic administration of <sup>14</sup>C labeled ELP2-[V<sub>1</sub>A<sub>8</sub>G<sub>7</sub>-160]. The highest distribution is seen in organs with the highest blood content: liver, kidneys, spleen, and lungs.</p><heading id="h-0025" level="1">Example 5: Exendin-4 ELP Fusion</heading><p id="p-0218" num="0222">The DNA sequence for Exendin-4 (Ex-4) (SEQ ID NO: 14) was reverse translated from the amino acid sequence using codons optimized for <i>E. coli </i>expression. The DNA sequence encoding Exendin-4 was constructed by annealing together synthetic oligonucleotides with overhanging 5&#x2032; and 3&#x2032; ends compatible with the restriction sites NdeI and XhoI in the plasmid pET24d-ELP1-90 (<figref idref="DRAWINGS">FIG. <b>1</b></figref>). This plasmid was digested with the restriction enzymes NdeI and XhoI and the annealed DNA sequence was ligated into the cut vector. Insertion was confirmed by restriction digest and DNA sequencing. The resulting plasmid was designated as pET24d-Ex-4 ELP1-90 (<figref idref="DRAWINGS">FIG. <b>2</b>A</figref>), and the sequence of the resulting Exendin-4-ELP fusion shown in <figref idref="DRAWINGS">FIG. <b>2</b>B</figref>. Primers for construction of the fusion are also indicated.</p><p id="p-0219" num="0223">pET24d-Ex-4 ELP1-90 was used to transform the <i>E. coli </i>strain BRL (Invitrogen) and selected transformants were grown in media 3 (1.2% Tryptone Peptone, 2.4% yeast extract, 5 g/L casamino acids, 2% glycerol, 2.313 g Potassium phosphate dibasic/L, 12.541 g Potassium phosphate monobasic/L) in shake flasks. Production proceeded by autoinduction by inoculating 1 OD cells into 1L of media 3 and allowing growth to proceed for 17 hr at 37&#xb0; C. without addition of inducer. The product was recovered by collection of the cell pellet, sonicated to disrupt the cells and recovered by thermal and/or salt induced transition modulated by the ELP moiety (<i>Improved Non</i>-<i>chromatographic Purification of a Recombinant Protein by Cationic Elastin</i>-<i>like Polypeptides</i>, Dong Woo Lim, Kimberly Trabbic-Carison, J. Andrew MacKay, and Ashutosh Chilkoti. <i>Biomacromolecules </i>2007, 8, 1417-1424).</p><p id="p-0220" num="0224">This example is with the ELP designated 1-90. This is based on the VPGXG (SEQ ID NO: 3) motif where X is a V, G or A in the ratio 5:3:2 in a 10 unit repeat, repeated 8&#xd7; with a final (C-terminal) 10-unit repeat where X is a V, G, A and W in the ratio 4:3:2:1.</p><p id="p-0221" num="0225">[(VPGXG)10]<sub>9 </sub>where the X residue in the ten sequential iterations of the repeat unit (numerical subscript) can be described as [(V<sub>1, 4, 5, 6, 10</sub>G<sub>2, 7, 9</sub>A<sub>3, 8</sub>)<sub>8 </sub>(V<sub>1, 4, 5, 6</sub>G<sub>2, 7, 9</sub>A<sub>3, 8 </sub>W<sub>10</sub>)].</p><p id="p-0222" num="0226">The ELP may be any combination of VPGXG (SEQ ID NO: 3) units where X is any of the 20 natural amino, acids, except proline, in any combination of repeat units of any length. In addition, the amino acid may be an unnatural amino acid for which the host strain has been engineered to accept an engineered tRNA for incorporation at specific codon (Wang L, Brock A, Herberich B, Schultz PG. <i>Expanding the genetic code of Escherichia coli. </i>[2001] Science 292, 498-500).</p><p id="p-0223" num="0227">This construct was produced in the cytosol with an N-terminal methionine, which is normally removed by methionine aminopeptidase. Complete and accurate processing of the methionine, however, cannot be assumed; this enzyme may also remove the N-terminal histidine of the Exendin-4 moiety. This could result in a mixture of, unprocessed, processed and incorrectly processed products. Consequently, further constructs were developed to generate products with correctly processed N-termini.</p><p id="p-0224" num="0228">Primers were designed to add a Tev protease (Tobacco Etch Virus cysteine protease) cleavage site between the N-terminal methionine and the histidine at the N-terminus of Exendin-4. This allows for removal of the methionine and the Tev recognition sequence to give the mature N-terminus of Exendin-4 (histidine). This can be done post-production or the Tev protease can be co-expressed to cleave the recognition sequence during production, for instance, as an intein (Ge, X., Yang, D. S. C., Trabbic-Carison, K., Kim, B., Chilkoti, A. and Filipe, C. D. M. <i>Self</i>-<i>Cleavable Stimulus Responsive Taos for Protein Purification without Chromatography. J. Am. Chem. Soc. </i>127, 11228-11229, 2005). The Tev Exendin-4 sequence is shown in <figref idref="DRAWINGS">FIG. <b>3</b>A</figref>. <figref idref="DRAWINGS">FIG. <b>3</b>B</figref> shows additional sequences added, labeled as &#x201c;Linker Tev,&#x201d; provide a better target for the Tev protease.</p><p id="p-0225" num="0229">An alternative route to obtaining a correctly processed N-terminus for Ex-4 is to use a leader or signal sequence that directs the product to the periplasm and which is cleaved by a signal peptidase in the process. In this instance, a signal sequence, DsbA, that directs the transcript to the signal recognition particle for direct secretion of the polypeptide into the periplasm is given. (See <figref idref="DRAWINGS">FIG. <b>4</b>A</figref>). The plasmid pET24d-DsbA-Ex-4 ELP1-90 is shown in <figref idref="DRAWINGS">FIG. <b>4</b>B</figref>.</p><p id="p-0226" num="0230">While this example illustrates the preparation of therapeutic agents with Exendin-4 sequences, such sequences can be replaced with GLP-1, insulin, Factor VII/VIIa, or other therapeutic protein listed in Table 1, generated in exactly or a similar manner as detailed for Exendin-4.</p><heading id="h-0026" level="1">Example 6: GLP1-ELP Fusion Protein</heading><p id="p-0227" num="0231">The ELP plasmid constructs were used to prepare two GLP1-ELP fusion proteins, GLP1(A8G,7-37)ELP1-90 and GLP1(A8G,7-37)ELP1-120. The plasmid constructs, fusion-encoding nucleotide sequence, as well as the amino acid sequence of the resulting fusion proteins are shown in <figref idref="DRAWINGS">FIGS. <b>5</b> and <b>6</b></figref>.</p><p id="p-0228" num="0232">Both constructs contain an N-terminal Tev protease site to allow processing to the mature form where His<sup>7 </sup>of GLP1 is at the N-terminus. The processed fusion proteins have calculated molecular weights of about 39,536 and about 50,828, respectively.</p><heading id="h-0027" level="1">Example 7: FVII ELP Fusion Protein</heading><p id="p-0229" num="0233">The coagulation factor VII (FVII) gene was modified by PCR from a cDNA clone (Oragene) to add restriction sites at the 5&#x2032; and 3&#x2032; ends for cloning into the ELP-containing vector. At the 5&#x2032; end an NheI site was added and at the 3&#x2032; end a NotI site was added. The DNA and amino acid sequences of the Factor VII gene are shown in the accompanying Sequence Listing as SEQ ID NOS: 34 and 33, respectively. The DNA sequences of the 5&#x2032; and 3&#x2032; primers used to PCR amplify the factor VII (FVII) gene were:</p><p id="p-0230" num="0000"><tables id="TABLE-US-00004" num="00004"><table frame="none" colsep="0" rowsep="0" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="2"><colspec colname="offset" colwidth="35pt" align="left"/><colspec colname="1" colwidth="182pt" align="left"/><tbody valign="top"><row><entry/><entry>P13:</entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO.:&#x2003;49)</entry></row><row><entry/><entry>CTAGCTAGCATGGTCTCCCAGGCCCTC</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>P14:</entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO.:&#x2003;50)</entry></row><row><entry/><entry>TATTCTTGCGGCCGCGGGAAATGGGGCTCGCAG</entry></row></tbody></tgroup></table></tables></p><p id="p-0231" num="0234">The resulting PCR fragment was digested with the restriction enzymes NheI and NotI and ligated into the plasmid pcDNA3.1+ ELP1-90 previously digested with the restriction enzymes NheI and NotI (<figref idref="DRAWINGS">FIG. <b>7</b>A</figref>).</p><p id="p-0232" num="0235">The resulting plasmid, pcDNA3.1+ FVII-ELP1-90, was transiently transfected into HEK293 cells and culture media harvested. The ELP fusion was purified by phase transition (<figref idref="DRAWINGS">FIGS. <b>9</b> and <b>10</b></figref>).</p><p id="p-0233" num="0236">The nucleotide and amino acid sequences of the FactorVII-ELP fusion is shown in <figref idref="DRAWINGS">FIG. <b>7</b>B</figref>. As shown, the FactorVII-ELP fusion protein contains a Tev protease linker between the FactorVII component and the ELP component. This linker is optional.</p><heading id="h-0028" level="1">Example 8: Insulin ELP Fusion Protein</heading><p id="p-0234" num="0237">The cDNA for the human insulin gene is modified at the 5&#x2032; and 3&#x2032; ends for insertion in to pET24d-ELP1-90. The 5&#x2032; primer adds an N-terminal methionine for bacterial expression and an NdeI restriction enzyme site. The 3&#x2032; primer adds an XhoI restriction enzyme site. The PCR product and the plasmid are both digested with the restriction enzymes NdeI and XhoI and ligated together. The sequence of the insulin (Chains B, C, and A fused to ELP1 is shown in <figref idref="DRAWINGS">FIG. <b>8</b>A</figref>.</p><p id="p-0235" num="0238">Correct insertion is determined by restriction digest and DNA sequencing. The resulting plasmid, designated pET24d Insulin-ELP1-90, is shown in <figref idref="DRAWINGS">FIG. <b>8</b>B</figref>.</p><p id="p-0236" num="0239">The native insulin form is generated after recovery from <i>E. coli </i>by treatment with trypsin and carboxypeptidase B to remove the C-peptide chain.</p><p id="p-0237" num="0240">For correct processing of the N-terminus of the B-chain similar modifications to those made for the Exendin-4 fusion (protease cleavage site, signal sequence) can be implemented (see Example 4). Alternatively, the first two residues can be Met-Arg, which can also be removed by trypsin digestion in production of the final material (R. M. Belagaje, S. G. Reams, S. C. Ly and W. F. Prouty, <i>Increased production of low molecular weight recombinant proteins in Escherichia coli. Protein Sci. </i>6, 1953-1962, 1997).</p><p id="p-0238" num="0241">Additional constructs would place the insulin cDNA at the 3&#x2032; end of the ELP for a C-terminal fusion, add linkers between the Insulin and ELP sequences, and/or use modified forms of insulin which have no C-peptide (single chain insulins as described) removing the need for additional processing.</p><heading id="h-0029" level="1">Example 9: Synthesis of the ELP Gene for Conjugation</heading><p id="p-0239" num="0242">A gene encoding a 50 amino acid sequence was constructed from chemically-synthesized oligonucleotides using standard molecular biology protocols. The 50 amino acid sequence contained 10 repeats of the pentapeptide VPGXG (SEQ ID NO: 3), where the guest residues (V, G, and A in a 5:3:2 molar ratio) were selected to provide a Tt of 40&#xb0; C. The gene was oligomerized end-to-end by standard molecular biology techniques, to produce an oligomeric ELP gene. Additionally a single 50 amino acid sequence was constructed containing the 10 repeat pentapeptide VPGXG (SEQ ID NO: 3) polypeptide where the guest residues were V, G, A and C in a 4:3:2:1 molar ratio. This sequence could be added at any cycle of the oligomerization process to introduce a single cysteine residue into the final construct at a chosen point along the length of the construct.</p><p id="p-0240" num="0243">The example given here is with the ELP designated 1-90. This is based on the VPGXG (SEQ ID NO: 3) motif where X is a V, G or A in the ratio 5:3:2 in a 10-unit repeat, repeated 8&#xd7; with a final (C-terminal) 10-unit repeat where X is a V, G, A and C in the ratio 4:3:2:1, i.e., [(VPGXG)10]9 (SEQ ID NO.: 3).</p><p id="p-0241" num="0244">Alternatively, the residue could be one of either arginine, lysine, aspartic acid or glutamic acid. The purpose of these amino acids is to provide a reactive side chain for the chemical conjugation of, for example, insulin. In this particular case the use of an ELP would be to extend the circulating half-life of the therapeutic protein (e.g., insulin) to provide prolonged basal glucose control. Conjugated to an ELP that transitions at body temperature, the insulin would form a precipitated depot at the site of injection in a similar manner to Lantus&#xae; (Sanofi Aventis) but without the requirement for formulation in acidic (pH 4.0) conditions with m-cresol for a more tolerable injection.</p><heading id="h-0030" level="1">Example 10: Potency and Half-Life of Factor VII-ELP</heading><p id="p-0242" num="0245"><figref idref="DRAWINGS">FIG. <b>11</b></figref> shows the activation of Factor X by FactorVIIa-ELP1-90, and by Factor VIIa as a comparison. Factor VII-ELP was produced in HEK cells. Factor VIIa was derived from human plasma. As shown, FactorVIIa-ELP retains full activity.</p><p id="p-0243" num="0246">When administered to rats by i.v., Factor VII-ELP demonstrated a half-life of about 690 minutes. In contrast, Factor VII demonstrated a half-life of 45-60 minutes. Half-life in this example was measured by sandwich ELISA for FactorVII. <figref idref="DRAWINGS">FIG. <b>12</b></figref>.</p><p id="p-0244" num="0247">Also in contrast, the reported half-life for NovoSeven&#x2122; is 45 minutes, the reported half-life for FactorVIIa-albumin fusion is 263 minutes, and the reported half-life for Factor VIIa-PEG is 300 minutes in mice and 600 minutes in dog.</p><heading id="h-0031" level="1">Example 11: GLP-1 (or Exendin-4) In Vitro Bioassay</heading><p id="p-0245" num="0248">Activation of the GLP-1 receptor (GLP1R) results in production of cAMP secondary messenger within the cell. Therefore, GLP-1 or Exendin-4 analogs and corresponding therapeutic agents may be tested by their ability to activate GLP1R on the cell surface and produce cAMP.</p><p id="p-0246" num="0249">For this bioassay CHO cells transfected with cDNA coding for GLP1R are used. These cells respond to stimulation by GLP-1 and produce high levels of cAMP. Log phase growing cells are plated and increasing concentrations of test compounds (e.g., therapeutic agent of the invention, or GLP-1 or exendin-4 functional analog) are added to the cells. After an appropriate incubation period (usually 15-60 min) in physiological buffer at 37&#xb0; C. the cAMP produced is measured using a CatchPoint cAMP assay kit from Molecular Devices (Sunnyvale, Calif.). The EC<sub>50 </sub>of each test compound as compared to GLP-1 peptide or Exendin-4 peptide (or as compared to an unfused or unconjugated counterpart of a therapeutic agent of the invention) is indicative of the changes in activity due to a specific modifications introduced into the peptide, or due to particular chemical or recombinant coupling to an ELP component.</p><p id="p-0247" num="0250">As shown in <figref idref="DRAWINGS">FIG. <b>13</b></figref>, both GLP1-ELP (PB0868) and Exendin-4-ELP (PB 0859) maintain high activity in vitro, shown in comparison to Exendin alone. It is of note that the specific activity of Albugon&#xae; and Liraglutide&#xae; run 50-100 fold less than the exendin peptide.</p><heading id="h-0032" level="1">Example 12: GLP-1 (or Exendin-4) In Vivo Bioassay</heading><p id="p-0248" num="0251">The activity of GLP-1 or Exendin analogues or corresponding therapeutic agents may be tested in animals. For this assay, normal or diabetic animals may be used. Diabetic animals with blood glucose concentration 300-500 mg/dl are injected with different doses of GLP-1 or Exendin analogues or corresponding therapeutic agent, and changes in blood glucose monitored with a glucometer. The drop in glucose at different times points post administration is compared to that resulting with standard amounts of GLP-1 or Exendin-4 peptide, or compared to an unfused or unconjugated counterpart of a therapeutic agent of the invention. Alternatively, the blood glucose excursion in normal or diabetic animals during specific time period after administration of exogenous glucose is compared to GLP-1 or Exendin-4 (or to unfused or unconjugated counterparts of therapeutic agents). In this way the activity of the analogues and fusion proteins can be compared to the natural peptides.</p><p id="p-0249" num="0252"><figref idref="DRAWINGS">FIG. <b>14</b></figref> shows the pharmacokinetics of GLP1-ELP1-120 in rats administered both by i.v. and subcutaneously. Three rats were used for each time point. The dose was &#x2dc;10 mg/kg. The T<sub>1/2 </sub>when administered by i.v. was about 12.9 hours. The T<sub>1/2 </sub>when administered subcutaneously was about 8.6 hours.</p><p id="p-0250" num="0253"><figref idref="DRAWINGS">FIG. <b>15</b></figref> shows the pharmacokinetics of GLP1-ELP1-120 in rabbits administered both by i.v. and subcutaneously. Three rabbits were used for each time point. The dose was &#x2dc;1 mg/kg. The T<sub>1/2 </sub>when administered by i.v. was about 20 hours. The T<sub>1/2 </sub>when administered subcutaneously was about 24 hours.</p><p id="p-0251" num="0254"><figref idref="DRAWINGS">FIG. <b>16</b></figref> shows the sustained glycemic control in diabetic mice with GLP1-ELP1-90.</p><p id="p-0252" num="0255">All reference cited herein are hereby incorporated by reference in their entireties. While the invention has been has been described herein in reference to specific aspects, features and illustrative embodiments of the invention, it will be appreciated that the utility of the invention is not thus limited, but rather extends to and encompasses numerous other variations, modifications and alternative embodiments, as will suggest themselves to those of ordinary skill in the field of the present invention, based on the disclosure herein</p><?detailed-description description="Detailed Description" end="tail"?></description><us-sequence-list-doc id="SEQLST-1"><sequence-list file="US20230000952A1-20230105-S00001.XML" carriers="internal-electronic" seq-file-type="ST.25"/></us-sequence-list-doc><us-claim-statement>What is claimed is:</us-claim-statement><claims id="claims"><claim id="CLM-00001" num="00001"><claim-text><b>1</b>. A therapeutic agent comprising an elastin-like peptide (ELP) component and a therapeutic component, the therapeutic component having an extended circulatory half-life and/or a lower therapeutically effective dose when compared to the therapeutic component alone.</claim-text></claim><claim id="CLM-00002" num="00002"><claim-text><b>2</b>. The therapeutic agent of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the therapeutic component is a therapeutic protein listed in Table 1 or a functional portion or functional analog thereof.</claim-text></claim><claim id="CLM-00003" num="00003"><claim-text><b>3</b>. The therapeutic agent of <claim-ref idref="CLM-00002">claim 2</claim-ref>, wherein an ELP component is covalently bonded to the therapeutic protein at an N- and/or C-terminus thereof.</claim-text></claim><claim id="CLM-00004" num="00004"><claim-text><b>4</b>. The therapeutic agent of any one of <claim-ref idref="CLM-00001">claims 1</claim-ref>-<claim-ref idref="CLM-00003">3</claim-ref>, wherein a therapeutic component is covalently bonded to the ELP component at the N-terminus of the ELP component, and a second therapeutic component is covalently bonded to the ELP component at the C-terminus of the ELP component.</claim-text></claim><claim id="CLM-00005" num="00005"><claim-text><b>5</b>. The therapeutic agent of any one of <claim-ref idref="CLM-00001">claims 1</claim-ref>-<claim-ref idref="CLM-00004">4</claim-ref>, wherein a therapeutic component is covalently bonded to the ELP component at an N- and/or C-terminus thereof.</claim-text></claim><claim id="CLM-00006" num="00006"><claim-text><b>6</b>. The therapeutic agent of any one of <claim-ref idref="CLM-00001">claims 1</claim-ref>-<claim-ref idref="CLM-00005">5</claim-ref>, wherein a first ELP component is covalently bonded to the therapeutic component at the N-terminus of the therapeutic component, and a second ELP component is covalently bonded to the therapeutic component at the C-terminus of the therapeutic component.</claim-text></claim><claim id="CLM-00007" num="00007"><claim-text><b>7</b>. The therapeutic agent of any one of <claim-ref idref="CLM-00001">claims 1</claim-ref>-<claim-ref idref="CLM-00006">6</claim-ref>, further comprising a spacer moiety between the ELP component and the therapeutic component.</claim-text></claim><claim id="CLM-00008" num="00008"><claim-text><b>8</b>. The therapeutic agent of <claim-ref idref="CLM-00007">claim 7</claim-ref>, wherein the spacer moiety comprises one or more of a protease-resistant moiety, a non-peptide chemical moiety, and a protease cleavage site.</claim-text></claim><claim id="CLM-00009" num="00009"><claim-text><b>9</b>. The therapeutic agent of <claim-ref idref="CLM-00008">claim 8</claim-ref>, wherein the protease cleavage site is a thrombin cleavage site, a factor Xa cleavage site, a metalloprotease cleavage site, an enterokinase cleavage site, a Tev cleavage site, and a cathepsin cleavage site.</claim-text></claim><claim id="CLM-00010" num="00010"><claim-text><b>10</b>. The therapeutic agent of <claim-ref idref="CLM-00009">claim 9</claim-ref>, wherein the spacer moiety comprises a non-cleavable moiety having the formula [(Gly)<sub>n</sub>-Ser]<sub>m </sub>(SEQ ID NO: 22) where n is from 1 to 4, inclusive, and m is from 1 to 4, inclusive.</claim-text></claim><claim id="CLM-00011" num="00011"><claim-text><b>11</b>. The therapeutic agent of any one of <claim-ref idref="CLM-00001">claims 1</claim-ref>-<claim-ref idref="CLM-00010">10</claim-ref>, wherein the ELP comprises at least one repeating unit selected from SEQ ID NOS: 1-12.</claim-text></claim><claim id="CLM-00012" num="00012"><claim-text><b>12</b>. The therapeutic agent of <claim-ref idref="CLM-00011">claim 11</claim-ref>, wherein said repeating unit is VPGXG (SEQ ID NO: 3).</claim-text></claim><claim id="CLM-00013" num="00013"><claim-text><b>13</b>. The therapeutic agent of <claim-ref idref="CLM-00012">claim 12</claim-ref>, wherein X is any natural or non-natural amino acid residue, and wherein X varies among at least two units.</claim-text></claim><claim id="CLM-00014" num="00014"><claim-text><b>14</b>. The therapeutic agent of <claim-ref idref="CLM-00013">claim 13</claim-ref>, wherein each X is independently selected from alanine, arginine, asparagine, aspartic acid, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, serine, threonine, tryptophan, tyrosine and valine residues.</claim-text></claim><claim id="CLM-00015" num="00015"><claim-text><b>15</b>. The therapeutic agent of any one of <claim-ref idref="CLM-00001">claims 1</claim-ref>-<claim-ref idref="CLM-00014">14</claim-ref>, wherein the therapeutic agent has a molecular weight of less than about 50 kDa.</claim-text></claim><claim id="CLM-00016" num="00016"><claim-text><b>16</b>. The therapeutic agent of any one of <claim-ref idref="CLM-00001">claims 1</claim-ref>-<claim-ref idref="CLM-00015">15</claim-ref>, wherein the ELP component has a Tt greater than 37&#xb0; C.</claim-text></claim><claim id="CLM-00017" num="00017"><claim-text><b>17</b>. The therapeutic agent of any one of <claim-ref idref="CLM-00001">claims 1</claim-ref>-<claim-ref idref="CLM-00016">16</claim-ref>, wherein the therapeutic agent is a genetically encoded fusion protein.</claim-text></claim><claim id="CLM-00018" num="00018"><claim-text><b>18</b>. A polynucleotide comprising a nucleotide sequence encoding the therapeutic agent of <claim-ref idref="CLM-00017">claim 17</claim-ref>.</claim-text></claim><claim id="CLM-00019" num="00019"><claim-text><b>19</b>. The polynucleotide of <claim-ref idref="CLM-00018">claim 18</claim-ref>, further comprising an expression control element operably linked to said nucleotide sequence.</claim-text></claim><claim id="CLM-00020" num="00020"><claim-text><b>20</b>. The polynucleotide of <claim-ref idref="CLM-00019">claim 19</claim-ref>, wherein said expression control element comprises a promoter.</claim-text></claim><claim id="CLM-00021" num="00021"><claim-text><b>21</b>. A vector comprising the polynucleotide of any one of <claim-ref idref="CLM-00018">claims 18</claim-ref>-<claim-ref idref="CLM-00020">20</claim-ref>.</claim-text></claim><claim id="CLM-00022" num="00022"><claim-text><b>22</b>. An isolated host cell containing the vector of <claim-ref idref="CLM-00021">claim 21</claim-ref> or the polynucleotide of any one of <claim-ref idref="CLM-00018">claims 18</claim-ref>-<claim-ref idref="CLM-00020">20</claim-ref>.</claim-text></claim><claim id="CLM-00023" num="00023"><claim-text><b>23</b>. A pharmaceutical composition comprising the therapeutic agent of any one of <claim-ref idref="CLM-00001">claims 1</claim-ref>-<claim-ref idref="CLM-00018">18</claim-ref>, and a pharmaceutically acceptable carrier and/or excipient.</claim-text></claim><claim id="CLM-00024" num="00024"><claim-text><b>24</b>. A method of treating or preventing a disease, disorder, or condition in a subject, comprising administering an effective amount of the therapeutic agent of any one of <claim-ref idref="CLM-00001">claims 1</claim-ref>-<claim-ref idref="CLM-00017">17</claim-ref> or the pharmaceutical composition of <claim-ref idref="CLM-00023">claim 23</claim-ref> to a subject in need thereof.</claim-text></claim><claim id="CLM-00025" num="00025"><claim-text><b>25</b>. The method of <claim-ref idref="CLM-00024">claim 24</claim-ref>, wherein the subject has an indication listed in Table 1.</claim-text></claim><claim id="CLM-00026" num="00026"><claim-text><b>26</b>. A therapeutic agent comprising an elastin-like peptide (ELP) component and a glucagon-like peptide (GLP)-1 receptor agonist.</claim-text></claim><claim id="CLM-00027" num="00027"><claim-text><b>27</b>. The therapeutic agent of <claim-ref idref="CLM-00026">claim 26</claim-ref>, wherein the GLP-1 receptor agonist is GLP-1 or functional analog thereof.</claim-text></claim><claim id="CLM-00028" num="00028"><claim-text><b>28</b>. The therapeutic agent of <claim-ref idref="CLM-00026">claim 26</claim-ref>, wherein the GLP-1 receptor agonist is an exendin-4 or functional analog thereof.</claim-text></claim><claim id="CLM-00029" num="00029"><claim-text><b>29</b>. The therapeutic agent of any one of <claim-ref idref="CLM-00026">claims 26</claim-ref>-<claim-ref idref="CLM-00028">28</claim-ref>, wherein the ELP component is covalently bonded to the GLP-1 receptor agonist at an N- and/or C-terminus thereof.</claim-text></claim><claim id="CLM-00030" num="00030"><claim-text><b>30</b>. The therapeutic agent of any one of <claim-ref idref="CLM-00026">claims 26</claim-ref>-<claim-ref idref="CLM-00029">29</claim-ref>, wherein a first GLP-1 receptor agonist is covalently bonded to the ELP component at the N-terminus of the ELP component, and a second GLP-1 receptor agonist is covalently bonded to the ELP component at the C-terminus of the ELP component.</claim-text></claim><claim id="CLM-00031" num="00031"><claim-text><b>31</b>. The therapeutic agent of any one of <claim-ref idref="CLM-00026">claims 26</claim-ref>-<claim-ref idref="CLM-00030">30</claim-ref>, wherein the GLP-1 receptor agonist is covalently bonded to the ELP component at an N- and/or C-terminus thereof.</claim-text></claim><claim id="CLM-00032" num="00032"><claim-text><b>32</b>. The therapeutic agent of any one of <claim-ref idref="CLM-00026">claims 26</claim-ref>-<claim-ref idref="CLM-00031">31</claim-ref>, wherein a first ELP component is covalently bonded to the GLP-1 receptor agonist at the N-terminus of the GLP-1 receptor agonist, and a second ELP component is covalently bonded to the GLP-1 receptor agonist at the C-terminus of the GLP-1 receptor agonist.</claim-text></claim><claim id="CLM-00033" num="00033"><claim-text><b>33</b>. The therapeutic agent of any one of <claim-ref idref="CLM-00026">claims 26</claim-ref>-<claim-ref idref="CLM-00032">32</claim-ref>, further comprising a spacer moiety between the ELP component and GLP-receptor agonist.</claim-text></claim><claim id="CLM-00034" num="00034"><claim-text><b>34</b>. The therapeutic agent of <claim-ref idref="CLM-00033">claim 33</claim-ref>, wherein the spacer moiety comprises one or more of a protease-resistant moiety, a non-peptide chemical moiety, and a protease cleavage site.</claim-text></claim><claim id="CLM-00035" num="00035"><claim-text><b>35</b>. The therapeutic agent of <claim-ref idref="CLM-00034">claim 34</claim-ref>, wherein the protease cleavage site is a thrombin cleavage site, a factor Xa cleavage site, a metalloprotease cleavage site, an enterokinase cleavage site, a Tev cleavage site, and a cathepsin cleavage site.</claim-text></claim><claim id="CLM-00036" num="00036"><claim-text><b>36</b>. The therapeutic agent of <claim-ref idref="CLM-00034">claim 34</claim-ref>, wherein the spacer moiety comprises a non-cleavable moiety having the formula [(Gly)<sub>n</sub>-Ser]<sub>m </sub>(SEQ ID NO.: 22) where n is from 1 to 4, inclusive, and m is from 1 to 4, inclusive.</claim-text></claim><claim id="CLM-00037" num="00037"><claim-text><b>37</b>. The therapeutic agent of any one of <claim-ref idref="CLM-00026">claims 26</claim-ref>-<claim-ref idref="CLM-00036">36</claim-ref>, wherein the ELP comprises at least one repeating unit selected from SEQ ID NOS: 1-12.</claim-text></claim><claim id="CLM-00038" num="00038"><claim-text><b>38</b>. The therapeutic agent of <claim-ref idref="CLM-00037">claim 37</claim-ref>, wherein said repeating unit is VPGXG (SEQ ID NO: 3).</claim-text></claim><claim id="CLM-00039" num="00039"><claim-text><b>39</b>. The therapeutic agent of <claim-ref idref="CLM-00038">claim 38</claim-ref>, wherein X is any natural or non-natural amino acid residue, and wherein X varies among at least two units.</claim-text></claim><claim id="CLM-00040" num="00040"><claim-text><b>40</b>. The therapeutic agent of <claim-ref idref="CLM-00038">claim 38</claim-ref>, wherein each X is independently selected from alanine, arginine, asparagine, aspartic acid, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, serine, threonine, tryptophan, tyrosine and valine residues.</claim-text></claim><claim id="CLM-00041" num="00041"><claim-text><b>41</b>. The therapeutic agent of any one of <claim-ref idref="CLM-00026">claims 26</claim-ref>-<claim-ref idref="CLM-00040">40</claim-ref>, wherein the therapeutic agent has a molecular weight of less than about 50 kDa.</claim-text></claim><claim id="CLM-00042" num="00042"><claim-text><b>42</b>. The therapeutic agent of any one of <claim-ref idref="CLM-00026">claims 26</claim-ref>-<claim-ref idref="CLM-00040">40</claim-ref>, wherein the ELP component has a Tt greater than 37&#xb0; C.</claim-text></claim><claim id="CLM-00043" num="00043"><claim-text><b>43</b>. The therapeutic agent of any one of <claim-ref idref="CLM-00026">claims 26</claim-ref>-<claim-ref idref="CLM-00042">42</claim-ref>, wherein the therapeutic agent is a genetically encoded fusion protein.</claim-text></claim><claim id="CLM-00044" num="00044"><claim-text><b>44</b>. A polynucleotide comprising a nucleotide sequence encoding the therapeutic agent of <claim-ref idref="CLM-00043">claim 43</claim-ref>.</claim-text></claim><claim id="CLM-00045" num="00045"><claim-text><b>45</b>. The polynucleotide of <claim-ref idref="CLM-00044">claim 44</claim-ref>, further comprising an expression control element operably linked to said nucleotide sequence.</claim-text></claim><claim id="CLM-00046" num="00046"><claim-text><b>46</b>. The polynucleotide of <claim-ref idref="CLM-00045">claim 45</claim-ref>, wherein said expression control element comprises a promoter.</claim-text></claim><claim id="CLM-00047" num="00047"><claim-text><b>47</b>. A vector comprising the polynucleotide of any one of <claim-ref idref="CLM-00044">claims 44</claim-ref>-<claim-ref idref="CLM-00046">46</claim-ref>.</claim-text></claim><claim id="CLM-00048" num="00048"><claim-text><b>48</b>. An isolated host cell containing the vector of <claim-ref idref="CLM-00047">claim 47</claim-ref> or the polynucleotide of any one of <claim-ref idref="CLM-00044">claims 44</claim-ref>-<claim-ref idref="CLM-00046">46</claim-ref>.</claim-text></claim><claim id="CLM-00049" num="00049"><claim-text><b>49</b>. A pharmaceutical composition comprising the therapeutic agent of any one of <claim-ref idref="CLM-00026">claims 26</claim-ref>-<claim-ref idref="CLM-00043">43</claim-ref>, and a pharmaceutically acceptable carrier and/or excipient.</claim-text></claim><claim id="CLM-00050" num="00050"><claim-text><b>50</b>. A method of treating or preventing a biological condition, disorder, or disease in a subject, comprising administering an effective amount of the therapeutic agent of any one of <claim-ref idref="CLM-00026">claims 26</claim-ref>-<claim-ref idref="CLM-00043">43</claim-ref> or the pharmaceutical composition of <claim-ref idref="CLM-00049">claim 49</claim-ref> to a subject in need thereof.</claim-text></claim><claim id="CLM-00051" num="00051"><claim-text><b>51</b>. The method of <claim-ref idref="CLM-00050">claim 50</claim-ref>, wherein the subject has diabetes.</claim-text></claim><claim id="CLM-00052" num="00052"><claim-text><b>52</b>. A therapeutic agent comprising an elastin-like peptide (ELP) component and an insulin or functional analog thereof.</claim-text></claim><claim id="CLM-00053" num="00053"><claim-text><b>53</b>. The therapeutic agent of <claim-ref idref="CLM-00052">claim 52</claim-ref>, wherein the ELP component is covalently bonded to the insulin or functional analog at an N- and/or C-terminus thereof.</claim-text></claim><claim id="CLM-00054" num="00054"><claim-text><b>54</b>. The therapeutic agent of <claim-ref idref="CLM-00052">claim 52</claim-ref> or <claim-ref idref="CLM-00053">53</claim-ref>, wherein a first insulin or functional analog is covalently bonded to the ELP component at the N-terminus of the ELP component, and a second insulin or functional analog is covalently bonded to the ELP component at the C-terminus of the ELP component.</claim-text></claim><claim id="CLM-00055" num="00055"><claim-text><b>55</b>. The therapeutic agent of <claim-ref idref="CLM-00052">claim 52</claim-ref>, wherein the insulin or functional analog is covalently bonded to the ELP component at an N- and/or C-terminus thereof.</claim-text></claim><claim id="CLM-00056" num="00056"><claim-text><b>56</b>. The therapeutic agent of <claim-ref idref="CLM-00052">claim 52</claim-ref> or <claim-ref idref="CLM-00053">53</claim-ref>, wherein a first ELP component is covalently bonded to the insulin or functional analog at an N-terminus thereof, and a second ELP component is covalently bonded to the insulin or functional analog at a C-terminus thereof.</claim-text></claim><claim id="CLM-00057" num="00057"><claim-text><b>57</b>. The therapeutic agent of any one of <claim-ref idref="CLM-00052">claims 52</claim-ref>-<claim-ref idref="CLM-00056">56</claim-ref>, further comprising a spacer moiety between the ELP component and the insulin or functional analog.</claim-text></claim><claim id="CLM-00058" num="00058"><claim-text><b>58</b>. The therapeutic agent of <claim-ref idref="CLM-00057">claim 57</claim-ref>, wherein the spacer moiety comprises one or more of a protease-resistant moiety, a non-peptide chemical moiety, and a protease cleavage site.</claim-text></claim><claim id="CLM-00059" num="00059"><claim-text><b>59</b>. The therapeutic agent of <claim-ref idref="CLM-00058">claim 58</claim-ref>, wherein the protease cleavage site is a thrombin cleavage site, a factor Xa cleavage site, a metalloprotease cleavage site, an enterokinase cleavage site, a Tev cleavage site, or a cathepsin cleavage site.</claim-text></claim><claim id="CLM-00060" num="00060"><claim-text><b>60</b>. The therapeutic agent of <claim-ref idref="CLM-00058">claim 58</claim-ref>, wherein the spacer moiety comprises a non-cleavable moiety having the formula [(Gly)<sub>n</sub>-Ser]<sub>m </sub>(SEQ ID NO: 22) where n is from 1 to 4, inclusive, and m is from 1 to 4, inclusive.</claim-text></claim><claim id="CLM-00061" num="00061"><claim-text><b>61</b>. The therapeutic agent of any one of <claim-ref idref="CLM-00052">claims 52</claim-ref>-<claim-ref idref="CLM-00060">60</claim-ref>, wherein the ELP component comprises at least one repeating unit selected from SEQ ID NOS: 1-12.</claim-text></claim><claim id="CLM-00062" num="00062"><claim-text><b>62</b>. The therapeutic agent of <claim-ref idref="CLM-00061">claim 61</claim-ref>, wherein said repeating unit is VGPXG (SEQ ID NO: 3).</claim-text></claim><claim id="CLM-00063" num="00063"><claim-text><b>63</b>. The therapeutic agent of <claim-ref idref="CLM-00061">claim 61</claim-ref>, wherein the repeating unit is Ile-Pro-Gly-X-Gly (SEQ ID NO: 5) or Leu-Pro-Gly-X-Gly (SEQ ID NO: 7), wherein X is any natural or non-natural amino acid residue, and wherein X varies among at least two units.</claim-text></claim><claim id="CLM-00064" num="00064"><claim-text><b>64</b>. The therapeutic agent of <claim-ref idref="CLM-00062">claim 62</claim-ref> or <claim-ref idref="CLM-00063">63</claim-ref>, wherein each X is independently selected from alanine, arginine, asparagine, aspartic acid, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, serine, threonine, tryptophan, tyrosine and valine residues.</claim-text></claim><claim id="CLM-00065" num="00065"><claim-text><b>65</b>. The therapeutic agent of any one of <claim-ref idref="CLM-00052">claims 52</claim-ref>-<claim-ref idref="CLM-00064">64</claim-ref>, wherein the therapeutic agent has a molecular weight of less than about 50 kDa.</claim-text></claim><claim id="CLM-00066" num="00066"><claim-text><b>66</b>. The therapeutic agent of any one of <claim-ref idref="CLM-00052">claims 52</claim-ref>-<claim-ref idref="CLM-00065">65</claim-ref>, wherein the ELP component has a Tt greater than 37&#xb0; C.</claim-text></claim><claim id="CLM-00067" num="00067"><claim-text><b>67</b>. The therapeutic agent of any one of <claim-ref idref="CLM-00052">claims 52</claim-ref>-<claim-ref idref="CLM-00066">66</claim-ref>, wherein the therapeutic agent is a genetically encoded fusion protein.</claim-text></claim><claim id="CLM-00068" num="00068"><claim-text><b>68</b>. A polynucleotide comprising a nucleotide sequence encoding the therapeutic agent of <claim-ref idref="CLM-00067">claim 67</claim-ref>.</claim-text></claim><claim id="CLM-00069" num="00069"><claim-text><b>69</b>. The polynucleotide of <claim-ref idref="CLM-00068">claim 68</claim-ref>, further comprising an expression control element operably linked to said nucleotide sequence.</claim-text></claim><claim id="CLM-00070" num="00070"><claim-text><b>70</b>. The polynucleotide of <claim-ref idref="CLM-00069">claim 69</claim-ref>, wherein said expression control element comprises a promoter.</claim-text></claim><claim id="CLM-00071" num="00071"><claim-text><b>71</b>. A vector comprising the polynucleotide of any one of <claim-ref idref="CLM-00068">claims 68</claim-ref>-<claim-ref idref="CLM-00070">70</claim-ref>.</claim-text></claim><claim id="CLM-00072" num="00072"><claim-text><b>72</b>. An isolated host cell containing the vector of <claim-ref idref="CLM-00071">claim 71</claim-ref> or the polynucleotide of any one of <claim-ref idref="CLM-00068">claims 68</claim-ref>-<claim-ref idref="CLM-00070">70</claim-ref>.</claim-text></claim><claim id="CLM-00073" num="00073"><claim-text><b>73</b>. A pharmaceutical composition comprising the therapeutic agent of any one of <claim-ref idref="CLM-00052">claims 52</claim-ref>-<claim-ref idref="CLM-00067">67</claim-ref>, and a pharmaceutically acceptable carrier and/or excipient.</claim-text></claim><claim id="CLM-00074" num="00074"><claim-text><b>74</b>. A method of preventing or treating a biological condition, disorder, or disease in a subject, comprising administering an effective amount of the therapeutic agent of any one of <claim-ref idref="CLM-00052">claims 52</claim-ref>-<claim-ref idref="CLM-00067">67</claim-ref> or the pharmaceutical composition of <claim-ref idref="CLM-00073">claim 73</claim-ref> to a subject in need thereof.</claim-text></claim><claim id="CLM-00075" num="00075"><claim-text><b>75</b>. The method of <claim-ref idref="CLM-00074">claim 74</claim-ref>, wherein the subject has diabetes.</claim-text></claim><claim id="CLM-00076" num="00076"><claim-text><b>76</b>. A therapeutic agent comprising an elastin-like peptide (ELP) component and a Factor VII/VIIa or functional analog thereof.</claim-text></claim><claim id="CLM-00077" num="00077"><claim-text><b>77</b>. The therapeutic agent of <claim-ref idref="CLM-00076">claim 76</claim-ref>, wherein the ELP component is covalently bonded to the Factor VII/VIIa or functional analog at an N- and/or C-terminus of the Factor VII/VIIa.</claim-text></claim><claim id="CLM-00078" num="00078"><claim-text><b>78</b>. The therapeutic agent of <claim-ref idref="CLM-00076">claim 76</claim-ref> or <claim-ref idref="CLM-00077">77</claim-ref>, wherein a first Factor VII/VIIa or functional analog is covalently bonded to the ELP at the N-terminus of the ELP component, and a second Factor VII/VIIa or functional analog is covalently bonded to the ELP component at the C-terminus of the ELP component.</claim-text></claim><claim id="CLM-00079" num="00079"><claim-text><b>79</b>. The therapeutic agent of <claim-ref idref="CLM-00076">claim 76</claim-ref>, wherein the Factor VII/VIIa or functional analog is covalently bonded to the ELP component at an N- and/or C-terminus of the ELP component.</claim-text></claim><claim id="CLM-00080" num="00080"><claim-text><b>80</b>. The therapeutic agent of <claim-ref idref="CLM-00076">claim 76</claim-ref> or <claim-ref idref="CLM-00077">77</claim-ref>, wherein a first ELP component is covalently bonded to the Factor VII/VIIa or functional analog at an N-terminus thereof, and a second ELP component is covalently bonded to the Factor VII/VIIa or functional analog at a C-terminus thereof.</claim-text></claim><claim id="CLM-00081" num="00081"><claim-text><b>81</b>. The therapeutic agent of any one of <claim-ref idref="CLM-00076">claims 76</claim-ref>-<claim-ref idref="CLM-00080">80</claim-ref>, further comprising a spacer moiety between the ELP component and factor VII/VIIa or functional analog.</claim-text></claim><claim id="CLM-00082" num="00082"><claim-text><b>82</b>. The therapeutic agent of <claim-ref idref="CLM-00081">claim 81</claim-ref>, wherein the spacer moiety comprises one or more of a protease-resistant moiety, a non-peptide chemical moiety, and a protease cleavage site.</claim-text></claim><claim id="CLM-00083" num="00083"><claim-text><b>83</b>. The therapeutic agent of <claim-ref idref="CLM-00082">claim 82</claim-ref>, wherein the protease cleavage site is a thrombin cleavage site, a factor Xa cleavage site, a metalloprotease cleavage site, an enterokinase cleavage site, a Tev cleavage site, and a cathepsin cleavage site.</claim-text></claim><claim id="CLM-00084" num="00084"><claim-text><b>84</b>. The therapeutic agent of <claim-ref idref="CLM-00082">claim 82</claim-ref>, wherein the spacer moiety comprises a non-cleavable moiety having the formula [(Gly)<sub>n</sub>-Ser]<sub>m </sub>(SEQ ID NO: 22) where n is from 1 to 4, inclusive, and m is from 1 to 4, inclusive.</claim-text></claim><claim id="CLM-00085" num="00085"><claim-text><b>85</b>. The therapeutic agent of any one of <claim-ref idref="CLM-00076">claims 76</claim-ref>-<claim-ref idref="CLM-00084">84</claim-ref>, wherein the ELP component comprises at least one repeating unit selected from SEQ ID NOS: 1-12.</claim-text></claim><claim id="CLM-00086" num="00086"><claim-text><b>86</b>. The therapeutic agent of <claim-ref idref="CLM-00085">claim 85</claim-ref>, wherein said repeating unit is VPGXG (SEQ ID NO: 3).</claim-text></claim><claim id="CLM-00087" num="00087"><claim-text><b>87</b>. The therapeutic agent of <claim-ref idref="CLM-00086">claim 86</claim-ref>, wherein X is any natural or non-natural amino acid residue, and wherein X varies among at least two units.</claim-text></claim><claim id="CLM-00088" num="00088"><claim-text><b>88</b>. The therapeutic agent of <claim-ref idref="CLM-00086">claim 86</claim-ref>, wherein each X is independently selected from alanine, arginine, asparagine, aspartic acid, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, serine, threonine, tryptophan, tyrosine and valine residues.</claim-text></claim><claim id="CLM-00089" num="00089"><claim-text><b>89</b>. The therapeutic agent of any one of <claim-ref idref="CLM-00076">claims 76</claim-ref>-<claim-ref idref="CLM-00088">88</claim-ref>, wherein the therapeutic agent has a molecular weight of less than about 70 kDa.</claim-text></claim><claim id="CLM-00090" num="00090"><claim-text><b>90</b>. The therapeutic agent of any one of <claim-ref idref="CLM-00076">claims 76</claim-ref>-<claim-ref idref="CLM-00089">89</claim-ref>, wherein the ELP component has a Tt greater than 37&#xb0; C.</claim-text></claim><claim id="CLM-00091" num="00091"><claim-text><b>91</b>. The therapeutic agent of any one of <claim-ref idref="CLM-00076">claims 76</claim-ref>-<claim-ref idref="CLM-00090">90</claim-ref>, wherein the therapeutic agent is a genetically encoded fusion protein.</claim-text></claim><claim id="CLM-00092" num="00092"><claim-text><b>92</b>. A polynucleotide comprising a nucleotide sequence encoding the therapeutic agent of <claim-ref idref="CLM-00091">claim 91</claim-ref>.</claim-text></claim><claim id="CLM-00093" num="00093"><claim-text><b>93</b>. The polynucleotide of <claim-ref idref="CLM-00092">claim 92</claim-ref>, further comprising an expression control element operably linked to said nucleotide sequence.</claim-text></claim><claim id="CLM-00094" num="00094"><claim-text><b>94</b>. The polynucleotide of <claim-ref idref="CLM-00093">claim 93</claim-ref>, wherein said expression control element comprises a promoter.</claim-text></claim><claim id="CLM-00095" num="00095"><claim-text><b>95</b>. A vector comprising the polynucleotide of any one of <claim-ref idref="CLM-00092">claims 92</claim-ref>-<claim-ref idref="CLM-00094">94</claim-ref>.</claim-text></claim><claim id="CLM-00096" num="00096"><claim-text><b>96</b>. An isolated host cell containing the vector of <claim-ref idref="CLM-00095">claim 95</claim-ref> or the polynucleotide of any one of <claim-ref idref="CLM-00092">claims 92</claim-ref>-<claim-ref idref="CLM-00095">95</claim-ref>.</claim-text></claim><claim id="CLM-00097" num="00097"><claim-text><b>97</b>. A pharmaceutical composition comprising the therapeutic agent of any one of <claim-ref idref="CLM-00076">claims 76</claim-ref>-<claim-ref idref="CLM-00091">91</claim-ref>, and a pharmaceutically acceptable carrier and/or excipient.</claim-text></claim><claim id="CLM-00098" num="00098"><claim-text><b>98</b>. A method of preventing or treating a subject for a biological condition, disorder, or disease, comprising administering an effective amount of the therapeutic agent of any one of <claim-ref idref="CLM-00076">claims 76</claim-ref>-<claim-ref idref="CLM-00091">91</claim-ref> or the pharmaceutical composition of <claim-ref idref="CLM-00097">claim 97</claim-ref> to a subject in need thereof.</claim-text></claim><claim id="CLM-00099" num="00099"><claim-text><b>99</b>. The method of <claim-ref idref="CLM-00098">claim 98</claim-ref>, wherein the subject has a hemorrhage.</claim-text></claim><claim id="CLM-00100" num="00100"><claim-text><b>100</b>. The method of <claim-ref idref="CLM-00098">claim 98</claim-ref> or <claim-ref idref="CLM-00099">99</claim-ref>, wherein the subject has hemophilia.</claim-text></claim></claims></us-patent-application>